Global report on hypertension

The race against a silent killer
Global report on hypertension

The race against a silent killer
## Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Foreword</td>
<td>v</td>
</tr>
<tr>
<td>Acknowledgements</td>
<td>vi</td>
</tr>
<tr>
<td>Acronyms and abbreviations</td>
<td>vii</td>
</tr>
<tr>
<td>Executive summary</td>
<td>ix</td>
</tr>
<tr>
<td>1 Hypertension and the global public health agenda</td>
<td>1</td>
</tr>
<tr>
<td>1.1 Purpose of the report</td>
<td>3</td>
</tr>
<tr>
<td>2 The global burden of hypertension</td>
<td>5</td>
</tr>
<tr>
<td>2.1 The global prevalence of hypertension</td>
<td>6</td>
</tr>
<tr>
<td>2.2 Risk factors for age-related increase in blood pressure</td>
<td>9</td>
</tr>
<tr>
<td>2.3 Status of hypertension care</td>
<td>10</td>
</tr>
<tr>
<td>2.4 Uncontrolled hypertension and progress toward the 2025 target</td>
<td>12</td>
</tr>
<tr>
<td>2.5 Trends in hypertension care</td>
<td>13</td>
</tr>
<tr>
<td>2.6 Deaths due to high systolic blood pressure</td>
<td>15</td>
</tr>
<tr>
<td>2.7 Data used to monitor hypertension and hypertension treatment</td>
<td>16</td>
</tr>
<tr>
<td>2.8 Summary</td>
<td>18</td>
</tr>
<tr>
<td>3 Benefits of hypertension interventions</td>
<td>19</td>
</tr>
<tr>
<td>3.1 Health benefits of hypertension prevention and control programmes</td>
<td>20</td>
</tr>
<tr>
<td>3.2 Costs and benefits of hypertension prevention and control interventions</td>
<td>24</td>
</tr>
<tr>
<td>3.3 Summary</td>
<td>26</td>
</tr>
<tr>
<td>4 Risk factors for hypertension</td>
<td>27</td>
</tr>
<tr>
<td>4.1 Population-based hypertension risk factors</td>
<td>27</td>
</tr>
<tr>
<td>4.1.1 Dietary sodium</td>
<td>27</td>
</tr>
<tr>
<td>4.1.2 Alcohol consumption</td>
<td>29</td>
</tr>
<tr>
<td>4.1.3 Tobacco use</td>
<td>30</td>
</tr>
<tr>
<td>4.1.4 Physical inactivity</td>
<td>30</td>
</tr>
<tr>
<td>4.1.5 Air pollution</td>
<td>32</td>
</tr>
<tr>
<td>4.2 Summary</td>
<td>33</td>
</tr>
<tr>
<td>5 Diagnosing and managing hypertension</td>
<td>35</td>
</tr>
<tr>
<td>5.1 Clinical presentation of high blood pressure and hypertension</td>
<td>35</td>
</tr>
<tr>
<td>5.2 Diagnosis and early detection</td>
<td>35</td>
</tr>
<tr>
<td>5.2.1 Early detection of hypertension</td>
<td>36</td>
</tr>
<tr>
<td>5.3 Management of hypertension</td>
<td>37</td>
</tr>
<tr>
<td>5.3.1 Guideline for the pharmacological treatment of hypertension</td>
<td>37</td>
</tr>
<tr>
<td>5.4 HEARTS for hypertension control</td>
<td>37</td>
</tr>
<tr>
<td>5.5 Healthy lifestyle counselling</td>
<td>39</td>
</tr>
<tr>
<td>5.5.1 Evidence-based protocols</td>
<td>40</td>
</tr>
<tr>
<td>5.5.2 Access to essential medicines and health technologies</td>
<td>42</td>
</tr>
<tr>
<td>5.5.3 Blood pressure monitoring devices</td>
<td>46</td>
</tr>
<tr>
<td>5.5.4 Risk-based management</td>
<td>46</td>
</tr>
<tr>
<td>5.5.5 Team-based care</td>
<td>48</td>
</tr>
<tr>
<td>5.5.6 Systems for monitoring</td>
<td>50</td>
</tr>
<tr>
<td>5.6 National scale-up of HEARTS for hypertension</td>
<td>51</td>
</tr>
<tr>
<td>5.7 Co-morbidities and hypertension</td>
<td>53</td>
</tr>
<tr>
<td>5.7.1 Diabetes</td>
<td>53</td>
</tr>
<tr>
<td>5.7.2 Chronic kidney disease hypertension</td>
<td>54</td>
</tr>
<tr>
<td>5.8 HIV and hypertension</td>
<td>54</td>
</tr>
<tr>
<td>5.9 Summary</td>
<td>56</td>
</tr>
<tr>
<td>6 Conclusion</td>
<td>57</td>
</tr>
<tr>
<td>References</td>
<td>58</td>
</tr>
<tr>
<td>Annex 1. Methodology for analysis of impact and cost</td>
<td>71</td>
</tr>
<tr>
<td>Annex 2. Hypertension profiles and explanatory notes</td>
<td>75</td>
</tr>
</tbody>
</table>
Figures

Fig. 1. Voluntary global targets for prevention and control of noncommunicable diseases (as of August 2023)

Fig. 2. Prevalence of hypertension, by control status, among adults aged 30–79, by country, in 2019

Fig. 3. Number of adults aged 30–79 years with hypertension, by region and year, 1990 and 2019

Fig. 4. Hypertension treatment cascade in 2019, for adults 30–79 years of age globally, by sex. Age-standardized rates

Fig. 5. Percentage of adults aged 30–79 years currently being treated (taking medication) for their hypertension in 2019, out of those with hypertension, by country, sex, and country income group

Fig. 6. Global prevalence of uncontrolled hypertension, by category among adults aged 30–79 years of age, and the voluntary global target for uncontrolled hypertension (raised blood pressure) for 2025

Fig. 7. Trends in age-standardized prevalence of hypertension, 1999–2019, disaggregated by control, treatment, and diagnosis status

Fig. 8. Percentage of global deaths attributable to high systolic blood pressure (1990 and 2019), by cause of death

Fig. 9. Deaths attributable to high systolic blood pressure (1990 and 2019), by WHO region

Fig. 10. Required improvements in hypertension cascade of care to achieve 50% (progress scenario) or 75% (aspirational scenario) blood pressure control by 2050

Fig. 11. Implications of improved hypertension care for global blood pressure distribution

Fig. 12. Reductions in cardiovascular mortality inequalities resulting from improved blood pressure control

Fig. 13. Simple hypertension treatment protocol, Sri Lanka, 2021–present

Fig. 14. Supply-chain strengthening interventions

Fig. 15. Increment in procurement of amlodipine over four years in four states of India

Tables

Table 1. Key terms and their definitions used for monitoring blood pressure and hypertension in populations

Table 2. Age-standardized prevalence of hypertension among adults aged 30–79 years, and among those with hypertension, diagnosis, treatment and effective treatment coverage in 2019, by WHO region

Table 3. Impact of a 10-mmHg reduction in blood pressure on risk of different cardiovascular outcomes and by level of blood pressure elevation

Table 4. Cumulative health gains (2023–2050) from improved population blood pressure control

Table 5. Total incremental costs and cumulative economic gains (2023–2050) from scenarios involving improved population blood pressure control compared to business-as-usual scenario

Table 6. WHO guideline recommendations on the pharmacological treatment of hypertension in adults

Table 7. Examples of specific factors influencing HEARTS hypertension control programme readiness-to-scale domains

Boxes

Box 1: Population sodium reduction programme

Box 2: Implementation of HEARTS

Box 3: Incorporating WHO guideline into simple treatment protocol

Box 4: Strengthening access to medicines

Box 5: HEARTS in the Americas

Box 6: Scaling up hypertension care in India

Box 7: Team-based care by local health workers

Box 8: National scale-up of HEARTS

Box 9: HIV and hypertension
Foreword

High blood pressure kills. In fact, cardiovascular diseases are the world’s leading cause of death. Globally, an estimated 1.3 billion adults were affected by hypertension in 2019. I know the dangers of hypertension from personal experience, because it is a condition I live with. I am fortunate that I was diagnosed, have access to good medical care and medicines, and that I understand my condition and can make sure it is controlled. Unfortunately, the same is not true for the majority of those with hypertension, a disease that is often dubbed the “silent killer”.

This report compiles data for the first time on the far-reaching consequences of uncontrolled hypertension, including heart attacks, strokes and premature death, along with substantial economic losses for communities and countries. It also contains information on the global, regional and country-level burden of hypertension and progress of control efforts.

Perhaps most importantly, the report shows a way forward, by highlighting key aspects of guidance from the World Health Organization’s HEARTS: technical package for cardiovascular disease management in primary health care and the Guideline for the pharmacological treatment of hypertension in adults. These tools were developed to provide guidance for countries in establishing early detection, management, control and monitoring of hypertension as part of primary health care services.

In fact, hypertension can be controlled effectively with simple, low-cost medication regimens, and yet only about one in five people with hypertension has controlled it. Hypertension control programmes remain neglected, under-prioritized and vastly underfunded. Strengthening hypertension control must be part of every country’s journey towards universal health coverage, based on well-functioning, equitable and resilient health systems, built on a foundation of primary health care.

There are many challenges to tackling hypertension but, as this report shows, there are also many reasons for hope. By implementing programmes we can improve hypertension control rates and prevent millions of deaths from heart attack and stroke.

Dr Tedros Adhanom Ghebreyesus
Director-General
World Health Organization (WHO)
Acknowledgements

This report was developed and produced by Taskeen Khan of the Department of Noncommunicable Diseases, World Health Organization (WHO) in collaboration with a statistics team that includes Gretchen Stevens and Melanie Cowan (Department of Noncommunicable Diseases, WHO), and David Watkins and Sarah Pickersgill (University of Washington), coordinated by Slim Slama and Leanne Riley (Department of Noncommunicable Diseases, WHO). Bente Mikkelsen (Department of Noncommunicable Diseases, WHO) and Jerome Salomon (Assistant Director-General, Universal Health Coverage/Communicable and Noncommunicable Diseases, WHO) provided strategic direction.

The valuable technical contributions from colleagues across WHO are recognized: Virginia Arnold Clark, Prebo Barango, Fiona Bull, Roberta Caixeta, Mohamed Cheikh, Luz Maria De-Regil, Rolando Enrique Domingo, Hicham El Berri, Bashier Enoos, Jill Farrington, Doris Ma Fat, Hebe Gouda, Sophie Gumy, Nalika Gunawardena, Pradheep Joshi, Tomo Kanda, Abhishek Kunwar, Mary-Anne Land, Pierpaolo Mudu, Pedro Ordunez, Samantha Pegoraro, Vinayak Prasad, Ivo Rakovac, Patricia Rarau, Dag Rekve, Susannah Robinson, Rauell John Santos, Kerstin Schotte, Josaia Tiko, Lai Duc Truong, Cherian Varghese, Juana Willumsen.

WHO also recognizes the valuable contributions made by Jessica Leighton (Bloomberg Philanthropies), Andrew Moran (Columbia University); Majid Ezzati and Bin Zhou (Imperial College London); Prabheep Kaur (Indian Council of Medical Research); Marc Jaffe (Kaiser Permanente); Pablo Perel (London School of Hygiene and Tropical Medicine); Flávio Danni Fuchs (National Council for Scientific and Technological Development, Brazil); Bolanle Banigbe, Danielle Cazabon, Laura Cobb, Vivek Elluri, Tom Frieden, Renu Garg, Nicole Ide, Swagata Kumar Sahoo and Ge Zeng (Resolve to Save Lives); Bader Almustafa (Saudi Ministry of Health); Vivek Jha (The George Institute for Global Health); Sheila Martins (Universidade Federal do Rio Grande do Sul Hospital de Clinicas de Porto Alegre); Kathryn Foti (University of Alabama at Birmingham); Reena Gupta (University of California at San Francisco); Mayowa Owolabi (University of Ibadan); Alta Schutte (University of New South Wales); Donald DiPette (University of South Carolina); Paul Whelton (University of Tulane); Ruxana Jina (Vital Strategies).

All Member States are acknowledged for the actions taken to diagnose, treat and control hypertension.

Financial support

WHO is grateful for the financial support to develop this report from Resolve to Save Lives. Resolve to Save Lives is funded by grants from Bloomberg Philanthropies; the Bill and Melinda Gates Foundation; and the Chan Zuckerberg Initiative DAF, an advised fund of Silicon Valley Community Foundation.
Acronyms and abbreviations

BP  blood pressure
BPMD  blood pressure monitoring device
CKD  chronic kidney disease
CVD  cardiovascular disease
DALYs  disability-adjusted life years
DBP  diastolic blood pressure
IHCI  India Hypertension Control Initiative
LMICs  low- and middle-income countries
PAHO  Pan American Health Organization
PHC  primary health care
PM$_{2.5}$  particulate matter of a diameter ≤2.5 µm
SBP  systolic blood pressure
SDG  Sustainable Development Goal
SMASH  Shandong Ministry of Health Action on Salt and Hypertension
NCD  noncommunicable disease
WHO  World Health Organization
Executive summary

High blood pressure is one of the world’s leading risk factors for death and disability. The number of people living with hypertension (blood pressure of ≥140 mmHg systolic or ≥90 mmHg diastolic or on medication) doubled between 1990 and 2019, from 650 million to 1.3 billion (1).

This common, deadly condition is an important public health problem that leads to stroke, heart attack, heart failure, kidney damage and many other health problems (2, 3). A study of 87 behavioural, environmental, occupational and metabolic risk factors found that high systolic blood pressure (≥110–115 mmHg) was the single most important risk factor for early death worldwide, leading to an estimated 10.8 million avoidable deaths every year, and a burden of 235 million years of life lost or lived with a disability (disability-adjusted life years, DALYs) annually (3). High blood pressure causes more deaths than other leading risk factors, including tobacco use and high blood sugar.

Hypertension and its associated complications also have enormous economic costs – for patients and their families, health systems and national economies. People living with the condition incur direct medical costs and lose wages, often in their prime working years, which can be impoverishing for entire families. Hospital and outpatient care for heart attacks and strokes caused by uncontrolled hypertension are expensive for health systems. National economies lose tax income, have decreased productivity, increased health care costs, and increased societal needs for the support of adults surviving heart attack and stroke, and of children whose parents have died or become disabled. By one estimate, the economic benefits of improved hypertension treatment programmes outweigh the costs by about 18 to one.

Addressing risk factors and managing hypertension

The good news is that hypertension and its associated complications can be addressed. Risk-factor strategies include ensuring that people eat a healthy diet low in sodium, maintain a healthy weight, avoid alcohol and tobacco and take regular physical activity (all of which also contribute to good health more generally). Policies and practices to support these strategies are most effective when implemented across entire populations or within specific settings, such as in schools and at workplaces.

“Hypertension and its associated complications have enormous economic costs for patients and their families, health systems and national economies.”
For people who have hypertension, there are ways to minimize its impact on health and wellbeing. The starting point for living well with hypertension and preventing complications is early diagnosis and early, effective treatment – the longer a person lives with undiagnosed and inadequately treated hypertension, the worse their health outcomes are likely to be. Currently, among adults aged 30–79 years with hypertension, only 54% have been diagnosed with the condition, 42% are being treated for their hypertension, and 21% are considered to have their hypertension controlled (4).

In some countries and health care systems, large-scale hypertension control programmes have achieved hypertension control for many patients, giving them longer, healthier lives. The World Health Organization (WHO) HEARTS technical package provides cost-effective strategies that can be implemented at the primary health care level to control blood pressure and prevent heart attack, stroke and other complications. Components of the package include the use of a standardized drug- and dose-specific treatment protocol, uninterrupted access to quality-assured medications, team-based care, patient-centred services, and a robust monitoring system to track patient progress and health system performance. Follow-up and referral systems are also important to improve treatment outcomes. Implementation of the HEARTS package and the system improvements this requires in terms of integrated health care services, demonstrates that many of its components support, and can also be applied to, other health problems requiring consistent, long-term care, including diabetes, chronic kidney disease and HIV/AIDS.

Although hypertension can be prevented and treated, few countries currently do so effectively. Better hypertension management will save lives. Increasing the percentage of people whose hypertension is under control globally to 50% would prevent 76 million deaths between 2023 and 2050. Treating hypertension is one of the most important interventions to meet the Sustainable Development Goal (SDG) target 3.4 of a one third reduction in premature mortality from the leading noncommunicable diseases.

**Conclusions and key messages**

Improving the prevention and treatment of hypertension is feasible, low-cost, safe and necessary to achieve global and national targets, including those of the SDGs. Effective hypertension management will bring health, wellbeing, and economic benefits. It will reduce burdens on acute-care services, increase integration of health care systems and, most importantly, reduce the deaths, suffering and costs arising from complications such as heart attack, stroke and kidney failure.
To improve the prevention and treatment of hypertension, countries should:

- Provide national leadership accountable for steady progress in preventing heart attack and stroke, especially through improved control of hypertension by:
  - establishing national mechanisms such as a national steering committee, coordinated by strategic leadership from the ministry of health, to monitor and improve resource allocation and implementation of an integrated response to noncommunicable diseases, with specific attention to hypertension control rates;
  - ensuring representation on such a steering committee comes from inside and outside government and includes clinicians committed to improving the management and control of hypertension through primary health care services;
  - setting and monitoring, at least annually and ideally quarterly, national targets and indicators to foster accountability, which should include the number of patients with hypertension whose treatment has brought their blood pressure to the target level of control selected by the country, and this number as a proportion of the estimated total number of people living with hypertension in the country;
  - ensuring that national policies and plans addressing hypertension are fully costed, funded and implemented.

- Develop comprehensive programmes that address risk factors for hypertension and other noncommunicable diseases (e.g. encouraging healthy diets low in sodium, reducing tobacco and alcohol use, and making regular physical activity a normal part of daily life).

- Implement the WHO HEARTS package by:
  - selecting a drug- and dose-specific treatment protocol at the national, subnational or health system level;
  - ensuring an uninterrupted supply of quality-assured drugs and of externally validated automated digital blood pressure monitors;
  - establishing team-based care for patients with hypertension and other chronic conditions, with nurses, pharmacists, outreach workers and others collaborating with clinicians to support patient care;
  - making health care services patient-friendly, reducing barriers to care through improved patient education and treatment at convenient times and locations close to the patient’s home or work. Care should include medications that are free of cost to the patient and, for stable patients, multi-month (e.g. 3- and 6-month) refills, reducing the effort needed for patients to continue to take medications and the burden on health care systems as treatment coverage increases;
  - establishing an accurate and practical information system that supports
frontline health care workers and enables longitudinal tracking of the WHO data indicators for hypertension care, with particular attention to facility-based control rate and estimated community-wide control rates.

- Address broader factors to enable health care systems to support patient care by:
  - ensuring there are enough trained and supported health care staff at all levels;
  - including hypertension management in essential benefit packages as part of universal health coverage;
  - providing sustainable finance for the delivery of health care programmes so that treatment is not interrupted in times of financial or other difficulties;
  - improving information systems to empower providers, programme managers and patients;
  - progressively adding services, as permitted by human and financial resources, to provide integrated, comprehensive primary care to all people; and
  - strengthening the national capacity to collect, analyse and use representative data on the burden and trends of hypertension in order to continuously improve and optimize the programme.
Hypertension and the global public health agenda

Cardiovascular diseases (CVDs) are the leading cause of death worldwide, and many of these deaths can be prevented by treating hypertension.

The United Nations General Assembly political declaration of 2011 on the prevention and control of noncommunicable diseases (NCDs) (5) recognized that the incidence and impacts of CVDs and other NCDs can be largely prevented or reduced with an approach that incorporates evidence-based, affordable, cost-effective, population-wide and multisectoral interventions. To catalyse national action, the World Health Assembly adopted a comprehensive Global Monitoring Framework in 2013, comprised of nine voluntary global targets to be reached by 2025 (Fig. 1), which included a “25% relative reduction in the prevalence of raised blood pressure”.

These targets were included in Appendix 2 of the Global action plan for the prevention and control of noncommunicable diseases 2013–2020 (6), which provides a roadmap and policy options to attain the nine voluntary global targets. More recently, the Seventy-sixth World Health Assembly in 2023 (7) approved an updated Appendix 3 Menu of policy options and cost-effective interventions. This reflects the most recent scientific evidence, and includes, as a recommended intervention to address cardiovascular diseases, the pharmacological treatment of hypertension in adults in line with the 2021 Guideline for the pharmacological treatment of hypertension in adults (8).

Commitments to reducing hypertension were deepened in 2015 following the United Nations General Assembly’s adoption of the 2030 Agenda for Sustainable Development and, specifically, Sustainable Development Goal (SDG) target 3.4: reduce by one third premature mortality from noncommunicable diseases through prevention and treatment (9). Actions to control the burden of hypertension – including population-level interventions to prevent hypertension and scale up treatment – are key steps to achieving this, and also make a contribution to other SDG targets, including those relating to universal health coverage and access to affordable essential medicines.

At present, approximately four out of every five people with hypertension are not adequately treated (4). At the same time, high systolic blood pressure – a silent killer – is responsible for more than 10 million deaths every year – more deaths than from any other risk to health. Many of these deaths are
preventable through policies that reduce the risk of hypertension, including a healthy diet with less sodium and healthy levels of potassium, and improved treatment. Improving treatment of hypertension can save millions of lives and also strengthen primary health care systems.

Effective management of hypertension in primary health care requires accurate diagnosis, with screening of every adult patient, immediate treatment initiation for patients with confirmed very high (>160/100) blood pressure and prompt rechecking of all other patients with elevated blood pressure within one to four weeks, accessible standardized treatment free to the patient, and rigorous monitoring of progress at each facility, each sub-national area and nationally.

Every national health leader should regularly assess progress towards improving control of blood pressure to meet their country’s targets.

Fig. 1. Voluntary global targets for prevention and control of noncommunicable diseases (as of August 2023)

1. A one third relative reduction in the overall mortality from cardiovascular diseases, cancer, diabetes, or chronic respiratory diseases by 2030

2. A 20% relative reduction in the harmful use of alcohol by 2030

3. A 15% relative reduction in prevalence of insufficient physical activity by 2030

4. A 30% relative reduction in mean population intake of salt/sodium

5. A 30% relative reduction in prevalence of current tobacco use

6. A 25% relative reduction in the prevalence of raised blood pressure or to contain the prevalence of raised blood pressure

7. Halt the rise in diabetes and obesity

8. At least 50% of eligible people (aged 40 years and older with a 10-year cardiovascular risk ≥20%) including those with CVD to receive drug therapy and counselling (including glycaemic control) to prevent heart attacks and strokes

9. An 80% availability of the affordable basic technologies and essential medicines, including generics, required to treat major noncommunicable diseases in both public and private facilities

Note: The target date for targets 4–9 is 2025.

1.1 Purpose of the report

This report advances global work to address noncommunicable diseases. It aims to draw focused attention to the priority noncommunicable diseases targeted by world leaders, in particular the public health challenge of hypertension, and to generate momentum for national, regional and global action. The world has made substantial progress by focusing on specific communicable diseases such as HIV, tuberculosis, malaria, vaccine-preventable diseases and childhood infections. Progress in reducing today’s leading causes of death, of which hypertension is the most deadly, will similarly require focused attention along with coordination to strengthen primary health care.

Section 1 has introduced hypertension as a global health issue and has outlined the goals of this report.

Section 2 presents an overview of the global prevalence, treatment and control of, and risk factors for, hypertension, the burden of mortality related to high systolic blood pressure, and the progress of countries towards the voluntary global target to reduce raised blood pressure by 25% (6). It discusses the importance of strong health information systems to enable the collection, analysis, interpretation and dissemination of data, and for robust systems for monitoring and recording blood pressure.

Section 3 focuses on the health and cost impacts of hypertension, and provides scenarios for how we can save lives by scaling up hypertension treatment.

Section 4 presents some of the risk factors for hypertension: unhealthy diet containing excess sodium, use of tobacco and alcohol, physical inactivity and air pollution.

Section 5, which includes case studies from the WHO regions, discusses diagnosis and early detection of hypertension, and models of care, including those for co-morbidities, and describes the HEARTS approach to managing hypertension.

Section 6 presents a short conclusion.

Annex 1 discusses the methodology used in the analysis of the impact and cost of the treatment of hypertension.

Annex 2 provides country-by-country profiles of the status of hypertension.
Hypertension is a serious, chronic medical condition that increases mortality from cardiovascular and kidney disease. It occurs when the pressure in blood vessels is too high (12). Blood pressure is created by the force of blood pushing against the walls of blood vessels (arteries) as it is pumped by the heart. The higher the pressure, the harder the heart must pump and the more damage this excess pressure causes to many parts of the body, especially the brain, heart and kidneys (13).

Consideration of the burden of high blood pressure, including hypertension, involves looking at it from different angles, using different types of data and statistical methods. Table 1 lists key terms and their definitions used in this section to build up as complete a picture as possible. There is further discussion of the source of the data used in this section, and suggestions for ways in which Member States can improve data collection on hypertension, in Section 2.7.

<table>
<thead>
<tr>
<th><strong>Table 1. Key terms and their definitions used for monitoring blood pressure and hypertension in populations</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Hypertension prevalence</strong></td>
</tr>
<tr>
<td><strong>Numerator:</strong> systolic blood pressure (SBP) ≥140 mmHg or diastolic blood pressure (DBP) ≥90 mmHg or taking medication for hypertension</td>
</tr>
<tr>
<td><strong>Denominator:</strong> adults aged 30–79 years</td>
</tr>
<tr>
<td><strong>Uncontrolled hypertension prevalence</strong></td>
</tr>
<tr>
<td><strong>Numerator:</strong> SBP ≥140 mmHg or DBP ≥90 mmHg</td>
</tr>
<tr>
<td><strong>Denominator:</strong> adults aged 30–79 years</td>
</tr>
<tr>
<td><strong>Diagnosis coverage</strong></td>
</tr>
<tr>
<td><strong>Numerator:</strong> has hypertension and has received previous hypertension diagnosis</td>
</tr>
<tr>
<td><strong>Denominator:</strong> adults aged 30–79 with hypertension, as defined above</td>
</tr>
<tr>
<td><strong>Treatment coverage</strong></td>
</tr>
<tr>
<td><strong>Numerator:</strong> has hypertension and is taking medication for hypertension</td>
</tr>
<tr>
<td><strong>Denominator:</strong> adults aged 30–79 with hypertension, as defined above</td>
</tr>
<tr>
<td><strong>Effective treatment coverage</strong></td>
</tr>
<tr>
<td><strong>Numerator:</strong> has controlled hypertension: taking medication for hypertension and SBP &lt;140 mmHg and DBP &lt;90 mmHg</td>
</tr>
<tr>
<td><strong>Denominator:</strong> adults aged 30–79 with hypertension, as defined above</td>
</tr>
<tr>
<td><strong>High systolic blood pressure</strong></td>
</tr>
<tr>
<td>The concept of high SBP is used for comparative risk assessment (3). It refers to any SBP above the theoretical minimum risk level, estimated to be at 110–115 mmHg.</td>
</tr>
</tbody>
</table>
2.1 The global prevalence of hypertension

For the purpose of monitoring population health, hypertension is defined as having systolic blood pressure (SBP) ≥140 mmHg or diastolic blood pressure (DBP) ≥90 mmHg or taking medication for hypertension (Table 1). Hypertension is estimated to affect 33% of adults aged 30–79 worldwide (age-standardized estimate) (4).

Blood pressure and hypertension prevalence increase with age. In this report, prevalence estimates are age-standardized to ensure that comparisons between populations with different proportions of younger and older adults are not affected by their respective age structures.

*Blood pressure and hypertension prevalence increase with age. In this report, prevalence estimates are age-standardized to ensure that comparisons between populations with different proportions of younger and older adults are not affected by their respective age structures.*

*All hypertension, hypertension coverage and uncontrolled hypertension estimates in this section are from, or are calculated from, the estimates produced by the NCD Risk Factor Collaboration (NCD-RisC) (1), which are also available from the Global Health Observatory (GHO) (4).*
Prevalence of hypertension is similar across groups of countries defined by income level (14), with only a slight difference from 32% of adults aged 30–79 years in high-income countries to 34% in low-income countries. Regional and country variability is more notable. Regional variation ranges from 28% in the WHO Western Pacific Region to 38% in the WHO Eastern Mediterranean Region (Table 2). At the country level, 29 countries (out of 192 with data) distributed across all WHO regions and country income groups have a prevalence below 30%, and 27 countries in all income groups and all WHO regions except the WHO South-East Asia Region have a prevalence above 45% (Fig. 2).

Note: for further explanation of controlled and uncontrolled hypertension see Table 1. The sum of controlled hypertension and uncontrolled hypertension is hypertension.

Globally, the prevalence of hypertension is slightly higher among males (34%) than females (32%). This female advantage is age-related: the global age-standardized prevalence of hypertension among people aged 30–49 years is 19% for women versus 24% for men. This pattern of lower hypertension prevalence among women aged under 50 years holds in most countries worldwide. However, for people aged 50–79 years, both men and women globally are estimated to have equivalent hypertension prevalence of 49%.

Globally, the estimated age-standardized prevalence of hypertension changed little from 1990 to 2019, increasing from 32% to 33%. Hypertension prevalence declined in high-income countries (from 38% in 1990 to 32% in 2019) and in the WHO European Region (from 45% in 1990 to 37% in 2019). These declines were offset by slight to moderate increases in other regions, including the WHO Western Pacific Region (24% to 28%) and the WHO South-East Asia Region (29% to 32%).

However, the total number of adults in the world is increasing as a result of population growth and because the age structure of the population is shifting, with older groups accounting for a larger proportion of the total population. Since the rate of hypertension increases with age, these two trends are increasing the number of adults aged 30–79 years with hypertension. The number of adults with hypertension doubled from 650 million in 1990 to 1.3 billion in 2019 (Fig. 3).

About 78% of adults with hypertension live in low- and middle-income countries (LMICs). The greatest number of people with hypertension live in the most populous WHO regions: Western Pacific Region and South-East Asia Region.

Table 2. Age-standardized prevalence of hypertension among adults aged 30–79 years, and among those with hypertension, diagnosis, treatment and effective treatment coverage in 2019, by WHO region

<table>
<thead>
<tr>
<th>Region</th>
<th>Hypertension (%)</th>
<th>Diagnosis coverage (%)</th>
<th>Treatment coverage (%)</th>
<th>Effective treatment coveragea (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>African</td>
<td>36 (38, 33)</td>
<td>43 (46, 39)</td>
<td>27 (30, 24)</td>
<td>12 (14, 9)</td>
</tr>
<tr>
<td>The Americas</td>
<td>35 (38, 33)</td>
<td>70 (73, 67)</td>
<td>60 (64, 57)</td>
<td>36 (41, 32)</td>
</tr>
<tr>
<td>South-East Asia</td>
<td>32 (36, 29)</td>
<td>39 (44, 34)</td>
<td>30 (34, 25)</td>
<td>14 (18, 10)</td>
</tr>
<tr>
<td>European</td>
<td>37 (39, 35)</td>
<td>66 (69, 63)</td>
<td>53 (56, 50)</td>
<td>26 (29, 23)</td>
</tr>
<tr>
<td>Eastern Mediterranean</td>
<td>38 (41, 35)</td>
<td>49 (53, 45)</td>
<td>39 (43, 34)</td>
<td>15 (19, 13)</td>
</tr>
<tr>
<td>Western Pacific</td>
<td>28 (32, 25)</td>
<td>54 (59, 48)</td>
<td>41 (47, 35)</td>
<td>18 (23, 14)</td>
</tr>
<tr>
<td>Global</td>
<td>33 (35, 32)</td>
<td>54 (56, 51)</td>
<td>42 (45, 40)</td>
<td>21 (23, 19)</td>
</tr>
</tbody>
</table>

a. Controlled hypertension among all hypertension. Controlled hypertension is defined as blood pressure <140 mmHg systolic and <90 mmHg diastolic and taking medication for hypertension.

Note: Data in parentheses are 95% uncertainty intervals.

Source: Global Health Observatory (GHO). Noncommunicable diseases: risk factors [online database].
2.2 Risk factors for age-related increase in blood pressure

Many factors contribute to the age-related increase in blood pressure that is common in most countries, although the exact causes remain unknown. Genetics undoubtedly play a role, but their specific contribution remains unclear. Several general environmental exposures can also contribute to increases in blood pressure, including pollution \(^{(16, 17)}\), very cold temperatures and extreme elevations in altitude \(^{(18)}\). However, the main contributors seem to be personal environmental exposures such as poor-quality diet high in sodium and low in potassium, overweight and obesity, consumption of alcohol, use of tobacco and physical inactivity \(^{(19)}\).

More than three-quarters of adults with hypertension live in LMICs.

Fig. 3. Number of adults aged 30–79 years with hypertension, by region and year, 1990 and 2019

Notes: The area of each circle is proportional to the number of adults with hypertension in the region. m: millions.

Source: NCD Risk Factor Collaboration (NCD-RisC) \(^{(1)}\) and additional calculations.

The global burden of hypertension
2.3 Status of hypertension care

Among adults aged 30–79 years with hypertension, an estimated 54% have been diagnosed with hypertension, 42% are being treated for their hypertension, and 21% have had their hypertension controlled (see Table 2 for confidence intervals). Diagnosis, treatment, and effective treatment coverage varies by sex, region and country income level. In every region and in all but four countries, women with hypertension were more likely to be treated than men (Fig. 4). Globally, the percentage of women with hypertension who are currently being treated is estimated to be 47%, compared with only 38% of men. The same gender pattern holds for the likelihood of being diagnosed and the likelihood of having controlled hypertension.

Treatment coverage varies by WHO region and country income level. Treatment coverage is highest in the Region of the Americas (60%) and lowest in the African Region (27%). Treatment coverage tends to be higher in wealthier countries. In low-income countries, only 26% of adults with hypertension were receiving treatment vs 58% in high-income countries. Nevertheless, some middle-income countries have achieved treatment coverage as high as the best-performing high-income countries (Fig.5).

Fig. 4. Hypertension treatment cascade in 2019, for adults 30–79 years of age globally, by sex. Age-standardized rates

Source: NCD Risk Factor Collaboration (NCD-RisC) (1).
The rate of effective treatment coverage, or hypertension control (out of those with hypertension), follows similar patterns to treatment coverage: rates are highest in high-income countries (36%) and the Region of the Americas (36%) and lowest in low-income countries (11%) and the African Region (12%).

Among those with uncontrolled hypertension who had not previously been diagnosed, globally nearly 30% have systolic blood pressure measurements $\geq 160$ mmHg or diastolic blood pressure measurements $\geq 100$ mmHg. This is significantly higher than the threshold for hypertension (SPB $\geq 140$ mmHg, DPB $\geq 90$ mmHg), and indicates an urgent need for treatment.

Fig. 5. Percentage of adults aged 30–79 years currently being treated (taking medication) for their hypertension in 2019, out of those with hypertension, by country, sex, and country income group

Source: NCD Risk Factor Collaboration (NCD-RisC) (1).

The global burden of hypertension
2.4 Uncontrolled hypertension and progress toward the 2025 target

The voluntary global target on blood pressure, endorsed by the Sixty-sixth World Health Assembly in 2013, envisages a 25% reduction in raised blood pressure (uncontrolled hypertension) by 2025 against a 2010 baseline (20). Uncontrolled hypertension is defined as systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg. It includes individuals who have not been diagnosed with hypertension and those who have been diagnosed but are not on treatment or whose blood pressure is not controlled despite treatment (Fig. 6).

Globally, the prevalence of uncontrolled hypertension declined slightly from 29% in 2010 to 26% in 2019, but this rate of decline is insufficient to achieve the voluntary global target of 21% (a 25% relative decline 2010–2025). Improving systems in order to provide effective treatment to about half of the adults who have already been diagnosed with hypertension would be sufficient to meet the target. Although no WHO region or country income group is on track to meet the target, a handful of countries are on track.\(^1\)

---

\(^1\) Target prevalence was computed on unrounded prevalence estimates, and then rounded.

\(^2\) WHO/NCD-RisC estimates (1, 4) were projected to 2025 as described in WHO NCD Accountability Framework, including Global Monitoring Framework for NCD prevention and control (2021 update), in alignment with the extension of the NCD Global Action Plan to 2030.

---

Fig. 6. Global prevalence of uncontrolled hypertension, by category among adults aged 30–79 years of age, and the voluntary global target for uncontrolled hypertension (raised blood pressure) for 2025

Note: The 2025 voluntary global target is to reduce prevalence of raised blood pressure (uncontrolled hypertension) from 2010 levels by 25% by 2025. Estimates are age-standardized values for adults aged 30–79 years.

Source: NCD Risk Factor Collaboration (NCD-RisC) (1) and additional calculations.
2.5 Trends in hypertension care

As described above, global hypertension prevalence changed little from 1990 to 2019. Although declines in the prevalence of hypertension were observed in high-income countries and in the WHO European Region, these were offset by small increases in other regions. Nevertheless, detection, treatment and control of hypertension improved globally in all WHO regions and country income levels between 1990 and 2019 (Fig. 7).

Globally, treatment coverage – the percentage of adults aged 30–70 years with hypertension who were taking medication for their hypertension – increased from 22% in 1990 to 42% in 2019 (age-standardized estimates). Effective treatment coverage is estimated to have quadrupled from 5% to 21% in three decades.

A pharmacist preparing medicine at a hospital in Ethiopia.
Fig. 7. Trends in age-standardized prevalence of hypertension, 1999–2019, disaggregated by control, treatment, and diagnosis status

<table>
<thead>
<tr>
<th>Region</th>
<th>Adult Prevalence (%)</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>1990</td>
</tr>
<tr>
<td><strong>High-income</strong></td>
<td></td>
<td>1990</td>
</tr>
<tr>
<td>African Region</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Region of the Americas</td>
<td></td>
<td></td>
</tr>
<tr>
<td>South–East Asia Region</td>
<td></td>
<td></td>
</tr>
<tr>
<td>European Region</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Western Pacific Region</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Global</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Upper-middle-income</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>African Region</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Region of the Americas</td>
<td></td>
<td></td>
</tr>
<tr>
<td>South–East Asia Region</td>
<td></td>
<td></td>
</tr>
<tr>
<td>European Region</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Western Pacific Region</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Global</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Lower-middle-income</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>African Region</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Region of the Americas</td>
<td></td>
<td></td>
</tr>
<tr>
<td>South–East Asia Region</td>
<td></td>
<td></td>
</tr>
<tr>
<td>European Region</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Western Pacific Region</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Global</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Low-income</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>African Region</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Region of the Americas</td>
<td></td>
<td></td>
</tr>
<tr>
<td>South–East Asia Region</td>
<td></td>
<td></td>
</tr>
<tr>
<td>European Region</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Western Pacific Region</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Global</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Source: NCD Risk Factor Collaboration (NCD-RisC) (1) and additional calculations.
2.6 Deaths due to high systolic blood pressure

Hypertension increases mortality from cardiovascular diseases and kidney disease. In fact, high blood pressure increases risk of death even when systolic blood pressure is in the 115 to 130 mmHg range, which is below the threshold for treatment of hypertension in most guidelines (21, 22, 23). Calculating additional mortality due to high blood pressure compared to a theoretical level which results in the lowest mortality risk – called the “theoretical minimum risk level” – can give an idea of the impact of high blood pressure on population mortality (24). While the theoretical minimum risk level may not be achievable given current interventions, comparing multiple risk factors to their theoretical minimum risk levels allows a comparison of how these risks affect populations.

When considered in this framework, high systolic blood pressure (i.e. ≥110–115 mmHg) is the world’s leading risk factor for mortality, causing more deaths than any other behavioural, metabolic or environmental risk factor assessed (3). If all adults in the world had a theoretical minimum risk-level systolic blood pressure in 2019 (estimated as 110–115 mmHg), about 19% of all deaths worldwide (10.8 million) would have been averted in that year (Fig. 8, Fig. 9).

If all adults had 110–115 mmHg SBP in 2019, about 19% of deaths would have been averted in that year.

High systolic blood pressure is responsible for one in every five deaths.

Fig. 8. Percentage of global deaths attributable to high systolic blood pressure (1990 and 2019), by cause of death

Fig. 9. Deaths attributable to high systolic blood pressure (1990 and 2019), by WHO region

Source: Global Burden of Disease Collaborative Network (25) and additional calculations.
Globally, in 2019, more than half of all cardiovascular deaths were attributable to high systolic blood pressure – including all deaths from hypertensive heart disease, 53% of ischaemic heart disease deaths, and 53% of stroke deaths (25). In addition, 62% of deaths from chronic kidney disease are attributed to high systolic blood pressure. Together, these deaths from high systolic blood pressure comprise 18% of male deaths and 20% of female deaths. Although 62% of deaths attributed to high systolic blood pressure occur among adults aged 70 and over, 38% – 4 million deaths – occur in adults under the age of 70 years. This proportion is even higher in LMICs, in which 42% of deaths attributable to high blood pressure are among people younger than age 70.

High systolic blood pressure affects people in all geographic regions and at all country income levels. Even in low-income countries, 11% of deaths are caused by higher-than-ideal systolic blood pressure. This increases to 24% of deaths in upper-middle-income countries. Altogether, more than 80% of deaths attributed to high systolic blood pressure occur in low- and middle-income countries (14).

High systolic blood pressure is also a leading risk factor for disease burden when considering years of life lived in ill health and age at time of death, causing 9% of disability-adjusted life years (DALYs; 235 million) (25).

2.7 Data used to monitor hypertension and hypertension treatment

Strong health information systems that enable the continuous and systematic collection of data on hypertension – and the analysis, interpretation and dissemination of that data – are crucial in the race against hypertension. Only with such comprehensive information on the burden of hypertension – including its underlying determinants and risk factors – can health ministries devise effective prevention and treatment strategies and monitor their progress. And only with such information can an accurate assessment be made of the problem presented by hypertension at the regional and global level.

Effective surveillance of hypertension relies on multiple sources of data: death registration data that include cause of death, population-based surveys, and health-facility data.

Recording the cause of every death is the most fundamental source of information for tracking the health of populations. Calculating the burden of mortality due to hypertension requires information on deaths from cardiovascular diseases and kidney diseases, together with health examination survey data on the distribution of blood pressure levels in the population.

Although hypertension is diagnosed at a primary health care facility, in most cases, health facility data cannot be used for determining hypertension
coverage and control in the total population. Instead, data on hypertension prevalence, diagnosis, treatment and control needs to be captured in population-based surveys.

Systematic population surveys of blood pressure status, previous diagnosis and treatment is essential if Member States are to address the prevalence and distribution of hypertension, and design targeted and effective prevention and control strategies to mitigate the impact of hypertension on individuals and communities. In these surveys, such as the WHO STEPwise approach surveys (STEPS) (26), blood pressure is measured, and diagnosis and treatment are reported by individuals. Respondents are considered to be receiving treatment if they report taking medication for hypertension, and to have their blood pressure controlled if, in addition, their systolic blood pressure is <140 mmHg and diastolic is <90 mmHg.

However, survey data are not available for every Member State, or for every year. A median of only one nationally representative data source per Member State (since 2010) was identified for the estimates presented in this report. To make country estimates, national data were used together with subnational data. These data were then combined in a statistical model that borrows strength from other time periods and countries to make estimates for every country and year.

Survey data are limited, as hypertension diagnosis is typically confirmed between one and three weeks after an initial measurement; identification of undiagnosed hypertension within a survey carried out in one day may misclassify some individuals.

Hypertension monitoring systems in primary health care are vital, as these take place during the patient’s first point of contact with integrated, comprehensive and continuous care. Tracking data in these services, ideally electronic, can play a pivotal role in monitoring and guiding improvements in service quality and coverage, patient outcomes and overall public health. WHO has strengthened guidance on facility-based patient monitoring through the Noncommunicable disease facility-based monitoring guidance, which includes a comprehensive framework and list of indicators, including the indicators for hypertension (27).

Regular monitoring of the health governance and infrastructure within a Member State is also of paramount importance in ensuring a strong and efficient response to hypertension in that it allows policy-makers and stakeholders to assess the capacity of the system to address hypertension.

Monitoring the health infrastructure ensures that facilities are adequately equipped, maintained, and staffed to meet the hypertension-related needs of the population. This process also assists in addressing disparities in access to
health care and in strengthening health care systems’ resilience during emergencies. Ultimately, continuous monitoring of health governance and infrastructure plays a vital role in fostering a robust health care system, capable of providing optimal health outcomes and well-being for the entire population.

2.8 Summary

• High systolic blood pressure is the world’s leading risk factor for mortality.
• Hypertension affects one in three adults and presents with no symptoms – the “silent killer”. Almost half of people with hypertension are unaware of their condition.
• Over the past three decades, the number of adults aged 30–79 years living with hypertension has doubled to an estimated 1.3 billion. More than three-quarters of adults with hypertension live in LMICs.
• Only about one in five people with hypertension have controlled their hypertension.
• The world is not on track to meet the voluntary global target of a 25% reduction in the prevalence of raised blood pressure (uncontrolled hypertension) by 2025.
• Comprehensive data, including population-based surveys and death registration data, are essential to monitor hypertension in countries.
• Monitoring the performance of health governance and infrastructure assists in the creation of a robust health care system, capable of addressing pervasive health problems such as hypertension.
Pharmacological treatment of hypertension is not new; drugs that treat hypertension have been around since the 1950s (28), and improved population blood pressure has been responsible for at least 20% of the decline in cardiovascular disease mortality in high-income countries over the past four decades (29).

Section 5 will demonstrate that hypertension management is a core element of primary health care, and that a practical, simple hypertension treatment approach quickly leads to improved hypertension control. Unfortunately, most health systems in LMICs were designed to provide episodic care for acute problems or routine services such as immunization, and not to provide care for lifelong, chronic conditions such as hypertension (30). As a result, effective coverage of hypertension care globally is low, with four out of five people with hypertension not having controlled blood pressure (1).

Providing drugs to adults with asymptomatic elevation in blood pressure rarely captures hearts and minds in the same way as some health problems do, but ignoring a public health problem as enormous as hypertension can cause huge strains on health systems over the long term because of costly downstream cardiovascular care demands that could have been avoided with preventive care. Section 5 highlights the WHO HEARTS technical package (31), which provides specific tools for planners and providers, including simple protocols for screening and treatment. We now have evidence that implementation of HEARTS in several demonstration sites across Latin America and the Caribbean, South and East Asia, Europe and sub-Saharan Africa raises hypertension control substantially, and that programmes can be scaled up relatively quickly if there is political and financial commitment. However, hypertension programme coverage and blood pressure control are only steps along the way to the ultimate goal of saving lives by preventing and treating hypertension. This section of the report makes the case for investing in hypertension control by exploring the potential health and economic benefits of implementing HEARTS recommendations worldwide.
3.1 Health benefits of hypertension prevention and control programmes

Decades of robust clinical trials have established the efficacy and safety of hypertension treatment. Numerous systematic reviews have summarized this evidence in guidelines (32). This section focuses on the impact of hypertension treatment on preventing future incident cardiovascular disease. A 2016 meta-analysis looked at this issue, and the evidence for risk reduction at different levels of blood pressure elevation (i.e. stages of hypertension). Overall, cardiovascular risk declines by 20% for every 10-mmHg reduction in systolic blood pressure, though the reduction is somewhat larger for stroke and hypertensive heart failure as compared to ischaemic heart disease, and there is a trend towards greater reductions among those with more severe hypertension. Table 3 summarizes the pooled effect sizes for these subgroups (33).

Using this evidence and recent experience with the HEARTS country demonstration programmes, a modelling study in 2022 assessed the potential impact of scaling up hypertension treatment coverage (34). For this section of the report the findings of that study were updated in several important ways:

- Cardiovascular mortality inputs were updated using the 2019 Global Health Estimates (35).

Table 3. Impact of a 10-mmHg reduction in blood pressure on risk of different cardiovascular outcomes and by level of blood pressure elevation

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Relative risk per 10 mmHg reduction in blood pressure (95% confidence interval)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>By type of cardiovascular outcome</strong></td>
<td></td>
</tr>
<tr>
<td>Ischaemic heart disease</td>
<td>0.83 (0.78 - 0.88)</td>
</tr>
<tr>
<td>Stroke</td>
<td>0.73 (0.68 - 0.77)</td>
</tr>
<tr>
<td>Heart failure</td>
<td>0.72 (0.67 - 0.78)</td>
</tr>
<tr>
<td><strong>By level of blood pressure elevation for the composite outcome of major cardiovascular events</strong></td>
<td></td>
</tr>
<tr>
<td>130–139mmHg</td>
<td>0.87 (0.82 - 0.92)</td>
</tr>
<tr>
<td>140–149mmHg</td>
<td>0.79 (0.72 - 0.87)</td>
</tr>
<tr>
<td>150–159mmHg</td>
<td>0.80 (0.71 - 0.91)</td>
</tr>
<tr>
<td>160mmHg</td>
<td>0.74 (0.69 - 0.79)</td>
</tr>
</tbody>
</table>

a. Fatal and non-fatal myocardial infarction, sudden cardiac death, revascularization, fatal and non-fatal stroke, and fatal and non-fatal heart failure.

Note: data are from a meta-analysis by Ettehad and colleagues of large-scale blood-pressure-lowering trials (33).
The nonfatal outcomes of myocardial infarction, stroke, and heart failure were added.

Population health impact was summarized in disability-adjusted life years (DALYs).

The cost of hypertension treatment, and the economic impact of hypertension treatment, were added.

In quantifying the health and economic gains from hypertension control, this report follows the assumptions of three different scenarios: the “business as usual”, “progress” and “aspirational” scenarios (34), (for details see Annex 1).

- **Business as usual**: The hypertension cascade of care (including trends in treatment and control) continues to improve gradually into the future, according to rates of change observed in the recent past (1). This scenario shows what would happen if Member States continued to scale up hypertension treatment at their current rates with no additional effort to scale up interventions, and it serves as a comparator for the progress and aspirational scenarios.

- **Progress**: The hypertension cascade of care improves at rates observed historically in high-performing countries (e.g. South Korea, Canada, and

---

**Fig. 10. Required improvements in hypertension cascade of care to achieve 50% (progress scenario) or 75% (aspirational scenario) blood pressure control by 2050**

<table>
<thead>
<tr>
<th>Business as usual</th>
<th>Progress</th>
<th>Aspirational</th>
</tr>
</thead>
<tbody>
<tr>
<td>2023</td>
<td>2050</td>
<td></td>
</tr>
</tbody>
</table>

**Note:** Business-as-usual scenario data are based on NCD Risk Factor Collaboration (NCD-RisC) estimates (1). Given uncertainty about scale-up during the COVID-19 pandemic, the values for 2023 are assumed to be the same as for the NCD-RisC estimates for 2019. Improvements in the cascade by 2050 are extrapolated from annual rates of change in hypertension treatment and control, by country, over 2010–2019.
Improved global blood pressure control to ≥50% would avert 76 million cardiovascular deaths, 120 million strokes, 79 million myocardial infarctions, and 17 million cases of heart failure between 2023 and 2050. This scenario implies an acceleration of trends in improved access to quality hypertension care.

- **Aspirational**: Hypertension control accelerates to rates of improvement that are faster than observed historically in high-performing countries (for example, about 4% per year at intermediate levels of intervention coverage) but slower than the most successful global health programme: anti-retroviral drug therapy for HIV (about 5% per year).

The difference in projected health outcomes between the two “intervention scenarios” as compared to business as usual gives the deaths and nonfatal events averted. Fig. 10 illustrates how the cascade of care would evolve between 2023 and 2050 in the average Member State included in this analysis.

These improvements translate into a leftward shift in the population blood pressure distribution for the average Member State, illustrated in Fig. 11, so that most individuals with hypertension would have systolic blood pressure levels below 140 mmHg.

The consequences of these shifts on projected cardiovascular disease outcomes are shown in Table 4. The estimates are aggregated from 182 Member States that cover 98% of the world population. The figures are cumulative, beginning in 2023, when accelerations in hypertension care are assumed to start, and ending in 2050, the year in which nearly all Member States could feasibly achieve the targets specified in the progress and aspirational scenarios by replicating the successes of high-performing countries (34). Improved blood pressure control to ≥50% would avert 76 million cardiovascular deaths, 120 million strokes, 79 million myocardial infarctions, and 17 million cases of heart failure between 2023 and 2050.

**Fig. 11. Implications of improved hypertension care for global blood pressure distribution**

![Graph showing blood pressure distribution](image)

*Note: See notes for Fig. 10. In the progress scenario, improvements in hypertension treatment and control lead to a leftward shift in the population blood pressure distribution over time, which results in fewer incident and fatal cases of CVD. It was conservatively estimated that individuals whose blood pressure is newly controlled would have an SBP of 130–139 mmHg; some individuals will achieve greater reductions, so future population blood pressure levels will probably be more normally distributed.*
control would avert 76 million cardiovascular deaths, 120 million strokes, 79 million myocardial infarctions, and 17 million cases of heart failure between 2023 and 2050.

Better hypertension care would not only improve cardiovascular outcomes in the aggregate, but would also improve the distribution of these outcomes across Member States. Fig. 12 illustrates how the largest absolute reductions in cardiovascular mortality would be achieved in the least-developed countries, where mortality rates are the highest because of low access to care (36).

### Table 4. Cumulative health gains (2023–2050) from improved population blood pressure control

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Projected number (progress scenario)</th>
<th>Projected number (aspirational scenario)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nonfatal myocardial infarctions averted</td>
<td>79 million</td>
<td>140 million</td>
</tr>
<tr>
<td>Nonfatal strokes averted</td>
<td>120 million</td>
<td>200 million</td>
</tr>
<tr>
<td>Nonfatal cases of heart failure averted</td>
<td>17 million</td>
<td>31 million</td>
</tr>
<tr>
<td>Cardiovascular deaths averted</td>
<td>76 million</td>
<td>130 million</td>
</tr>
</tbody>
</table>

Note: Projections represent the difference in outcomes between the progress and aspirational scenarios as compared to the business-as-usual scenario, with results presented as the aggregate of 182 Member States. See Pickersgill et al. (34) for list of Member States included in the analysis.

### Fig. 12. Reductions in cardiovascular mortality inequalities resulting from improved blood pressure control

Note: The plots show the changes in probability of death from cardiovascular disease between ages 30 and 80 (i.e. CVD-specific 50q30), a modification of the Sustainable Development Goal 3.4 indicator (37) in the business-as-usual and two intervention scenarios, disaggregated into the four World Bank income groups. LIC: low-income countries; LMIC: lower-middle-income countries; UMIC: upper-middle-income countries; HIC: high-income countries.
3.2 Costs and benefits of hypertension prevention and control interventions

Better access to hypertension care can provide obvious health benefits. It is also important to consider the costs and economic benefits of accelerated progress towards prevention and control of hypertension.

A recent systematic review summarized the findings of 71 studies on the cost and/or cost-effectiveness of hypertension treatment (38). While these studies employed a range of designs (including trials, cross-sectional analyses and modelling), together they provide a reasonably clear picture of the overall value for money in hypertension care.

There are large variations in the cost of hypertension treatment across countries. Differences in costing methods explain some of this variation, but a lot of the variation is due to different medication costs (38). The largest variations in prices among countries appear to be for ACE inhibitors and angiotensin II receptor blockers, especially in studies that looked at monotherapy with these agents.

A systematic review (38) identified 42 cost-effectiveness analyses conducted in 15 countries. Again, the studies reveal considerable variation in cost-effectiveness ratios, but most studies found that hypertension treatment cost less than US$ 1000 per DALY averted. In studies that stratified cost-effectiveness ratios by individual patients’ baseline cardiovascular risk, there was a trend towards better value for money in treating higher-risk subgroups. While this concept is not new (39), selectively treating high-risk hypertension might be impractical in real-world settings and raises important ethical problems in not giving treatment to patients with a life-threatening condition.

The incremental cost of scaling up hypertension care according to the assumptions of the progress scenario reported in Section 3.1 can be estimated using a range of studies. The cost of scaling up hypertension care would include the health system costs of implementing hypertension control programmes, including outpatient visit costs, costs of drugs and, the costs of delivering drugs. First, the cost of the drugs comes from the updated Appendix 3 of the Global action plan for the prevention and control of noncommunicable diseases (40, 41), specifically the intervention “Pharmacological treatment of hypertension in adults using either of the following: thiazide and thiazide-like agents; angiotensin-converting enzyme inhibitors (ACE-Is)/angiotensin-receptor blocker (ARBs); calcium channel blockers (CCBs)”. Including health care delivery costs, the average unit cost of hypertension care (drugs and delivery costs) across all 62 countries included in the analysis is Int$ 43 per person-year. With increased volumes and more efficient procurement, drug costs may be able to be reduced substantially.
The additional costs required to do population-based hypertension screening were calculated using default data on typical screening programme costs from the HEARTS costing tool (42). However, implementing a hypertension programme involves more than just the costs incurred at primary health care facilities. Health systems also need to be strengthened to provide screening and care. Estimates by a 2009 WHO task force were used to generate programme costs such as health management information systems, administration and financing (43). CHOICE estimates of the cost of strengthening supply chains were used to generate a markup for logistics (44). In total, the health system strengthening costs add 26% to the direct costs of service delivery.

The economic benefits from the progress scenario compared to the business-as-usual scenario were estimated by calculating the difference in the number of healthy life years remaining, based on estimates of fatal and nonfatal events averted, age-specific remaining life expectancy, and disability weights from the Global Burden of Disease Study. Following the human capital approach, the difference in DALYs averted were valued at the world average gross domestic product per capita, expressed in International Dollars.

Table 5 shows the results of the economic analysis. Achieving 50% population blood pressure control by 2050 (compared with the business-as-usual scenario) would cost about Int$ 660 per DALY averted, on average, which is comparable to some of the best investments in global health – including interventions for the “unfinished agenda” of communicable, perinatal and nutritional diseases (45). Overall, the economic benefits of hypertension control could outweigh these costs by nearly 18 to one.

Table 5. Total incremental costs and cumulative economic gains (2023–2050) from scenarios involving improved population blood pressure control compared to business-as-usual scenario

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Projected number (progress scenario)</th>
<th>Projected number (aspirational scenario)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Incremental costs (compared to current level of blood pressure control globally)</td>
<td>Int$ 300 billion</td>
<td>Int$ 630 billion</td>
</tr>
<tr>
<td>DALYs averted</td>
<td>450 million</td>
<td>720 million</td>
</tr>
<tr>
<td>Cost per DALY averted</td>
<td>Int$ 660</td>
<td>Int$ 870</td>
</tr>
<tr>
<td>Economic benefits</td>
<td>Int$ 5.3 trillion</td>
<td>Int$ 8.5 trillion</td>
</tr>
<tr>
<td>Benefit–cost ratio</td>
<td>18</td>
<td>14</td>
</tr>
</tbody>
</table>

Source: DALYs are calculated from World Population Prospects 2022 life tables (46) and average disability weights for different cardiovascular outcomes as reported in the Global Burden of Disease 2019 Study (47). Costs are taken from the Draft updated Appendix 3 to the Global action plan for the prevention and control of noncommunicable diseases (40), and are expressed in 2020 International Dollars. A DALY averted is valued at average global GDP per capita, also in International Dollars. The International Dollar is a hypothetical unit of currency that has the same purchasing power parity that the US dollar had in the United States of America at a given point in time. Costs and economic benefits are discounted at 3%.
The additional resources required to achieve these two scenarios would be considerable. The progress scenario would require an average of US$ 6.7 billion annually worldwide. The aspirational scenario would require an average of US$ 14 billion annually worldwide. Achieving the greater population health benefits of the aspirational scenario would cost more, but could generate significant returns (14 to one).

### 3.3 Summary

- If countries mobilize to achieve the goal of 50% population hypertension control by the year 2050, 76 million cardiovascular deaths and 450 million DALYs would be avoided.
- Though the costs of achieving 50% blood pressure control are substantial, the economic benefits generated are estimated to be 18 times greater than business as usual.

---

1 These costs are presented in US dollars rather than International Dollars since they represent the value of the monetary transactions that would be required to finance hypertension programmes worldwide. They are different from the incremental cost estimates in International Dollars in Table 6, which are discounted at 3% to construct cost-effectiveness and benefit–cost ratios.
Risk factors for hypertension

4.1 Population-based hypertension risk factors

The WHO Guideline for the pharmacological treatment of hypertension in adults notes the importance of addressing noncommunicable disease risk factors, such as a diet high in sodium and low in potassium, the consumption of alcohol and physical inactivity, in both the treatment and the prevention of hypertension (8).

This section presents some risk factors for hypertension, with the limitation that systematic reviews may not have been conducted for all of the approaches presented below.

4.1.1 Dietary sodium

Consuming a healthy diet throughout the life-course helps to prevent and control hypertension. The exact make-up of a diversified, balanced and healthy diet will vary, depending on individual characteristics, cultural context, locally available foods and dietary customs. However, the basic principles of what constitutes a healthy diet remain the same (48).

For hypertension specifically, reducing sodium and eating a diet that includes lots of fibre, such as wholegrain rice, bread and pasta, and plenty of fruit and vegetables high in potassium and nitrates also helps lower blood pressure (49).

Excess sodium intake increases blood pressure. Of all the deaths from cardiovascular causes that occurred in 2019, almost 2 million were attributed to sodium consumption that results in 24-hour urinary sodium excretion above the reference level of 1 to 5 grams per day (3). This is a larger number than from any other dietary factor (50).

Fortunately, blood pressure is reduced when dietary sodium intake is reduced and when potassium intake is increased. Reducing sodium intake is one of the most cost-effective ways to improve health, as it can avert many cardiovascular events and deaths at very low total programme costs (51). In 2011, the United Nations General Assembly adopted a political declaration that committed Member States to the prevention and control of noncommunicable diseases. A reduction in sodium intake was noted as one of the top priority actions, and a 30% reduction in sodium intake by 2025, with an eventual target of <2000 mg/day worldwide, was adopted in 2013.
The global average sodium intake is estimated to be 4310 mg/day (10.78 g of salt per day)\(^{(50)}\), which far exceeds the physiological requirement and is more than double the WHO recommendation of <2000 mg/day of sodium (equivalent to <5 g of salt) in adults. WHO regional sodium estimates range from 2687 mg/day (6.7 g/day salt) in the WHO African Region to 6247 mg/day (15.6 g/day salt) in the WHO Western Pacific Region. In many high-income countries, and increasingly in LMICs, a significant proportion of sodium in the diet comes from processed foods such as bread, cereal and grains, processed meats and dairy products \(^{(50)}\).

**Sodium reduction policies and other measures**

WHO provides several sodium-related best-buy policies as practical actions that should be undertaken immediately, to prevent cardiovascular disease and its associated costs \(^{(40)}\).

These include:

- lowering sodium content in food products;
- implementing front-of-pack labelling to help consumers select food products with lower sodium content;
- conducting mass-media campaigns to alter consumer behaviour around sodium; and
- implementing public food procurement and service policies to reduce sodium content in food served or sold.

**Box 1: Population sodium reduction programme**

**Shandong Province, China**

The Shandong Ministry of Health Action on Salt and Hypertension (SMASH) programme was a government-led initiative aimed at curbing salt intake and reducing the prevalence of hypertension among adults. The programme employed various strategies, including a media campaign, distribution of scaled salt spoons and public education activities.

The results of the programme were remarkable, with a significant 24.8% reduction in sodium intake observed over a five-year period. This decrease was measured through 24-hour urine sodium excretion, which dropped from 5338 mg/day to 4013 mg/day. Additionally, potassium excretion increased by 15.1%, and the sodium to potassium ratio decreased by 37.7%, indicating positive dietary changes. Beyond decreased sodium consumption, the SMASH programme demonstrated downstream improvement in blood pressure levels. The adjusted mean SBP decreased by 1.8 mmHg, and the adjusted mean DBP decreased by 3.1 mmHg, most likely due to decreased sodium intake.

Alongside these physiological changes, the programme positively impacted systematically assessed knowledge, attitudes and behaviours related to sodium reduction and hypertension.

**Participants showed increased awareness of the recommended salt intake, paid more attention to the labelling on processed foods, and took action to reduce sodium in their diets.**
A moderate reduction in sodium intake and increase in potassium intake causes a significant reduction in blood pressure and can prevent millions of premature deaths. Potassium-enriched salt substitutes is an affordable strategy to reduce sodium and increase potassium intake simultaneously, with proven benefit to reduce blood pressure and prevent cardiovascular events (52).

WHO monitors country progress in making national commitments and taking a multifaceted approach to implementing policies to reduce sodium intake. The result is published as the Sodium Country Score Card (51). In 2023, just over a quarter (27.6%) of the world’s population lived in countries with any mandatory measures towards sodium reduction.

4.1.2 Alcohol consumption

Alcohol consumption ranked eighth among the mortality risks worldwide in 2019 (25, 3). The risks associated with alcohol use manifest in various ways, including injuries, liver toxicity and an increased risk of cancer.

The relationship between alcohol consumption and the incidence of coronary heart disease in different racial groups (53), along with other pieces of evidence, implies that the reduced risk observed among moderate drinkers of wine or other beverages could be attributed to a health cohort effect (54).

Although alcohol acutely lowers blood pressure, this is followed by a rebound increase a few hours after ingestion (55, 56). Furthermore, chronic alcohol consumption is linked to a high incidence of hypertension (57), even when consumed at low to moderate levels (58).

Due to the absence of clinical trials demonstrating alcohol’s beneficial impact on major cardiovascular events, and considering the risks of hypertension and other diseases, alcohol intake to promote cardiovascular disease prevention is not supported.

WHO introduced the SAFER initiative in 2018, in collaboration with partners. “SAFER” (59) is an acronym for the five most cost-effective interventions to reduce alcohol-related harm, and stands for the following interventions:

- **Strengthen restrictions on alcohol availability**
- **Advance and enforce drink driving counter measures**
- **Facilitate access to screening, brief interventions and treatment**
- **Enforce bans or comprehensive restrictions on alcohol advertising, sponsorship, and promotion**
- **Raise prices on alcohol through excise taxes and pricing policies.**

**Chronic alcohol consumption, even at low levels, is linked to a high incidence of hypertension.**
4.1.3 Tobacco use

Tobacco caused 8.7 million deaths globally in 2019, including 3.2 million deaths from cardiovascular diseases (60). The relationship between tobacco use and blood pressure is complex. While scientific evidence on the impact of tobacco use on chronic high blood pressure levels is inconclusive (61), tobacco smoking and exposure to secondhand smoke acutely exert a hypertensive effect, mainly through the stimulation of the sympathetic nervous system (62, 63, 64). Similarly, research has shown that smokeless tobacco use may acutely elevate blood pressure (65, 66, 67, 68). These and other effects of tobacco use not only reduce life expectancy amongst those who consume tobacco and are exposed to tobacco smoke but also adversely affect quality of life.

Cessation of tobacco use is the most effective lifestyle measure for the prevention of many cardiovascular diseases and may have significant benefits for hypertensive patients (8). The WHO Framework Convention on Tobacco Control (FCTC) (69) is an evidence-based treaty that reaffirms the right of all people to the highest standard of health. Based on a review of the evidence, the MPOWER package was introduced in 2008 by WHO as a technical package to help countries implement the cost-effective demand-reduction measures of the WHO FCTC. The MPOWER technical package is made up of the following measures.

- Monitoring tobacco use and prevention policies
- Protecting people from secondhand smoke
- Offering people help to quit
- Warning about the dangers of tobacco
- Enforcing tobacco advertising, promotion and sponsorship bans
- Raising taxes.

All MPOWER measures are part of the NCD “best-buy” interventions. The WHO best-buys are considered affordable, cost-effective and evidence-based interventions that can help tackle the global burden caused by noncommunicable diseases.

4.1.4 Physical inactivity

Physical activity promotes many physiological responses that result in lowered risk of hypertension due to beneficial short- and long-term autonomic and haemodynamic adaptations. There is strong evidence of an inverse relationship between physical activity and incidence of hypertension among adults with normal blood pressure, and that physical activity reduces blood pressure among adults with prehypertension and normal blood pressure (70).

Physical activity is associated with hypertension based on evidence that increased physical activity improves physical function and reduces
cardiovascular disease progression and mortality in people living with hypertension (71). For example, compared with control groups of people who do not exercise, people with hypertension who are physically active can reduce systolic blood pressure by approximately 12 mmHg and diastolic blood pressure by approximately 6 mmHg (72).

In addition, emerging evidence shows that people with hypertension who are physically active can significantly improve their health-related quality of life compared with those who are inactive (73). For adults living with hypertension, evidence supports aerobic activity, muscle-strengthening activity, and combinations of the two for improving cardiovascular disease progression (74).

Sedentary behaviour, on the other hand, and particularly for extended periods of time, is associated with higher all-cause mortality, cardiovascular mortality and cardiovascular disease incidence (74).

If the current prevalence of physical inactivity does not change, almost 240 million new, preventable cases of hypertension will occur globally from 2020 to 2030, which will place a burden of more than Int$ 115 billion on the public health care system (75).

The WHO toolkit ACTIVE, which was launched in 2019, proposes policy options that can be adapted and tailored to local cultures and contexts to help increase levels of physical activity globally (76). These include:

- the development and implementation of national guidelines for physical activity for all age groups;
• establishing national coordinating mechanisms involving all relevant government departments and key non-government stakeholders to develop and implement coherent and sustainable policy and actions plans;
• implementing community-wide communication campaigns to raise awareness and knowledge of the multiple health, economic and social benefits of being physically active;
• investing in new technologies, innovation and research to develop cost-effective approaches to increasing physical activity, particularly in low-resource contexts;
• ensuring regular surveillance and monitoring of physical activity and policy implementation.

Further WHO publications offering guidance for policy-makers and programme managers include:
• the Global action plan on physical activity (GAPPA) 2018–2030 (77), which sets out multiple policy actions to support people in being regularly active as part of work, transport (walking and cycling), recreation or play; and
• Promoting physical activity through primary health care: a toolkit, which promotes physical activity through brief counselling interventions in primary health care (78).

Many other interventions support and encourage physical activity, whether through promotion of walking and cycling, provision of public open space, or affordable and accessible digital programmes such as Be he@lthy, be mobile: a handbook on how to implement mobile health for physical activity (79).

4.1.5 Air pollution

Air pollution is one of the major risk factors for noncommunicable diseases (80); it accounts for an estimated 6.7 million deaths every year worldwide (81). Around the globe, 99% of the population is exposed to air quality that does not meet the levels recommended in the WHO global air quality guidelines (81) and 2.3 billion people globally relied primarily on polluting fuels and devices for cooking in 2021, which exposed them to dangerous levels of air pollutants, especially in LMICs where access to clean energy is still challenging (80, 82). The best indicator for estimating the health impacts of air pollution, fine particulate matter (PM$_{2.5}$), ranked fourth among mortality risks worldwide in 2019 (25). Cardiovascular diseases such as ischaemic heart disease and stroke are among the main diseases attributable to air pollution exposure (83). These are health outcomes for which hypertension is a well-known etiological factor. In addition, consolidated evidence shows an increased risk of high blood pressure in adults with each 10-µg/m$^3$ increase in long-term exposure to PM$_{2.5}$ (84, 85), while the evidence is limited and inconsistent for short-term exposure (86). Pre-existing conditions such as cardiovascular and respiratory diseases,
obesity, and low socioeconomic status increase the risk of experiencing the negative health effects of air pollution, particularly those related to PM$_{2.5}$.

While struggling to find consideration in most clinical guidelines, the burden of disease that can be attributed to air pollution should not be neglected by the public health community and it needs to be incorporated in guideline development, among other interlinked environmental and planetary health risk factors (87).

Improving air quality would constitute an opportunity for primary prevention of hypertension as well as other noncommunicable diseases. WHO has provided guidance on personal interventions and risk communication on air pollution (88), and training opportunities for the education of health professionals (89). Yet the major efforts needed to improve air quality remain to be addressed by countries and regions in reducing emissions of health-damaging air pollutants. WHO promotes interventions and initiatives for healthy sectoral policies (including energy, transport, housing, urban development and electrification of health care facilities), addressing key risks to health from air pollution indoors and outdoors, and contributing to achieving health co-benefits from climate change mitigation policies (90).

4.2 Summary

- About one-third of the world’s adults live with hypertension and are at risk of heart disease, stroke, or death.

- WHO supports the reduction of dietary sodium (and increase in potassium), the reduction of alcohol consumption, the control of tobacco use, the promotion of physical activity, and a reduction in air pollution to prevent hypertension.

- The most effective ways to control these hypertension risk factors is via large-scale, population-level public health programmes.
5.1 Clinical presentation of high blood pressure and hypertension

Because it is usually asymptomatic, hypertension has appropriately been labelled the “silent killer”; unless their blood pressure is measured, most people will be unaware of their condition until they have a clinical complication such as a heart attack, stroke or kidney failure.

Cohort studies and reports using electronic record linkage have both documented a strong, continuous and progressive association between systolic blood pressure and the risk of CVD (91, 92, 93). The association has been documented at all ages for both systolic blood pressure (SBP) and diastolic blood pressure (DBP), for all major forms of CVD, and throughout the entire range of blood pressure (from SBP as low as 115 mmHg) (94). Classic cohort studies have shown that, starting at a blood pressure of 115/75 mmHg, the risk of death from a heart attack or stroke at ages 35–69 doubles with every 20-point increase in systolic blood pressure (95). For most patients, lower blood pressure is better, down to the 115–120 mmHg range, although for clinical practice considerations, a target of <140/90 mmHg is most common.

The significance of high blood pressure as a risk factor for CVD is modified by the presence or absence of other CVD risk factors (96). As a result, the absolute risk associated with elevated blood pressure is much higher at an older age, when it is common to find high blood pressure accompanied by several other CVD risk factors. However, high blood pressure at younger ages is also harmful, since long-term studies show that damage to blood vessels accumulates over a lifetime (97). In addition to CVD, high blood pressure is associated with many other adverse outcomes, including kidney disease, cognitive impairment and dementia (94).

5.2 Diagnosis and early detection

The starting point for living well with hypertension is early diagnosis. The longer a person lives with undiagnosed and inadequately treated hypertension, the worse the health outcomes are likely to be. Easy and sustained access to basic validated automated blood pressure measuring devices in primary health care...
facilities is therefore essential, and diagnosis should be available in primary health care settings. Blood pressure measurements should be conducted by a trained staff member in a standardized way, with an appropriate cuff and the patient comfortably seated with their back supported, an empty bladder and legs uncrossed. It is efficient and acceptable to conduct two blood pressure readings at first and use results of the second reading to guide decisions about the need to schedule a follow-up visit to complete the diagnostic work-up.

If blood pressure is confirmed to be either ≥160 mmHg systolic or ≥100 mmHg diastolic on two readings on a single day, medications to reduce blood pressure should begin on that day. If blood pressure is in the 140–159 mmHg/90–99 mmHg range, the diagnosis of hypertension should be confirmed at an additional patient follow-up visit, usually 1 to 4 weeks after the first set of measurements.

In general, hypertension is diagnosed if, on the two visits:
- systolic blood pressure on both days is ≥140 mmHg and/or
- diastolic blood pressure on both days is ≥90 mmHg (98).

Counselling to improve diet, physical activity and other risk factors should be provided, but should not delay initiation of pharmacological treatment. Note that for people with pre-existing CVD and those without CVD but living with co-morbid diabetes, chronic kidney disease, or considered at high cardiovascular risk, the WHO Guideline for the pharmacological treatment of hypertension in adults (8) recommends also considering blood-pressure-lowering treatment if SBP is ≥130–139 mmHg. It is now clear that reducing blood pressure to lower levels provides additional benefits to essentially all patients.

5.2.1 Early detection of hypertension

Evidence supports the benefits of early diagnosis and effective treatment of hypertension, both because vascular disease results from cumulative exposure to high blood pressure, and because earlier screening reduces the lead time between diagnosis and treatment (99). The asymptomatic nature of high blood pressure also means that active clinical screening in the health care system is essential if the necessary treatment for hypertension is to be provided.

Screening for hypertension is only useful when it is closely linked to follow up at a health care facility able to measure blood pressure accurately and treat high blood pressure effectively. Many individuals with high blood pressure in a population screening setting do not meet the criteria for hypertension when they are more carefully evaluated on follow up. Also, many individuals are lost to follow up; in population screening programmes in countries around the world, effective follow up of patients with abnormal blood pressure is the exception rather than the norm, which is why detection in health care facilities is the priority to improve hypertension control.
Population screening programmes increase the number of clinically diagnosed cases of hypertension and, as such, will increase the workload in the health care system, not only in terms of the process of early detection but, more importantly, in dealing with the increased number of clinically diagnosed cases who will be identified and will require long-term, usually life-long, care (100). With prevalence rates close to a quarter of the adult population globally (1), no population screening system should be established without consideration of whether local health care resources are sufficient to cope with delivering standard hypertension treatment services to the large number of extra patients identified. Simply adding new cases to a health care system without expanding the capacity for treatment will, in the absence of compensating efficiencies, result in low-quality care unlikely to result consistently in adequate control of blood pressure (101).

It is recommended that blood pressure measurements be done “opportunistically”: that is, on adults during routine visits to primary health care facilities, including all adults at first presentation to the facility, and, if normal, periodically thereafter (e.g. annually). Every patient with elevated blood pressure readings requires immediate follow up for treatment. Population-based screening is not recommended as the primary method for detection and early diagnosis of hypertension (102).

5.3 Management of hypertension

5.3.1 Guideline for the pharmacological treatment of hypertension

In 2021, the World Health Organization launched its Guideline for the pharmacological treatment of hypertension in adults, which provides recommendations on the threshold for the initiation of pharmacological treatment for hypertension, recommendations for the basis on which to decide whether to initiate treatment with monotherapy, dual therapy or single-pill combinations, as well as guidance for countries selecting medicines and algorithms for hypertension control for their national guideline for hypertension management.

The guideline provides implementation targets, including those on intervals for follow up, target blood pressure to be achieved for control, and the cadre of health care workers who may initiate treatment. Lastly, the guideline provides examples of a drug- and dose-specific protocol for managing hypertension which can be adapted based on country context (8). A summary of the 2021 WHO guideline recommendations is provided in Table 6.

5.4 HEARTS for hypertension control

WHO and the United States Centers for Disease Control (CDC) launched the Global Hearts Initiative in 2016 (103), including the HEARTS: technical package for cardiovascular disease management in primary health care (104) to support
### Table 6. WHO guideline recommendations on the pharmacological treatment of hypertension in adults

<table>
<thead>
<tr>
<th>1. <strong>Recommendation on blood pressure threshold for initiation of pharmacological treatment</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>WHO recommends initiation of pharmacological antihypertensive treatment of individuals with a confirmed diagnosis of hypertension and systolic blood pressure of ≥140 mmHg or diastolic blood pressure of ≥90 mmHg.</td>
</tr>
<tr>
<td>WHO recommends pharmacological antihypertensive treatment of individuals with existing cardiovascular disease and systolic blood pressure of 130–139 mmHg.</td>
</tr>
<tr>
<td>WHO suggests pharmacological antihypertensive treatment of individuals without cardiovascular disease but with high cardiovascular risk, diabetes mellitus, or chronic kidney disease, and systolic blood pressure of 130–139 mmHg.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2. <strong>Recommendation on laboratory testing</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>When starting pharmacological therapy for hypertension, WHO suggests obtaining tests to screen for comorbidities and secondary hypertension, but only when testing does not delay or impede starting treatment.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>3. <strong>Recommendation on cardiovascular disease risk assessment</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>WHO suggests cardiovascular disease risk assessment at or after the initiation of pharmacological treatment for hypertension, but only where this is feasible and does not delay treatment.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>4. <strong>Recommendation on drug classes to be used as first-line agents</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>For adults with hypertension requiring pharmacological treatment, WHO recommends the use of drugs from any of the following three classes of pharmacological antihypertensive medications as an initial treatment:</td>
</tr>
<tr>
<td>1. thiazide and thiazide-like agents</td>
</tr>
<tr>
<td>2. angiotensin converting-enzyme inhibitors (ACEis)/angiotensin receptor blockers (ARBs)</td>
</tr>
<tr>
<td>3. long-acting dihydropyridine calcium channel blockers (CCBs).</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>5. <strong>Recommendation on combination therapy</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>For adults with hypertension requiring pharmacological treatment, WHO suggests combination therapy, preferably with a single-pill combination (to improve adherence and persistence), as an initial treatment. Antihypertensive medications used in combination therapy should be chosen from the following three drug classes: diuretics (thiazide or thiazide-like), angiotensin-converting enzyme inhibitors (ACEis)/angiotensin-receptor blockers (ARBs), and long-acting dihydropyridine calcium channel blockers (CCBs).</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>6. <strong>Recommendations on target blood pressure</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>WHO recommends a target blood pressure treatment goal of &lt;140/90 mmHg in all patients with hypertension without comorbidities.</td>
</tr>
<tr>
<td>WHO recommends a target systolic blood pressure treatment goal of &lt;130 mmHg in patients with hypertension and known cardiovascular disease (CVD).</td>
</tr>
<tr>
<td>WHO suggests a target systolic blood pressure treatment goal of &lt;130 mmHg in high-risk patients with hypertension (those with high CVD risk, diabetes mellitus, chronic kidney disease).</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>7. <strong>Recommendations on frequency of assessment</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>WHO suggests a monthly follow up after initiation or a change in antihypertensive medications until patients reach target.</td>
</tr>
<tr>
<td>WHO suggests a follow up every 3–6 months for patients whose blood pressure is under control.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>8. <strong>Recommendation on treatment by nonphysician professionals</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>WHO suggests that pharmacological treatment of hypertension can be provided by nonphysician professionals such as pharmacists and nurses, as long as the following conditions are met: proper training, prescribing authority, specific management protocols and physician oversight.</td>
</tr>
</tbody>
</table>
governments to strengthen the prevention and control of CVD and to facilitate achievements of the UN health-related SDG goals. The package is endorsed by 11 partner organizations: American Heart Association (AHA), Centre for Chronic Disease Control (CCDC), International Society of Hypertension (ISH), International Society of Nephrology (ISN), Pan American Health Organization, Resolve to Save Lives (RTSL), US CDC, World Heart Federation (WHF), World Hypertension League (WHL), WHO and World Stroke Organization (WSO). Hypertension control is a pathfinder for improved primary health care and universal health coverage.

The HEARTS technical package was launched in 2018 as the core technical package of the Global Hearts Initiative. The package is the public health approach to managing hypertension and other CVD risk factors, such as dyslipidaemia, at the primary health care level, with the aim of incorporating it into universal health coverage benefit packages. Six modules and an implementation guide make up the package: Healthy-lifestyle counselling, Evidence-based treatment protocols, Access to essential medicines and technology, Risk-based CVD management, Team-based care and Systems for monitoring (31).

The sections below will expand on each of these modules, highlighting relevant and country examples of contextualization and implementation.

### 5.5 Healthy lifestyle counselling

The WHO Guideline for the pharmacological treatment of hypertension in adults emphasises that non-pharmacological treatment is an important component of hypertension management. Smoking cessation, limiting use of alcohol, healthy diet and sufficient physical activity are advised for all newly diagnosed patients. An evidence-based diet to lower blood pressure in populations includes a lower-sodium diet and potassium-enriched foods. Recent evidence from China demonstrates that low-sodium, potassium-enriched cooking salts lower blood pressure and prevent stroke in people living with hypertension (52). However, the impact of diet and lifestyle changes is modest, as evidenced by primary-care-based trials that have demonstrated only a modest blood pressure-lowering effect (overall 1.3 mmHg lower systolic and 0.5 mmHg lower diastolic blood pressure) (105). Thus, nearly all people diagnosed with hypertension will continue to have uncontrolled blood pressure, despite making diet and exercise changes to lower blood pressure, and will have to take medications to keep their blood pressure controlled whilst still maintaining healthy lifestyles (106). Lifestyle changes may be considered as adjunctive therapy to antihypertensive medications, which will be essential in the care of nearly all patients diagnosed with hypertension.

Self-care may include making lifestyle changes, such as adopting a healthy diet and engaging in regular physical activity, as well as ensuring proper medication adherence and monitoring blood pressure.
Simple evidence-based treatment protocols for the treatment of individuals with hypertension increase treatment effectiveness and efficiency (107, 108). Recent guidelines (8) and successful hypertension control programmes (109) improved on early, complicated treatment guidelines, and advise treatment using a simple evidence-based protocol with a linear progression of treatment intensification steps and specific medicines and doses. Medications recommended in protocols are selected based on value (low cost and high efficacy), availability, infrequent adverse event rates, reduced need for laboratory monitoring, and once-daily dosing. An additional benefit of a simple protocol is that it also delineates the return visit time (usually four weeks or less) to allow for rapid up-titration of doses and medications until hypertension control is achieved. It is becoming increasingly clear that, in addition to the overarching goal of improved hypertension control rate within a population, goals such as

Box 2: Implementation of HEARTS

The roll-out of HEARTS across the world

The HEARTS technical package is being implemented in nearly 40 Member States. Approximately 35,000 facilities are implementing HEARTS. Regional programmes facilitate dissemination of best practices across countries within the region. Additionally, three regional programmes, HEARTS in the Americas (Pan American Health Organization/WHO), SEA-HEARTS (WHO South-East Asia Region) initiative and the Signature Initiative (WHO European Region), demonstrate the accelerated commitments and movements to scaling up HEARTS.

Over 17.4 million patients are now enrolled in a contextualized HEARTS hypertension management programme and are being treated according to standardized treatment.
reduced time to control and longer time kept under control also result in prevented events related to CVDs. A simple evidence-based treatment protocol for hypertension clarifies the treatment steps for patient and clinician, and helps reduce therapeutic inertia (a tendency not to act to intensify treatment despite blood pressure remaining uncontrolled).

Developing and adopting a standardized and evidence-based simple treatment protocol has additional programme implementation benefits. Training activities will be more efficient and simplified, as treatment becomes more standardized using a shared protocol. Because protocols identify a shortlist of between two and three preferred medicines, medicine procurement,

---

**Box 3: Incorporating WHO guideline into simple treatment protocol**

**Sri Lanka’s adaptation of the WHO guideline**

In Sri Lanka, 35.6% of adults have hypertension and 15.5% of them have their blood pressure under control (110). To tackle this burden, the Sri Lanka Ministry of Health began implementing the WHO HEARTS technical package for hypertension control in 2021. Along with key stakeholders, it developed a simple hypertension treatment protocol based on recommendations from the 2021 WHO *Guideline for the pharmacological treatment of hypertension in adults*. This was adapted to the Sri Lankan context with the introduction of a two-part protocol: for all adults aged 18–79 years old the five-step protocol follows the WHO recommendation to initiate therapy with a dual drug combination (Fig. 13), whereas for patients over 80 years old, the seven-step protocol recommends initiating treatment with an initial amlodipine monotherapy to avoid potential side-effects in elderly patients.

By 2023 the treatment protocol covered a population of 96,900 adults in Kalutara district and had registered 8,600 patients in the programme; the cross-sectional facility-based blood pressure control rate was 57%.

The programme has a high retention rate – 86% of adults in the programme are returning for care every three months, which contributes in part to the high programme control. Lessons learned from the demonstration project include the ease of training on, and implementation of, a simple treatment protocol, the feasibility of treating hypertension at primary care level, success with referring to higher levels of care when needed, and the straightforward monitoring of patient progress to blood pressure control due to clear blood pressure control goals.

**Due to the success of the demonstration project, the programme will be expanded to a new district and then scaled up nationally.**

---

Fig. 13. Simple hypertension treatment protocol, Sri Lanka, 2021–present
inventory, forecasting, and supply chain can all be simplified. Because most patients should receive similar, standardized care for hypertension, attention to known health disparities can be assessed and addressed.

The process of generating wide consensus to develop, select or adapt a hypertension treatment protocol can catalyse launching, or recommitting to, hypertension control in the community adopting the protocol. Participants often include clinical leaders and multidisciplinary teams, consisting of academic leaders, medical system administrators, pharmacy and equipment procurement experts, clinicians (such as primary care clinicians, family physicians, cardiologists, internal medicine physicians and nephrologists), ministers of health or government representatives and other key stakeholders. In addition, selecting just two or three medications can result in substantial reductions in the unit cost of each, which can facilitate extending treatment and improving adherence as more patients are initiated into, and continue in, care.

5.5.2 Access to essential medicines and health technologies

Improving access to medicines and health technologies for the diagnosis, management and treatment of hypertension is essential for ensuring universal access to quality health care. Ensuring an adequate supply of good-quality medicines and health technologies requires a robust health system, which includes good leadership and governance, adequate financing, access to information and evidence, quality service delivery, a strong health workforce, and equitable access to essential medicines and health products of assured quality, safety, efficacy and cost-effectiveness. When hypertension control programmes are expanding, good procurement practices play a key role in securing quality products at affordable prices and ensuring adequate and timely supply, while good supply-chain management ensures that quality products are available at all levels of the health system to meet the growing needs for medicines and health technologies (111).

Although about 80% of hypertensive patients reside in LMICs (112), the demand in LMICs for antihypertensive medicines is undermined by significant under-diagnosis, weak quantification, and under-developed treatment and follow-up programmes, along with at times weak procurement and supply-chain systems. Furthermore, in most LMICs, social security systems, when they exist, tend not to cover all citizens and/or not to reimburse all essential medicines and medical devices for noncommunicable diseases, including those for treating hypertension. As a result, in many countries, most of the costs of treatment, including medications, end up being paid out-of-pocket by people living with hypertension, who additionally may not recognize the need for lifetime medication when the disease is asymptomatic (113, 114).

There is no component of a hypertension control programme more important than the adequate supply of good-quality, essential antihypertensive medicines. Currently, prices for the same essential antihypertensive medicines vary by more than ten-fold between countries.
The IHCI is a collaborative initiative of the Ministry of Health and Family Welfare, Government of India, state governments, Indian Council of Medical Research (ICMR), WHO-India and Resolve to Save Lives as a technical partner. The IHCI was started in 2018 to improve hypertension control in the community using the WHO HEARTS strategy of evidence-based treatment protocol, uninterrupted drug supply, patient-centred care, task sharing and digital information system. IHCI launched in selected districts of five states and, as of June 2023, had scaled up to 155 districts of 27 states with enrolment of 5.8 million hypertension patients.

Although protocol-based treatment and minimum 30 days’ prescription were key agreed and accepted strategies, availability of medicines emerged as the biggest challenge soon after initiation of the programme. This situation initially discouraged a patient from returning to facilities for follow-up visits in some areas. The programme was at risk of losing credibility.

In addition to the challenges of public procurement experienced in most countries, the conventional method of forecasting and procurement – adding a percentage to the prior year’s use – was not adequate to meet the medication requirements of a rapidly scaled-up hypertension control programme. Also, there was no mechanism to facilitate linking patient load to drug stock in order to ensure a continuous supply at health facilities. The WHO-recruited consultants, in conjunction with the Ministry of Health and Family Welfare and partners, provided technical and training support on strengthening the medicine supply chain, including facilitating development of state-specific hypertension treatment protocols, inclusion of protocol drugs in states’ list of essential medicines, forecasting requirements of drugs, support for budgeting, facilitating last-mile distribution and developing a ready-reckoner tool linking drug requirements to the patient load (Fig. 14. Supply-chain strengthening interventions). These proved helpful in ensuring adequate stock and equitable distribution to all service delivery points. With an adequate and uninterrupted availability of drugs, it was possible to decentralize the programme to 18 000+ Ayushman Bharat Health and Wellness Centres for improved access to care.

Together, these efforts resulted in increased procurement of protocol medicines by the participating states (Fig. 15. Increment in procurement of amlodipine over four years in four states of India).

By 2020, the IHCI had ensured that more than 70% of health care facilities had ensured one month’s stock of the protocol medicines, and fewer than 10% had experienced stock-outs.

Fig. 14. Supply-chain strengthening interventions

Source: The Indian Hypertension Control Initiative

Fig. 15. Increment in procurement of amlodipine over four years in four states of India

<table>
<thead>
<tr>
<th>State</th>
<th>2017/18</th>
<th>2018/19</th>
<th>2019/20</th>
<th>2020/21</th>
</tr>
</thead>
<tbody>
<tr>
<td>Punjab</td>
<td>1.7</td>
<td>5.1</td>
<td>17</td>
<td>36</td>
</tr>
<tr>
<td>Madhya Pradesh</td>
<td>2.7</td>
<td>12</td>
<td>22</td>
<td>37</td>
</tr>
<tr>
<td>Kerala</td>
<td>43</td>
<td>48</td>
<td>67</td>
<td>n/a</td>
</tr>
<tr>
<td>Maharashtra</td>
<td>0</td>
<td>23</td>
<td>78</td>
<td>123</td>
</tr>
<tr>
<td>Telangana</td>
<td>39</td>
<td>44</td>
<td>174</td>
<td>209</td>
</tr>
</tbody>
</table>

Box 4: Strengthening access to medicines

The India Hypertension Control Initiative (IHCI)
by more than ten-fold between countries, and many country governments and hypertension patients are paying prices that are higher than necessary (115). Medicines for hypertension are too often not reliably available in primary health care facility pharmacies. A lack of standardized national protocols and treatment algorithms for hypertension that name preferred, evidence-based medicines incentivize a market fragmented into a vast number of formulations prescribed and sold within the same therapeutic classes, especially in the private sector. This leads to poor visibility of market opportunities for manufacturers, potentially resulting in irregular or no supply. Other potential factors include challenges to timely registration of medications in all countries (particularly in the case of single-pill combinations) or establishing a reliable supply chain and distribution in-country.

Components of the medicine supply chain system, including forecasting, procurement, storage, stock-management and distribution, need to be strengthened and maintained to avoid stock-outs and disruption of treatment. Additionally, there needs to be a robust monitoring system in place to ensure timely reporting, and so that these challenges can be identified early and mitigated promptly. Lastly, medication must be dispensed correctly and used rationally by the health care provider and patient alike (116).

Although there are differences in countries and regions, two of the basic anti-hypertensive medications, amlodipine and hydrochlorothiazide, are generally available at a price of US$ 0.01 per tablet, or less. Losartan, telmisartan and enalapril, the other commonly used class of medications, can cost only slightly more. Therefore, a full year of treatment with quality-assured, state-of-the-art medications in most countries need not cost more than between US$ 5 and US$ 10 (114).

Finally, in markets where there are multiple manufacturers of varying quality, manufacturers of high-quality products may find it challenging to offer competitive prices, particularly where patients are purchasing medicines out-of-pocket. Quality health products are imperative and such sustainable production comes at a cost (117). At the same time, some quality products that are sold by the manufacturer at affordable prices may be subsequently rendered unaffordable by multiple markups in the supply chain (118). In the absence of consolidated procurement, manufacturers sell to distributors, who sell to wholesalers, who sell to dispensing points, often with substantial markups along the way. For example, one study in Kenya found highly variable pricing throughout the public and private health sector, with markups exceeding 340% on amlodipine and 280% on hydrochlorothiazide (119).
HEARTS in the Americas is an initiative being implemented in 32 countries of the Region of the Americas with technical cooperation by PAHO. It includes approximately 3000 health centres and covers approximately 30 million adults. The goal is to improve population hypertension control and promote the secondary prevention of CVDs, with the emphasis on primary health care settings. Measurement of blood pressure is an important component of continuous quality improvement of the initiative, which includes clinical training, use of a protocol and clinically validated devices.

When the initiative was first launched, a small study showed that not only did countries not have the regulations necessary to ensure that only validated blood pressure monitoring devices (BPMDs) were registered to be sold, but ministries of health and other health authorities had no record of the types of devices, brands and models that were being used in primary health care facilities. As in other parts of the world, the market in Latin America is dominated by non-validated BPMDs.

To address that issue, HEARTS started working with both health authorities and national regulatory authorities, and this work evolved into a two-fold approach:

- efforts to introduce regulation of marketing authorization; and
- measures to regulate purchases of BPMDs using public funds

A guidance document was published by PAHO to be used as a tool in this process and the manifold strategy to improve the regulatory environment has been described elsewhere.

The initiative promoted the use of validated BPMDs by increasing awareness of the importance of validation and accuracy, knowledge of what validation is, and mechanisms to verify whether a device has been validated or not.

While working towards implementation of regulatory measures, health authorities of several countries began procuring validated BPMDs with technical support from PAHO. Ministries of health that are not able to regulate purchasing of BPMDs at the national level have issued recommendations for local health authorities to purchase validated BPMDs exclusively.

Because of the increase in demand and the observed market limitations, the PAHO Strategic Fund has included selected validated BPMDs in its list of products, and countries in the Region of the Americas can use its pooled procurement and financing mechanisms.

HEARTS is advocating for government transparency, which could be achieved by the creation or improvement of publicly available databases documenting brands and models granted marketing authorization and bought with public funds.

The challenges have been numerous, and include lack of knowledge and political will, market limitations, resistance by the medical profession, budgetary constraints, and the complexity of institutional and legislative environment, among others.

Results have been promising, as many countries are in the process of developing regulatory measures, while others have already changed their purchase profile, or are promoting validation through social media and training health personnel.

The importance of having exclusive use of clinically validated BPMDs in primary health care has become part of the public health debate in the Region of the Americas.
5.5.3 Blood pressure monitoring devices

Although a deceptively simple aspect, major barriers in obtaining quality blood pressure measurements have been reported across low- and high-resource settings. These barriers refer to the type of devices used, the accuracy of the devices and a lack of knowledge in purchasing preferred devices.

Regarding the type of devices used, WHO published, in 2020 (126), clear technical guidance on the specifications of blood pressure measuring devices to use. Due to environmental concerns about mercury, key issues with poor calibration of aneroid devices, and improper manual blood pressure measurement techniques, manual blood pressure measurement devices need to be replaced by independently validated electronic automated devices.

Across many recent guideline documents (32, 127), the consensus is that due to these limitations of manual devices, automated upper-arm cuff monitors are strongly recommended, as they eliminate human error (e.g. caused by hearing impairment and digit preference) and require less training. In recent years, numerous new types of cuffless devices have entered the global market, including popular wrist-band devices. Despite the considerable potential of these devices to take many readings day and night without any user awareness, the use of these devices is not currently recommended for the management of hypertension due to remaining questions regarding their accuracy, performance and ability to track changes in blood pressure (128).

While there are many benefits of automated cuff-based electronic monitors, the most significant drawback is that only one in five of the available automated upper-arm and wrist-based cuff devices has evidence of validation testing for accuracy (122) and, in general, validated devices are more costly than those without validation. New technologies may make blood pressure measurement easier, but as of 2023 there is no alternative to upper-arm validated blood pressure cuffs that has sufficient consistency and accuracy to be recommended for diagnosis and management of hypertension in health care facilities.

The response to the challenge of access to medicine and technology requires a multi-faceted approach. Bulk procurement resulting from a protocol specifying the medicines required can drive down costs, even within a country, especially as most health care systems tend to become decentralized to state, district or local levels of government.

5.5.4 Risk-based management

The WHO Guideline for the pharmacological treatment of hypertension in adults strongly recommends that all hypertension patients should have blood pressure controlled to <140 mmHg systolic and <90 mmHg diastolic. The guideline also recommends further treatment to <130 mmHg systolic in patients with hypertension complicated by existing CVD, diabetes, chronic kidney disease, or
Diagnosing and managing hypertension

at high risk of developing CVD (8). Complete assessment of CVD risk in patients without a CVD diagnosis requires laboratory testing, which many low-resource settings do not have ready access to, therefore there is a potential to delay or miss the opportunity for treatment. The guideline therefore recommends initiating immediate treatment for hypertension on the day of hypertension diagnosis, based on raised blood pressure alone, followed by a CVD risk assessment (8). This new guidance is clear in that the approach to initiating treatment for hypertension does not have to be limited by a CVD risk approach and that dose- and drug-specific protocols with clear thresholds should be used for implementation in countries.

Box 6: Scaling up hypertension care in India

The scale-up of the India Hypertension Control Initiative (IHCI) (see Box 4) was implemented at state and district level by government officials and staff, with technical support from specially trained consultants, recruited by WHO.

WHO consultants supported more than 20 states in the implementation of the IHCI and, as of June 2023, 27 states or union territories in India had developed a standard treatment protocol for hypertension, based on the WHO HEARTS technical package. In addition, a few states were also working on adding fixed-dose combinations to the protocol in order to improve patient adherence. WHO and other partners support states in calculating the annual drug demand for antihypertensives so that they can plan effectively for the implementation of the treatment protocols. Regular feedback given by WHO consultants on drug availability at facility and district level helps districts to maintain optimum drugs at every level.

The technical support provided by these consultants has played a pivotal role in training more than 8000 medical officers, 4500 pharmacists, 9000 staff nurses and more than 20 000 other health care workers on IHCI strategies, blood pressure measurement, use of standard protocol, follow-up care, drug stock management, team-based care, patient-centred care and counselling on lifestyle management.

WHO is assisting states to implement a national NCD portal, a uniform digital information system for noncommunicable diseases such as hypertension, diabetes and three common cancers. Feedback about the NCD Portal, and expertise in this domain, is helping to improve uptake. As of June 2023, there were 5.8 million hypertension patients under treatment in IHCI implementation districts in 27 states. WHO assisted states to plan decentralization of hypertension follow-up care to Ayushman Bharat Health and Wellness Centres – primary health care health units under national health mission. Drug refills to ensure continuity of care at these centres helped more than 38% of patients in the first wave of the COVID-19 pandemic (129). These centres are providing follow-up care to hypertension patients near to their village.

WHO consultants and government staff monitor the quality of programme implementation by supportive supervision to identify gaps and share good practices. Regular data analysis and feedback is crucial in data-driven policy level decisions.

With special focus on hypertension and diabetes care, the Ministry of Health and Family Welfare, Government of India has decided to put 75 million patients with hypertension or diabetes on standard care by 2025.

Consultants from WHO and the Government of India, as well as state and district governments, will play important role in achieving this ambitious target.
The HEARTS module on risk-based management of CVD was launched in 2020 after updated risk-prediction charts were developed for 21 global regions. The charts are divided into non-laboratory-based and laboratory-based charts. The threshold for the level of CVD risk when treatment is required remains something for countries to decide upon using the laboratory-based charts (130).

Application of the total CVD risk approach will be better informed through country-level implementation research. Many areas, including the level of the facility at which CVD risk can be assessed (primary, secondary or tertiary), screening factors, thresholds for treatment, adaptation of protocols, follow-up intervals and other logistics are best defined in the local context (130).

5.5.5 Team-based care

The world is facing a substantial and ongoing shortage of trained health workers. WHO projects a global shortfall of 10 million health workers by 2030, mostly in LMICs (131). In order to provide patient-centred continuous care more effectively, primary care systems can include team-based care strategies in their clinic workflows and protocols.

Team-based care uses multidisciplinary teams (which may involve new staff or the shifting of tasks among existing staff). Teams can include patients themselves, primary care physicians, and other allied health professionals such as nurses, pharmacists, counsellors, social workers, nutritionists, community health workers and others. Teams reduce the burden on physicians by utilizing the skills of trained health workers. Strong evidence shows that team-based care is effective in improving hypertension control among patients in a cost-effective way. A degree of task shifting/team-based care is already taking place in many settings; WHO provides further guidance on how to maximize this approach for greater impact (132).

The context in which teams operate varies significantly between and within countries, as does the task allocation. Recommendation 8 in the Guideline for the pharmacological treatment of hypertension in adults encourages team-based care: “that pharmacological treatment of hypertension can be provided by nonphysician professionals such as pharmacists and nurses, as long as the following conditions are met: proper training, prescribing authority, specific management protocols and physician oversight (8). However, local implementation factors are fundamental when designing team-based care for hypertension management:

- Community health care workers may assist in tasks such as education, delivery of medications, blood pressure measurement and monitoring through an established collaborative care model. The scope of hypertension care practised by community health care workers depends on local regulations and currently varies by country.
- Telemonitoring, community- or home-based blood pressure monitoring, and health care worker support are encouraged to enhance hypertension
Diagnosing and managing hypertension

The Republic of the Philippines, a country composed of more than 42,000 barangays or villages, has long been implementing the delivery of team-based health care services, cascaded by the Department of Health. At the community level, barangay health workers serve as the first point of contact between the community and the health care system under the primary health care framework. They are community volunteers who provide primary health care services and cover at least 20 households at the minimum. They report to the barangay health station under the supervision of a nurse or a midwife. After complying with training requirements and being accredited by the local health board in their village, barangay health workers become official members of the health service delivery team.

Barangay health workers have significant roles in realizing universal health coverage in the country, where health services are provided to all, especially the poor and disadvantaged. The Republic Act 7883, otherwise known as the Barangay Health Workers’ Benefits and Incentives Act of 1995, outlines their critical role in providing a voluntary health service in the community, where they are considered community organizers, educators, and frontline providers of primary health care at the grassroots level.

Cognizant of the roles of the barangay health workers in the community, the Philippines Healthy Hearts Programme (HHP) leveraged their support toward reaching its initial objectives – implementing the standard WHO HEARTS package in selected facilities within Iloilo Province, thereby improving population hypertension control in the catchment area. They were engaged as part of the health care team implementing the following community-level interventions across the hypertension care cascade:

- Measuring and recording blood pressure during risk assessment of patients at the barangay health station or at home during house visits, after which blood pressure readings are reported to the nurse or midwife supervisor for collation and submission to the rural health unit or urban health centre;
- Providing education on the prevention and control of noncommunicable diseases, particularly hypertension, during patient visits;
- Informing the community on the availability of hypertension care services and medicines;
- Delivering medications to far-flung rural areas and to households where patients are unable to visit regularly visit the health facility; and
- Tracking patients who have missed their quarterly clinic visits for hypertension treatment follow up.

With the expansion of the Healthy Hearts programme, the barangay health workers remain a driving force in reaching out to patients in the community.

A barangay health worker with patient.
management as part of an integrated chronic disease management system, if community-based care is deemed appropriate by the treating medical team and found feasible and affordable by patients.

- Physician oversight can be done through innovative methods such as tele-monitoring of patients and coordination with team members to ensure access to treatment is not delayed.

- When team-based hypertension care is delivered in the community, this allows hypertension patients with stable, controlled blood pressure to visit the clinic less frequently. Corresponding changes must be made to ensure access to essential antihypertensive medicines, namely multi-month refills (ideally, 90-days) and community or home delivery of medication refills.

5.5.6 Systems for monitoring

Effective hypertension control programmes require a robust information system to enable the monitoring of blood pressure control at the individual patient level and to assess progress on improving outcomes at the facility and health system levels (133). In many LMIC primary health care facilities, staff record and report data on inefficient paper-based systems. The creation of a secure, accurate, non-duplicated longitudinal patient record, readily available during clinical visits, is essential for the care of patients with hypertension, diabetes and other conditions requiring long-term care. In many LMIC primary care contexts, patient encounters last less than five minutes; digital information systems therefore need to be simple and quick to use by front-line health care workers.

User-centred, simple digital information systems facilitate rapid capture of essential patient-level data, reduce health care worker data entry burden, and support rapid scale-up. An optimal system replaces paper, so that health care workers only need to record the information once, reducing the risk of loss of data and of inaccurate data. One example of a user-friendly mobile application for hypertension management is the DHIS-2 Hypertension Tracker app used to monitor patients and programme performance (134).

Whether digital or paper-based, strong information systems provide rapid data feedback loops on key indicators to enable supportive supervision and continuous quality improvement. Focus on a list of core HEARTS indicators directs attention to the most important outcomes:

- number of hypertension patients enrolled from the catchment area (to estimate programme coverage);
- proportion of enrolled patients with controlled blood pressure (<140/90 mmHg in the past three months);
- proportion of patients not retained in care (with no visit in the past three and twelve months); and
availability of core hypertension medications and blood pressure monitoring devices (135).

When programme managers receive monthly data on this limited set of core indicators, they can identify lagging facilities and implement programme improvements. HEARTS global and country leaders have identified that improving hypertension control requires formalized quality improvement teams, including supervisory staff and facility managers, who set annual outcome goals and plan interventions to address root causes and improve outcomes. The quality improvement strategy relies upon accurate, timely, actionable data to address core areas of hypertension quality gaps: a reliable supply of antihypertensive medications, retention in care, decentralization and therapeutic inertia.

Improved hypertension control demands retaining patients in care and maintaining them on effective treatment. Digital information systems can be leveraged as a powerful mechanism to support retention in care and facilitate team-based care. Loss to follow up is a leading barrier to hypertension control, often occurring in 50% or more of patients in low-resource settings (136). Digital tools can generate lists of patients overdue for care, send automated SMS text and telephone reminders, and prompt community outreach, thereby reducing loss to follow up. Evidence shows that digital interventions can also contribute to improving patients’ adherence to medication and their engagement with their treatment, can provide background information and increase patients’ adherence to their health provider’s guidelines, thereby increasing blood pressure control (137, 138).

The primary goal of a robust information system for large-scale hypertension programmes is ultimately to support clinicians and programme managers by providing data feedback loops to improve quality of care and thereby increase the proportion of patients whose blood pressure is controlled.

### 5.6 National scale-up of HEARTS for hypertension

As of 2023, multiple countries have successfully implemented the WHO HEARTS package, demonstrating progressively improved population coverage, diagnosis rates, linkage to care, and blood pressure control. However, to maximize the population health impact of the HEARTS hypertension control programmes and reduce deaths and disability, it is crucial to expand these successful demonstration programmes from limited areas to full national scale. HEARTS programmes in India and Cuba (see Boxes 6 and 8) have made significant progress towards achieving national scale, and other countries are poised to reach national scale.

When is a HEARTS hypertension control programme ready for national scale-up? Determining the readiness involves assessing key scale-up factors, which can be undertaken once the programme’s demonstration phase is completed.
Box 8: National scale-up of HEARTS

Cuba’s hypertension control programme

HEARTS in the Region of the Americas is a regional programme involving 32 countries in Latin America and the Caribbean. Cuba joined HEARTS in the Americas as one of four founder countries in 2016. The country developed a simple hypertension treatment protocol, starting with dual drug treatment, and leveraged a strong primary health care infrastructure centred on a polyclinic facility that offers both treatment and preventative care, and from which doctor and nurse teams deploy to serve the wider local community. Unique features of the Cuba HEARTS programme include health care team home visits to patients to follow up on hypertension care, local manufacturing of the protocol medicines and the design, validation, and manufacture of the automated blood pressure monitoring device used for the programme.

In 2016 the HEARTS package technical elements were introduced at a demonstration site and, in 2018, Cuba HEARTS expanded from one to three community primary health care facilities; the programme expanded to 22 facilities by 2021. By that time, 78% of the catchment area hypertension population were enrolled in the programme, and the programme achieved 59% facility-based blood pressure control.

Inspired by the success of the first expansion phase, the Ministry of Public Health of Cuba declared 2022–2023 the “Year of Hypertension Control”, and HEARTS hypertension control programme expanded nationally to implement the same standard package in all 451 primary care polyclinics in the country. A national database for hypertension was established between September 2022 and January 2023, facilitating data audits in each area and identifying individuals with uncontrolled hypertension as baseline data for the new areas. National scale-up was supported by a strong public health infrastructure, team-based care, locally manufactured medicines and blood pressure monitoring devices, and a national campaign to inform and inspire health workers and the general population about the importance of controlling hypertension in communities.

By the beginning of 2023, out of an estimated 3 million individuals with hypertension in Cuba, over 2 million were currently registered under the programme.
WHO provides general guidance on how to systematically analyse and support necessary actions for sustainable national scale-up using a systems approach (139, 140, 141, 142). For hypertension control programmes, the key components of readiness-for-scale include clinical capacity, delivery of a standard service package based on HEARTS, clinical quality of care, a reliable supply of protocol medicines sufficient to meet the demand from the anticipated influx of new patients, a robust health information system for tracking patients and monitoring the programme, and government commitment in terms of political will and financing (Table 7). At the same time, pragmatism is important. When political will and commitments align, HEARTS programmes can transition to a national scale-up process with most scale-up factors addressed, and minor gaps able to be filled in along the way.

5.7 Co-morbidities and hypertension

5.7.1 Diabetes

Diabetes is not only a risk factor for CVD; people with diabetes are particularly vulnerable to health damage if they also have untreated hypertension, which is common in people with diabetes in many countries (143). To support this evidence, WHO Member States have adopted global targets on diabetes including a target focusing on blood pressure: 80% of people with diagnosed diabetes have good control of blood pressure (144).

<table>
<thead>
<tr>
<th>Scale-up domain</th>
<th>Scale factor 1</th>
<th>Scale factor 2</th>
<th>Scale factor 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical capacity</td>
<td>PHC facilities</td>
<td>PHC staffing</td>
<td>Decentralization</td>
</tr>
<tr>
<td>Service delivery</td>
<td>Simple protocol</td>
<td>90-day Rx</td>
<td>Team-based care</td>
</tr>
<tr>
<td>Clinical quality</td>
<td>Blood pressure control &gt;50%</td>
<td>Missed visit rate &lt;25%*</td>
<td>–</td>
</tr>
<tr>
<td>Medication supply</td>
<td>Protocol medicine patient-days ≥30 in 100% of pharmacies</td>
<td>Facility digital drug inventory of protocol medicines</td>
<td>Morbidity-based medicine supply forecasting</td>
</tr>
<tr>
<td>Information system</td>
<td>Digital information system for managing hypertension</td>
<td>HEARTS indicators integrated into information system</td>
<td>Hypertension programme outcomes synthesized in programme-wide dashboard</td>
</tr>
<tr>
<td>Political will</td>
<td>Hypertension services included in national universal health coverage package</td>
<td>Medicines free for patients or minimal out-of-pocket cost</td>
<td>No out-of-pocket fees for hypertension follow-up visits</td>
</tr>
</tbody>
</table>

*Defined as no return for scheduled clinic visit in the prior three or six months
Given the overlap of diabetes and CVD risk factors, combined management for risk of both conditions is a rational approach. The decision to systematically look for people at high risk of diabetes and CVD is a strategic one specific to each health care setting, and will depend, at least in part, on the number likely to be identified and the resources available to adequately care for them.

Uncontrolled hypertension and high cholesterol – not hyperglycaemia – are the risk factors most strongly associated with premature death and disability among people living with diabetes. Treatment for hypertension is among the best-value treatments for people living with diabetes, as the treatment is inexpensive and treatment lowers the risk of CVD, the biggest killer for people with diabetes (143). Treatment of hypertension can also reduce the risk of kidney failure, an important and common complication of diabetes. Primary health care services need to be equipped to manage people with type 2 diabetes.

5.7.2 Chronic kidney disease hypertension

The bidirectional relationship between hypertension and chronic kidney disease (CKD) is an interplay involving intricate pathophysiological mechanisms and mutual exacerbation of each condition. Hypertension is a well-established risk factor for development and progression of CKD and is responsible for the second-highest global age-standardized rates of DALYs related to CKD (145). Optimal treatment and control of hypertension with commonly available therapies are critical to reducing the risk of CKD progression.

On the other hand, the appearance of hypertension can often be the first indicator of CKD, as renal parenchymal disease is the most common cause of secondary hypertension. Therefore, people with newly diagnosed hypertension should be screened for the presence of kidney disease whenever possible. The interplay between hypertension and CKD creates a vicious cycle, with each condition exacerbating the other. This bidirectional association underscores the imperative for early CKD and hypertension detection, rigorous blood pressure control, and optimal management of CKD to prevent disease progression and thereby avoid or delay downstream cardiovascular events and renal complications. Guideline-recommended blood pressure targets are more stringent in people with CKD to optimise the preservation of kidney function over time and protect from adverse cardiovascular outcomes. For patients with heavy proteinuria and renal damage, drugs that block the renin-angiotensin system are particularly valuable in this regard (146).

5.8 HIV and hypertension

Ageing among people living with HIV, coupled with the epidemiological transition underway in many LMICs, has led to an increased burden of CVD (147, 148, 149). Hypertension is the most prevalent CVD risk factor among people living with HIV; globally, an estimated 27% of people living with HIV on antiretroviral
therapy (ART) also have hypertension (150), and it is estimated that only one quarter of these individuals are receiving treatment. People living with HIV may be at higher risk of CVD than HIV-negative adults owing to the higher prevalence of traditional CVD risk factors, adverse effects of some antiretroviral therapy medications, and HIV-related chronic inflammation (147, 151).

National HIV programmes, in collaboration with partners such as PEPFAR and the Global Fund, have already successfully strengthened health systems in LMICs for HIV care and treatment, and these can be leveraged to improve care for hypertension among people living with HIV via integration (148, 149, 152): the coordination, location or simultaneous delivery of HIV and hypertension services to patients who need it, when they need it (149). This makes sense because of the marked similarities in the care cascade for both conditions. Furthermore, integrated treatment models reduce the number of clinic appointments people living with HIV with comorbid disease must keep, promote early hypertension diagnosis and treatment, reduce service duplication which may lead to cost savings, allow providers to have a comprehensive view of their patient’s history, and promote patient-centred care (153, 154). HIV–hypertension integration is also highly effective for blood pressure control without negatively impacting HIV disease outcomes (155, 156, 157, 158).

Once hypertension has been diagnosed, the provision of organized and evidence-based health services can ensure that people with this chronic condition receive key interventions and regular follow up necessary to minimize complications and help them live long and healthy lives.

**Box 9: HIV and hypertension**

The integration of HIV and hypertension care, based on the WHO HEARTS technical package, has demonstrated that high levels of HIV viral suppression can be maintained while simultaneously achieving high blood pressure control.

A HIV–hypertension integration pilot in Uganda resulted in control of 73% at 24 months, up from 5.1% at baseline, while maintaining an HIV viral load suppression rate of 98%. Ninety-six percent of the patients were also retained in care while receiving integrated multi-month dispensing for both hypertension and HIV medications within a differentiated service delivery model (155). This arose from a two-year grant awarded in 2019 by Resolve to Save Lives (RTSL) to Makerere University Joint AIDS Program (MJAP) to pilot HIV–hypertension care at Mulago ISS, the largest HIV clinic in Uganda. Uganda is home to about 1.4 million people living with HIV with an HIV prevalence of 5.1% among adults aged 15–49 years (159; 160). Prior to the pilot, while more than 95% of the clinic’s HIV patients were virally suppressed, of the 24.4% of patients diagnosed with hypertension, only 1% were initiated on treatment. Of those initiated on treatment, only 5.1% had achieved blood pressure control (155; 156).
5.9 Summary

- When hypertension is diagnosed, simple, low-cost treatments are available to control blood pressure and prevent heart disease, stroke or death.

- The WHO-HEARTS technical package has been implemented in nearly 40 Member States and demonstrates that hypertension can be controlled in large-scale national programmes based in primary health care facilities and communities.

- Little more than five years after the HEARTS package was introduced, country governments are mobilizing the resources to grow HEARTS-based hypertension control programmes to national scale.
Conclusion

This first WHO *Global report on hypertension* underscores the enormous scale of the hypertension problem, which affects populations across the world, and the potential to reverse current trends. The political basis for concerted action to address hypertension is there, woven into targets and actions on cardiovascular diseases in the Sustainable Development Goals, the 2011 Political declaration of the high-level meeting of the General Assembly on the prevention and control of noncommunicable diseases, the WHO *Global action plan for the prevention and control of noncommunicable diseases* and the WHO Implementation roadmap 2013–2030. Where they are built upon, these foundations will catalyse action by all.
References


47. GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis


91. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Prospective Studies C. Age-specific relevance of usual blood pressure to vascular mortality: a


2 August 2023).


doi: 10.1136/bmjopen-2020-039237.


Annex 1. Methodology for analysis of impact and cost

The methods used in the analysis of hypertension treatment impact and cost have been detailed in previous publications (1, 2). This annex provides a brief overview, including adaptations made for Section 3 of this report.

The hypertension outcomes model used a combination of state-transition modelling and demographic projections methods. We modelled the evolution of population demography, blood pressure distributions, and fatal and nonfatal cardiovascular disease (CVD) by age and sex. We looked at mortality from four specific CVD causes, ischaemic heart disease (IHD), hypertensive heart disease (HHD), ischaemic stroke, and haemorrhagic stroke. Additionally, we looked at nonfatal myocardial infarction (MI), stroke, and heart failure (HF). One hundred and eighty-two Member States comprising 98% of the world population were included in our analysis.

As described by Pickersgill and colleagues (1), we used four state-transition (Markov) models to represent the risk of incident and fatal CVD from the four causes listed above. Each model includes four mutually exclusive states: “well”, “sick”, “dead from cause X” and “dead from any other cause”. The transition probabilities within these models were specific to each age, sex, and location. We calculated the transition probabilities using data from the Global Burden of Disease (GBD) 2019 study (3), which captures the relationship between new CVD, prevalent CVD, and fatal CVD risk over time within 5-year age cohorts. Transition probabilities were calibrated by running our model over 2010–2019 and making post hoc adjustments to the transition probabilities to maximize the fit to “observed” GBD 2019 values. Pickersgill and colleagues provide more details on the models and relevant formulae (1). Nonfatal event rates were modelled as a function of fatal event rates using data from the Prospective Urban-Rural Epidemiological (PURE) Study (4).

The state-transition models were then linked to a demographic projection model that tracked survival in age cohorts over time as they age. Population and all-cause mortality data were taken from the World Population Prospects (WPP) 2022 Revision, and the base-case (i.e. no additional scale-up) demographic projections in the model were calibrated to WPP medium variant projections over the period 2020–2050. We incorporated excess mortality from COVID-19 into our model as a temporary “shock” in all-cause mortality, as described by Watkins and colleagues (2).

Mortality levels for each CVD cause were re-scaled from GBD 2019 values to
values reported in the Global Health Estimates 2019 (5). We assumed that the age-, sex-, and location-specific incidence of each CVD cause would be constant over 2020–2050 (at 2019 levels). We assumed that case-fatality from each CVD cause, as well as background mortality, would continue to (modestly) decline over 2020–2050, following average annual rates of change observed over 2010–2019, reflecting continued advances in CVD care and in health care more generally.

To generate population blood pressure distributions by age, sex, and location, we used hypertension “cascade of care” data and mean systolic blood pressure estimates from the NCD Risk Factors Collaboration (NCD-RisC) (6) along with estimates of age-specific and sex-specific 5th-percentile blood pressure levels in populations free of CVD and anti-hypertensive drug use. These parameters, and an assumed Gaussian distribution, allowed us to compute the prevalence of raised blood pressure corresponding to increasing levels of risk (e.g., 130–139mmHg, 140–149mmHg, and so on). We combined these distributions with estimates of blood-pressure-specific reductions in the incidence of CVD, as described in a recent meta-analysis of hypertension treatment trials (7). This allowed us to model the reduction in CVD incidence that would result from a greater proportion of the population with hypertension having controlled blood pressure. Pickersgill and colleagues provide more details on this procedure and relevant formulae (1).

In addition to modelling a reduction in CVD incidence, we modelled a reduction in CVD case-fatality from greater use of antihypertensive drug therapy, i.e. secondary prevention. We assumed a 26% relative reduction in case-fatality among persons with IHD without heart failure (8) (70% of IHD cases) and a 20% relative reduction among persons with heart failure (9). We assumed 36% and 76% relative reductions in case-fatality from ischaemic and haemorrhagic stroke respectively (10). Finally, we assumed the same effect size for HHD as for IHD with heart failure.

Pickersgill and colleagues explore historical trends in the rate of improvement in the hypertension cascade of care and describe a series of assumptions around realistic scale-up patterns for hypertension care (1). In brief, they looked at the rates of change in blood pressure treatment and control observed in high-performing countries (e.g. Canada) in the NCD-RisC data, as well as recent experiences implementing the HEARTS technical package in several countries. They modelled annual increases in hypertension coverage using a parabolic function, which implies that improvements in hypertension coverage occur faster at intermediate coverage levels as compared to low or high coverage levels. Practically, this approach is intended to represent the slowing of progress that countries inevitably experience as they expand health care to harder-to-reach populations, meaning that our projections are conservative.
Finally, we estimated the cost of hypertension care using our model and cost data from the Updated Appendix 3 of the Global action plan for the prevention and control of noncommunicable diseases (11). Specifically, we obtained estimates of the “unit cost” of hypertension treatment per person per year; these were multiplied by hypertension prevalence counts and treatment coverage rates to compute total costs. These estimates assume all persons with hypertension would be on a calcium-channel blocker and 60% would require a second medication, assumed to be an angiotensin II receptor blocker.

The additional costs required to do hypertension screening were calculated using default data on typical screening programme costs from the HEARTS costing tool (12). However, implementing a hypertension programme involves more than just the costs incurred at primary health care facilities. Health systems also need to be strengthened to provide screening and care. Estimates by a 2009 WHO task force were used to generate programme costs such as health management information systems, administration and financing. CHOICE estimates of the cost of strengthening supply chains were used to generate a markup for logistics (13). In total, the health system strengthening costs add 26% to the direct costs of service delivery.

The difference in costs between scenarios (progress or aspirational vs. business as usual) gives the incremental cost of accelerated progress.

As noted in the report, incremental health gains were converted into disability adjusted life-years, which were multiplied by average gross domestic product per capita to give the incremental economic benefits and benefit–cost ratio, calculated as DALYs using established procedures for cost-effectiveness analysis, but without an age-weighting function (14). (Of note, the DALYs estimated for economic evaluation are not directly comparable with the DALYs estimated for burden of disease analysis since they use different reference life-expectancy values, and disease-burden DALYs are not discounted.) We discounted both costs and benefits at 3% when computing cost-effectiveness and benefit–cost ratios.

Annex 1 references


2. NCD Countdown collaborators. NCD Countdown 2030: efficient pathways and strategic investments to accelerate progress towards the Sustainable Development Goal target 3.4 in low-income and middle-income countries. Lancet. 2022;399(10331):1266-78.


Annex 2. Hypertension profiles and explanatory notes

Background

Hypertension – also known as high blood pressure – is one of the world’s leading risk factors for death and disability. The aim of the hypertension profiles is to highlight the current status of hypertension for each WHO Member State (194 total) curated from multiple data sources. These profiles help to establish a baseline for the country and support monitoring trends toward the prevention and control of hypertension as a public health problem.

The profiles include the following information:

- **Morbidity and mortality:** prevalence of hypertension; coverage of hypertension diagnosis, treatment and control; trends in the prevalence of uncontrolled hypertension; hypertension control rate scenarios; probability of premature mortality from NCDs; cardiovascular disease (CVD) deaths; and the percentage of CVD deaths attributable to high systolic blood pressure;

- **Risk factors:** related risk factors including dietary salt intake, tobacco use, obesity, alcohol consumption and physical inactivity prevalence; and

- **National response:** national targets for blood pressure (BP) and salt consumption; national survey on BP/hypertension and sodium intake; functioning system for mortality data; guidelines for hypertension management.

All data are rounded to the nearest whole number; additional rounding was carried out on some statistics as described in the explanatory notes.

For further details see the Explanatory notes at the end of the document.
Afghanistan

Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)

Total population (2019): 37 769 000
Total deaths (2019): 255 000

Prevalence of hypertension – global comparison (both sexes)

Of the 3.8 million adults aged 30–79 years with hypertension:

In order to achieve a 50% control rate, 1.4 million more people with hypertension would need to be effectively treated.

Mortality

Probability of premature mortality from NCDs (%)
Cardiovascular disease deaths
Cardiovascular disease deaths attributable to high systolic blood pressure (%)

Risk factors

Mean population salt intake, adults aged 25+ years (g/day)
Current tobacco use, adults aged 15+ years (%)
Obesity, adults aged 18+ years (%)
Total alcohol per capita consumption, adults aged 15+ years (litres)
Physical inactivity, adults aged 18+ years (%)

National response

Targets
National target for blood pressure
National target for salt consumption

Surveillance
Conducted recent, national survey measuring raised blood pressure/hypertension
Conducted recent, national survey on salt/sodium intake
Functioning system for generating reliable cause-specific mortality data on a routine basis

Footnotes: a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.

Global report on hypertension: the race against a silent killer

76
**Albania**

**Hypertension profile**

**Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)**

- **Total population (2019):** 2,874,000
- **Total deaths (2019):** 31,200

- **Probability of premature mortality from NCDs (%):**
  - Both sexes: 11%
  - Males: 17%
  - Females: 6%
  - Year: 2019

- **Cardiovascular disease deaths attributable to high systolic blood pressure (%):**
  - Both sexes: 37,500
  - Males: 35,300
  - Females: 2,200
  - Year: 2019

**Risk factors**

- Mean population salt intake, adults aged 25+ years (g/day): 13
- Current tobacco use, adults aged 15+ years (%): 23
- Obesity, adults aged 18+ years (%): 22
- Total alcohol per capita consumption, adults aged 15+ years (litres): 5
- Physical inactivity, adults aged 18+ years (%): no data

**National response**

- **Targets**
  - National target for blood pressure
  - National target for salt consumption

- **Surveillance**
  - Conducted recent, national survey measuring raised blood pressure/hypertension
  - Conducted recent, national survey on salt/sodium intake

- **Treatment**
  - Guidelines for management of hypertension

**Footnotes:**

a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.

A. **Notes:**

- **Afghanistan**
- **Surveillance**
- **National target for salt consumption**

- **Current tobacco use, adults aged 15+ years (%):**
  - Male: 42%
  - Female: 43%
  - Total: 41%

- **Mean population salt intake, adults aged 25+ years (g/day):**
  - Male: 3.8 million
  - Female: 1.4 million
  - Total: 123,000

- **Cardiovascular disease deaths attributable to high systolic blood pressure (%):**
  - Male: 54%
  - Female: 17%

- **Probability of premature mortality from NCDs (%):**
  - Male: 45%
  - Female: 35%

- **Notes:**

  a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg.

- **In order to achieve a 50% control rate, 310,000 more people with hypertension would need to be effectively treated.**

- **Trends in uncontrolled hypertension in adults aged 30–79 years:**
  - Past trends: male 29%, female 54%
  - Projected trends: male 19%, female 44%
  - Global target: male 5%, female 12%

- **Hypertension control rate scenarios:**
  - If the progress scenario were achieved, 42,000 deaths would be averted by 2040.

- **Projected hypertension control rates by scenario:**
  - Business as usual
  - Progress
  - Aspirational

- **Footnotes:**

  a. 50% control rate, global adults aged 30–79 years with hypertension:
  - Male: 30%
  - Female: 40%
  - Total: 35%

  b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg.

- **World Health Organization – Hypertension profiles, 2023**

- **Total population (2019):** 2,874,000
- **Total deaths (2019):** 31,200

- **Notes:**

  a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.
  b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg.

- **Functioning system for generating reliable cause-specific mortality data on a routine basis**

- **Annex 2. Hypertension profiles and explanatory notes**
Algeria

Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)  

- Total population (2019): 42 705 000  
- Total deaths (2019): 203 000

Prevalence of hypertension – global comparison (both sexes)

Trends in uncontrolled hypertension in adults aged 30–79 years

Hypertension control rate scenarios

Mortality

Probability of premature mortality from NCDs (%)

Cardiovascular disease deaths

Cardiovascular disease deaths attributable to high systolic blood pressure (%)

Risk factors

- Mean population salt intake, adults aged 25+ years (g/day)
- Current tobacco use, adults aged 15+ years (%)
- Obesity, adults aged 18+ years (%)
- Total alcohol per capita consumption, adults aged 15+ years (litres)
- Physical inactivity, adults aged 18+ years (%)

National response

- National target for blood pressure
- National target for salt consumption
- Surveillance

Conducted recent, national survey measuring raised blood pressure/hypertension

Conducted recent, national survey on salt/sodium intake

Functioning system for generating reliable cause-specific mortality data on a routine basis

Footnotes: a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control. e. Age-standardized estimates are presented for all indicators except salt intake.
Andorra

Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)°

Prevalence of hypertension – global comparison (both sexes)°

Of the 6.6 million adults aged 30–79 years with hypertension, a 50% control rate would need to be effectively treated. b

Trends in uncontrolled hypertension in adults aged 30–79 years°

Hypertension control rate scenarios

Data not available

Mortality

Probability of premature mortality from NCDs (%)
Cardiovascular disease deaths
Cardiovascular disease deaths attributable to high systolic blood pressure (%)

Risk factors°

Mean population salt intake, adults aged 25+ years (g/day)
Current tobacco use, adults aged 15+ years (%)°
Obesity, adults aged 18+ years (%)
Total alcohol per capita consumption, adults aged 15+ years (litres)
Physical inactivity, adults aged 18+ years (%)

National response

Targets
National target for blood pressure
National target for salt consumption

Surveillance
Conducted recent, national survey measuring raised blood pressure/hypertension
Conducted recent, national survey on salt/sodium intake
Functioning system for generating reliable cause-specific mortality data on a routine basis

Treatment
Guidelines for management of hypertension

Footnotes: a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Age-standardized estimates are presented for all indicators except salt intake. e. Data refer to tobacco smoking only, in the absence of sufficient data on all tobacco use.
Angola

Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)\(^a\)  
- Male: 39%  
- Female: 41%

Prevalence of hypertension – global comparison (both sexes)\(^a\)

Trends in uncontrolled hypertension in adults aged 30–79 years\(^c\)

Hypertension control rate scenarios

Mortality

- Probability of premature mortality from NCDs (%)
- Cardiovascular disease deaths
- Cardiovascular disease deaths attributable to high systolic blood pressure (%)

Risk factors\(^e\)

- Mean population salt intake, adults aged 25+ years (g/day)
- Current tobacco use, adults aged 15+ years (%)
- Obesity, adults aged 18+ years (%)
- Total alcohol per capita consumption, adults aged 15+ years (litres)
- Physical inactivity, adults aged 18+ years (%)

National response

- National target for blood pressure
- National target for salt consumption

Surveillance

- Conducted recent, national survey measuring raised blood pressure/hypertension
- Conducted recent, national survey on salt/sodium intake
- Functioning system for generating reliable cause-specific mortality data on a routine basis

Footnotes: a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control. e. Age-standardized estimates are presented for all indicators except salt intake.
Antigua and Barbuda

Hypertension profile

Total population (2019): 92 100
Total deaths (2019): 650

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)  

Prevalence of hypertension – global comparison (both sexes)

Of the 23 000 adults aged 30–79 years with hypertension:

- 53% of population aged 30–79 years diagnosed
- 40% of population aged 30–79 years treated
- 18% of population aged 30–79 years controlled

If the progress scenario were achieved, 430 deaths would be averted by 2040.

Mortality

Probability of premature mortality from NCDs (%)
Cardiovascular disease deaths
Cardiovascular disease deaths attributable to high systolic blood pressure (%)

Risk factors

Mean population salt intake, adults aged 25+ years (g/day)
Current tobacco use, adults aged 15+ years (%)
Obesity, adults aged 18+ years (%)
Total alcohol per capita consumption, adults aged 15+ years (litres)
Physical inactivity, adults aged 18+ years (%)

National response

Targets
- National target for blood pressure
- National target for salt consumption

Surveillance
- Conducted recent, national survey measuring raised blood pressure/hypertension
- Conducted recent, national survey on salt/sodium intake

Footnotes: a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control. e. Age-standardized estimates are presented for all indicators except salt intake.
Argentina

Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019) a

Prevalence of hypertension – global comparison (both sexes) a

Of the 10.8 million adults aged 30–79 years with hypertension:

In order to achieve a 50% control rate, 3.7 million more people with hypertension would need to be effectively treated. b

Mortality

Probability of premature mortality from NCDs (%)
Cardiovascular disease deaths
Cardiovascular disease deaths attributable to high systolic blood pressure (%)

Risk factors a

Mean population salt intake, adults aged 25+ years (g/day)
Current tobacco use, adults aged 15+ years (%)
Obesity, adults aged 18+ years (%)
Total alcohol per capita consumption, adults aged 15+ years (litres)
Physical inactivity, adults aged 18+ years (%)

National response

Targets
National target for blood pressure
National target for salt consumption
Surveillance
Conducted recent, national survey measuring raised blood pressure/hypertension
Conducted recent, national survey on salt/sodium intake
Functioning system for generating reliable cause-specific mortality data on a routine basis

Footnotes: a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control. e. Age-standardized estimates are presented for all indicators except salt intake.

Global report on hypertension: the race against a silent killer

82
Argentina

Conducted recent, national survey on salt/sodium intake
Conducted recent, national survey measuring raised blood pressure/hypertension
National target for salt consumption
National target for blood pressure
Targets

National response

Physical inactivity, adults aged 18+ years (%)
Obesity, adults aged 18+ years (%)

Risk factorse
Cardiovascular disease deaths attributable to high systolic blood pressure (%)
Cardiovascular disease deaths
Probability of premature mortality from NCDs (%)
Mortality

Footnotes: a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.
e. Age-standardized estimates are presented for all indicators except salt intake.
Australia

Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)

- 29% of the population aged 30–79 years
- 32% of males
- 26% of females

Prevalence of hypertension – global comparison (both sexes)

Trends in uncontrolled hypertension in adults aged 30–79 years

Hypertension control rate scenarios

- Of the 4.8 million adults aged 30–79 years with hypertension:
  - 59% diagnosed
  - 48% treated
  - 26% controlled

Mortality

Probability of premature mortality from NCDs (%)
- 52% of the population aged 30–79 years
- 48% males
- 58% females

Risk factors

Mean population salt intake, adults aged 25+ years (g/day)
- 8 g/day

National response

Targets
- National target for blood pressure
- National target for salt consumption

Surveillance
- Conducted recent, national survey measuring raised blood pressure/hypertension
- Conducted recent, national survey on salt/sodium intake
- Functioning system for generating reliable cause-specific mortality data on a routine basis

Footnotes:
- a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.
- b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg.
- c. SBP ≥140 mmHg or DBP ≥90 mmHg.
- d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.
- e. Age-standardized estimates are presented for all indicators except salt intake.
- f. Data refer to tobacco smoking only, in the absence of sufficient data on all tobacco use.
Australia

Trends in uncontrolled hypertension in adults aged 30–79 years (2019)

Functioning system for generating reliable cause-specific mortality data on a routine basis

Conducted recent, national survey on salt/sodium intake

Conducted recent, national survey measuring raised blood pressure/hypertension

National target for salt consumption

National target for blood pressure

Surveillance

Guidelines for management of hypertension

Treatment

Completed recent, national survey on salt/sodium intake

Functioning system for generating reliable cause-specific mortality data on a routine basis

Notes:

a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.

b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg.

c. SBP ≥140 mmHg or DBP ≥90 mmHg.

d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.

e. Age-standardized estimates are presented for all indicators except salt intake.

f. Data refer to tobacco smoking only, in the absence of sufficient data on all tobacco use.

Annex 2. Hypertension profiles and explanatory notes
**Azerbaijan**

**Hypertension profile**

**Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)**

- Male: 41%
- Female: 42%

**Prevalence of hypertension – global comparison (both sexes)**

- Azerbaijan: 20%
- Global: 30%

**Trends in uncontrolled hypertension in adults aged 30–79 years**

- Past trends: 47%
- Projected trends: 33%
- Male: 63%
- Female: 33%

**Hypertension control rate scenarios**

- Business as usual: 9%
- Progress: 18%
- Aspirational: 50%

**Mortality**

- Probability of premature mortality from NCDs (%)
  - Both sexes: 27%
  - Males: 34%
  - Females: 20%
  - Year: 2019
- Cardiovascular disease deaths: 51,300
- Females: 26,100
- Year: 2019
- Cardiovascular disease deaths attributable to high systolic blood pressure (%)
  - Both sexes: 55%
  - Males: 42%
  - Females: 14%
  - Year: 2019

**Risk factors**

- Mean population salt intake, adults aged 25+ years (g/day)
  - Both sexes: 9 g
  - Males: 10 g
  - Females: 7 g
  - Year: 2019
- Current tobacco use, adults aged 15+ years (%)
  - Males: 24%
  - Females: 20%
  - Year: 2019
- Obesity, adults aged 18+ years (%)
  - Males: 24%
  - Females: 20%
  - Year: 2019
- Total alcohol per capita consumption, adults aged 15+ years (litres)
  - Male: 2 l
  - Female: 2 l
  - Year: 2019
- Physical inactivity, adults aged 18+ years (%)
  - Male: 57%
  - Female: 43%
  - Year: 2019

**National response**

- National target for blood pressure
  - No data
- National target for salt consumption
  - No data

**Surveillance**

- Conducted recent, national survey measuring raised blood pressure/hypertension
  - Yes
- Conducted recent, national survey on salt/sodium intake
  - Yes
- Functioning system for generating reliable cause-specific mortality data on a routine basis
  - No

**Footnotes:**
- a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.
- b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP 140 mmHg or DBP 90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.
- e. Age-standardized estimates are presented for all indicators except salt intake.
Bahamas

Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)  
45%  
46%  
44%

Prevalence of hypertension – global comparison (both sexes)a

Trends in uncontrolled hypertension in adults aged 30–79 yearsc

Hypertension control rate scenarios

Mortality

Probability of premature mortality from NCDs (%)
Cardiovascular disease deaths
Cardiovascular disease deaths attributable to high systolic blood pressure (%)

Risk factorsa

Mean population salt intake, adults aged 25+ years (g/day)
Current tobacco use, adults aged 15+ years (%)
Obesity, adults aged 18+ years (%)
Total alcohol per capita consumption, adults aged 15+ years (litres)
Physical inactivity, adults aged 18+ years (%)

National response

Targets
National target for blood pressure
National target for salt consumption

Surveillance
Conducted recent, national survey measuring raised blood pressure/hypertension
Conducted recent, national survey on salt/sodium intake
Functioning system for generating reliable cause-specific mortality data on a routine basis

Footnotes: a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control. e. Age-standardized estimates are presented for all indicators except salt intake.

Annex 2. Hypertension profiles and explanatory notes  
87
Bahrain

Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)$^a$

<table>
<thead>
<tr>
<th></th>
<th>both sexes</th>
<th>males</th>
<th>females</th>
<th>year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Probability of premature mortality from NCDs (%)</td>
<td>16</td>
<td>16</td>
<td>15</td>
<td>2019</td>
</tr>
<tr>
<td>Cardiovascular disease deaths</td>
<td>1400</td>
<td>910</td>
<td>540</td>
<td>2019</td>
</tr>
<tr>
<td>Cardiovascular disease deaths attributable to high systolic blood pressure (%)</td>
<td>56</td>
<td>56</td>
<td>57</td>
<td>2019</td>
</tr>
</tbody>
</table>

Risk factors$^b$

- Mean population salt intake, adults aged 25+ years (g/day)
  - 6
- Current tobacco use, adults aged 15+ years (%)$^f$
  - 15
- Obesity, adults aged 18+ years (%)
  - 30
- Total alcohol per capita consumption, adults aged 15+ years (litres)
  - 2
- Physical inactivity, adults aged 18+ years (%)
  - no data

National response

- National target for blood pressure
- National target for salt consumption

Surveillance

- Conducted recent, national survey measuring raised blood pressure/hypertension
- Conducted recent, national survey on salt/sodium intake
- Functioning system for generating reliable cause-specific mortality data on a routine basis

Footnotes: a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control. e. Age-standardized estimates are presented for all indicators except salt intake. f. Data refer to tobacco smoking only, in the absence of sufficient data on all tobacco use.
Bangladesh

Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019) attending clinics, pharmacies, and home visits.

Prevalence of hypertension – global comparison (both sexes)

% of population aged 30–79 years

Global

Bangladesh

Trends in uncontrolled hypertension in adults aged 30–79 years

% of population aged 30–79 years

Past trends

Projected trends

Global target

Mortality

Probability of premature mortality from NCDs (%)
Cardiovascular disease deaths
Cardiovascular disease deaths attributable to high systolic blood pressure (%)

Risk factors

Mean population salt intake, adults aged 25+ years (g/day)
Current tobacco use, adults aged 15+ years (%)
Obesity, adults aged 18+ years (%)
Total alcohol per capita consumption, adults aged 15+ years (litres)
Physical inactivity, adults aged 18+ years (%)

National response

Targets

National target for blood pressure
National target for salt consumption

Surveillance

Conducted recent, national survey measuring raised blood pressure/hypertension
Conducted recent, national survey on salt/sodium intake
Functioning system for generating reliable cause-specific mortality data on a routine basis

Footnotes:
a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.
b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg.
c. SBP ≥140 mmHg or DBP ≥90 mmHg.
d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.
e. Age-standardized estimates are presented for all indicators except salt intake.

Total deaths (2019): 793 000

Trends in uncontrolled hypertension in adults aged 30–79 years

% of population aged 30–79 years

Past trends

Projected trends

Global target

Hypertension control rate scenarios

Projected hypertension control rates by scenario:

Business as usual
Progress
Aspirational

If the progress scenario were achieved, 479 000 deaths would be averted by 2040.

In order to achieve a 50% control rate, 6.9 million more people with hypertension would need to be effectively treated.

Footnotes:
a.SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.
b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg.
c. SBP ≥140 mmHg or DBP ≥90 mmHg.
d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.
e. Age-standardized estimates are presented for all indicators except salt intake.

Annex 2. Hypertension profiles and explanatory notes

89
Barbados

Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)**

Of the 80 000 adults aged 30–79 years with hypertension:

- % of population aged 30–79 years with hypertension:
  - 71% diagnosed (62% male, 68% female)
  - 61% treated (51% male, 68% female)
  - 34% controlled (29% male, 38% female)

In order to achieve a 50% control rate, 12 000 more people with hypertension would need to be effectively treated.**

Global report on hypertension: the race against a silent killer

Mortality

Probability of premature mortality from NCDs (%)

Cardiovascular disease deaths

Cardiovascular disease deaths attributable to high systolic blood pressure (%)

Risk factors**

Mean population salt intake, adults aged 25+ years (g/day)

Current tobacco use, adults aged 15+ years (%)

Obesity, adults aged 18+ years (%)

Total alcohol per capita consumption, adults aged 15+ years (litres)

Physical inactivity, adults aged 18+ years (%)

National response

Targets

National target for blood pressure

National target for salt consumption

Surveillance

Conducted recent, national survey measuring raised blood pressure/hypertension

Conducted recent, national survey on salt/sodium intake

Functioning system for generating reliable cause-specific mortality data on a routine basis

Footnotes: a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control. e. Age-standardized estimates are presented for all indicators except salt intake.
Belarus

Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)  
- Men: 49%
- Women: 52%
- Total: 47%

Prevalence of hypertension – global comparison (both sexes)

Trends in uncontrolled hypertension in adults aged 30–79 years

Hypertension control rate scenarios

Mortality

Probability of premature mortality from NCDs (%)
- Both sexes: 24%
- Men: 36%
- Women: 73,200
- 2019
- Men: 33,000
- Women: 40,200
- 2019
- Women: 56
- 2019

Risk factors

Mean population salt intake, adults aged 25+ years (g/day)
- Both sexes: 7
- Men: 8
- Women: 6
- 2019
- Men: 31
- Women: 48
- 2019
- Men: 25
- Women: 18
- 2019
- Men: 11
- Women: 14
- 2019

National response

Targets
- National target for blood pressure
- Treatment
- Guidelines for management of hypertension

Surveillance
- Conducted recent, national survey measuring raised blood pressure/hypertension
- Yes
- Conducted recent, national survey on salt/sodium intake
- Yes
- Functioning system for generating reliable cause-specific mortality data on a routine basis
- No

Footnotes: a. SBP ≥140 mmHg or DBP ≥90 mmHg. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.

Annex 2. Hypertension profiles and explanatory notes
Belgium

Hypertension profile

Total population (2019): 11 511 000
Total deaths (2019): 113 000

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)

- Male: 30%
- Female: 34%
- Overall: 26%

Prevalence of hypertension – global comparison (both sexes)

<table>
<thead>
<tr>
<th>% of population aged 30–79 years</th>
</tr>
</thead>
<tbody>
<tr>
<td>Global</td>
</tr>
<tr>
<td>Belgium</td>
</tr>
</tbody>
</table>

Of the 2.5 million adults aged 30–79 years with hypertension:

- Diagnosed: 67%
- Treated: 59%
- Controlled: 38%

If the progress scenario were achieved, 19 000 deaths would be averted by 2040.

Mortality

Probability of premature mortality from NCDs (%)
- Both sexes: 11
- Males: 13
- Females: 8
- Year: 2019
- Count: 30 800

Cardiovascular disease deaths
- Both sexes: 49
- Males: 49
- Females: 49
- Year: 2019
- Count: 16 800

Cardiovascular disease deaths attributable to high systolic blood pressure (%)
- Both sexes: 8
- Males: 9
- Females: 7
- Year: 2019
- Count: 21 000

Risk factors

- Mean population salt intake, adults aged 25+ years (g/day): 8
- Current tobacco use, adults aged 15+ years (%): 24
- Obesity, adults aged 18+ years (%): 22
- Total alcohol per capita consumption, adults aged 15+ years (litres): 10
- Physical inactivity, adults aged 18+ years (%): 36

National response

Targets
- National target for blood pressure
- National target for salt consumption

Surveillance
- Conducted recent, national survey measuring raised blood pressure/hypertension
- Conducted recent, national survey on salt/sodium intake
- Functioning system for generating reliable cause-specific mortality data on a routine basis

Footnotes:
- a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.
- b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg.
- c. SBP ≤140 mmHg or DBP ≤90 mmHg.
- d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.
- e. Age-standardized estimates are presented for all indicators except salt intake.

Global report on hypertension: the race against a silent killer
Belgium

National response

Mean population salt intake, adults aged 25+ years (g/day)
Risk factors

Mortality

Probability of premature mortality from NCDs (%)
Cardiovascular disease deaths
Cardiovascular disease deaths attributable to high systolic blood pressure (%)

Risk factors

Mean population salt intake, adults aged 25+ years (g/day)
Current tobacco use, adults aged 15+ years (%)
Obesity, adults aged 18+ years (%)
Total alcohol per capita consumption, adults aged 15+ years (litres)
Physical inactivity, adults aged 18+ years (%)

National response

Treatment

Guidelines for management of hypertension

Footnotes: a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.

Annex 2. Hypertension profiles and explanatory notes
Benin
Hypertension profile

Total population (2019): 12,290,000
Total deaths (2019): 93,400

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019) 31% ♂ 29% ♂ 33% ♀

Prevalence of hypertension – global comparison (both sexes)

Trends in uncontrolled hypertension in adults aged 30–79 years

Hypertension control rate scenarios

Mortality
Probability of premature mortality from NCDs (%)
Cardiovascular disease deaths
Cardiovascular disease deaths attributable to high systolic blood pressure (%)

Risk factors
Mean population salt intake, adults aged 25+ years (g/day)
Current tobacco use, adults aged 15+ years (%)
Obesity, adults aged 18+ years (%)
Total alcohol per capita consumption, adults aged 15+ years (litres)
Physical inactivity, adults aged 18+ years (%)

National response
 Targets
National target for blood pressure
National target for salt consumption

Surveillance
Conducted recent, national survey measuring raised blood pressure/hypertension
Conducted recent, national survey on salt/sodium intake
Functioning system for generating reliable cause-specific mortality data on a routine basis

Footnotes: a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.
e. Age-standardized estimates are presented for all indicators except salt intake.
**Bhutan**

**Hypertension profile**

**Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)**

<table>
<thead>
<tr>
<th>both sexes</th>
<th>males</th>
<th>females</th>
</tr>
</thead>
<tbody>
<tr>
<td>18</td>
<td>20</td>
<td>17</td>
</tr>
<tr>
<td>1300</td>
<td>750</td>
<td>530</td>
</tr>
<tr>
<td>51</td>
<td>51</td>
<td>52</td>
</tr>
</tbody>
</table>

**Probability of premature mortality from NCDs (%)**

- Cardiovascular disease deaths: 43%
- Cardiovascular disease deaths attributable to high systolic blood pressure: 44%
- Total alcohol per capita consumption, adults aged 15+ years (litres): 43%
- Physical inactivity, adults aged 18+ years (%): 44%

**Mean population salt intake, adults aged 25+ years (g/day)**

- Both sexes: 9
- Males: 9
- Females: 8

**National response**

- National target for blood pressure
- National target for salt consumption

**Footnotes:**

- a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.
- b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg.
- c. SBP ≥140 mmHg or DBP ≥90 mmHg.
- d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.
- e. Age-standardized estimates are presented for all indicators except salt intake.
Bolivia (Plurinational State of)

Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)  
- Males: 28%
- Females: 29%
- Overall: 27%

Prevalence of hypertension – global comparison (both sexes)

<table>
<thead>
<tr>
<th>Country</th>
<th>% of population aged 30–79 years with hypertension</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bolivia</td>
<td>61%</td>
</tr>
</tbody>
</table>

Of the 1.3 million adults aged 30–79 years with hypertension:

- Diagnosed: 51% (M) 71% (F)
- Treated: 39% (M) 60% (F)
- Controlled: 19% (M) 34% (F)

Mortality

- Probability of premature mortality from NCDs (%)
  - Both sexes: 18%
  - Males: 17%
  - Females: 18%
  - Year: 2019

- Cardiovascular disease deaths
  - Both sexes: 22,400
  - Males: 10,400
  - Females: 12,000
  - Year: 2019

- Cardiovascular disease deaths attributable to high systolic blood pressure (%)
  - Both sexes: 43
  - Males: 42
  - Females: 44
  - Year: 2019

Risk factors

- Mean population salt intake, adults aged 25+ years (g/day)
  - Both sexes: 9
  - Males: 10
  - Females: 8
  - Year: 2019

- Current tobacco use, adults aged 15+ years (%)
  - Both sexes: 13
  - Males: 21
  - Females: 5
  - Year: 2019

- Obesity, adults aged 18+ years (%)
  - Both sexes: 20
  - Males: 15
  - Females: 26
  - Year: 2016

- Total alcohol per capita consumption, adults aged 15+ years (litres)
  - Both sexes: 4
  - Males: 6
  - Females: 2
  - Year: 2019

- Physical inactivity, adults aged 18+ years (%)
  - No data

National response

- National target for blood pressure
- National target for salt consumption

Surveillance

- Conducted recent, national survey measuring raised blood pressure/hypertension
- Conducted recent, national survey on salt/sodium intake
- Functioning system for generating reliable cause-specific mortality data on a routine basis

Footnotes:
- a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.
- b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg.
- c. SBP ≥140 mmHg or DBP ≥90 mmHg.
- d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.
- e. Age-standardized estimates are presented for all indicators except salt intake.
Bosnia and Herzegovina
Hypertension profile

Total population (2019): 3 361 000
Total deaths (2019): 37 800

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019) a

<table>
<thead>
<tr>
<th>% of population aged 30–79 years</th>
<th>Hypertension profile</th>
</tr>
</thead>
<tbody>
<tr>
<td>44%</td>
<td>47%</td>
</tr>
</tbody>
</table>

Prevalence of hypertension – global comparison (both sexes)a

Trends in uncontrolled hypertension in adults aged 30–79 yearsc

Hypertension control rate scenarios

Mortality

Probability of premature mortality from NCDs (%)
- Cardiovascular death: 2019: 19 700, 2025: 54
- Cardiovascular disease deaths attributable to high systolic blood pressure (%)

Risk factors*

Mean population salt intake, adults aged 25+ years (g/day)
- 2019: 13
Current tobacco use, adults aged 15+ years (%)f
- 2019: 36
Obesity, adults aged 18+ years (%)
- 2019: 18
Total alcohol per capita consumption, adults aged 15+ years (litres)
- 2019: 6
Physical inactivity, adults aged 18+ years (%)
- 2019: 25

National response

Targets
- National target for blood pressure
- National target for salt consumption

Surveillance
- Conducted recent, national survey measuring raised blood pressure/hypertension
- Conducted recent, national survey on salt/sodium intake
- Functioning system for generating reliable cause-specific mortality data on a routine basis

Treatment
- Guidelines for management of hypertension

Footnotes: a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control. e. Age-standardized estimates are presented for all indicators except salt intake. f. Data refer to tobacco smoking only, in the absence of sufficient data on all tobacco use.
**Botswana**

**Hypertension profile**

**Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)**

<table>
<thead>
<tr>
<th>% of population aged 30–79 years</th>
<th>both sexes</th>
<th>males</th>
<th>females</th>
</tr>
</thead>
<tbody>
<tr>
<td>30%</td>
<td>27</td>
<td>33</td>
<td>23</td>
</tr>
<tr>
<td>40%</td>
<td>4100</td>
<td>2000</td>
<td>2100</td>
</tr>
<tr>
<td>50%</td>
<td>63</td>
<td>64</td>
<td>61</td>
</tr>
<tr>
<td>60%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>70%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>80%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>90%</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Global report on hypertension: the race against a silent killer**

Of the 364 000 adults aged 30–79 years with hypertension:

- **59%** diagnosed
- **41%** treated
- **19%** controlled

In order to achieve a 50% control rate, 119 000 more people with hypertension would need to be effectively treated.

**Risk factors**

- Mean population salt intake, adults aged 25+ years (g/day)
- Current tobacco use, adults aged 15+ years (%)
- Obesity, adults aged 18+ years (%)
- Total alcohol per capita consumption, adults aged 15+ years (litres)
- Physical inactivity, adults aged 18+ years (%)

**Mortality**

- Probability of premature mortality from NCDs (%)
- Cardiovascular disease deaths
- Cardiovascular disease deaths attributable to high systolic blood pressure (%)

**National response**

- National target for blood pressure
- National target for salt consumption
- Surveillanance
- Conducted recent, national survey measuring raised blood pressure/hypertension
- Conducted recent, national survey on salt/sodium intake
- Functioning system for generating reliable cause-specific mortality data on a routine basis

---

Footnotes: a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control. e. Age-standardized estimates are presented for all indicators except salt intake.
Brazil
Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)

Of the 50.7 million adults aged 30–79 years with hypertension:

- Diagnosed: 67%
- Treated: 62%
- Controlled: 33%

In order to achieve a 50% control rate, 8.4 million more people with hypertension would need to be effectively treated.

Mortality

<table>
<thead>
<tr>
<th>Probability of premature mortality from NCDs (%)</th>
<th>Cardiovascular disease deaths</th>
<th>Cardiovascular disease deaths attributable to high systolic blood pressure (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>both sexes 15</td>
<td>males 19</td>
<td>females 13</td>
</tr>
<tr>
<td>381 000</td>
<td>202 000</td>
<td>179 000</td>
</tr>
<tr>
<td>54</td>
<td>55</td>
<td>52</td>
</tr>
</tbody>
</table>

Risk factors

- Mean population salt intake, adults aged 25+ years (g/day)
- Current tobacco use, adults aged 15+ years (%)
- Obesity, adults aged 18+ years (%)
- Total alcohol per capita consumption, adults aged 15+ years (litres)
- Physical inactivity, adults aged 18+ years (%)

National response

<table>
<thead>
<tr>
<th>Targets</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>National target for blood pressure</td>
<td>Guidelines for management of hypertension</td>
</tr>
<tr>
<td>National target for salt consumption</td>
<td></td>
</tr>
</tbody>
</table>

Surveillance

- Conducted recent, national survey measuring raised blood pressure/hypertension
- Conducted recent, national survey on salt/sodium intake
- Functioning system for generating reliable cause-specific mortality data on a routine basis

Footnotes: a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.

Annex 2. Hypertension profiles and explanatory notes
Brunei Darussalam

Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)\textsuperscript{a}  

<table>
<thead>
<tr>
<th>Country</th>
<th>Men (%)</th>
<th>Women (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brunei Darussalam</td>
<td>46%</td>
<td>47%</td>
</tr>
</tbody>
</table>

Prevalence of hypertension – global comparison (both sexes)\textsuperscript{a}

Trends in uncontrolled hypertension in adults aged 30–79 years\textsuperscript{c}

Hypertension control rate scenarios

Mortality

Probability of premature mortality from NCDs (%)

<table>
<thead>
<tr>
<th>both sexes</th>
<th>males</th>
<th>females</th>
<th>year</th>
</tr>
</thead>
<tbody>
<tr>
<td>19</td>
<td>20</td>
<td>17</td>
<td>2019</td>
</tr>
<tr>
<td>670</td>
<td>400</td>
<td>270</td>
<td>2019</td>
</tr>
<tr>
<td>53</td>
<td>55</td>
<td>50</td>
<td>2019</td>
</tr>
</tbody>
</table>

Cardiovascular disease deaths

Cardiovascular disease deaths attributable to high systolic blood pressure (%)

Risk factors\textsuperscript{e}

<table>
<thead>
<tr>
<th>both sexes</th>
<th>males</th>
<th>females</th>
<th>year</th>
</tr>
</thead>
<tbody>
<tr>
<td>11</td>
<td>12</td>
<td>10</td>
<td>2019</td>
</tr>
<tr>
<td>16</td>
<td>30</td>
<td>2</td>
<td>2019</td>
</tr>
<tr>
<td>14</td>
<td>13</td>
<td>16</td>
<td>2016</td>
</tr>
<tr>
<td>0</td>
<td>1</td>
<td>0</td>
<td>2019</td>
</tr>
<tr>
<td>27</td>
<td>21</td>
<td>34</td>
<td>2016</td>
</tr>
</tbody>
</table>

Total alcohol per capita consumption, adults aged 15+ years (litres)

Physical inactivity, adults aged 18+ years (%)

National response

Targets

<table>
<thead>
<tr>
<th></th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>National target for blood pressure</td>
<td>✔</td>
</tr>
<tr>
<td>National target for salt consumption</td>
<td>x</td>
</tr>
</tbody>
</table>

Surveillance

| Conducted recent, national survey measuring raised blood pressure/hypertension | x         |
| Conducted recent, national survey on salt/sodium intake | x         |
| Functioning system for generating reliable cause-specific mortality data on a routine basis | ✔         |

Footnotes: a. SBP $\geq$140 mmHg or DBP $\geq$90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP $<140$ mmHg and DBP $<90$ mmHg. c. SBP $\geq$140 mmHg or DBP $\geq$90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control. e. Age-standardized estimates are presented for all indicators except salt intake. f. Data refer to tobacco smoking only, in the absence of sufficient data on all tobacco use.
Bulgaria

Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)  
- 45%
- 49%
- 41%

Prevalence of hypertension – global comparison (both sexes)  

Trends in uncontrolled hypertension in adults aged 30–79 years  

Hypertension control rate scenarios  

Mortality  

Probability of premature mortality from NCDs (%)  
- Cardiovascular disease deaths  
- Cardiovascular disease deaths attributable to high systolic blood pressure (%)  

Risk factors  

- Mean population salt intake, adults aged 25+ years (g/day)  
- Current tobacco use, adults aged 15+ years (%)  
- Obesity, adults aged 18+ years (%)  
- Total alcohol per capita consumption, adults aged 15+ years (litres)  
- Physical inactivity, adults aged 18+ years (%)  

National response  

Targets  
- National target for blood pressure  
- National target for salt consumption  

Surveillance  
- Conducted recent, national survey measuring raised blood pressure/hypertension  
- Conducted recent, national survey on salt/sodium intake  
- Functioning system for generating reliable cause-specific mortality data on a routine basis  

Footnotes:  
a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.  
b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg.  
c. SBP ≥140 mmHg or DBP ≥90 mmHg.  
d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.  
e. Age-standardized estimates are presented for all indicators except salt intake.  
f. Data refer to tobacco smoking only, in the absence of sufficient data on all tobacco use.
Burkina Faso

Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)

<table>
<thead>
<tr>
<th>Sex</th>
<th>Prevalence (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Both</td>
<td>31%</td>
</tr>
<tr>
<td>Males</td>
<td>29%</td>
</tr>
<tr>
<td>Females</td>
<td>32%</td>
</tr>
</tbody>
</table>

Of the 1.5 million adults aged 30–79 years with hypertension:

- In order to achieve a 50% control rate, 626 000 more people with hypertension would need to be effectively treated.

Trends in uncontrolled hypertension in adults aged 30–79 years

<table>
<thead>
<tr>
<th>Year</th>
<th>% of population aged 30–79 years with hypertension</th>
</tr>
</thead>
<tbody>
<tr>
<td>2000</td>
<td>38%</td>
</tr>
<tr>
<td>2005</td>
<td>21%</td>
</tr>
<tr>
<td>2010</td>
<td>9%</td>
</tr>
</tbody>
</table>

Hypertension control rate scenarios

- Projected hypertension control rates by scenario:
  - Business as usual
  - Progress
  - Aspirational

Mortality

- Probability of premature mortality from NCDs (%)
  - Both sexes: 24%
  - Males: 26%
  - Females: 22%

Risk factors

- Mean population salt intake, adults aged 25+ years (g/day)
  - Both sexes: 7 g/day
  - Males: 7 g/day
  - Females: 7 g/day

- Current tobacco use, adults aged 15+ years (%)
  - Both sexes: 15%
  - Males: 23%
  - Females: 7%

- Obesity, adults aged 18+ years (%)
  - Both sexes: 6%
  - Males: 3%
  - Females: 8%

- Total alcohol per capita consumption, adults aged 15+ years (litres)
  - Both sexes: 10 litres
  - Males: 17 litres
  - Females: 3 litres

- Physical inactivity, adults aged 18+ years (%)
  - Both sexes: 20%
  - Males: 18%
  - Females: 23%

National response

- Targets
  - National target for blood pressure
  - National target for salt consumption

- Surveillance
  - Conducted recent, national survey measuring raised blood pressure/hypertension
  - Conducted recent, national survey on salt/sodium intake
  - Functioning system for generating reliable cause-specific mortality data on a routine basis

- Treatment
  - Guidelines for management of hypertension

Footnotes:

a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.

b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg.

c. SBP ≥140 mmHg or DBP ≥90 mmHg.

d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.

e. Age-standardized estimates are presented for all indicators except salt intake.
Burundi

Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)ᵃ

- Total population (2019): 11 875 000
- Total deaths (2019): 76 800

Of the 907 000 adults aged 30–79 years with hypertension:

- 33% of population aged 30–79 years
- 36% of population aged 30–79 years

In order to achieve a 50% control rate, 359 000 more people with hypertension would need to be effectively treated.ᵇ

Mortality

- Probability of premature mortality from NCDs (%)
- Cardiovascular disease deaths
- Cardiovascular disease deaths attributable to high systolic blood pressure (%)

Risk factorsᵃ

- Mean population salt intake, adults aged 25+ years (g/day)
- Current tobacco use, adults aged 15+ years (%)
- Obesity, adults aged 18+ years (%)
- Total alcohol per capita consumption, adults aged 15+ years (litres)
- Physical inactivity, adults aged 18+ years (%)

National response

- National target for blood pressure
- National target for salt consumption

Surveillance

- Conducted recent, national survey measuring raised blood pressure/hypertension
- Conducted recent, national survey on salt/sodium intake
- Functioning system for generating reliable cause-specific mortality data on a routine basis

Footnotes: a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.

e. Age-standardized estimates are presented for all indicators except salt intake.
Cabo Verde

Hypertension profile

Total population (2019): 577 000
Total deaths (2019): 2850

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)\(^a\)

Of the 95 000 adults aged 30–79 years with hypertension:

- 53% diagnosed
- 36% treated
- 14% controlled

In order to achieve a 50% control rate, 35 000 more people with hypertension would need to be effectively treated.\(^b\)

Footnotes: a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.

e. Age-standardized estimates are presented for all indicators except salt intake.

Prevalence of hypertension – global comparison (both sexes)\(^a\)

Of the 95 000 adults aged 30–79 years with hypertension:

- 41% diagnosed
- 25% treated
- 9% controlled

If the progress scenario were achieved, 3100 deaths would be averted by 2040.

Mortality

Probability of premature mortality from NCDs (%)
- Cardiovascular disease deaths
- Cardiovascular disease deaths attributable to high systolic blood pressure (%)

Risk factors\(^e\)

- Mean population salt intake, adults aged 25+ years (g/day)
- Current tobacco use, adults aged 15+ years (%)
- Obesity, adults aged 18+ years (%)
- Total alcohol per capita consumption, adults aged 15+ years (litres)
- Physical inactivity, adults aged 18+ years (%)

National response

Targets
- National target for blood pressure
- National target for salt consumption

Surveillance
- Conducted recent, national survey measuring raised blood pressure/hypertension
- Conducted recent, national survey on salt/sodium intake
- Functioning system for generating reliable cause-specific mortality data on a routine basis

Treatment
- Guidelines for management of hypertension

In order to achieve a 50% control rate, 35 000 more people with hypertension would need to be effectively treated.\(^b\)
Cambodia

Hypertension profile

Prevalence of hypertension – global comparison (both sexes)\(^a\)

<table>
<thead>
<tr>
<th>% of population aged 30–79 years with hypertension</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cambodia</td>
</tr>
<tr>
<td>global</td>
</tr>
</tbody>
</table>

Trends in uncontrolled hypertension in adults aged 30–79 years\(^c\)

<table>
<thead>
<tr>
<th>% of population aged 30–79 years with hypertension</th>
</tr>
</thead>
<tbody>
<tr>
<td>past trends</td>
</tr>
<tr>
<td>projected trends</td>
</tr>
<tr>
<td>global target</td>
</tr>
</tbody>
</table>

Hypertension control rate scenarios

<table>
<thead>
<tr>
<th>% of population aged 30–79 years with hypertension</th>
</tr>
</thead>
<tbody>
<tr>
<td>2023</td>
</tr>
<tr>
<td>2025</td>
</tr>
<tr>
<td>2030</td>
</tr>
<tr>
<td>2035</td>
</tr>
<tr>
<td>2040</td>
</tr>
</tbody>
</table>

Mortality

Probability of premature mortality from NCDs (%)

<table>
<thead>
<tr>
<th>both sexes</th>
<th>males</th>
<th>females</th>
<th>year</th>
</tr>
</thead>
<tbody>
<tr>
<td>cardiovascular disease deaths</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>23</td>
<td>27</td>
<td>19</td>
<td>2019</td>
</tr>
<tr>
<td>27 100</td>
<td>13 400</td>
<td>13 700</td>
<td>2019</td>
</tr>
<tr>
<td>44</td>
<td>45</td>
<td>44</td>
<td>2019</td>
</tr>
</tbody>
</table>

Cardiovascular disease deaths attributable to high systolic blood pressure (%)

<table>
<thead>
<tr>
<th>both sexes</th>
<th>males</th>
<th>females</th>
<th>year</th>
</tr>
</thead>
<tbody>
<tr>
<td>10</td>
<td>11</td>
<td>10</td>
<td>2019</td>
</tr>
<tr>
<td>22</td>
<td>37</td>
<td>6</td>
<td>2019</td>
</tr>
<tr>
<td>4</td>
<td>3</td>
<td>5</td>
<td>2016</td>
</tr>
<tr>
<td>8</td>
<td>14</td>
<td>3</td>
<td>2019</td>
</tr>
<tr>
<td>11</td>
<td>10</td>
<td>11</td>
<td>2016</td>
</tr>
</tbody>
</table>

Risk factors\(^a\)

Mean population salt intake, adults aged 25+ years (g/day)

<table>
<thead>
<tr>
<th>both sexes</th>
<th>males</th>
<th>females</th>
<th>year</th>
</tr>
</thead>
<tbody>
<tr>
<td>10</td>
<td>11</td>
<td>10</td>
<td>2019</td>
</tr>
<tr>
<td>22</td>
<td>37</td>
<td>6</td>
<td>2019</td>
</tr>
<tr>
<td>4</td>
<td>3</td>
<td>5</td>
<td>2016</td>
</tr>
<tr>
<td>8</td>
<td>14</td>
<td>3</td>
<td>2019</td>
</tr>
<tr>
<td>11</td>
<td>10</td>
<td>11</td>
<td>2016</td>
</tr>
</tbody>
</table>

Cardiovascular disease deaths attributable to high systolic blood pressure (%)

<table>
<thead>
<tr>
<th>both sexes</th>
<th>males</th>
<th>females</th>
<th>year</th>
</tr>
</thead>
<tbody>
<tr>
<td>10</td>
<td>11</td>
<td>10</td>
<td>2019</td>
</tr>
<tr>
<td>22</td>
<td>37</td>
<td>6</td>
<td>2019</td>
</tr>
<tr>
<td>4</td>
<td>3</td>
<td>5</td>
<td>2016</td>
</tr>
<tr>
<td>8</td>
<td>14</td>
<td>3</td>
<td>2019</td>
</tr>
<tr>
<td>11</td>
<td>10</td>
<td>11</td>
<td>2016</td>
</tr>
</tbody>
</table>

National response

Targets

National target for blood pressure

Treatment

Guidelines for management of hypertension

Surveillance

Conducted recent, national survey measuring raised blood pressure/hypertension

Functional system for generating reliable cause-specific mortality data on a routine basis

Footnotes: a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. e. National target for salt consumption. f. Projected hypertension control rates by scenario. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control. e. Age-standardized estimates are presented for all indicators except salt intake.
Cameroon

Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)a

<table>
<thead>
<tr>
<th>Age-standardized prevalence (%)</th>
<th>Male</th>
<th>Female</th>
</tr>
</thead>
<tbody>
<tr>
<td>diagnosis</td>
<td>37%</td>
<td>43%</td>
</tr>
<tr>
<td>treated</td>
<td>19%</td>
<td>16%</td>
</tr>
<tr>
<td>controlled</td>
<td>8%</td>
<td>10%</td>
</tr>
</tbody>
</table>

Of the 2.4 million adults aged 30–79 years with hypertension:

- In order to achieve a 50% control rate, 1 million more people with hypertension would need to be effectively treated.

- If the progress scenario were achieved, 53,000 deaths would be averted by 2040.

Mortality

- Probability of premature mortality from NCDs (%)
  - Cardiovascular disease deaths (2019): 27,200
  - Cardiovascular disease deaths attributable to high systolic blood pressure (%)

Risk factors

- Mean population salt intake, adults aged 25+ years (g/day)
  - 60
- Current tobacco use, adults aged 15+ years (%)
  - 8
- Obesity, adults aged 18+ years (%)
  - 11
- Total alcohol per capita consumption, adults aged 15+ years (litres)
  - 10
- Physical inactivity, adults aged 18+ years (%)
  - 29

National response

- National target for blood pressure
- National target for salt consumption
- Surveillance

Footnotes:
- a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.
- b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.
- e. Age-standardized estimates are presented for all indicators except salt intake.
Canada

Hypertension profile

Total population (2019): 37 523 000
Total deaths (2019): 278 000

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)a

<table>
<thead>
<tr>
<th>Prevalence of hypertension – global comparison (both sexes)a</th>
</tr>
</thead>
<tbody>
<tr>
<td>% of population aged 30–79 years</td>
</tr>
<tr>
<td>10%</td>
</tr>
<tr>
<td>20%</td>
</tr>
<tr>
<td>30%</td>
</tr>
<tr>
<td>40%</td>
</tr>
<tr>
<td>50%</td>
</tr>
<tr>
<td>60%</td>
</tr>
<tr>
<td>70%</td>
</tr>
<tr>
<td>80%</td>
</tr>
<tr>
<td>90%</td>
</tr>
<tr>
<td>100%</td>
</tr>
</tbody>
</table>

Of the 6.3 million adults aged 30–79 years with hypertension:

- A 50% hypertension control rate has already been achieved.b

Trends in uncontrolled hypertension in adults aged 30–79 yearsc

<table>
<thead>
<tr>
<th>Trends in uncontrolled hypertension in adults aged 30–79 years</th>
</tr>
</thead>
<tbody>
<tr>
<td>% of population aged 30–79 years</td>
</tr>
<tr>
<td>2000</td>
</tr>
<tr>
<td>2005</td>
</tr>
<tr>
<td>2010</td>
</tr>
<tr>
<td>2015</td>
</tr>
<tr>
<td>2020</td>
</tr>
<tr>
<td>2025</td>
</tr>
</tbody>
</table>

Hypertension control rate scenarios

- Projected hypertension control rates by scenario:d
  - business as usual
  - progress
  - aspirational

Mortality

- Probability of premature mortality from NCDs (%)
- Cardiovascular disease deaths
- Cardiovascular disease deaths attributable to high systolic blood pressure (%)

Risk factorsc

- Mean population salt intake, adults aged 25+ years (g/day)
- Current tobacco use, adults aged 15+ years (%)
- Obesity, adults aged 18+ years (%)
- Total alcohol per capita consumption, adults aged 15+ years (litres)
- Physical inactivity, adults aged 18+ years (%)

National response

- Targets
  - National target for blood pressure
  - National target for salt consumption
- Surveillance
  - Conducted recent, national survey measuring raised blood pressure/hypertension
  - Conducted recent, national survey on salt/sodium intake
  - Functioning system for generating reliable cause-specific mortality data on a routine basis

Footnotes:

a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control. e. Age-standardized estimates are presented for all indicators except salt intake.
Central African Republic

Hypertension profile

Total population (2019): 5 209 000
Total deaths (2019): 56 700

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)\(^a\)

- **41%**
- **40%**
- **43%**

Prevalence of hypertension – global comparison (both sexes)\(^a\)

![Bar chart showing prevalence of hypertension globally and by sex.]

Of the 467 000 adults aged 30–79 years with hypertension:

- **33%** diagnosed
- **18%** treated
- **6%** controlled

- **25%** males
- **40%** females
- **14%** males
- **21%** females
- **5%** males
- **6%** females

Trends in uncontrolled hypertension in adults aged 30–79 years\(^c\)

- **50%** past trends
- **30%** projected trends

Hypertension control rate scenarios

- **80%** global target

Mortality

- Probability of premature mortality from NCDs (%)
  - Both sexes
  - Males
  - Females
  - 2019
  - 36
  - 41
  - 32

- Cardiovascular disease deaths
  - 8300
  - 4000
  - 4300

- Cardiovascular disease deaths attributable to high systolic blood pressure (%)
  - Both sexes
  - Males
  - 63
  - 61
  - 65

Risk factors\(^e\)

- Mean population salt intake, adults aged 25+ years (g/day)
  - Both sexes
  - Males
  - 7
  - No data

- Current tobacco use, adults aged 15+ years (%)
  - Both sexes
  - Males
  - No data

- Obesity, adults aged 18+ years (%)
  - Both sexes
  - Males
  - 2

- Total alcohol per capita consumption, adults aged 15+ years (litres)
  - Both sexes
  - Males
  - 14

- Physical inactivity, adults aged 18+ years (%)
  - Both sexes
  - Males
  - 14

National response

- **Targets**
  - National target for blood pressure
  - National target for salt consumption

- **Surveillance**
  - Conducted recent, national survey measuring raised blood pressure/hypertension
  - Conducted recent, national survey on salt/sodium intake
  - Functioning system for generating reliable cause-specific mortality data on a routine basis

Footnotes:

- a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.
- b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.
- e. Age-standardized estimates are presented for all indicators except salt intake.
Chad

Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)

Prevalence of hypertension – global comparison (both sexes)

Trends in uncontrolled hypertension in adults aged 30–79 years

Hypertension control rate scenarios

In order to achieve a 50% control rate, 526 000 more people with hypertension would need to be effectively treated.

Of the 1.3 million adults aged 30–79 years with hypertension:

- 33% diagnosed
- 20% treated
- 9% controlled

Mortality

Probability of premature mortality from NCDs (%)
Cardiovascular disease deaths
Cardiovascular disease deaths attributable to high systolic blood pressure (%)

Risk factors

Mean population salt intake, adults aged 25+ years (g/day)
Current tobacco use, adults aged 15+ years (%)
Obesity, adults aged 18+ years (%)
Total alcohol per capita consumption, adults aged 15+ years (litres)
Physical inactivity, adults aged 18+ years (%)

National response

Targets
- National target for blood pressure
- National target for salt consumption

Surveillance
- Conducted recent, national survey measuring raised blood pressure/hypertension
- Conducted recent, national survey on salt/sodium intake
- Functioning system for generating reliable cause-specific mortality data on a routine basis

Treatment
- Guidelines for management of hypertension

Footnotes: a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.

Total population (2019): 16 127 000
Total deaths (2019): 149 000

An expan2. Hypertension profiles and explanatory notes

109
Chile

Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)  | 36%  | 39%  | 33%

Prevalence of hypertension – global comparison (both sexes)

Of the 4 million adults aged 30–79 years with hypertension:

Trends in uncontrolled hypertension in adults aged 30–79 years

Hypertension control rate scenarios

Mortality

Probability of premature mortality from NCDs (%)
Cardiovascular disease deaths
Cardiovascular disease deaths attributable to high systolic blood pressure (%)

Risk factors

Mean population salt intake, adults aged 25+ years (g/day)
Current tobacco use, adults aged 15+ years (%)
Obesity, adults aged 18+ years (%)
Total alcohol per capita consumption, adults aged 15+ years (litres)
Physical inactivity, adults aged 18+ years (%)

National response

Targets
National target for blood pressure
National target for salt consumption
Surveillance
Conducted recent, national survey measuring raised blood pressure/hypertension
Conducted recent, national survey on salt/sodium intake
Functioning system for generating reliable cause-specific mortality data on a routine basis

Treatment
Guidelines for management of hypertension

Footnotes: a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control. e. Age-standardized estimates are presented for all indicators except salt intake. f. Data refer to tobacco smoking only, in the absence of sufficient data on all tobacco use.
China
Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)  
- Both sexes: 27%
- Males: 30%
- Females: 24%

Prevalence of hypertension – global comparison (both sexes)

Trends in uncontrolled hypertension in adults aged 30–79 years

Hypertension control rate scenarios

Mortality

- Probability of premature mortality from NCDs (%)
- Cardiovascular disease deaths
- Cardiovascular disease deaths attributable to high systolic blood pressure (%)

Risk factors

- Mean population salt intake, adults aged 25+ years (g/day)
- Current tobacco use, adults aged 15+ years (%)
- Obesity, adults aged 18+ years (%)
- Total alcohol per capita consumption, adults aged 15+ years (litres)
- Physical inactivity, adults aged 18+ years (%)

National response

- National target for blood pressure
- National target for salt consumption

Surveillance

Conducted recent, national survey measuring raised blood pressure/hypertension
Conducted recent, national survey on salt/sodium intake
Functioning system for generating reliable cause-specific mortality data on a routine basis

Footnotes:
- a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.
- b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg.
- d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.
- e. Age-standardized estimates are presented for all indicators except salt intake.
- f. Data refer to tobacco smoking only, in the absence of sufficient data on all tobacco use.
**Colombia**

**Hypertension profile**

**Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)**

- Total population (2019): 50 187 000
- Total deaths (2019): 239 000

---

**Prevalence of hypertension – global comparison (both sexes)**

- Of the **7.8 million** adults aged 30–79 years with hypertension:
  - **69%** diagnosed
  - **55%** treated
  - **33%** controlled

---

**Trends in uncontrolled hypertension in adults aged 30–79 years**

- Past trends
- Projected trends
- Global target

---

**Mortality**

- Probability of premature mortality from NCDs (%)
  - Cardiovascular disease deaths
  - Cardiovascular disease deaths attributable to high systolic blood pressure (%)

---

**Risk factors**

- Mean population salt intake, adults aged 25+ years (g/day)
- Current tobacco use, adults aged 15+ years (%)
- Obesity, adults aged 18+ years (%)
- Total alcohol per capita consumption, adults aged 15+ years (litres)
- Physical inactivity, adults aged 18+ years (%)

---

**National response**

- National target for blood pressure
- National target for salt consumption
- Guidelines for management of hypertension
- Functioning system for generating reliable cause-specific mortality data on a routine basis

---

Footnotes: a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control. e. Age-standardized estimates are presented for all indicators except salt intake.
Comoros

Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)

Prevalence of hypertension – global comparison (both sexes)

Trends in uncontrolled hypertension in adults aged 30–79 years

Hypertension control rate scenarios

Mortality

Probability of premature mortality from NCDs (%)
Cardiovascular disease deaths
Cardiovascular disease deaths attributable to high systolic blood pressure (%)

Risk factors

Mean population salt intake, adults aged 25+ years (g/day)
Current tobacco use, adults aged 15+ years (%)
Obesity, adults aged 18+ years (%)
Total alcohol per capita consumption, adults aged 15+ years (litres)
Physical inactivity, adults aged 18+ years (%)

National response

Targets
National target for blood pressure
National target for salt consumption

Surveillance
Conducted recent, national survey measuring raised blood pressure/hypertension
Conducted recent, national survey on salt/sodium intake
Functioning system for generating reliable cause-specific mortality data on a routine basis

Treatment
Guidelines for management of hypertension

Footnotes: a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control. e. Age-standardized estimates are presented for all indicators except salt intake.

Total population (2019): 791 000
Total deaths (2019): 5030

Of the 82 000 adults aged 30–79 years with hypertension:

In order to achieve a 50% control rate, 32 000 more people with hypertension would need to be effectively treated.

If the progress scenario were achieved, 1700 deaths would be averted by 2040.

Projected hypertension control rates by scenario:

- Business as usual
- Progress
- Aspirational

Annex 2. Hypertension profiles and explanatory notes

113
Congo

Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)  

<table>
<thead>
<tr>
<th>Sex</th>
<th>Prevalence (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Both sexes</td>
<td>40%</td>
</tr>
<tr>
<td>Males</td>
<td>38%</td>
</tr>
<tr>
<td>Females</td>
<td>42%</td>
</tr>
</tbody>
</table>

Prevalence of hypertension – global comparison (both sexes)

Of the 617 000 adults aged 30–79 years with hypertension:

- In order to achieve a 50% control rate, 252 000 more people with hypertension would need to be effectively treated.\(^b\)

- If the progress scenario were achieved, 16 000 deaths would be averted by 2040.

Mortality

Probability of premature mortality from NCDs (%)

<table>
<thead>
<tr>
<th>Sex</th>
<th>Probability (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Both sexes</td>
<td>23</td>
</tr>
<tr>
<td>Males</td>
<td>23</td>
</tr>
<tr>
<td>Females</td>
<td>22</td>
</tr>
</tbody>
</table>

Cardiovascular disease deaths

<table>
<thead>
<tr>
<th>Sex</th>
<th>Number (2019)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Both sexes</td>
<td>6300</td>
</tr>
<tr>
<td>Males</td>
<td>2700</td>
</tr>
<tr>
<td>Females</td>
<td>3600</td>
</tr>
</tbody>
</table>

Cardiovascular disease deaths attributable to high systolic blood pressure (%)

<table>
<thead>
<tr>
<th>Sex</th>
<th>Number (2019)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Both sexes</td>
<td>66</td>
</tr>
<tr>
<td>Males</td>
<td>63</td>
</tr>
<tr>
<td>Females</td>
<td>68</td>
</tr>
</tbody>
</table>

Risk factors\(^c\)

<table>
<thead>
<tr>
<th>Factor</th>
<th>Both sexes</th>
<th>Males</th>
<th>Females</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean population salt intake, adults aged 25+ years (g/day)</td>
<td>7</td>
<td>7</td>
<td>7</td>
<td>2019</td>
</tr>
<tr>
<td>Current tobacco use, adults aged 15+ years (%)</td>
<td>14</td>
<td>26</td>
<td>2</td>
<td>2019</td>
</tr>
<tr>
<td>Obesity, adults aged 18+ years (%)</td>
<td>10</td>
<td>6</td>
<td>14</td>
<td>2016</td>
</tr>
<tr>
<td>Total alcohol per capita consumption, adults aged 15+ years (litres)</td>
<td>6</td>
<td>10</td>
<td>3</td>
<td>2019</td>
</tr>
<tr>
<td>Physical inactivity, adults aged 18+ years (%)</td>
<td>28</td>
<td>25</td>
<td>31</td>
<td>2016</td>
</tr>
</tbody>
</table>

National response

<table>
<thead>
<tr>
<th>Targets</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>National target for blood pressure</td>
<td><strong>Guidelines for management of hypertension</strong></td>
</tr>
<tr>
<td>National target for salt consumption</td>
<td></td>
</tr>
</tbody>
</table>

Surveillance

- Conducted recent, national survey measuring raised blood pressure/hypertension
- Conducted recent, national survey on salt/sodium intake
- Functioning system for generating reliable cause-specific mortality data on a routine basis

Footnotes:

a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.

b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.

e. Age-standardized estimates are presented for all indicators except salt intake.
**Cook Islands**

**Hypertension profile**

<table>
<thead>
<tr>
<th>Total population (2019):</th>
<th>17 100</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total deaths (2019):</td>
<td>no data</td>
</tr>
</tbody>
</table>

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)  
- Women: 43%  
- Men: 45%  
- Overall: 41%

### Prevalence of hypertension – global comparison (both sexes) commune

- **Global trend:** 60%

### Trends in uncontrolled hypertension in adults aged 30–79 years

- **Past trends:**
  - Women: 50%
  - Men: 45%

- **Projected trends:**
  - Women: 45%
  - Men: 40%

- **Global target:** 30%

### Hypertension control rate scenarios

- **4500 adults** aged 30–79 years with hypertension

  - **Diagnosed:**
    - Women: 57%
    - Men: 42%
    - Overall: 50%

  - **Treated:**
    - Women: 42%
    - Men: 30%
    - Overall: 35%

  - **Controlled:**
    - Women: 17%
    - Men: 12%
    - Overall: 15%

### Mortality

- **Probability of premature mortality from NCDs (%):**
  - No data

- **Cardiovascular disease deaths:**
  - No data

- **Cardiovascular disease deaths attributable to high systolic blood pressure (%):**
  - No data

### Risk factors

- **Mean population salt intake, adults aged 25+ years (g/day):**
  - Women: 8 g/day
  - Men: 9 g/day

- **Current tobacco use, adults aged 15+ years (%):**
  - Women: 25%
  - Men: 28%

- **Obesity, adults aged 18+ years (%):**
  - Women: 56%
  - Men: 53%

- **Total alcohol per capita consumption, adults aged 15+ years (litres):**
  - Women: 11 l
  - Men: 18 l

- **Physical inactivity, adults aged 18+ years (%):**
  - Women: 18%
  - Men: 10%

### National response

**Targets**

- National target for blood pressure
- National target for salt consumption

**Surveillance**

- Conducted recent, national survey measuring raised blood pressure/hypertension
- Conducted recent, national survey on salt/sodium intake
- Functioning system for generating reliable cause-specific mortality data on a routine basis

**Treatment**

- Guidelines for management of hypertension

### Footnotes

- a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.
- b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg.
- c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Projected trends global target.
- e. Age-standardized estimates are presented for all indicators except salt intake.
- f. Data refer to tobacco smoking only, in the absence of sufficient data on all tobacco use.
Costa Rica

Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)a

<table>
<thead>
<tr>
<th>Gender</th>
<th>Prevalence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Males</td>
<td>38%</td>
</tr>
<tr>
<td>Females</td>
<td>39%</td>
</tr>
</tbody>
</table>

Prevalence of hypertension – global comparison (both sexes)a

<table>
<thead>
<tr>
<th>Country</th>
<th>Prevalence of hypertension (2019)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Costa Rica</td>
<td>50%</td>
</tr>
</tbody>
</table>

Trends in uncontrolled hypertension in adults aged 30–79 yearsc

<table>
<thead>
<tr>
<th>Year</th>
<th>Males</th>
<th>Females</th>
<th>Both sexes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2020</td>
<td>10</td>
<td>8</td>
<td>10.5</td>
</tr>
<tr>
<td>2025</td>
<td>9.5</td>
<td>9.5</td>
<td>9.5</td>
</tr>
</tbody>
</table>

Hypertension control rate scenarios

<table>
<thead>
<tr>
<th>Scenario</th>
<th>Males</th>
<th>Females</th>
<th>Both sexes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Business as usual</td>
<td>72%</td>
<td>82%</td>
<td>77%</td>
</tr>
<tr>
<td>Progress</td>
<td>64%</td>
<td>76%</td>
<td>70%</td>
</tr>
<tr>
<td>Aspirational</td>
<td>45%</td>
<td>54%</td>
<td>50%</td>
</tr>
</tbody>
</table>

Mortality

Probability of premature mortality from NCDs (%)

<table>
<thead>
<tr>
<th>Disease</th>
<th>Probability</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiovascular disease deaths</td>
<td>10%</td>
</tr>
<tr>
<td>Cardiovascular disease deaths attributable to high systolic blood pressure (%)</td>
<td>6%</td>
</tr>
</tbody>
</table>

Risk factors*

<table>
<thead>
<tr>
<th>Risk factor</th>
<th>Mean population salt intake, adults aged 25+ years (g/day)</th>
<th>Current tobacco use, adults aged 15+ years (%)</th>
<th>Obesity, adults aged 18+ years (%)</th>
<th>Total alcohol per capita consumption, adults aged 15+ years (litres)</th>
<th>Physical inactivity, adults aged 18+ years (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>10</td>
<td>9</td>
<td>26</td>
<td>3</td>
<td>46</td>
</tr>
</tbody>
</table>

National response

Targets

- National target for blood pressure
- National target for salt consumption

Surveillance

- Conducted recent, national survey measuring raised blood pressure/hypertension
- Conducted recent, national survey on salt/sodium intake
- Functioning system for generating reliable cause-specific mortality data on a routine basis

Treatment

- Guidelines for management of hypertension

Footnotes: a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control. e. Age-standardized estimates are presented for all indicators except salt intake.

Global report on hypertension: the race against a silent killer

116
Côte d'Ivoire

Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)  
- 37% (♂), 37% (♀), 38% (♂)  

Prevalence of hypertension – global comparison (both sexes)

Trends in uncontrolled hypertension in adults aged 30–79 years

Hypertension control rate scenarios

Mortality

Probability of premature mortality from NCDs (%)
- Both sexes: 22, Males: 24, Females: 19  
- Year: 2019
- Cardiovascular disease deaths
- Both sexes: 25,900, Males: 15,800, Females: 10,200  
- Year: 2019
- Cardiovascular disease deaths attributable to high systolic blood pressure (%)
- Both sexes: 63, Males: 63, Females: 63  
- Year: 2019

Risk factors

Mean population salt intake, adults aged 25+ years (g/day)
- Both sexes: 7, Males: 7, Females: 7  
- Year: 2019
- Current tobacco use, adults aged 15+ years (%)
- Both sexes: 10, Males: 19, Females: 1  
- Year: 2019
- Obesity, adults aged 18+ years (%)
- Both sexes: 10, Males: 6, Females: 15  
- Year: 2016
- Total alcohol per capita consumption, adults aged 15+ years (litres)
- Both sexes: 3, Males: 5, Females: 1  
- Year: 2019
- Physical inactivity, adults aged 18+ years (%)  

National response

Targets
- National target for blood pressure  
- National target for salt consumption

Surveillance
- Conducted recent, national survey measuring raised blood pressure/hypertension  
- Conducted recent, national survey on salt/sodium intake

Treatment
- Guidelines for management of hypertension

Footnotes:  
a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.  
b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg.  
c. SBP ≥140 mmHg or DBP ≥90 mmHg.  
d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.  
e. Age-standardized estimates are presented for all indicators except salt intake.
Croatia

Hypertension profile

Total population (2019): 4,130,000
Total deaths (2019): 51,800

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)α

<table>
<thead>
<tr>
<th></th>
<th>% of population aged 30–79 years with hypertension</th>
</tr>
</thead>
<tbody>
<tr>
<td>all</td>
<td>% of population aged 30–79 years</td>
</tr>
<tr>
<td>males</td>
<td>70%</td>
</tr>
<tr>
<td>females</td>
<td>46%</td>
</tr>
</tbody>
</table>

Of the 1.5 million adults aged 30–79 years with hypertension:

In order to achieve a 50% control rate, 425,000 more people with hypertension would need to be effectively treated.β

Prevalence of hypertension – global comparison (both sexes)α

Trends in uncontrolled hypertension in adults aged 30–79 yearsβ

Hypertension control rate scenarios

Mortality

Probability of premature mortality from NCDs (%)
Cardiovascular disease deaths
Cardiovascular disease deaths attributable to high systolic blood pressure (%)

Risk factorsα

Mean population salt intake, adults aged 25+ years (g/day)
Current tobacco use, adults aged 15+ years (%)
Obesity, adults aged 18+ years (%)
Total alcohol per capita consumption, adults aged 15+ years (litres)
Physical inactivity, adults aged 18+ years (%)

National response

Targets
National target for blood pressure
National target for salt consumption

Surveillance
Conducted recent, national survey measuring raised blood pressure/hypertension
Conducted recent, national survey on salt/sodium intake
Functioning system for generating reliable cause-specific mortality data on a routine basis

Footnotes: a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.

© 2023 World Health Organization

Global report on hypertension: the race against a silent killer
118
Footnotes: a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control. e. Age-standardized estimates are presented for all indicators except salt intake.

Annex 2. Hypertension profiles and explanatory notes

119
Cyprus
Hypertension profile

Total population (2019): 1 229 000
Total deaths (2019): 6 760

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)¹

Gender: %

- Males: 31%
- Females: 36%
- Overall: 26%

Prevalence of hypertension – global comparison (both sexes)¹

Of the 235 000 adults aged 30–79 years with hypertension:

- Diagnosed: 65%
- Treated: 55%
- Controlled: 33%

Notes:
- a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.
- b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg.
- c. SBP ≥140 mmHg or DBP ≥90 mmHg.
- d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.
- e. Age-standardized estimates are presented for all indicators except salt intake.
- f. Data refer to tobacco smoking only, in the absence of sufficient data on all tobacco use.

In order to achieve a 50% control rate, 37 000 more people with hypertension would need to be effectively treated.²

If the progress scenario were achieved, 2400 deaths would be averted by 2040.

Mortality

Probability of premature mortality from NCDs (%)
- Females: 2019
- Males: 2019

Cardiovascular disease deaths
- Both sexes: 2019
- Males: 2019
- Females: 2019

Cardiovascular disease deaths attributable to high systolic blood pressure (%)
- Both sexes: 2019
- Males: 2019
- Females: 2019

Risk factors²

- Mean population salt intake, adults aged 25+ years (g/day)
- Current tobacco use, adults aged 15+ years (%)
- Obesity, adults aged 18+ years (%)
- Total alcohol per capita consumption, adults aged 15+ years (litres)
- Physical inactivity, adults aged 18+ years (%)

National response

Targets
- National target for blood pressure
- National target for salt consumption

Surveillance
- Conducted recent, national survey measuring raised blood pressure/hypertension
- Conducted recent, national survey on salt/sodium intake

Treatment
- Guidelines for management of hypertension

Footnotes:
- a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.
- b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg.
- c. SBP ≥140 mmHg or DBP ≥90 mmHg.
- d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.
- e. Age-standardized estimates are presented for all indicators except salt intake.
- f. Data refer to tobacco smoking only, in the absence of sufficient data on all tobacco use.
Czechia

Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019) 
- both sexes: 42%
- males: 49%
- females: 34%

Prevalence of hypertension – global comparison (both sexes)

Trends in uncontrolled hypertension in adults aged 30–79 years

Of the 3.3 million adults aged 30–79 years with hypertension:
- 73% diagnosed
- 63% treated
- 36% controlled

In order to achieve a 50% control rate, 414,000 more people with hypertension would need to be effectively treated.

Mortality

Probability of premature mortality from NCDs (%)
- both sexes: 14
- males: 19
- females: 10
- year: 2019
- Cardiovascular disease deaths
  - both sexes: 47,900
  - males: 22,600
  - females: 25,400
  - year: 2019
- Cardiovascular disease deaths attributable to high systolic blood pressure (%)
  - both sexes: 47
  - males: 51
  - females: 43
  - year: 2019

Risk factors

Mean population salt intake, adults aged 25+ years (g/day)
- both sexes: 13
- males: 15
- females: 11
- year: 2019

Current tobacco use, adults aged 15+ years (%)
- both sexes: 31
- males: 35
- females: 27
- year: 2019

Obesity, adults aged 18+ years (%)
- both sexes: 26
- males: 26
- females: 25
- year: 2016

Total alcohol per capita consumption, adults aged 15+ years (litres)
- both sexes: 13
- males: 21
- females: 6
- year: 2019

Physical inactivity, adults aged 18+ years (%)
- both sexes: 31
- males: 28
- females: 34
- year: 2016

National response

Targets
- National target for blood pressure
- National target for salt consumption

Surveillance
- Conducted recent, national survey measuring raised blood pressure/hypertension
- Conducted recent, national survey on salt/sodium intake
- Functioning system for generating reliable cause-specific mortality data on a routine basis

Footnotes: a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control. e. Age-standardized estimates are presented for all indicators except salt intake. f. Data refer to tobacco smoking only, in the absence of sufficient data on all tobacco use.
Democratic People's Republic of Korea

**Hypertension profile**

**Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)**

<table>
<thead>
<tr>
<th>Both sexes</th>
<th>Males</th>
<th>Females</th>
</tr>
</thead>
<tbody>
<tr>
<td>% of population aged 30–79 years</td>
<td>27%</td>
<td>28%</td>
</tr>
</tbody>
</table>

---

**Prevalence of hypertension – global comparison (both sexes)**

- Democratic People's Rep. of Korea: 54%
- Global: 43%
- Controlled: 23%

---

**Trends in uncontrolled hypertension in adults aged 30–79 years**

- Past trends
- Projected trends
- Global target

---

**Mortality**

- Probability of premature mortality from NCDs (%)
  - both sexes: 24, males: 30, females: 19
  - Cardiovascular disease deaths: 90,900, 41,400, 49,500
  - 2019

---

**Risk factors**

- Mean population salt intake, adults aged 25+ years (g/day): 12
- Current tobacco use, adults aged 15+ years (%): 18
- Obesity, adults aged 18+ years (%): 7
- Total alcohol per capita consumption, adults aged 15+ years (litres): 4
- Physical inactivity, adults aged 18+ years (%): no data

---

**National response**

**Targets**

| National target for blood pressure | ✔ |
| National target for salt consumption | ✔ |

**Surveillance**

- Conducted recent, national survey measuring raised blood pressure/hypertension: ✗
- Conducted recent, national survey on salt/sodium intake: ✗
- Functioning system for generating reliable cause-specific mortality data on a routine basis: ✗

---

**Footnotes:**

- a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.
- b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.
- e. Age-standardized estimates are presented for all indicators except salt intake.
- f. Data refer to tobacco smoking only, in the absence of sufficient data on all tobacco use.
Democratic Republic of the Congo

Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)a

- Total population (2019): 89,907,000
- Total deaths (2019): 722,000

Prevalence of hypertension – global comparison (both sexes)a

Of the 7.4 million adults aged 30–79 years with hypertension:

- 40% diagnosed
- 26% treated
- 12% controlled

Trends in uncontrolled hypertension in adults aged 30–79 yearsc

Hypertension control rate scenarios

If the progress scenario were achieved, 276,000 deaths would be averted by 2040.

Mortality

- Probability of premature mortality from NCDs (%)
  - both sexes 24 98,600 47,700 50,900 2019
  - males 26 47,700 62 2019
  - females 22 50,900 2019

- Cardiovascular disease deaths
  - both sexes 61 18 2019
  - males 59 2019
  - females 62 2019

- Cardiovascular disease deaths attributable to high systolic blood pressure (%)
  - both sexes 27% 2019
  - males 27% 2019
  - females 27% 2019

Risk factorsa

- Mean population salt intake, adults aged 25+ years (g/day)
  - both sexes 6 2019
  - males 6 2019
  - females 5 2019

- Current tobacco use, adults aged 15+ years (%)
  - both sexes 13 2019
  - males 23 2019
  - females 3 2019

- Obesity, adults aged 18+ years (%)
  - both sexes 7 2016
  - males 4 2016
  - females 10 2016

- Total alcohol per capita consumption, adults aged 15+ years (litres)
  - both sexes 2 2019
  - males 3 2019
  - females 1 2019

- Physical inactivity, adults aged 18+ years (%)
  - both sexes 24 2016
  - males 21 2016
  - females 27 2016

National response

- Targets
  - National target for blood pressure
  - National target for salt consumption

- Surveillance
  - Conducted recent, national survey measuring raised blood pressure/hypertension
  - Conducted recent, national survey on salt/sodium intake
  - Functioning system for generating reliable cause-specific mortality data on a routine basis

Footnotes: a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.

e. Age-standardized estimates are presented for all indicators except salt intake.
Denmark

Hypertension profile

Total population (2019): 5,796,000
Total deaths (2019): 54,000

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)\(^a\)

\(36\% \quad 43\% \quad 29\%\)

Prevalence of hypertension – global comparison (both sexes)\(^a\)

![Graph showing prevalence of hypertension globally and in Denmark.]

Of the 1.5 million adults aged 30–79 years with hypertension:

- In order to achieve a 50% control rate, 574,000 more people with hypertension would need to be effectively treated.\(^b\)

Trends in uncontrolled hypertension in adults aged 30–79 years\(^c\)

![Graph showing trends in uncontrolled hypertension.]

Mortality

Probability of premature mortality from NCDs (%)
Cardiovascular disease deaths
Cardiovascular disease deaths attributable to high systolic blood pressure (%)

Risk factors\(^e\)

Mean population salt intake, adults aged 25+ years (g/day)
Current tobacco use, adults aged 15+ years (%)\(^f\)
Obesity, adults aged 18+ years (%)
Total alcohol per capita consumption, adults aged 15+ years (litres)
Physical inactivity, adults aged 18+ years (%)

National response

Target
- National target for blood pressure
- National target for salt consumption

Surveillance
- Conducted recent, national survey measuring raised blood pressure/hypertension
- Conducted recent, national survey on salt/sodium intake
- Functioning system for generating reliable cause-specific mortality data on a routine basis

Footnotes:

a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control. e. Age-standardized estimates are presented for all indicators except salt intake. f. Data refer to tobacco smoking only, in the absence of sufficient data on all tobacco use.
**Djibouti**

**Hypertension profile**

**Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)**

- **Both sexes**: 34%
- **Males**: 33%
- **Females**: 36%

---

**Trends in uncontrolled hypertension in adults aged 30–79 years**

**Hypertension control rate scenarios**

- **Projected hypertension control rates by scenario**
  - **Business as usual**: 0%
  - **Progress**: 5%
  - **Aspirational**: 10%

**Mortality**

- **Probability of premature mortality from NCDs (%):**
  - **Both sexes**: 22
  - **Males**: 23
  - **Females**: 21
  - **Year**: 2019

- **Cardiovascular disease deaths**: 1700
- **Cardiovascular disease deaths attributable to high systolic blood pressure (%):**
  - **Both sexes**: 7
  - **Males**: 6
  - **Females**: 8
  - **Year**: 2019

**Risk factors**

- **Mean population salt intake, adults aged 25+ years (g/day):**
  - **Both sexes**: 7
  - **Males**: 6
  - **Females**: 8
  - **Year**: 2019

- **Current tobacco use, adults aged 15+ years (%):**
  - **Both sexes**: 14
  - **Males**: 15
  - **Females**: 18
  - **Year**: 2019

- **Obesity, adults aged 18+ years (%):**
  - **Both sexes**: 0
  - **Males**: 0
  - **Females**: 0
  - **Year**: 2019

- **Physical inactivity, adults aged 18+ years (%):**
  - **Both sexes**: 0
  - **Males**: 0
  - **Females**: 0
  - **Year**: 2019

**National response**

**Targets**

- **National target for blood pressure**
- **National target for salt consumption**

**Surveillance**

- Conducted recent, national survey measuring raised blood pressure/hypertension
- Conducted recent, national survey on salt/sodium intake
- Functioning system for generating reliable cause-specific mortality data on a routine basis

**Footnotes:**

a. SBP ≥140 mmHg or DBP ≥90 mmHg. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.

---

Annex 2. Hypertension profiles and explanatory notes

---

125
Dominica
Hypertension profile

Total population (2019): 71 400
Total deaths (2019): no data

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)²

- 48% men
- 46% women
- 50% overall

Prevalence of hypertension – global comparison (both sexes)²

Of the 18 000 adults aged 30–79 years with hypertension:
- 48% diagnosed
- 36% treated
- 14% controlled

In order to achieve a 50% control rate, 5900 more people with hypertension would need to be effectively treated.³

Trends in uncontrolled hypertension in adults aged 30–79 years³

Hypertension control rate scenarios

- Data not available

Mortality

- Probability of premature mortality from NCDs (%)
- Cardiovascular disease deaths
- Cardiovascular disease deaths attributable to high systolic blood pressure (%)

Risk factors⁴

- Mean population salt intake, adults aged 25+ years (g/day)
- Current tobacco use, adults aged 15+ years (%)
- Obesity, adults aged 18+ years (%)
- Total alcohol per capita consumption, adults aged 15+ years (litres)
- Physical inactivity, adults aged 18+ years (%)

National response

- Treatment
- Guidelines for management of hypertension

Footnotes: a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Age-standardized estimates are presented for all indicators except salt intake.
Dominican Republic

Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)\(^a\) 49% 49% 49%

**Prevalence of hypertension – global comparison (both sexes)\(^a\)**

- **Dominican Republic**
- Global

Of the **2.3 million** adults aged 30–79 years with hypertension:
- **Diagnosed**
  - Males 61%
  - Females 75%
- **Treated**
  - Males 46%
  - Females 48%
- **Controlled**
  - Males 18%
  - Females 25%

In order to achieve a 50% control rate, **663 000 more people** with hypertension would need to be effectively treated.\(^b\)

**Trends in uncontrolled hypertension in adults aged 30–79 years**\(^c\)

- Past trends
- Projected trends
- Global target

**Hypertension control rate scenarios**

- Projected hypertension control rates by scenario\(^d\)
  - Business as usual
  - Progress
  - Aspirational

If the progress scenario were achieved, **49 000 deaths** would be averted by 2040.

**Mortality**

- Probability of premature mortality from NCDs (%)
- Cardiovascular disease deaths
- Cardiovascular disease deaths attributable to high systolic blood pressure (%)

**Risk factors**\(^e\)

- Mean population salt intake, adults aged 25+ years (g/day)
- Current tobacco use, adults aged 15+ years (%)
- Obesity, adults aged 18+ years (%)
- Total alcohol per capita consumption, adults aged 15+ years (litres)
- Physical inactivity, adults aged 18+ years (%)

**Targets**

- National target for blood pressure
- National target for salt consumption

**Surveillance**

- Conducted recent, national survey measuring raised blood pressure/hypertension
- Conducted recent, national survey on salt/sodium intake
- Functioning system for generating reliable cause-specific mortality data on a routine basis

**Footnotes:**
- a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.
- b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg.
- c. SBP ≥140 mmHg or DBP ≥90 mmHg.
- d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.
- e. Age-standardized estimates are presented for all indicators except salt intake.
Ecuador

Hypertension profile

Total population (2019): 17 344 000
Total deaths (2019): 80 200

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019) \( a \) - 27%  29%  25%

Prevalence of hypertension - global comparison (both sexes) \( a \)

Of the 2 million adults aged 30–79 years with hypertension:

- 51% diagnosed
- 37% treated
- 18% controlled

Trends in uncontrolled hypertension in adults aged 30–79 years \( c \)

Mortality

Probability of premature mortality from NCDs (%)
- Cardiovascular disease deaths
- Cardiovascular disease deaths attributable to high systolic blood pressure (%)

Risk factors \( e \)

Mean population salt intake, adults aged 25+ years (g/day)
- Current tobacco use, adults aged 15+ years (%)
- Obesity, adults aged 18+ years (%)
- Total alcohol per capita consumption, adults aged 15+ years (litres)
- Physical inactivity, adults aged 18+ years (%)

National response

- National target for blood pressure
- National target for salt consumption
- Surveillancen
- Conducted recent, national survey measuring raised blood pressure/hypertension
- Conducted recent, national survey on salt/sodium intake
- Functioning system for generating reliable cause-specific mortality data on a routine basis

Footnotes:
- a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.
- b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg.
- c. SBP ≥140 mmHg or DBP ≥90 mmHg.
- d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.
- e. Age-standardized estimates are presented for all indicators except salt intake.

Global report on hypertension: the race against a silent killer

Page 128
El Salvador

Hypertension profile

Total population (2019): 6,280,000
Total deaths (2019): 40,700

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)

- 33% males
- 31% females
- 34% total

Prevalence of hypertension – global comparison (both sexes)

Trends in uncontrolled hypertension in adults aged 30–79 years

Hypertension control rate scenarios

Mortality

Probability of premature mortality from NCDs (%)
- Cardiovascular disease deaths
- Cardiovascular disease deaths attributable to high systolic blood pressure (%)

Risk factors

- Mean population salt intake, adults aged 25+ years (g/day)
- Current tobacco use, adults aged 15+ years (%)
- Obesity, adults aged 18+ years (%)
- Total alcohol per capita consumption, adults aged 15+ years (litres)
- Physical inactivity, adults aged 18+ years (%)

National response

Targets
- National target for blood pressure
- National target for salt consumption

Surveillance
- Conducted recent, national survey measuring raised blood pressure/hypertension
- Conducted recent, national survey on salt/sodium intake
- Functioning system for generating reliable cause-specific mortality data on a routine basis

Footnotes: a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.

In order to achieve a 50% control rate, 96,000 more people with hypertension would need to be effectively treated.

If the progress scenario were achieved, 6,800 deaths would be averted by 2040.
Equatorial Guinea
Hypertension profile

Total population (2019): 1 553 000
Total deaths (2019): 10 200

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)

- Men: 38%
- Women: 40%

Prevalence of hypertension – global comparison (both sexes)

Of the 141 000 adults aged 30–79 years with hypertension:
- Diagnosed: 34%
- Treated: 23%
- Controlled: 10%

Mortality

- Probability of premature mortality from NCDs (%): 22 (males), 23 (females)
- Cardiovascular disease deaths: 1200 (males), 65 (females)
- Cardiovascular disease deaths attributable to high systolic blood pressure (%): 660 (males), 68 (females)

Risk factors

- Mean population salt intake, adults aged 25+ years (g/day): 7 (both sexes)
- Current tobacco use, adults aged 15+ years (%): 8 (males), 7 (females)
- Obesity, adults aged 18+ years (%): no data (both sexes)
- Total alcohol per capita consumption, adults aged 15+ years (litres): 4 (males), 3 (females)
- Physical inactivity, adults aged 18+ years (%): no data (both sexes)

National response

- National target for blood pressure: ✔
- National target for salt consumption: ×

Surveillance

- Conducted recent, national survey measuring raised blood pressure/hypertension: ×
- Conducted recent, national survey on salt/sodium intake: ×
- Functioning system for generating reliable cause-specific mortality data on a routine basis: ×

Footnotes:
- a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.
- b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.
- e. Age-standardized estimates are presented for all indicators except salt intake.
Eritrea

Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)  

<table>
<thead>
<tr>
<th>Boys</th>
<th>Girls</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>24%</td>
<td>23%</td>
<td>25%</td>
</tr>
</tbody>
</table>

Total population (2019): 3,499,000  
Total deaths (2019): 27,800

Prevalence of hypertension – global comparison (both sexes)  

Of the 236,000 adults aged 30–79 years with hypertension:

- 39% diagnosed
- 24% treated
- 13% controlled

In order to achieve a 50% control rate, 89,000 more people with hypertension would need to be effectively treated.

Trends in uncontrolled hypertension in adults aged 30–79 years  

If the progress scenario were achieved, 14,000 deaths would be averted by 2040.

Hypertension control rate scenarios

Mortality

- Probability of premature mortality from NCDs (%)
- Cardiovascular disease deaths
- Cardiovascular disease deaths attributable to high systolic blood pressure (%)

Risk factors  

- Mean population salt intake, adults aged 25+ years (g/day)
- Current tobacco use, adults aged 15+ years (%)
- Obesity, adults aged 18+ years (%)
- Total alcohol per capita consumption, adults aged 15+ years (litres)
- Physical inactivity, adults aged 18+ years (%)

National response

- Treatment
- Guidelines for management of hypertension

Footnotes:  
a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.  
b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg.  
c. SBP ≥140 mmHg or DBP ≥90 mmHg.  
d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.  
e. Age-standardized estimates are presented for all indicators except salt intake.
Estonia

Hypertension profile

Total population (2019): 1,327,000
Total deaths (2019): 15,200

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019) \(^a\)

<table>
<thead>
<tr>
<th>Risk factor</th>
<th>Both sexes</th>
<th>Males</th>
<th>Females</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiovascular disease deaths attributable to high systolic blood pressure (%)</td>
<td>15</td>
<td>22</td>
<td>9</td>
<td>2019</td>
</tr>
<tr>
<td></td>
<td>7,700</td>
<td>3,000</td>
<td>4,700</td>
<td>2019</td>
</tr>
<tr>
<td></td>
<td>63</td>
<td>63</td>
<td>63</td>
<td>2019</td>
</tr>
</tbody>
</table>

Mortality

Probability of premature mortality from NCDs (%)
Cardiovascular disease deaths
Cardiovascular disease deaths attributable to high systolic blood pressure (%)

Risk factors \(^e\)

<table>
<thead>
<tr>
<th>Risk factor</th>
<th>Both sexes</th>
<th>Males</th>
<th>Females</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean population salt intake, adults aged 25+ years (g/day)</td>
<td>6</td>
<td>7</td>
<td>5</td>
<td>2019</td>
</tr>
<tr>
<td>Current tobacco use, adults aged 15+ years (%)</td>
<td>31</td>
<td>37</td>
<td>24</td>
<td>2019</td>
</tr>
<tr>
<td>Obesity, adults aged 18+ years (%)</td>
<td>21</td>
<td>20</td>
<td>22</td>
<td>2016</td>
</tr>
<tr>
<td>Total alcohol per capita consumption, adults aged 15+ years (litres)</td>
<td>11</td>
<td>18</td>
<td>5</td>
<td>2019</td>
</tr>
<tr>
<td>Physical inactivity, adults aged 18+ years (%)</td>
<td>32</td>
<td>29</td>
<td>35</td>
<td>2016</td>
</tr>
</tbody>
</table>

National response

Targets
National target for blood pressure
National target for salt consumption

Surveillance
Conducted recent, national survey measuring raised blood pressure/hypertension
Conducted recent, national survey on salt/sodium intake
Functioning system for generating reliable cause-specific mortality data on a routine basis

Footnotes: a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP ≤140 mmHg and DBP ≤90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control. e. Age-standardized estimates are presented for all indicators except salt intake.
Eswatini

Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)a

Prevalence of hypertension – global comparison (both sexes)a

Trends in uncontrolled hypertension in adults aged 30–79 yearsc

Hypertension control rate scenarios

Mortality

Risk factorsb

National response

Footnotes: a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control. e. Age-standardized estimates are presented for all indicators except salt intake.
Ethiopia

Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019) 

- 27% females, 25% males, 30% overall

Prevalence of hypertension – global comparison (both sexes)

Trends in uncontrolled hypertension in adults aged 30–79 years

Hypertension control rate scenarios

- If the progress scenario were achieved, 211,000 deaths would be averted by 2040.

Mortality

- Probability of premature mortality from NCDs (%)
- Cardiovascular disease deaths
- Cardiovascular disease deaths attributable to high systolic blood pressure (%)

Risk factors

- Mean population salt intake, adults aged 25+ years (g/day)
- Current tobacco use, adults aged 15+ years (%)
- Obesity, adults aged 18+ years (%)
- Total alcohol per capita consumption, adults aged 15+ years (litres)
- Physical inactivity, adults aged 18+ years (%)

National response

Targets
- National target for blood pressure
- National target for salt consumption

Surveillance
- Conducted recent, national survey measuring raised blood pressure/hypertension
- Conducted recent, national survey on salt/sodium intake
- Functioning system for generating reliable cause-specific mortality data on a routine basis

Footnotes:

a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.

e. Age-standardized estimates are presented for all indicators except salt intake.
**Fiji**

**Hypertension profile**

**Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)**

<table>
<thead>
<tr>
<th>Sex</th>
<th>Prevalence (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male</td>
<td>39%</td>
</tr>
<tr>
<td>Female</td>
<td>41%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Total population (2019):</th>
<th>918 000</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total deaths (2019):</td>
<td>7 130</td>
</tr>
</tbody>
</table>

**Prevalence of hypertension – global comparison (both sexes)**

- Of the 153,000 adults aged 30–79 years with hypertension:
  - 54% diagnosed, 35% treated, 13% controlled

- In order to achieve a 50% control rate, 58,000 more people with hypertension would need to be effectively treated.

**Trends in uncontrolled hypertension in adults aged 30–79 years**

- If the progress scenario were achieved, 4,200 deaths would be averted by 2040.

**Mortality**

- Probability of premature mortality from NCDs (%)
  - Both sexes: 38%
  - Males: 42%
  - Females: 33%
  - Year: 2019

- Cardiovascular disease deaths
  - Both sexes: 2,500
  - Males: 1,500
  - Females: 970
  - Year: 2019

- Cardiovascular disease deaths attributable to high systolic blood pressure (%)
  - Both sexes: 62%
  - Males: 61%
  - Females: 65%
  - Year: 2019

**Risk factors**

- Mean population salt intake, adults aged 25+ years (g/day)
  - Both sexes: 7 g
  - Males: 8 g
  - Females: 7 g
  - Year: 2019

- Current tobacco use, adults aged 15+ years (%)
  - Both sexes: 23%
  - Males: 36%
  - Females: 11%
  - Year: 2019

- Obesity, adults aged 18+ years (%)
  - Both sexes: 30%
  - Males: 25%
  - Females: 35%
  - Year: 2016

- Total alcohol per capita consumption, adults aged 15+ years (litres)
  - Both sexes: 3 l
  - Males: 6 l
  - Females: 1 l
  - Year: 2019

- Physical inactivity, adults aged 18+ years (%)
  - Both sexes: 17%
  - Males: 11%
  - Females: 24%
  - Year: 2016

**National response**

- **Targets**
  - National target for blood pressure: ✔
  - National target for salt consumption: ✔

- **Surveillance**
  - Conducted recent, national survey measuring raised blood pressure/hypertension: ✔
  - Conducted recent, national survey on salt/sodium intake: ✔
  - Functioning system for generating reliable cause-specific mortality data on a routine basis: ✔

- **Treatment**
  - Guidelines for management of hypertension: ✔

Footnotes:

- a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.
- b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg.
- c. SBP ≥140 mmHg or DBP ≥90 mmHg.
- d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.
- e. Age-standardized estimates are presented for all indicators except salt intake.
- f. Data refer to tobacco smoking only, in the absence of sufficient data on all tobacco use.
Finland

Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)  
- Total population (2019): 5 522 000
- Total deaths (2019): 55 300

Prevalence of hypertension – global comparison (both sexes)

Of the 1.5 million adults aged 30–79 years with hypertension:

- In order to achieve a 50% control rate, 294 000 more people with hypertension would need to be effectively treated.

Mortality

Probability of premature mortality from NCDs (%)
- Cardiovascular disease deaths
- Cardiovascular disease deaths attributable to high systolic blood pressure (%)

Risk factors

Mean population salt intake, adults aged 25+ years (g/day)
- Current tobacco use, adults aged 15+ years (%)
- Obesity, adults aged 18+ years (%)
- Total alcohol per capita consumption, adults aged 15+ years (litres)
- Physical inactivity, adults aged 18+ years (%)

National response

Targets
- National target for blood pressure
- National target for salt consumption

Surveillance
- Conducted recent, national survey measuring raised blood pressure/hypertension
- Conducted recent, national survey on salt/sodium intake
- Functioning system for generating reliable cause-specific mortality data on a routine basis

Footnotes: a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.

e. Age-standardized estimates are presented for all indicators except salt intake.
France

Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)\textsuperscript{a}  

<table>
<thead>
<tr>
<th>Sex</th>
<th>Prevalence of Hypertension (% of population aged 30–79 years with hypertension)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Females</td>
<td>29%</td>
</tr>
<tr>
<td>Males</td>
<td>34%</td>
</tr>
<tr>
<td>Overall</td>
<td>24%</td>
</tr>
</tbody>
</table>

Total population (2019): 64 400 000  
Total deaths (2019): 598 000

Of the 14.1 million adults aged 30–79 years with hypertension:

- In order to achieve a 50% control rate, 2.8 million more people with hypertension would need to be effectively treated.\textsuperscript{b}

- If the progress scenario were achieved, 155 000 deaths would be averted by 2040.

---

**Notes:**

- \textsuperscript{a} SBP \geq 140 mmHg or DBP \geq 90 mmHg or taking medication for hypertension.
- \textsuperscript{b} Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg.
- \textsuperscript{c} Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.
- \textsuperscript{d} Age-standardized estimates are presented for all indicators except salt intake.
- \textsuperscript{e} Data refer to tobacco smoking only, in the absence of sufficient data on all tobacco use.
Gabon

Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)\(^a\)

<table>
<thead>
<tr>
<th>Percentage</th>
<th>Male (%)</th>
<th>Female (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>37%</td>
<td>36%</td>
<td>39%</td>
</tr>
</tbody>
</table>

Prevalence of hypertension – global comparison (both sexes)\(^a\)

Trends in uncontrolled hypertension in adults aged 30–79 years\(^c\)

Hypertension control rate scenarios

Of the 260 000 adults aged 30–79 years with hypertension:

- **Diagnosed**: 33% male, 52% female
- **Treated**: 23% male, 35% female
- **Controlled**: 11% male, 16% female

In order to achieve a 50% control rate, 99 000 more people with hypertension would need to be effectively treated.\(^b\)

Mortality

Probability of premature mortality from NCDs (%)

<table>
<thead>
<tr>
<th>Year</th>
<th>Both sexes</th>
<th>Males</th>
<th>Females</th>
</tr>
</thead>
<tbody>
<tr>
<td>2019</td>
<td>21</td>
<td>26</td>
<td>17</td>
</tr>
<tr>
<td>2019</td>
<td>2600</td>
<td>1400</td>
<td>1200</td>
</tr>
<tr>
<td>2019</td>
<td>62</td>
<td>61</td>
<td>63</td>
</tr>
</tbody>
</table>

Risk factors\(^e\)

| Description                                                                 | Both sexes | Males | Females | Year |
|----------------------------------------------------------------------------|------------|-------|---------|
| Mean population salt intake, adults aged 25+ years (g/day)                 | 7          | no data | no data | 2019 |
| Current tobacco use, adults aged 15+ years (%)                             | 15         | 10    | 20      | 2016 |
| Obesity, adults aged 18+ years (%)                                         | 7          | 11    | 3       | 2019 |
| Total alcohol per capita consumption, adults aged 15+ years (litres)       | 25         | 18    | 33      | 2016 |
| Physical inactivity, adults aged 18+ years (%)                             |            |       |         |      |

National response

Targets

- National target for blood pressure
- National target for salt consumption

Surveillance

- Conducted recent, national survey measuring raised blood pressure/hypertension
- Conducted recent, national survey on salt/sodium intake

Total population (2019): 2 243 000
Total deaths (2019): 14 300

Footnotes: a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control. e. Age-standardized estimates are presented for all indicators except salt intake.
Gambia
Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)

Of the 211 000 adults aged 30–79 years with hypertension:

- % of population aged 30–79 years with hypertension
  - Male 36%
  - Female 53%
  - Total 45%

- % of population aged 30–79 years
  - Diagnosed 28%
  - Treated 33%
  - Controlled 11%

In order to achieve a 50% control rate, 87 000 more people with hypertension would need to be effectively treated.b

Footnotes:

a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.
b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.
e. Age-standardized estimates are presented for all indicators except salt intake.
# Georgia

**Hypertension profile**

**Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)**

- **45%**
- **47%**
- **42%**

**Notes:**

- Conducted recent, national survey on salt/sodium intake
- National target for blood pressure
- National target for salt consumption
- Surveillance
  - Conducted recent, national survey measuring raised blood pressure/hypertension
  - Conducted recent, national survey on salt/sodium intake
  - Functioning system for generating reliable cause-specific mortality data on a routine basis

**Total population (2019):** 3,771,000

**Total deaths (2019):** 53,400

**Prevalence of hypertension – global comparison (both sexes)**

**Trends in uncontrolled hypertension in adults aged 30–79 years**

**Hypertension control rate scenarios**

- Of the 1.1 million adults aged 30–79 years with hypertension:
  - **64%**
  - **48%**
  - **17%**

- If the progress scenario were achieved, 55,000 deaths would be averted by 2040.

**Mortality**

- **Probability of premature mortality from NCDs (%)**
  - **25**
  - **34,200**
  - **62**

- **Cardiovascular disease deaths**
  - **36**
  - **16,500**
  - **64**

- **Cardiovascular disease deaths attributable to high systolic blood pressure (%)**
  - **15**
  - **17,700**
  - **60**

**Risk factors**

- **Mean population salt intake, adults aged 25+ years (g/day)**
  - **9**
  - **10**
  - **7**

- **Current tobacco use, adults aged 15+ years (%)**
  - **32**
  - **56**
  - **7**

- **Obesity, adults aged 18+ years (%)**
  - **22**
  - **19**
  - **24**

- **Total alcohol per capita consumption, adults aged 15+ years (litres)**
  - **14**
  - **24**
  - **6**

- **Physical inactivity, adults aged 18+ years (%)**
  - **18**
  - **17**
  - **19**

**National response**

- **Targets**
  - National target for blood pressure
  - National target for salt consumption

- **Surveillance**
  - Conducted recent, national survey measuring raised blood pressure/hypertension
  - Conducted recent, national survey on salt/sodium intake
  - Functioning system for generating reliable cause-specific mortality data on a routine basis

**Footnotes:**

- a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.
- b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg.
- c. SBP ≥140 mmHg or DBP ≥90 mmHg.
- d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.
- e. Age-standardized estimates are presented for all indicators except salt intake.
Germany

Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)  

| 30% | 34% | 25% |

Prevalence of hypertension – global comparison (both sexes)

Of the 19.8 million adults aged 30–79 years with hypertension:

- In order to achieve a 50% control rate, 515 000 more people with hypertension would need to be effectively treated.

Trends in uncontrolled hypertension in adults aged 30–79 years

Hypertension control rate scenarios

Mortality

Probability of premature mortality from NCDs (%)
- Cardiovascular disease deaths
- Cardiovascular disease deaths attributable to high systolic blood pressure (%)

Risk factors

- Mean population salt intake, adults aged 25+ years (g/day)
- Current tobacco use, adults aged 15+ years (%)
- Obesity, adults aged 18+ years (%)  
- Total alcohol per capita consumption, adults aged 15+ years (litres)
- Physical inactivity, adults aged 18+ years (%)

National response

<table>
<thead>
<tr>
<th>Targets</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>National target for blood pressure</td>
<td>Guidelines for management of hypertension</td>
</tr>
<tr>
<td>National target for salt consumption</td>
<td></td>
</tr>
</tbody>
</table>

Surveillance

- Conducted recent, national survey measuring raised blood pressure/hypertension
- Conducted recent, national survey on salt/sodium intake
- Functioning system for generating reliable cause-specific mortality data on a routine basis

Footnotes:  
a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.  
b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg.  
c. SBP ≥140 mmHg or DBP ≥90 mmHg.  
de. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.  
f. Data refer to tobacco smoking only, in the absence of sufficient data on all tobacco use.
Ghana
Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)  

<table>
<thead>
<tr>
<th>Projected hypertension control rates by scenario</th>
</tr>
</thead>
<tbody>
<tr>
<td>both sexes</td>
</tr>
<tr>
<td>22</td>
</tr>
<tr>
<td>35 100</td>
</tr>
<tr>
<td>61</td>
</tr>
</tbody>
</table>

Mortality

Probability of premature mortality from NCDs (%)
Cardiovascular disease deaths
Cardiovascular disease deaths attributable to high systolic blood pressure (%)

Risk factors

Mean population salt intake, adults aged 25+ years (g/day)
Current tobacco use, adults aged 15+ years (%)
Obesity, adults aged 18+ years (%)
Total alcohol per capita consumption, adults aged 15+ years (litres)
Physical inactivity, adults aged 18+ years (%)

National response

Targets
National target for blood pressure
National target for salt consumption

Surveillance
Conducted recent, national survey measuring raised blood pressure/hypertension
Conducted recent, national survey on salt/sodium intake
Functioning system for generating reliable cause-specific mortality data on a routine basis

Footnotes: a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control. e. Age-standardized estimates are presented for all indicators except salt intake.
**Greece**

**Hypertension profile**

**Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)**

- Of the **2.5 million** adults aged 30–79 years with hypertension:
  - **64%** were diagnosed
  - **60%** were treated
  - **33%** were controlled

- In order to achieve a 50% control rate, **363 000 more people** with hypertension would need to be effectively treated.

**Trends in uncontrolled hypertension in adults aged 30–79 years**

- **Past trends** vs. **projected trends** vs. **global target**

**Mortality**

- Probability of premature mortality from NCDs (%)
  - Both sexes: **12**
  - Males: **17**
  - Females: **8**
  - Year: **2019**

- Cardiovascular disease deaths
  - Both sexes: **42 300**
  - Males: **20 400**
  - Females: **21 900**
  - Year: **2019**

**Risk factors**

- Mean population salt intake, adults aged 25+ years (g/day)
  - Both sexes: **8**
  - Males: **9**
  - Females: **7**
  - Year: **2019**

**National response**

**Targets**

- National target for blood pressure
- National target for salt consumption

**Surveillance**

- Conducted recent, national survey measuring raised blood pressure/hypertension
- Conducted recent, national survey on salt/sodium intake

**Treatment**

- Guidelines for management of hypertension

---

Footnotes:  
a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.  
b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg.  
c. SBP ≥140 mmHg or DBP ≥90 mmHg.  
d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.  
e. Age-standardized estimates are presented for all indicators except salt intake.
**Grenada**

**Hypertension profile**

---

**Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)**

- 47% males
- 48% females
- 46% global

---

**Prevalence of hypertension – global comparison (both sexes)**

- Global prevalence: 50%
- Grenada: 35%

---

**Trends in uncontrolled hypertension in adults aged 30–79 years**

- Past trends: 50%
- Projected trends: 45%
- Global target: 30%

---

**Hypertension control rate scenarios**

- Projected hypertension control rates by scenario:
  - Business as usual: 30%
  - Progress: 40%
  - Aspirational: 50%

---

**Mortality**

- Probability of premature mortality from NCDs (%)
  - Both sexes: 23
  - Males: 26
  - Females: 20
  - Year: 2019

- Cardiovascular disease deaths
  - Both sexes: 330
  - Males: 170
  - Females: 160
  - Year: 2019

- Cardiovascular disease deaths attributable to high systolic blood pressure (%)
  - Both sexes: 52
  - Males: 53
  - Females: 50
  - Year: 2019

---

**Risk factors**

- Mean population salt intake, adults aged 25+ years (g/day)
  - Both sexes: 7
  - Males: 8
  - Females: 6
  - Year: 2019

- Current tobacco use, adults aged 15+ years (%)
  - Both sexes: no data
  - Males: no data
  - Females: no data
  - Year: 2019

- Obesity, adults aged 18+ years (%)
  - Both sexes: 21
  - Males: 13
  - Females: 29
  - Year: 2016

- Total alcohol per capita consumption, adults aged 15+ years (litres)
  - Both sexes: 8
  - Males: 13
  - Females: 3
  - Year: 2019

- Physical inactivity, adults aged 18+ years (%)
  - Both sexes: 29
  - Males: 22
  - Females: 35
  - Year: 2016

---

**National response**

**Targets**
- National target for blood pressure
- National target for salt consumption

**Surveillance**
- Conducted recent, national survey measuring raised blood pressure/hypertension
- Conducted recent, national survey on salt/sodium intake
- Functioning system for generating reliable cause-specific mortality data on a routine basis

**Treatment**
- Guidelines for management of hypertension

---

Footnotes: a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control. e. Age-standardized estimates are presented for all indicators except salt intake.
Guatemala

Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)\textsuperscript{a} 32% 32% 33%

Prevalence of hypertension – global comparison (both sexes)\textsuperscript{a}

Of the 1.8 million adults aged 30–79 years with hypertension:

In order to achieve a 50% control rate, 563 000 more people with hypertension would need to be effectively treated.\textsuperscript{b}

Trends in uncontrolled hypertension in adults aged 30–79 years\textsuperscript{c}

Hypertension control rate scenarios

If the progress scenario were achieved, 32 000 deaths would be averted by 2040.

Mortality

Probability of premature mortality from NCDs (%)
Cardiovascular disease deaths
Cardiovascular disease deaths attributable to high systolic blood pressure (%)

Risk factors\textsuperscript{e}

Mean population salt intake, adults aged 25+ years (g/day)
Current tobacco use, adults aged 15+ years (%)
Obesity, adults aged 18+ years (%)
Total alcohol per capita consumption, adults aged 15+ years (litres)
Physical inactivity, adults aged 18+ years (%)

National response

Targets
National target for blood pressure
National target for salt consumption

Surveillance
Conducted recent, national survey measuring raised blood pressure/hypertension
Conducted recent, national survey on salt/sodium intake
Functioning system for generating reliable cause-specific mortality data on a routine basis

Footnotes: a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.

e. Age-standardized estimates are presented for all indicators except salt intake.

Global report on hypertension: the race against a silent killer
### Guinea

**Hypertension profile**

**Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)**

- Female: 41%
- Male: 38%
- Total: 43%

**Total population (2019): 12 878 000**

**Total deaths (2019): 108 000**

---

**Prevalence of hypertension – global comparison (both sexes)**

![Graph showing prevalence of hypertension globally and for Guinea](image)

**Trends in uncontrolled hypertension in adults aged 30–79 years**

![Graph showing trends in uncontrolled hypertension](image)

**Hypertension control rate scenarios**

- **Past trends**
  - 2000: 10%
  - 2005: 15%
  - 2010: 20%
  - 2015: 25%
  - 2020: 30%
  - 2025: 35%

- **Projected trends**
  - 2025: 40%
  - 2030: 45%
  - 2035: 50%
  - 2040: 55%

**Global target**

- 2025: 50%
- 2030: 55%
- 2035: 60%
- 2040: 65%

---

**Mortality**

**Probability of premature mortality from NCDs (%)**

- Both sexes: 25
- Males: 25
- Females: 25
- Year: 2019

- Both sexes: 14 400
- Males: 5800
- Females: 8600
- Year: 2019

- Both sexes: 54
- Males: 52
- Females: 56
- Year: 2019

**Cardiovascular disease deaths**

- Both sexes: 25
- Males: 25
- Females: 25
- Year: 2019

**Cardiovascular disease deaths attributable to high systolic blood pressure (%)**

- Both sexes: 31
- Males: 31
- Females: 53
- Year: 2019

---

**Risk factors**

**Mean population salt intake, adults aged 25+ years (g/day)**

- Both sexes: 7
- Males: 7
- Females: 7
- Year: 2019

**Current tobacco use, adults aged 15+ years (%)**

- Both sexes: 8
- Males: 8
- Females: 4
- Year: 2016

**Obesity, adults aged 18+ years (%)**

- Both sexes: 0
- Males: 0
- Females: 0
- Year: 2019

**Total alcohol per capita consumption, adults aged 15+ years (litres)**

- Both sexes: 15
- Males: 11
- Females: 11
- Year: 2019

**Physical inactivity, adults aged 18+ years (%)**

- Both sexes: 20
- Males: 12
- Females: 18
- Year: 2016

---

**National response**

**Targets**

- National target for blood pressure
- National target for salt consumption

**Surveillance**

- Conducted recent, national survey measuring raised blood pressure/hypertension
- Conducted recent, national survey on salt/sodium intake
- Functioning system for generating reliable cause-specific mortality data on a routine basis

**Treatment**

- Guidelines for management of hypertension

---

Footnotes:

- a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.
- b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg.
- c. SBP ≥140 mmHg or DBP ≥90 mmHg.
- d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.
- e. Age-standardized estimates are presented for all indicators except salt intake.

---

**Annex 2. Hypertension profiles and explanatory notes**
**Guinea-Bissau**

**Hypertension profile**

**Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)**

- Of the **191 000** adults aged 30–79 years with hypertension:
  - 44% diagnosed
  - 27% treated
  - 11% controlled

- In order to achieve a **50% control rate**, 75 000 more people with hypertension would need to be effectively treated.

**Mortality**

- Probability of premature mortality from NCDs (%)
- Cardiovascular disease deaths
- Cardiovascular disease deaths attributable to high systolic blood pressure (%)

**Risk factors**

- Mean population salt intake, adults aged 25+ years (g/day)
- Current tobacco use, adults aged 15+ years (%)
- Obesity, adults aged 18+ years (%)
- Total alcohol per capita consumption, adults aged 15+ years (litres)
- Physical inactivity, adults aged 18+ years (%)

**National response**

- National target for blood pressure
- National target for salt consumption
- Conducted recent, national survey measuring raised blood pressure/hypertension
- Conducted recent, national survey on salt/sodium intake
- Functioning system for generating reliable cause-specific mortality data on a routine basis

Footnotes: a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control. e. Age-standardized estimates are presented for all indicators except salt intake.
Guyana
Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019) 40% 38% 42%

Prevalence of hypertension – global comparison (both sexes)

Trends in uncontrolled hypertension in adults aged 30–79 years

Hypertension control rate scenarios

Mortality

Probability of premature mortality from NCDs (%)
Cardiovascular disease deaths
Cardiovascular disease deaths attributable to high systolic blood pressure (%)

Risk factors

Mean population salt intake, adults aged 25+ years (g/day)
Current tobacco use, adults aged 15+ years (%)
Obesity, adults aged 18+ years (%)
Total alcohol per capita consumption, adults aged 15+ years (litres)
Physical inactivity, adults aged 18+ years (%)

National response

Targets
National target for blood pressure
National target for salt consumption

Surveillance
Conducted recent, national survey measuring raised blood pressure/hypertension
Conducted recent, national survey on salt/sodium intake
Functioning system for generating reliable cause-specific mortality data on a routine basis

Footnotes: a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.

e. Age-standardized estimates are presented for all indicators except salt intake.
Haiti

Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)  

Of the 1.7 million adults aged 30–79 years with hypertension:

In order to achieve a 50% control rate, 727 000 more people with hypertension would need to be effectively treated.

Trends in uncontrolled hypertension in adults aged 30–79 years

If the progress scenario were achieved, 57 000 deaths would be averted by 2040.

Mortality

Probability of premature mortality from NCDs (%)
Cardiovascular disease deaths
Cardiovascular disease deaths attributable to high systolic blood pressure (%)

Risk factors

Mean population salt intake, adults aged 25+ years (g/day)
Current tobacco use, adults aged 15+ years (%)
Obesity, adults aged 18+ years (%)
Total alcohol per capita consumption, adults aged 15+ years (litres)
Physical inactivity, adults aged 18+ years (%)

National response

Targets
National target for blood pressure
National target for salt consumption

Surveillance
Conducted recent, national survey measuring raised blood pressure/hypertension
Conducted recent, national survey on salt/sodium intake
Functioning system for generating reliable cause-specific mortality data on a routine basis

Footnotes:
a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.
b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg.  
c. SBP ≥140 mmHg or DBP ≥90 mmHg.
d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.
e. Age-standardized estimates are presented for all indicators except salt intake.
Honduras
Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)¹

Prevalence of hypertension – global comparison (both sexes)²

Of the 1.1 million adults aged 30–79 years with hypertension:

- 56% of population aged 30–79 years
- 74% of population aged 30–79 years
- 58% of population aged 30–79 years
- 48% of population aged 30–79 years
- 33% of population aged 30–79 years

Total population (2019): 9 959 000
Total deaths (2019): 55 000!

Mortality

- Probability of premature mortality from NCDs (%)
  - Cardiovascular disease deaths
  - Cardiovascular disease deaths attributable to high systolic blood pressure (%)

Risk factors³

- Mean population salt intake, adults aged 25+ years (g/day)
- Current tobacco use, adults aged 15+ years (%)
- Obesity, adults aged 18+ years (%)
- Total alcohol per capita consumption, adults aged 15+ years (litres)
- Physical inactivity, adults aged 18+ years (%)

National response

- National target for blood pressure
- National target for salt consumption

Surveillance

- Conducted recent, national survey measuring raised blood pressure/hypertension
- Conducted recent, national survey on salt/sodium intake
- Functioning system for generating reliable cause-specific mortality data on a routine basis

Footnotes:
1. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.
2. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.

Annex 2. Hypertension profiles and explanatory notes
Hungary

Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)

- **Total population (2019):** 9,772,000
- **Total deaths (2019):** 127,000

Prevalence of hypertension – global comparison (both sexes)

- Of the **3.4 million** adults aged 30–79 years with hypertension:
  - **52%** diagnosed
  - **46%** treated
  - **23%** controlled

If the progress scenario were achieved, **86,000 deaths would be averted by 2040.**

Mortality

- Probability of premature mortality from NCDs (%)
  - **both sexes:**
    - **22** (2019)
  - **males:**
    - **30** (2019)
  - **females:**
    - **15** (2019)

Risk factors

- Mean population salt intake, adults aged 25+ years (g/day)
  - **both sexes:**
    - **14** (2019)
  - **males:**
    - **17** (2019)
  - **females:**
    - **12** (2019)

National response

- **Targets**
  - National target for blood pressure
  - National target for salt consumption

- **Surveillance**
  - Conducted recent, national survey measuring raised blood pressure/hypertension
  - Conducted recent, national survey on salt/sodium intake
  - Functioning system for generating reliable cause-specific mortality data on a routine basis

Footnotes:
- a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.
- b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg.
- c. SBP ≥140 mmHg or DBP ≥90 mmHg.
- d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.
- e. Age-standardized estimates are presented for all indicators except salt intake.
- f. Data refer to tobacco smoking only, in the absence of sufficient data on all tobacco use.
Iceland

Hypertension profile

Total population (2019): 361 000
Total deaths (2019): 2340

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)\(^a\)

<table>
<thead>
<tr>
<th>Sex</th>
<th>Prevalence (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male</td>
<td>28%</td>
</tr>
<tr>
<td>Female</td>
<td>31%</td>
</tr>
<tr>
<td>Total</td>
<td>24%</td>
</tr>
</tbody>
</table>

Prevalence of hypertension – global comparison (both sexes)\(^a\)

<table>
<thead>
<tr>
<th>Year</th>
<th>Global</th>
<th>Iceland</th>
</tr>
</thead>
<tbody>
<tr>
<td>2000</td>
<td>40%</td>
<td>52%</td>
</tr>
<tr>
<td>2005</td>
<td>45%</td>
<td>57%</td>
</tr>
<tr>
<td>2010</td>
<td>50%</td>
<td>60%</td>
</tr>
<tr>
<td>2015</td>
<td>55%</td>
<td>63%</td>
</tr>
<tr>
<td>2020</td>
<td>60%</td>
<td>67%</td>
</tr>
<tr>
<td>2025</td>
<td>65%</td>
<td>70%</td>
</tr>
</tbody>
</table>

Trends in uncontrolled hypertension in adults aged 30–79 years\(^c\)

<table>
<thead>
<tr>
<th>Year</th>
<th>Total</th>
<th>Male</th>
<th>Female</th>
</tr>
</thead>
<tbody>
<tr>
<td>2016</td>
<td>22%</td>
<td>30%</td>
<td>12%</td>
</tr>
<tr>
<td>2017</td>
<td>24%</td>
<td>33%</td>
<td>11%</td>
</tr>
<tr>
<td>2018</td>
<td>26%</td>
<td>34%</td>
<td>10%</td>
</tr>
</tbody>
</table>

Cardiovascular disease deaths attributable to high systolic blood pressure (%)

<table>
<thead>
<tr>
<th>Sex</th>
<th>Year</th>
<th>Prevalence (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male</td>
<td>2019</td>
<td>7%</td>
</tr>
<tr>
<td>Female</td>
<td>2019</td>
<td>6%</td>
</tr>
<tr>
<td>Total</td>
<td>2019</td>
<td>6.5%</td>
</tr>
</tbody>
</table>

Probability of premature mortality from NCDs (%)

<table>
<thead>
<tr>
<th>Scenario</th>
<th>Probability (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Business as usual</td>
<td>-</td>
</tr>
<tr>
<td>Progress</td>
<td>-</td>
</tr>
<tr>
<td>Aspirational</td>
<td>-</td>
</tr>
</tbody>
</table>

Risk factors\(^e\)

<table>
<thead>
<tr>
<th>Risk Factor</th>
<th>Both Sexes</th>
<th>Males</th>
<th>Females</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean population salt intake, adults aged 25+ years (g/day)</td>
<td>8</td>
<td>10</td>
<td>7</td>
<td>2019</td>
</tr>
<tr>
<td>Current tobacco use, adults aged 15+ years (%)</td>
<td>13</td>
<td>13</td>
<td>13</td>
<td>2019</td>
</tr>
<tr>
<td>Obesity, adults aged 18+ years (%)</td>
<td>22</td>
<td>24</td>
<td>19</td>
<td>2016</td>
</tr>
<tr>
<td>Total alcohol per capita consumption, adults aged 15+ years (litres)</td>
<td>8</td>
<td>12</td>
<td>4</td>
<td>2019</td>
</tr>
<tr>
<td>Physical inactivity, adults aged 18+ years (%)</td>
<td>no data</td>
<td>no data</td>
<td>no data</td>
<td>2016</td>
</tr>
</tbody>
</table>

Mortality

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Probability (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiovascular disease deaths</td>
<td>7%</td>
</tr>
<tr>
<td>Cardiovascular disease deaths attributable to high systolic blood pressure</td>
<td>6.5%</td>
</tr>
</tbody>
</table>

Footnotes: a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control. e. A 50% control rate has already been achieved.b

National response

<table>
<thead>
<tr>
<th>Target</th>
<th>Description</th>
<th>Treatment</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>National target for blood pressure</td>
<td>Guidelines for management of hypertension</td>
<td>✔</td>
<td></td>
</tr>
<tr>
<td>National target for salt consumption</td>
<td>✔</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Surveillance

- Conducted recent, national survey measuring raised blood pressure/hypertension
- Conducted recent, national survey on salt/sodium intake
- Functioning system for generating reliable cause-specific mortality data on a routine basis

Footnotes: a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control. e. Age-standardized estimates are presented for all indicators except salt intake. f. Data refer to tobacco smoking only, in the absence of sufficient data on all tobacco use.

Annex 2. Hypertension profiles and explanatory notes

153
India

Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)

Prevalence of hypertension – global comparison (both sexes)

Trends in uncontrolled hypertension in adults aged 30–79 years

Hypertension control rate scenarios

India Hypertension profile

Of the 188.3 million adults aged 30–79 years with hypertension:

- Diagnosed: 37% (♂ 32%, ♀ 42%)
- Treated: 30% (♂ 25%, ♀ 35%)
- Controlled: 15% (♂ 11%, ♀ 19%)

In order to achieve a 50% control rate, 67 million more people with hypertension would need to be effectively treated.

Projected hypertension control rates by scenario:
- Business as usual: 37%
- Progress: 40%
- Aspirational: 45%

Mortality

Probability of premature mortality from NCDs (%)
- Cardiovascular disease deaths
- Cardiovascular disease deaths attributable to high systolic blood pressure (%)

Risk factors

Mean population salt intake, adults aged 25+ years (g/day)
- Current tobacco use, adults aged 15+ years (%)
- Obesity, adults aged 18+ years (%)
- Total alcohol per capita consumption, adults aged 15+ years (litres)
- Physical inactivity, adults aged 18+ years (%)

National response

Targets
- National target for blood pressure
- National target for salt consumption

Surveillance
- Conducted recent, national survey measuring raised blood pressure/hypertension
- Conducted recent, national survey on salt/sodium intake
- Functioning system for generating reliable cause-specific mortality data on a routine basis

Treatment
- Guidelines for management of hypertension

Footnotes:
- a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.
- b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg.
- c. SBP ≥140 mmHg or DBP ≥90 mmHg.
- d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.
- e. Age-standardized estimates are presented for all indicators except salt intake.
Indonesia

Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)  
- **Total population (2019): 269 600 000**  
- **Total deaths (2019): 1 816 000**  

**Prevalence of hypertension – global comparison (both sexes)**

<table>
<thead>
<tr>
<th>% of population aged 30–79 years</th>
<th>Indonesia</th>
<th>Global</th>
</tr>
</thead>
<tbody>
<tr>
<td>30%</td>
<td>40%</td>
<td>36%</td>
</tr>
<tr>
<td>40%</td>
<td>45%</td>
<td>40%</td>
</tr>
</tbody>
</table>

**Trends in uncontrolled hypertension in adults aged 30–79 years**

<table>
<thead>
<tr>
<th>% of population aged 30–79 years</th>
<th>past trends</th>
<th>projected trends</th>
<th>global target</th>
</tr>
</thead>
<tbody>
<tr>
<td>2000</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2005</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2010</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2015</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2020</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2025</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Mortality**

<table>
<thead>
<tr>
<th>Probability of premature mortality from NCDs (%)</th>
<th>both sexes</th>
<th>males</th>
<th>females</th>
<th>year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiovascular disease deaths</td>
<td>25</td>
<td>28</td>
<td>21</td>
<td>2019</td>
</tr>
<tr>
<td>Cardiovascular disease deaths attributable to high systolic blood pressure (%)</td>
<td>697 000</td>
<td>355 000</td>
<td>342 000</td>
<td>2019</td>
</tr>
<tr>
<td>Mean population salt intake, adults aged 25+ years (g/day)</td>
<td>69</td>
<td>67</td>
<td>71</td>
<td>2019</td>
</tr>
<tr>
<td>Current tobacco use, adults aged 15+ years (%)</td>
<td>37</td>
<td>71</td>
<td>4</td>
<td>2019</td>
</tr>
<tr>
<td>Obesity, adults aged 18+ years (%)</td>
<td>10</td>
<td>11</td>
<td>10</td>
<td>2019</td>
</tr>
<tr>
<td>Total alcohol per capita consumption, adults aged 15+ years (litres)</td>
<td>23</td>
<td>23</td>
<td>22</td>
<td>2019</td>
</tr>
<tr>
<td>Physical inactivity, adults aged 18+ years (%)</td>
<td>23</td>
<td>23</td>
<td>22</td>
<td>2019</td>
</tr>
</tbody>
</table>

**Risk factors**

<table>
<thead>
<tr>
<th>Risk factor</th>
<th>both sexes</th>
<th>males</th>
<th>females</th>
<th>year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean population salt intake, adults aged 25+ years (g/day)</td>
<td>10</td>
<td>11</td>
<td>10</td>
<td>2019</td>
</tr>
<tr>
<td>Current tobacco use, adults aged 15+ years (%)</td>
<td>37</td>
<td>71</td>
<td>4</td>
<td>2019</td>
</tr>
<tr>
<td>Obesity, adults aged 18+ years (%)</td>
<td>7</td>
<td>5</td>
<td>9</td>
<td>2016</td>
</tr>
<tr>
<td>Total alcohol per capita consumption, adults aged 15+ years (litres)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>2019</td>
</tr>
<tr>
<td>Physical inactivity, adults aged 18+ years (%)</td>
<td>23</td>
<td>23</td>
<td>22</td>
<td>2016</td>
</tr>
</tbody>
</table>

**National response**

**Targets**
- National target for blood pressure
- National target for salt consumption

**Surveillance**
- Conducted recent, national survey measuring raised blood pressure/hypertension
- Conducted recent, national survey on salt/sodium intake
- Functioning system for generating reliable cause-specific mortality data on a routine basis

**Treatment**
- Guidelines for management of hypertension

Footnotes:
- a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.  
- b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg.  
- c. SBP ≥140 mmHg or DBP ≥90 mmHg.  
- d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.  
- e. Age-standardized estimates are presented for all indicators except salt intake.
Iran (Islamic Republic of)

Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)\(^a\)

| % of population aged 30–79 years | Both sexes | Males | Females |
|--------------------------------||----------|-------|---------|
| Iran (Islamic Republic of)      | 26%      | 27%   | 26%     |

Prevalence of hypertension – global comparison (both sexes)\(^a\)

Of the 10 million adults aged 30–79 years with hypertension:

- Diagnosed: \(\text{49% (M), 69% (F)}\)
- Treated: \(\text{38% (M), 58% (F)}\)
- Controlled: \(\text{19% (M), 30% (F)}\)

In order to achieve a 50% control rate, 2.7 million more people with hypertension would need to be effectively treated.\(^b\)

Trends in uncontrolled hypertension in adults aged 30–79 years\(^c\)

Mortality

Probability of premature mortality from NCDs (%)

Cardiovascular disease deaths

Cardiovascular disease deaths attributable to high systolic blood pressure (%)

Risk factors\(^e\)

Mean population salt intake, adults aged 25+ years (g/day)

Current tobacco use, adults aged 15+ years (%)

Obesity, adults aged 18+ years (%)

Total alcohol per capita consumption, adults aged 15+ years (litres)

Physical inactivity, adults aged 18+ years (%)

National response

Targets

National target for blood pressure

National target for salt consumption

Surveillance

Conducted recent, national survey measuring raised blood pressure/hypertension

Conducted recent, national survey on salt/sodium intake

Functioning system for generating reliable cause-specific mortality data on a routine basis

Treatment

Guidelines for management of hypertension

Footnotes:

a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control. e. Age-standardized estimates are presented for all indicators except salt intake.
Iraq

Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)

Prevalence of hypertension – global comparison (both sexes)

![Graph showing prevalence of hypertension globally and for Iraq.]

Of the 5.6 million adults aged 30–79 years with hypertension:

- 44% of men (25% treated)
- 48% of women (15% treated)
- 13% controlled

Trends in uncontrolled hypertension in adults aged 30–79 years

![Graph showing trends in uncontrolled hypertension.]

Hypertension control rate scenarios

If the progress scenario were achieved, 142 000 deaths would be averted by 2040.

Mortality

Probability of premature mortality from NCDs (%)

- Males: 28% (2019), 33% (2019), 64% (2019)

Risk factors

- Mean population salt intake, adults aged 25+ years (g/day): 6 (2020), 7 (2020), 5 (2020)
- Total alcohol per capita consumption, adults aged 15+ years (litres): 0 (2019), 0 (2019), 0 (2019)

National response

- National target for blood pressure
- National target for salt consumption

Treatment

Guidelines for management of hypertension

Footnotes:

- a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.
- e. Age-standardized estimates are presented for all indicators except salt intake.
Ireland
Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)\(^a\)

<table>
<thead>
<tr>
<th>Sex</th>
<th>Prevalence (%)</th>
<th>Total Population (2019): 4,896,000</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Total deaths (2019): 30,800</td>
</tr>
<tr>
<td>Men</td>
<td>32%</td>
<td></td>
</tr>
<tr>
<td>Women</td>
<td>38%</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>27%</td>
<td></td>
</tr>
</tbody>
</table>

Of the 1 million adults aged 30–79 years with hypertension:

- Diagnosed: 50% (54% of men, 45% of women)
- Treated: 41% (38% of men, 45% of women)
- Controlled: 24% (21% of men, 28% of women)

In order to achieve a 50% control rate, 249,000 more people with hypertension would need to be effectively treated.\(^b\)

Projected hypertension control rates by scenario\(^d\):
- Business as usual
- Progress
- Aspirational

Mortality

Probability of premature mortality from NCDs (%)
- Cardiovascular disease deaths
- Cardiovascular disease deaths attributable to high systolic blood pressure (%)

Risk factors\(^e\)

<table>
<thead>
<tr>
<th>Risk Factor</th>
<th>Sexes</th>
<th>Males</th>
<th>Females</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean population salt intake, adults aged 25+ years (g/day)</td>
<td>both sexes</td>
<td>7</td>
<td>8</td>
<td>2019</td>
</tr>
<tr>
<td>Current tobacco use, adults aged 15+ years (%)(^f)</td>
<td>men</td>
<td>21</td>
<td>23</td>
<td>2019</td>
</tr>
<tr>
<td>Obesity, adults aged 18+ years (%)</td>
<td>women</td>
<td>25</td>
<td>25</td>
<td>2016</td>
</tr>
<tr>
<td>Total alcohol per capita consumption, adults aged 15+ years (litres)</td>
<td>both sexes</td>
<td>12</td>
<td>18</td>
<td>2019</td>
</tr>
<tr>
<td>Physical inactivity, adults aged 18+ years (%)</td>
<td>women</td>
<td>33</td>
<td>28</td>
<td>2016</td>
</tr>
</tbody>
</table>

National response

<table>
<thead>
<tr>
<th>Target</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood pressure</td>
<td>Guidelines for management of hypertension</td>
</tr>
<tr>
<td>Salt consumption</td>
<td>✔</td>
</tr>
</tbody>
</table>

Surveillance

- Conducted recent, national survey measuring raised blood pressure/hypertension
- Conducted recent, national survey on salt/sodium intake
- Functioning system for generating reliable cause-specific mortality data on a routine basis

Footnotes: a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≤140 mmHg or DBP ≤90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control. e. Age-standardized estimates are presented for all indicators except salt intake. f. Data refer to tobacco smoking only, in the absence of sufficient data on all tobacco use.
**Israel**

**Hypertension profile**

**Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)**  

<table>
<thead>
<tr>
<th>Both sexes</th>
<th>Males</th>
<th>Females</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>9</td>
<td>11</td>
<td>7</td>
<td>2019</td>
</tr>
<tr>
<td>10 200</td>
<td>5100</td>
<td>5100</td>
<td>2019</td>
</tr>
<tr>
<td>51</td>
<td>51</td>
<td>50</td>
<td>2019</td>
</tr>
</tbody>
</table>

**Total population (2019): 8 608 000**  

**Total deaths (2019): 45 400**

<table>
<thead>
<tr>
<th>% of population aged 30–79 years with hypertension</th>
<th>Male</th>
<th>Female</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP ≤140 mmHg and DBP ≤90 mmHg.</td>
<td>61%</td>
<td>66%</td>
<td>2016</td>
</tr>
<tr>
<td>50%</td>
<td>57%</td>
<td></td>
<td>2019</td>
</tr>
<tr>
<td>24%</td>
<td>31%</td>
<td></td>
<td>2025</td>
</tr>
</tbody>
</table>

**Of the 1.3 million adults aged 30–79 years with hypertension:**

- 63% diagnosed
- 53% treated
- 27% controlled

**In order to achieve a 50% control rate, 280 000 more people with hypertension would need to be effectively treated.**

**Mortality**

<table>
<thead>
<tr>
<th>Probability of premature mortality from NCDs (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiovascular disease deaths</td>
</tr>
<tr>
<td>Cardiovascular disease deaths attributable to high systolic blood pressure (%)</td>
</tr>
</tbody>
</table>

**Risk factors**

- Mean population salt intake, adults aged 25+ years (g/day)
- Current tobacco use, adults aged 15+ years (%)
- Obesity, adults aged 18+ years (%)
- Total alcohol per capita consumption, adults aged 15+ years (litres)
- Physical inactivity, adults aged 18+ years (%)

**National response**

**Targets**

- National target for blood pressure
- National target for salt consumption

**Surveillance**

- Conducted recent, national survey measuring raised blood pressure/hypertension
- Conducted recent, national survey on salt/sodium intake
- Functioning system for generating reliable cause-specific mortality data on a routine basis

**Footnotes:**  
a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.  
b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg.  
c. SBP ≥140 mmHg or DBP ≥90 mmHg.  
d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.  
e. Age-standardized estimates are presented for all indicators except salt intake.  
f. Data refer to tobacco smoking only, in the absence of sufficient data on all tobacco use.
Prevalence of hypertension – global comparison (both sexes)\textsuperscript{a}

Of the 16.6 million adults aged 30–79 years with hypertension:

- \textbf{62\%} diagnosed
- \textbf{54\%} treated
- \textbf{28\%} controlled

In order to achieve a 50\% control rate, 3.3 million more people with hypertension would need to be effectively treated.\textsuperscript{b}

Mortality

- Probability of premature mortality from NCDs (\%)
- Cardiovascular disease deaths
- Cardiovascular disease deaths attributable to high systolic blood pressure (\%)

Risk factors\textsuperscript{c}

- Mean population salt intake, adults aged 25+ years (g/day)
- Current tobacco use, adults aged 15+ years (\%)
- Obesity, adults aged 18+ years (\%)
- Total alcohol per capita consumption, adults aged 15+ years (litres)
- Physical inactivity, adults aged 18+ years (\%)

National response

- Targets
- National target for blood pressure
- National target for salt consumption
- Surveillance
- Conducted recent, national survey measuring raised blood pressure/hypertension
- Conducted recent, national survey on salt/sodium intake
- Functioning system for generating reliable cause-specific mortality data on a routine basis

Footnotes: a. SBP \geq 140 mmHg or DBP \geq 90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP < 140 mmHg and DBP < 90 mmHg. c. SBP \geq 140 mmHg or DBP \geq 90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control. e. Age-standardized estimates are presented for all indicators except salt intake. f. Data refer to tobacco smoking only, in the absence of sufficient data on all tobacco use.
Jamaica

Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)  
- Total population (2019): 2 814 000
- Total deaths (2019): 19 300

Prevalence of hypertension – global comparison (both sexes)

Of the 670 000 adults aged 30–79 years with hypertension:
- In order to achieve a 50% control rate, 206 000 more people with hypertension would need to be effectively treated.

Mortality

Probability of premature mortality from NCDs (%)
- Cardiovascular disease deaths
- Cardiovascular disease deaths attributable to high systolic blood pressure (%)

Risk factors

Mean population salt intake, adults aged 25+ years (g/day)
- Current tobacco use, adults aged 15+ years (%)
- Obesity, adults aged 18+ years (%)
- Total alcohol per capita consumption, adults aged 15+ years (litres)
- Physical inactivity, adults aged 18+ years (%)

National response

Targets
- National target for blood pressure
- National target for salt consumption

Surveillance
- Conducted recent, national survey measuring raised blood pressure/hypertension
- Conducted recent, national survey on salt/sodium intake
- Functioning system for generating reliable cause-specific mortality data on a routine basis

Treatment
- Guidelines for management of hypertension

Footnotes:
- a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.
- b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg.
- c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.
- e. Age-standardized estimates are presented for all indicators except salt intake.
- f. Data refer to tobacco smoking only, in the absence of sufficient data on all tobacco use.

Annex 2. Hypertension profiles and explanatory notes
Japan

Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)³

Of the 33.1 million adults aged 30–79 years with hypertension:

- 67% of the population were diagnosed
- 48% of the population were treated
- 26% of the population achieved blood pressure control

In order to achieve a 50% control rate, 6.1 million more people with hypertension would need to be effectively treated.³

Global report on hypertension: the race against a silent killer

Footnotes: a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control. e. Age-standardized estimates are presented for all indicators except salt intake. f. Data refer to tobacco smoking only, in the absence of sufficient data on all tobacco use.
**Jordan**

**Hypertension profile**

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)  

- Male: 38%  
- Female: 40%  
- Overall: 36%

**Prevalence of hypertension – global comparison (both sexes)**

- **Global**
  - Male: 40%  
  - Female: 35%  
  - Overall: 37.5%

- **Jordan**
  - Male: 64%  
  - Female: 55%  
  - Overall: 60%

**Trends in uncontrolled hypertension in adults aged 30–79 years**

- **Past trends**
  - Male: 72%  
  - Female: 66%  
  - Overall: 69%

- **Projected trends**
  - Male: 59%  
  - Female: 40%  
  - Overall: 49.5%

- **Global target**
  - Male: 29%  
  - Female: 36%  
  - Overall: 32.5%

**Mortality**

- Probability of premature mortality from NCDs (%)
  - Both sexes: 15  
  - Males: 17  
  - Females: 14  
  - Year: 2019  
  - Cardiovascular disease deaths: 9700  
  - Males: 4700  
  - Females: 5000  
  - Year: 2019  
  - Cardiovascular disease deaths attributable to high systolic blood pressure (%)
    - Both sexes: 60  
    - Males: 58  
    - Females: 62  
    - Year: 2019

**Risk factors**

- Mean population salt intake, adults aged 25+ years (g/day)
  - Both sexes: 6  
  - Males: 7  
  - Females: 5  
  - Year: 2019

- Current tobacco use, adults aged 15+ years (%)
  - Both sexes: 35  
  - Males: 57  
  - Females: 13  
  - Year: 2019

- Obesity, adults aged 18+ years (%)
  - Both sexes: 36  
  - Males: 28  
  - Females: 43  
  - Year: 2016

- Total alcohol per capita consumption, adults aged 15+ years (litres)
  - Both sexes: 0  
  - Males: 1  
  - Females: 0  
  - Year: 2019

- Physical inactivity, adults aged 18+ years (%)
  - Both sexes: 12  
  - Males: 10  
  - Females: 13  
  - Year: 2016

**National response**

**Targets**

- National target for blood pressure ✓
- National target for salt consumption ✗

**Surveillance**

- Conducted recent, national survey measuring raised blood pressure/hypertension ✓
- Conducted recent, national survey on salt/sodium intake ✓
- Functioning system for generating reliable cause-specific mortality data on a routine basis ✗

**Footnotes:**

a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.  
b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg.  
c. SBP ≥140 mmHg or DBP ≥90 mmHg.  
d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.  
e. Age-standardized estimates are presented for all indicators except salt intake.  
f. Data refer to tobacco smoking only, in the absence of sufficient data on all tobacco use.
Kazakhstan

Hypertension profile

Total population (2019): 18 754 000
Total deaths (2019): 127 000

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)¹

<table>
<thead>
<tr>
<th></th>
<th>Males</th>
<th>Females</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>42%</td>
<td>41%</td>
<td>43%</td>
<td></td>
</tr>
</tbody>
</table>

Of the 3.8 million adults aged 30–79 years with hypertension:

- In order to achieve a 50% control rate, 736 000 more people with hypertension would need to be effectively treated.²

Prevalence of hypertension – global comparison (both sexes)³

- % of population aged 30–79 years with hypertension:
  - 84% diagnosed
  - 71% treated
  - 31% controlled

Trends in uncontrolled hypertension in adults aged 30–79 years⁴

- % of population aged 30–79 years:
  - Past trends
  - Projected trends
  - Global target

Hypertension control rate scenarios

- Projected hypertension control rates by scenario:⁵
  - Business as usual
  - Progress
  - Aspirational

Mortality

Probability of premature mortality from NCDs (%)

<table>
<thead>
<tr>
<th>both sexes</th>
<th>males</th>
<th>females</th>
<th>year</th>
</tr>
</thead>
<tbody>
<tr>
<td>22</td>
<td>31</td>
<td>15</td>
<td>2019</td>
</tr>
<tr>
<td>60 300</td>
<td>27 500</td>
<td>32 800</td>
<td>2019</td>
</tr>
<tr>
<td>64</td>
<td>63</td>
<td>65</td>
<td>2019</td>
</tr>
</tbody>
</table>

Cardiovascular disease deaths

<table>
<thead>
<tr>
<th>both sexes</th>
<th>males</th>
<th>females</th>
<th>year</th>
</tr>
</thead>
<tbody>
<tr>
<td>9</td>
<td>10</td>
<td>7</td>
<td>2019</td>
</tr>
<tr>
<td>24</td>
<td>40</td>
<td>7</td>
<td>2019</td>
</tr>
<tr>
<td>21</td>
<td>19</td>
<td>23</td>
<td>2016</td>
</tr>
<tr>
<td>5</td>
<td>8</td>
<td>1</td>
<td>2019</td>
</tr>
<tr>
<td>28</td>
<td>26</td>
<td>29</td>
<td>2016</td>
</tr>
</tbody>
</table>

Cardiovascular disease deaths attributable to high systolic blood pressure (%)

Risk factors⁶

<table>
<thead>
<tr>
<th>both sexes</th>
<th>males</th>
<th>females</th>
<th>year</th>
</tr>
</thead>
</table>
| Mean population salt intake, adults aged 25+ years (g/day)
| 9          | 10    | 7       | 2019 |
| Current tobacco use, adults aged 15+ years (%)
| 24         | 40    | 7       | 2019 |
| Obesity, adults aged 18+ years (%)
| 21         | 19    | 23      | 2016 |
| Total alcohol per capita consumption, adults aged 15+ years (litres)
| 5          | 8     | 1       | 2019 |
| Physical inactivity, adults aged 18+ years (%)
| 28         | 26    | 29      | 2016 |

National response

Targets

- National target for blood pressure
- National target for salt consumption
- Surveillance
- Conducted recent, national survey measuring raised blood pressure/hypertension
- Conducted recent, national survey on salt/sodium intake
- Functioning system for generating reliable cause-specific mortality data on a routine basis

Treatment

- Guidelines for management of hypertension

Footnotes:

a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.
b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg.
c. SBP ≥140 mmHg or DBP ≥90 mmHg.
d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.
e. Age-standardized estimates are presented for all indicators except salt intake.
Kenya

Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)        

Of the 4.8 million adults aged 30–79 years with hypertension:

- 40% diagnosed
- 16% treated
- 6% controlled

- 28% † males
- 10% † females
- 5%  ‡ males
- 8%  ‡ females

Projected hypertension control rates by scenario:

- Business as usual
- Progress
- Aspirational

If the progress scenario were achieved, 74 000 deaths would be averted by 2040.

Mortality

- Probability of premature mortality from NCDs (%)
- Cardiovascular disease deaths
- Cardiovascular disease deaths attributable to high systolic blood pressure (%)

Risk factors

- Mean population salt intake, adults aged 25+ years (g/day)
- Current tobacco use, adults aged 15+ years (%)
- Obesity, adults aged 18+ years (%)
- Total alcohol per capita consumption, adults aged 15+ years (litres)
- Physical inactivity, adults aged 18+ years (%)

National response

Targets
- National target for blood pressure
- National target for salt consumption

Surveillance
- Conducted recent, national survey measuring raised blood pressure/hypertension
- Conducted recent, national survey on salt/sodium intake
- Functioning system for generating reliable cause-specific mortality data on a routine basis

Footnotes:

a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.
b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg.
c. SBP ≥140 mmHg or DBP ≥90 mmHg.
d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.
e. Age-standardized estimates are presented for all indicators except salt intake.
Kiribati

Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)\(^a\)

<table>
<thead>
<tr>
<th>Both sexes</th>
<th>Males</th>
<th>Females</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kiribati</td>
<td>42%</td>
<td>40%</td>
</tr>
<tr>
<td>Global</td>
<td>42%</td>
<td>40%</td>
</tr>
</tbody>
</table>

Prevalence of hypertension – global comparison (both sexes)\(^a\)

Of the 18,000 adults aged 30–79 years with hypertension:

- In order to achieve a 50% control rate, 7,800 more people with hypertension would need to be effectively treated.\(^b\)

Mortality

Probability of premature mortality from NCDs (%)

- Cardiovascular disease deaths
- Cardiovascular disease deaths attributable to high systolic blood pressure (%)

Risk factors\(^e\)

- Mean population salt intake, adults aged 25+ years (g/day)
- Current tobacco use, adults aged 15+ years (%)\(^f\)
- Obesity, adults aged 18+ years (%)
- Total alcohol per capita consumption, adults aged 15+ years (litres)
- Physical inactivity, adults aged 18+ years (%)

National response

Targets
- National target for blood pressure
- National target for salt consumption

Surveillance
- Conducted recent, national survey measuring raised blood pressure/hypertension
- Conducted recent, national survey on salt/sodium intake
- Functioning system for generating reliable cause-specific mortality data on a routine basis

Treatment
- Guidelines for management of hypertension

Footnotes:
- a. SBP ≥ 140 mmHg or DBP ≥ 90 mmHg or taking medication for hypertension.
- b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP < 140 mmHg and DBP < 90 mmHg.
- c. SBP ≥ 140 mmHg or DBP ≥ 90 mmHg.
- d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.
- e. Age-standardized estimates are presented for all indicators except salt intake.
- f. Data refer to tobacco smoking only, in the absence of sufficient data on all tobacco use.
Kuwait

Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)\(^a\)

Prevalence of hypertension – global comparison (both sexes)\(^a\)

<table>
<thead>
<tr>
<th>% of population aged 30–79 years</th>
<th>10%</th>
<th>15%</th>
<th>25%</th>
<th>30%</th>
<th>40%</th>
<th>45%</th>
<th>50%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Global</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kuwait</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Of the 921 000 adults aged 30–79 years with hypertension:

- % diagnosed: 63% (m), 56% (f)
- % treated: 58% (m), 51% (f)
- % controlled: 31% (m), 27% (f)

In order to achieve a 50% control rate, 210 000 more people with hypertension would need to be effectively treated.\(^b\)

Trends in uncontrolled hypertension in adults aged 30–79 years\(^c\)

<table>
<thead>
<tr>
<th>% of population aged 30–79 years</th>
<th>0%</th>
<th>5%</th>
<th>10%</th>
<th>15%</th>
<th>20%</th>
<th>25%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Past trends</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Projected trends</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Global target</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Mortality

- Probability of premature mortality from NCDs (%)
  - Cardiovascular disease deaths
  - Cardiovascular disease deaths attributable to high systolic blood pressure (%)

Risk factors\(^e\)

- Mean population salt intake, adults aged 25+ years (g/day)
- Current tobacco use, adults aged 15+ years (%)
- Obesity, adults aged 18+ years (%)
- Total alcohol per capita consumption, adults aged 15+ years (litres)
- Physical inactivity, adults aged 18+ years (%)

National response

- Targets
  - National target for blood pressure
  - National target for salt consumption
- Surveillance
  - Conducted recent, national survey measuring raised blood pressure/hypertension
  - Functioning system for generating reliable cause-specific mortality data on a routine basis

Footnotes:
- a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.
- b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg.
- c. SBP ≥140 mmHg or DBP ≥90 mmHg.
- d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.
- e. Age-standardized estimates are presented for all indicators except salt intake.
**Kyrgyzstan**

**Hypertension profile**

**Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)**

- **Global prevalence**: 55%
- **Kyrgyzstan**: 61%

**Notes:**
- a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.
- b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg.
- c. SBP ≥140 mmHg or DBP ≥90 mmHg.
- d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.
- e. Age-standardized estimates are presented for all indicators except salt intake.

**Prevalence of hypertension – global comparison (both sexes)**

- **% of population aged 30–79 years with hypertension**: 46% (men), 61% (women)

**Trends in uncontrolled hypertension in adults aged 30–79 years**

- **% of population aged 30–79 years with hypertension**: 10% (men), 11% (women)

**Hypertension control rate scenarios**

- **% of population aged 30–79 years with hypertension**: 49% (men), 44% (women)

**Mortality**

- **Probability of premature mortality from NCDs (%):**
  - Both sexes: 20% (2019), 14 000 (2019)

**Risk factors**

- **Mean population salt intake, adults aged 25+ years (g/day):**
  - Males: 10 (2019), 52 (2019)

**National response**

- **Targets**
  - National target for blood pressure
  - National target for salt consumption
- **Surveillance**
  - Conducted recent, national survey measuring raised blood pressure/hypertension
  - Conducted recent, national survey on salt/sodium intake
  - Functioning system for generating reliable cause-specific mortality data on a routine basis
- **Treatment**
  - Guidelines for management of hypertension

**Footnotes:**
- a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.
- b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg.
- c. SBP ≥140 mmHg or DBP ≥90 mmHg.
- d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.
- e. Age-standardized estimates are presented for all indicators except salt intake.
Lao People's Democratic Republic

Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)  
- 29%  
- 26%  
- 31%

Prevalence of hypertension – global comparison (both sexes)  

Trends in uncontrolled hypertension in adults aged 30–79 years  

Mortality

Probability of premature mortality from NCDs (%)
- Cardiovascular disease deaths
- Cardiovascular disease deaths attributable to high systolic blood pressure (%)

Risk factors

- Mean population salt intake, adults aged 25+ years (g/day)
- Current tobacco use, adults aged 15+ years (%)
- Obesity, adults aged 18+ years (%)
- Total alcohol per capita consumption, adults aged 15+ years (litres)
- Physical inactivity, adults aged 18+ years (%)

National response

- National target for blood pressure
- National target for salt consumption

Surveillance
- Conducted recent, national survey measuring raised blood pressure/hypertension
- Conducted recent, national survey on salt/sodium intake
- Functioning system for generating reliable cause-specific mortality data on a routine basis

Footnotes:
am. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control. e. Age-standardized estimates are presented for all indicators except salt intake.
Latvia

Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)  
- 44% males, 49% females

Total population (2019): 1,917,000  
Total deaths (2019): 29,800

Prevalence of hypertension – global comparison (both sexes)

Of the 605,000 adults aged 30–79 years with hypertension:
- 68% diagnosed
- 51% treated
- 17% controlled

Trends in uncontrolled hypertension in adults aged 30–79 years

Hypertension control rate scenarios

If the progress scenario were achieved, 22,000 deaths would be averted by 2040.

Mortality

Probability of premature mortality from NCDs (%)
- Both sexes: 22, males: 31, females: 14
- 2019

Cardiovascular disease deaths
- Both sexes: 16,900, males: 6,700, females: 10,200
- 2019

Cardiovascular disease deaths attributable to high systolic blood pressure (%)
- Both sexes: 58, males: 57, females: 59
- 2019

Risk factors

Mean population salt intake, adults aged 25+ years (g/day)
- Both sexes: 7, males: 10, females: 6
- 2019

Current tobacco use, adults aged 15+ years (%)
- Both sexes: 37, males: 51, females: 24
- 2019

Obesity, adults aged 18+ years (%)
- Both sexes: 24, males: 22, females: 25
- 2016

Total alcohol per capita consumption, adults aged 15+ years (litres)
- Both sexes: 13, males: 22, females: 6
- 2019

Physical inactivity, adults aged 18+ years (%)
- Both sexes: 30, males: 25, females: 33
- 2016

National response

Targets
- National target for blood pressure
- National target for salt consumption

Surveillance
- Conducted recent, national survey measuring raised blood pressure/hypertension
- Conducted recent, national survey on salt/sodium intake
- Functioning system for generating reliable cause-specific mortality data on a routine basis

Footnotes:
- a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.
- b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg.
- c. SBP ≥140 mmHg or DBP ≥90 mmHg.
- d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.
- e. Age-standardized estimates are presented for all indicators except salt intake.
**Lebanon**

**Hypertension profile**

**Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)**

- Total population (2019): 5,782,000
- Total deaths (2019): 37,800

---

**Prevalence of hypertension – global comparison (both sexes)**

- Of the 1.2 million adults aged 30–79 years with hypertension:
  - 55% diagnosed
  - 49% treated
  - 27% controlled

- In order to achieve a 50% control rate, 284,000 more people with hypertension would need to be effectively treated.

**Trends in uncontrolled hypertension in adults aged 30–79 years**

- Past and projected trends
- Global target

**Hypertension control rate scenarios**

- Projected hypertension control rates by scenario:
  - Business as usual
  - Progress
  - Aspirational

**Mortality**

- Probability of premature mortality from NCDs (%)
- Cardiovascular disease deaths
- Cardiovascular disease deaths attributable to high systolic blood pressure (%)

**Risk factors**

- Mean population salt intake, adults aged 25+ years (g/day)
- Current tobacco use, adults aged 15+ years (%)
- Obesity, adults aged 18+ years (%)
- Total alcohol per capita consumption, adults aged 15+ years (litres)
- Physical inactivity, adults aged 18+ years (%)

**National response**

- Targets
- National target for blood pressure
- National target for salt consumption
- Surveillance
- Conducted recent, national survey measuring raised blood pressure/hypertension
- Conducted recent, national survey on salt/sodium intake
- Functioning system for generating reliable cause-specific mortality data on a routine basis

---

Footnotes: a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control. e. Age-standardized estimates are presented for all indicators except salt intake.
Lesotho

Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)  
- **40%** (both sexes)  
- **32%** (males)  
- **47%** (females)  

Prevalence of hypertension – global comparison (both sexes)  
- **Lesotho**  
- **global**  

Trends in uncontrolled hypertension in adults aged 30–79 years  
- Past trends  
- Projected trends  
- Global target  

Hypertension control rate scenarios  
- Projected hypertension control rates by scenario  
- Business as usual  
- Progress  
- Aspirational  

Mortality  

Probability of premature mortality from NCDs (%)  
- **43%** (both sexes)  
- **49%** (males)  
- **37%** (females)  
- **2019**  

Cardiovascular disease deaths  
- 6600 (both sexes)  
- 3000 (males)  
- 3600 (females)  
- **2019**  

Cardiovascular disease deaths attributable to high systolic blood pressure (%)  
- **57%** (both sexes)  
- **55%** (males)  
- **60%** (females)  
- **2019**  

Risk factors  

Mean population salt intake, adults aged 25+ years (g/day)  
- 8 (both sexes)  
- 8 (males)  
- 7 (females)  
- **2019**  

Current tobacco use, adults aged 15+ years (%)  
- 24 (both sexes)  
- 43 (males)  
- 6 (females)  
- **2019**  

Obesity, adults aged 18+ years (%)  
- 17 (both sexes)  
- 5 (males)  
- 27 (females)  
- **2016**  

Total alcohol per capita consumption, adults aged 15+ years (litres)  
- 5 (both sexes)  
- 8 (males)  
- 1 (females)  
- **2019**  

Physical inactivity, adults aged 18+ years (%)  
- 6 (both sexes)  
- 7 (males)  
- 6 (females)  
- **2016**  

National response  

Targets  
- National target for blood pressure  
- National target for salt consumption  

Surveillance  
- Conducted recent, national survey measuring raised blood pressure/hypertension  
- Conducted recent, national survey on salt/sodium intake  
- Functioning system for generating reliable cause-specific mortality data on a routine basis  

Treatment  
- Guidelines for management of hypertension  

Footnotes:  
- a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.  
- b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg.  
- c. SBP ≥140 mmHg or DBP ≥90 mmHg.  
- d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.  
- e. Age-standardized estimates are presented for all indicators except salt intake.
**Lesotho**

Conducted recent national survey on salt/sodium intake
Conducted recent national survey measuring raised blood pressure/hypertension

**National target for salt consumption**

**National target for blood pressure**

**Physical inactivity, adults aged 18+ years (%)**

**Obesity, adults aged 18+ years (%)**

**Mean population salt intake, adults aged 25+ years (g/day)**

**Cardiovascular disease deaths attributable to high systolic blood pressure (%)**

**Cardiovascular disease mortality**

**SBP ≥140 mmHg or DBP ≥90 mmHg**

**In order to achieve a 50% control rate, 233 000 more people with hypertension would need to be effectively treated.**

**If the progress scenario were achieved, 9600 deaths would be averted by 2040.**

**Footnotes:**
- a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.
- b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP ≥140 mmHg and DBP ≥90 mmHg.
- c. SBP ≥140 mmHg or DBP ≥90 mmHg.
- d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.
- e. Age-standardized estimates are presented for all indicators except salt intake.
Libya
Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)

- 43% of both sexes
- 46% of males
- 39% of females

Prevalence of hypertension – global comparison (both sexes)

- Libya
- Global

Trends in uncontrolled hypertension in adults aged 30–79 years

- Past trends
- Projected trends
- Global target

Hypertension control rate scenarios

- If the progress scenario were achieved, 27,000 deaths would be averted by 2040.

Mortality

- Probability of premature mortality from NCDs (%)
  - Cardiovascular disease deaths
  - Cardiovascular disease deaths attributable to high systolic blood pressure (%)

Risk factors

- Mean population salt intake, adults aged 25+ years (g/day)
- Current tobacco use, adults aged 15+ years (%)
- Obesity, adults aged 18+ years (%)
- Total alcohol per capita consumption, adults aged 15+ years (litres)
- Physical inactivity, adults aged 18+ years (%)

National response

- Targets
  - National target for blood pressure
  - National target for salt consumption
- Surveillance
  - Conducted recent, national survey measuring raised blood pressure/hypertension
  - Conducted recent, national survey on salt/sodium intake
  - Functioning system for generating reliable cause-specific mortality data on a routine basis
- Treatment
  - Guidelines for management of hypertension

Footnotes:
- a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.
- b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg.
- c. SBP ≥140 mmHg or DBP ≥90 mmHg.
- d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.
- e. Age-standardized estimates are presented for all indicators except salt intake.

Total population (2019): 6,569,000
Total deaths (2019): 27,100

In order to achieve a 50% control rate, 477,000 more people with hypertension would need to be effectively treated.

Footnotes:
- a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.
- b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg.
- c. SBP ≥140 mmHg or DBP ≥90 mmHg.
- d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.
- e. Age-standardized estimates are presented for all indicators except salt intake.
Lithuania

Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019) 🌍

- Total population (2019): 2,849,000
- Total deaths (2019): 42,000
- Men: 48%
- Women: 54%
- Total: 42%

Prevalence of hypertension – global comparison (both sexes) 🌍

Of the 940,000 adults aged 30–79 years with hypertension:

- In order to achieve a 50% control rate, 339,000 more people with hypertension would need to be effectively treated.

Trends in uncontrolled hypertension in adults aged 30–79 years 🌍

Hypertension control rate scenarios 🌍

In order to achieve a 50% control rate, 339,000 more people with hypertension would need to be effectively treated.

Mortality

- Probability of premature mortality from NCDs (%)
  - Cardiovascular disease deaths
    - Both sexes: 19%
    - Males: 28%
    - Females: 12%
    - Year: 2019
  - Cardiovascular disease deaths attributable to high systolic blood pressure (%)
    - Both sexes: 24,000
    - Males: 9,400
    - Females: 14,500
    - Year: 2019

Risk factors 🌍

- Mean population salt intake, adults aged 25+ years (g/day)
- Current tobacco use, adults aged 15+ years (%)
- Obesity, adults aged 18+ years (%)
- Total alcohol per capita consumption, adults aged 15+ years (litres)
- Physical inactivity, adults aged 18+ years (%)

National response

- National target for blood pressure
- National target for salt consumption
- Surveillance:
  - Conducted recent, national survey measuring raised blood pressure/hypertension
  - Conducted recent, national survey on salt/sodium intake
  - Functioning system for generating reliable cause-specific mortality data on a routine basis

Footnotes:
- a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.
- b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg.
- c. SBP ≥140 mmHg or DBP ≥90 mmHg.
- d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.
- e. Age-standardized estimates are presented for all indicators except salt intake.
**Luxembourg**

**Hypertension profile**

**Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)**

- **Total population (2019): 620 000**
- **Total deaths (2019): 4250**
- **Women (%): 31**
- **Men (%): 37**
- **People (%): 24**

**Prevalence of hypertension – global comparison (both sexes)**

**Trends in uncontrolled hypertension in adults aged 30–79 years**

**Hypertension control rate scenarios**

**Mortality**

- Probability of premature mortality from NCDs (%)
  - Cardiovascular disease deaths
  - Cardiovascular disease deaths attributable to high systolic blood pressure (%)

**Risk factors**

- Mean population salt intake, adults aged 25+ years (g/day)
- Current tobacco use, adults aged 15+ years (%)
- Obesity, adults aged 18+ years (%)
- Total alcohol per capita consumption, adults aged 15+ years (litres)
- Physical inactivity, adults aged 18+ years (%)

**National response**

- **Targets**
  - National target for blood pressure
  - National target for salt consumption
- **Surveillance**
  - Conducted recent, national survey measuring raised blood pressure/hypertension
  - Conducted recent, national survey on salt/sodium intake
  - Functioning system for generating reliable cause-specific mortality data on a routine basis
- **Treatment**
  - Guidelines for management of hypertension

**Footnotes:**
- a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.
- b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg.
- c. SBP ≥140 mmHg or DBP ≥90 mmHg.
- d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.
- e. Age-standardized estimates are presented for all indicators except salt intake.
- f. Data refer to tobacco smoking only, in the absence of sufficient data on all tobacco use.
Luxembourg Hypertension profile

Of the 1.2 million adults aged 30–79 years with hypertension, 1.2 million more people with hypertension would need to be effectively treated. In order to achieve a 50% control rate, 79 000 deaths would be averted by 2040.

In order to achieve a 50% control rate, 1.2 million more people with hypertension would need to be effectively treated. If the progress scenario were achieved, 79 000 deaths would be averted by 2040.
Malawi

Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)

Of the 1.2 million adults aged 30–79 years with hypertension:

- 27% of males and 32% of females had hypertension.
- Of these, 24% of males and 11% of females had controlled hypertension.
- In order to achieve a 50% control rate, 508 000 more people with hypertension would need to be effectively treated.

In order to achieve a 50% control rate, 508 000 more people with hypertension would need to be effectively treated.

If the progress scenario were achieved, 23 000 deaths would be averted by 2040.

Mortality

- Probability of premature mortality from NCDs (%)
  - Cardiovascular disease deaths
  - Cardiovascular disease deaths attributable to high systolic blood pressure (%)

Risk factors

- Mean population salt intake, adults aged 25+ years (g/day)
- Current tobacco use, adults aged 15+ years (%)
- Obesity, adults aged 18+ years (%)
- Total alcohol per capita consumption, adults aged 15+ years (litres)
- Physical inactivity, adults aged 18+ years (%)

National response

- National target for blood pressure
- National target for salt consumption
- Surveillance
  - Conducted recent, national survey measuring raised blood pressure/hypertension
  - Conducted recent, national survey on salt/sodium intake
  - Functioning system for generating reliable cause-specific mortality data on a routine basis

Footnotes: a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control. e. Age-standardized estimates are presented for all indicators except salt intake.
Malaysia

Hypertension profile

Total population (2019): 32 804 000
Total deaths (2019): 185 000

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)

- Male: 41%
- Female: 41%

Of the 6.1 million adults aged 30–79 years with hypertension:

- Male: 50%
- Female: 43%

- Of the population aged 30–79 years
  - Male: 15%
  - Female: 20%

- Of the population aged 30–79 years
  - Male: 30%
  - Female: 25%

- Of the population aged 30–79 years
  - Male: 45%
  - Female: 50%

- Of the population aged 30–79 years
  - Male: 0%
  - Female: 0%

Projected hypertension control rates by scenario:

- Business as usual: 0%
- Progress: 50%
- Aspirational: 60%

If the progress scenario were achieved, 149 000 deaths would be averted by 2040.

Mortality

- Probability of premature mortality from NCDs (%)
  - Male: 18
  - Female: 15
  - Both sexes: 19

- Cardiovascular disease deaths
  - Male: 63 600
  - Female: 62
  - Both sexes: 62 100

- Cardiovascular disease deaths attributable to high systolic blood pressure (%)
  - Male: 22
  - Female: 13
  - Both sexes: 16

Risk factors

- Mean population salt intake, adults aged 25+ years (g/day)
  - Male: 10
  - Female: 10

- Current tobacco use, adults aged 15+ years (%)
  - Male: 23
  - Female: 16
  - Both sexes: 19

- Obesity, adults aged 18+ years (%)
  - Male: 44
  - Female: 1
  - Both sexes: 22

- Total alcohol per capita consumption, adults aged 15+ years (litres)
  - Male: 1
  - Female: 39
  - Both sexes: 1

- Physical inactivity, adults aged 18+ years (%)
  - Male: 11
  - Female: 35
  - Both sexes: 24

National response

- National target for blood pressure

- National target for salt consumption

- Surveillance
  - Conducted recent, national survey measuring raised blood pressure/hypertension
  - Conducted recent, national survey on salt/sodium intake

- Treatment
  - Guidelines for management of hypertension

Footnotes:

a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.
b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg.
c. SBP ≥140 mmHg or DBP ≥90 mmHg.
d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.
e. Age-standardized estimates are presented for all indicators except salt intake.
Maldives

Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)^[1^]  
- 34% of males
- 33% of females
- 35% overall

Prevalence of hypertension – global comparison (both sexes)^a^[2^]

<table>
<thead>
<tr>
<th>Year</th>
<th>Maldives</th>
<th>Global</th>
</tr>
</thead>
<tbody>
<tr>
<td>2019</td>
<td>43%</td>
<td>48%</td>
</tr>
</tbody>
</table>

Trends in uncontrolled hypertension in adults aged 30–79 years^[3^]

<table>
<thead>
<tr>
<th>Year</th>
<th>Past Trends</th>
<th>Projected Trends</th>
<th>Global Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>2000</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2025</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Hypertension control rate scenarios

<table>
<thead>
<tr>
<th>Scenario</th>
<th>Projected Hypertension Control Rates by Scenario^[4^]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Business as usual</td>
<td></td>
</tr>
<tr>
<td>Progress</td>
<td></td>
</tr>
<tr>
<td>Aspirational</td>
<td></td>
</tr>
</tbody>
</table>

Mortality

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Male</th>
<th>Female</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Probability of premature mortality from NCDs (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardiovascular disease deaths</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardiovascular disease deaths attributable to high systolic blood pressure (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Risk factors^[5^]

<table>
<thead>
<tr>
<th>Factor</th>
<th>Male</th>
<th>Female</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean population salt intake, adults aged 25+ years (g/day)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Current tobacco use, adults aged 15+ years (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Obesity, adults aged 18+ years (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total alcohol per capita consumption, adults aged 15+ years (litres)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Physical inactivity, adults aged 18+ years (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

National response

<table>
<thead>
<tr>
<th>Target/Risk Factor</th>
<th>National target for blood pressure</th>
<th>National target for salt consumption</th>
<th>Surveillan</th>
<th>Conducted recent, national survey measuring raised blood pressure/hypertension</th>
<th>Conducted recent, national survey on salt/sodium intake</th>
<th>Functioning system for generating reliable cause-specific mortality data on a routine basis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
<td>✗</td>
<td>✗</td>
<td>✗</td>
</tr>
</tbody>
</table>

Footnotes: a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control. e. Age-standardized estimates are presented for all indicators except salt intake.
Mali

Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)

<table>
<thead>
<tr>
<th>% of population aged 30-79 years</th>
<th>Male</th>
<th>Female</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total deaths (2019):</td>
<td>20 567 000</td>
<td>154 000</td>
</tr>
<tr>
<td>Probability of premature mortality from NCDs (%)</td>
<td>35%</td>
<td>31%</td>
</tr>
<tr>
<td>Cardiovascular disease deaths</td>
<td>15 300</td>
<td>9000</td>
</tr>
<tr>
<td>Cardiovascular disease deaths attributable to high systolic blood pressure (%)</td>
<td>50</td>
<td>55</td>
</tr>
</tbody>
</table>

Risk factors:

- Mean population salt intake, adults aged 25+ years (g/day)
- Current tobacco use, adults aged 15+ years (%)
- Obesity, adults aged 18+ years (%)
- Total alcohol per capita consumption, adults aged 15+ years (litres)
- Physical inactivity, adults aged 18+ years (%)

National response:

- National target for blood pressure
- National target for salt consumption
- Surveillance
  - Conducted recent, national survey measuring raised blood pressure/hypertension
  - Conducted recent, national survey on salt/sodium intake
  - Functioning system for generating reliable cause-specific mortality data on a routine basis

Footnotes: a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg or DBP ≤90 mmHg. c. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control. d. If the progress scenario were achieved, 37 000 deaths would be averted by 2040. e. Age-standardized estimates are presented for all indicators except salt intake.

Annex 2. Hypertension profiles and explanatory notes
### Malta

#### Hypertension profile

| Total population (2019): | 504 000 |
| Total deaths (2019):    | 3800    |

#### Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)\(^a\)

<table>
<thead>
<tr>
<th></th>
<th>♂</th>
<th>♂</th>
<th>♀</th>
<th>25%</th>
<th>30%</th>
<th>34%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Of the 103 000 adults aged 30–79 years with hypertension:</td>
<td>71%</td>
<td>66%</td>
<td>45%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>diagnosed</td>
<td>70%</td>
<td>69%</td>
<td>48%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>treated</td>
<td>74%</td>
<td>65%</td>
<td>50%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>controlled</td>
<td>43%</td>
<td>43%</td>
<td>43%</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Prevalence of hypertension – global comparison (both sexes)\(^a\)

In order to achieve a 50% control rate, 2900 more people with hypertension would need to be effectively treated.\(^b\)

#### Trends in uncontrolled hypertension in adults aged 30–79 years\(^c\)

Of the 103 000 adults aged 30–79 years with hypertension:

If the progress scenario were achieved, 700 deaths would be averted by 2040.

#### Mortality

<table>
<thead>
<tr>
<th>Probability of premature mortality from NCDs (%)</th>
<th>Cardiovascular disease deaths</th>
<th>Cardiovascular disease deaths attributable to high systolic blood pressure (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Risk factors\(^e\)

<table>
<thead>
<tr>
<th>Mean population salt intake, adults aged 25+ years (g/day)</th>
<th>Current tobacco use, adults aged 15+ years (%)(^f)</th>
<th>Obesity, adults aged 18+ years (%)</th>
<th>Total alcohol per capita consumption, adults aged 15+ years (litres)</th>
<th>Physical inactivity, adults aged 18+ years (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### National response

<table>
<thead>
<tr>
<th>Targets</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>National target for blood pressure</td>
<td>Guidelines for management of hypertension</td>
</tr>
<tr>
<td>National target for salt consumption</td>
<td>(-)</td>
</tr>
</tbody>
</table>

#### Surveillance

- Conducted recent, national survey measuring raised blood pressure/hypertension
- Conducted recent, national survey on salt/sodium intake
- Functioning system for generating reliable cause-specific mortality data on a routine basis

#### Footnotes:

- a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.
- b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg.
- c. Age-standardized estimates are presented for all indicators except salt intake.
- d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.
- e. Data refer to tobacco smoking only, in the absence of sufficient data on all tobacco use.
Marshall Islands

Hypertension profile

Total population (2019): 44 700
Total deaths (2019): no data

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)

Prevalence of hypertension – global comparison (both sexes)

Of the 6000 adults aged 30–79 years with hypertension:

Hypertension control rate scenarios

Data not available

Mortality

Probability of premature mortality from NCDs (%)
Cardiovascular disease deaths
Cardiovascular disease deaths attributable to high systolic blood pressure (%)

Risk factors

Mean population salt intake, adults aged 25+ years (g/day)
Current tobacco use, adults aged 15+ years (%)
Obesity, adults aged 18+ years (%)
Total alcohol per capita consumption, adults aged 15+ years (litres)
Physical inactivity, adults aged 18+ years (%)

National response

Targets
National target for blood pressure
National target for salt consumption

Surveillance
Conducted recent, national survey measuring raised blood pressure/hypertension
Conducted recent, national survey on salt/sodium intake
Functioning system for generating reliable cause-specific mortality data on a routine basis

Footnotes: a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Age-standardized estimates are presented for all indicators except salt intake.
Mauritania

Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)

Prevalence of hypertension – global comparison (both sexes)

Of the 501 000 adults aged 30–79 years with hypertension:

- In order to achieve a 50% control rate, 198 000 more people with hypertension would need to be effectively treated.

Trends in uncontrolled hypertension in adults aged 30–79 years

Hypertension control rate scenarios

Projected hypertension control rates by scenario:

- Global target
- Business as usual
- Progress
- Aspirational

Mortality

Probability of premature mortality from NCDs (%)

Cardiovascular disease deaths

Cardiovascular disease deaths attributable to high systolic blood pressure (%)

Risk factors

Mean population salt intake, adults aged 25+ years (g/day)

Current tobacco use, adults aged 15+ years (%)

Obesity, adults aged 18+ years (%)

Total alcohol per capita consumption, adults aged 15+ years (litres)

Physical inactivity, adults aged 18+ years (%)

National response

Targets

National target for blood pressure

National target for salt consumption

Surveillance

Conducted recent, national survey measuring raised blood pressure/hypertension

Conducted recent, national survey on salt/sodium intake

Functioning system for generating reliable cause-specific mortality data on a routine basis

Treatment

Guidelines for management of hypertension

Footnotes: a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control. e. Age-standardized estimates are presented for all indicators except salt intake.
Mauritius

Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)  
- Mauritania: 33%  
- Total population (2019): 1 296 000
- Total deaths (2019): 11 400

Prevalence of hypertension – global comparison (both sexes)

Trends in uncontrolled hypertension in adults aged 30–79 years

Hypertension control rate scenarios

Mortality

Probability of premature mortality from NCDs (%)
- Cardiovascular disease deaths
- Cardiovascular disease deaths attributable to high systolic blood pressure (%)

Risk factors

Mean population salt intake, adults aged 25+ years (g/day)
- Current tobacco use, adults aged 15+ years (%)
- Obesity, adults aged 18+ years (%)
- Total alcohol per capita consumption, adults aged 15+ years (litres)
- Physical inactivity, adults aged 18+ years (%)

National response

Targets
- National target for blood pressure
- National target for salt consumption

Surveillance
- Conducted recent, national survey measuring raised blood pressure/hypertension
- Conducted recent, national survey on salt/sodium intake
- Functioning system for generating reliable cause-specific mortality data on a routine basis

Treatment
- Guidelines for management of hypertension

Footnotes:
- a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.
- b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.
- e. Age-standardized estimates are presented for all indicators except salt intake. f. Data refer to tobacco smoking only, in the absence of sufficient data on all tobacco use.
**Mexico**

**Hypertension profile**

**Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)**

<table>
<thead>
<tr>
<th>Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)</th>
<th>32%</th>
<th>33%</th>
<th>31%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total population (2019): 125 100 000</td>
<td>Total deaths (2019): 712 000</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Of the **18.6 million** adults aged 30–79 years with hypertension:

- **58%** diagnosed
- **50%** treated
- **28%** controlled

In order to achieve a 50% control rate, **4.2 million more people** with hypertension would need to be effectively treated.

If the progress scenario were achieved, **290 000 deaths** would be averted by 2040.

### Mortality

<table>
<thead>
<tr>
<th>Probability of premature mortality from NCDs (%)</th>
<th>Cardiovascular disease deaths</th>
<th>Cardiovascular disease deaths attributable to high systolic blood pressure (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>past trends</td>
<td>projected trends</td>
<td>global target</td>
</tr>
<tr>
<td>2023</td>
<td>2025</td>
<td>2030</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Probability of premature mortality from NCDs (%)</th>
<th>Cardiovascular disease deaths</th>
<th>Cardiovascular disease deaths attributable to high systolic blood pressure (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>both sexes</td>
<td>males</td>
<td>females</td>
</tr>
<tr>
<td>16</td>
<td>18</td>
<td>13</td>
</tr>
<tr>
<td>188 000</td>
<td>98 600</td>
<td>89 300</td>
</tr>
<tr>
<td>52</td>
<td>52</td>
<td>52</td>
</tr>
</tbody>
</table>

### Risk factors

- Mean population salt intake, adults aged 25+ years (g/day)
- Current tobacco use, adults aged 15+ years (%)
- Obesity, adults aged 18+ years (%)
- Total alcohol per capita consumption, adults aged 15+ years (litres)
- Physical inactivity, adults aged 18+ years (%)

### National response

**Targets**

- National target for blood pressure
- National target for salt consumption

**Surveillance**

- Conducted recent, national survey measuring raised blood pressure/hypertension
- Conducted recent, national survey on salt/sodium intake
- Functioning system for generating reliable cause-specific mortality data on a routine basis

**Treatment**

- Guidelines for management of hypertension

---

Footnotes: a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control. e. Age-standardized estimates are presented for all indicators except salt intake.
Micronesia (Federated States of)

Hypertension profile

Total population (2019): 111,000
Total deaths (2019): 1,030

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)\textsuperscript{a}  ♂ 33%  ♀ 32%  ♀ 34%

Prevalence of hypertension – global comparison (both sexes)\textsuperscript{a}

Of the 14,000 adults aged 30–79 years with hypertension:

- % of population aged 30–79 years

Trends in uncontrolled hypertension in adults aged 30–79 years\textsuperscript{c}

Hypertension control rate scenarios

Mortality

Probability of premature mortality from NCDs (%)
Cardiovascular disease deaths
Cardiovascular disease deaths attributable to high systolic blood pressure (%)

Risk factors\textsuperscript{a}

Mean population salt intake, adults aged 25+ years (g/day)
Current tobacco use, adults aged 15+ years (%)
Obesity, adults aged 18+ years (%)
Total alcohol per capita consumption, adults aged 15+ years (litres)
Physical inactivity, adults aged 18+ years (%)

National response

Targets
- National target for blood pressure
- National target for salt consumption

Surveillance
- Conducted recent, national survey measuring raised blood pressure/hypertension
- Conducted recent, national survey on salt/sodium intake
- Functioning system for generating reliable cause-specific mortality data on a routine basis

Footnotes: a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control. e. Age-standardized estimates are presented for all indicators except salt intake.
### Monaco

**Hypertension profile**

**Total population (2019):** 37 000  
**Total deaths (2019):** no data

<table>
<thead>
<tr>
<th>Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Data not available</td>
</tr>
</tbody>
</table>

### Prevalence of hypertension – global comparison (both sexes)

Data not available

### Trends in uncontrolled hypertension in adults aged 30–79 years

Data not available

### Hypertension control rate scenarios

Data not available

### Mortality

<table>
<thead>
<tr>
<th>Probability of premature mortality from NCDs (%)</th>
<th>both sexes</th>
<th>males</th>
<th>females</th>
<th>year</th>
</tr>
</thead>
<tbody>
<tr>
<td>no data</td>
<td>no data</td>
<td>no data</td>
<td>2019</td>
<td></td>
</tr>
<tr>
<td>Cardiovascular disease deaths</td>
<td>no data</td>
<td>no data</td>
<td>no data</td>
<td>2019</td>
</tr>
<tr>
<td>Cardiovascular disease deaths attributable to high systolic blood pressure (%)</td>
<td>51</td>
<td>53</td>
<td>50</td>
<td>2019</td>
</tr>
</tbody>
</table>

### Risk factors<sup>a</sup>

<table>
<thead>
<tr>
<th>Mean population salt intake, adults aged 25+ years (g/day)</th>
<th>both sexes</th>
<th>males</th>
<th>females</th>
<th>year</th>
</tr>
</thead>
<tbody>
<tr>
<td>8</td>
<td>no data</td>
<td>no data</td>
<td>7</td>
<td>2019</td>
</tr>
<tr>
<td>Current tobacco use, adults aged 15+ years (%)</td>
<td>no data</td>
<td>no data</td>
<td>no data</td>
<td>2019</td>
</tr>
<tr>
<td>Obesity, adults aged 18+ years (%)</td>
<td>no data</td>
<td>no data</td>
<td>no data</td>
<td>2016</td>
</tr>
<tr>
<td>Total alcohol per capita consumption, adults aged 15+ years (litres)</td>
<td>no data</td>
<td>no data</td>
<td>no data</td>
<td>2019</td>
</tr>
<tr>
<td>Physical inactivity, adults aged 18+ years (%)</td>
<td>no data</td>
<td>no data</td>
<td>no data</td>
<td>2016</td>
</tr>
</tbody>
</table>

### National response

<table>
<thead>
<tr>
<th>Targets</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>National target for blood pressure</td>
<td>Guidelines for management of hypertension</td>
</tr>
<tr>
<td>National target for salt consumption</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Surveillance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Conducted recent, national survey measuring raised blood pressure/hypertension</td>
</tr>
<tr>
<td>Conducted recent, national survey on salt/sodium intake</td>
</tr>
<tr>
<td>Functioning system for generating reliable cause-specific mortality data on a routine basis</td>
</tr>
</tbody>
</table>

---

**Footnote:** a. Age-standardized estimates are presented for all indicators except salt intake.
Mongolia

Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019) 43% ♂ 45% ♂ 41% ♀

Total population (2019): 3 232 000

Total deaths (2019): 23 400

Prevalence of hypertension – global comparison (both sexes)⃣

Of the 578 000 adults aged 30–79 years with hypertension:

In order to achieve a 50% control rate, 144 000 more people with hypertension would need to be effectively treated.^

Trends in uncontrolled hypertension in adults aged 30–79 years

Hypertension control rate scenarios

If the progress scenario were achieved, 24 000 deaths would be averted by 2040.

Mortality

Probability of premature mortality from NCDs (%)
Cardiovascular disease deaths
Cardiovascular disease deaths attributable to high systolic blood pressure (%)

Risk factors^

Mean population salt intake, adults aged 25+ years (g/day)
Current tobacco use, adults aged 15+ years (%)
Obesity, adults aged 18+ years (%)
Total alcohol per capita consumption, adults aged 15+ years (litres)
Physical inactivity, adults aged 18+ years (%)

National response

Targets
National target for blood pressure
National target for salt consumption
Surveillance
Conducted recent, national survey measuring raised blood pressure/hypertension
Conducted recent, national survey on salt/sodium intake
Functioning system for generating reliable cause-specific mortality data on a routine basis

Footnotes: a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control. e. Age-standardized estimates are presented for all indicators except salt intake.

Annex 2. Hypertension profiles and explanatory notes
**Montenegro**

**Hypertension profile**

Total population (2019): 630 000

Total deaths (2019): 7280

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)

- **Prevalence of hypertension – global comparison (both sexes)**

  - **% of population aged 30-79 years**
    - Montenegro: 45%
    - Global: 50%
    - Females: 41%

  - Of the **185 000** adults aged 30–79 years with hypertension:
    - **Diagnosed**: 64%
    - **Treated**: 52%
    - **Controlled**: 23%

  - If the progress scenario were achieved, **8200 deaths would be averted by 2040**.

**Trends in uncontrolled hypertension in adults aged 30–79 years**

- Past trends: Female, Male, Global target

**Hypertension control rate scenarios**

- Projected hypertension control rates by scenario:
  - Business as usual
  - Progress
  - Aspirational

**Mortality**

- Probability of premature mortality from NCDs (%)
  - Cardiovascular disease deaths
    - Both sexes: 22 4600 56
    - Males: 29 2300 56
    - Females: 16 2300 56

- Cardiovascular disease deaths attributable to high systolic blood pressure (%)

**Risk factors**

- Mean population salt intake, adults aged 25+ years (g/day)
  - Both sexes: 13
  - Males: 15
  - Females: 11

- Current tobacco use, adults aged 15+ years (%)
  - Both sexes: 32
  - Males: 32
  - Females: 31

- Obesity, adults aged 18+ years (%)
  - Both sexes: 23
  - Males: 23
  - Females: 23

- Total alcohol per capita consumption, adults aged 15+ years (litres)
  - Both sexes: 10
  - Males: 17
  - Females: 4

- Physical inactivity, adults aged 18+ years (%)
  - Both sexes: no data
  - Males: no data
  - Females: no data

**National response**

- **Targets**
  - National target for blood pressure
  - National target for salt consumption

- **Treatment**
  - Guidelines for management of hypertension

- **Surveillance**
  - Conducted recent, national survey measuring raised blood pressure/hypertension
  - Conducted recent, national survey on salt/sodium intake

**Footnotes:**

a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.

b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg.

d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.

e. Age-standardized estimates are presented for all indicators except salt intake.
Montenegro

Prevalence of hypertension among adults aged 30–79 years (2019)

Mortality

Probability of premature mortality from NCDs (%)
Cardiovascular disease deaths
Cardiovascular disease deaths attributable to high systolic blood pressure (%)

Risk factors

Mean population salt intake, adults aged 25+ years (g/day)
Current tobacco use, adults aged 15+ years (%)
Obesity, adults aged 18+ years (%)
Total alcohol per capita consumption, adults aged 15+ years (litres)
Physical inactivity, adults aged 18+ years (%)

National response

Targets
National target for blood pressure
National target for salt consumption

Surveillance
Conducted recent, national survey measuring raised blood pressure/hypertension
Conducted recent, national survey on salt/sodium intake
Functioning system for generating reliable cause-specific mortality data on a routine basis

Footnotes: a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control. e. Age-standardized estimates are presented for all indicators except salt intake.
Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)\textsuperscript{a}  2.9 million  1.2 million  73 000

<table>
<thead>
<tr>
<th>Target</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>National target for blood pressure</td>
<td>✔</td>
</tr>
<tr>
<td>National target for salt consumption</td>
<td>✖</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Surveillance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Conducted recent, national survey measuring raised blood pressure/hypertension</td>
</tr>
<tr>
<td>Conducted recent, national survey on salt/sodium intake</td>
</tr>
<tr>
<td>Functioning system for generating reliable cause-specific mortality data on a routine basis</td>
</tr>
</tbody>
</table>

Notes: a. SBP ≥ 140 mmHg or DBP ≥ 90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP < 140 mmHg and DBP < 90 mmHg. c. SBP ≥ 140 mmHg or DBP ≥ 90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.

Mozambique

Total population (2019): 30 286 000
Total deaths (2019): 284 000\textsuperscript{1}

Footnotes: a. SBP ≥ 140 mmHg or DBP ≥ 90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP < 140 mmHg and DBP < 90 mmHg. c. SBP ≥ 140 mmHg or DBP ≥ 90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control. e. Age-standardized estimates are presented for all indicators except salt intake.
Myanmar
Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)a

<table>
<thead>
<tr>
<th>Total population (2019): 53 040 000</th>
<th>Total deaths (2019): 387 000</th>
</tr>
</thead>
</table>
| % of population aged 30–79 years    | ![](image)

Prevalence of hypertension – global comparison (both sexes)a

Of the 9.4 million adults aged 30–79 years with hypertension:

- % diagnosed: ![](image)
- % treated: ![](image)
- % controlled: ![](image)

Trends in uncontrolled hypertension in adults aged 30–79 yearsc

Hypertension control rate scenarios

If the progress scenario were achieved, 307 000 deaths would be averted by 2040.

Mortality

<table>
<thead>
<tr>
<th>Probability of premature mortality from NCDs (%)</th>
<th>Cardiovascular disease deaths</th>
<th>Cardiovascular disease deaths attributable to high systolic blood pressure (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>both sexes</td>
<td>males</td>
<td>females</td>
</tr>
<tr>
<td>25</td>
<td>31</td>
<td>20</td>
</tr>
<tr>
<td>119 000</td>
<td>58 500</td>
<td>60 700</td>
</tr>
<tr>
<td>57</td>
<td>58</td>
<td>56</td>
</tr>
</tbody>
</table>

Risk factorsa

<table>
<thead>
<tr>
<th>Mean population salt intake, adults aged 25+ years (g/day)</th>
<th>Current tobacco use, adults aged 15+ years (%)</th>
<th>Obesity, adults aged 18+ years (%)</th>
<th>Total alcohol per capita consumption, adults aged 15+ years (litres)</th>
<th>Physical inactivity, adults aged 18+ years (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>both sexes</td>
<td>males</td>
<td>females</td>
<td>year</td>
<td>both sexes</td>
</tr>
</tbody>
</table>

National response

<table>
<thead>
<tr>
<th>Targets</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>National target for blood pressure</td>
<td>Guidelines for management of hypertension</td>
</tr>
<tr>
<td>National target for salt consumption</td>
<td>✔</td>
</tr>
</tbody>
</table>

Surveillance

- Conducted recent, national survey measuring raised blood pressure/hypertension
- Conducted recent, national survey on salt/sodium intake
- Functioning system for generating reliable cause-specific mortality data on a routine basis

Footnotes: a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control. e. Age-standardized estimates are presented for all indicators except salt intake.
**Namibia**

**Hypertension profile**

**Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)**

- **Total population (2019):** 2,447,000
- **Total deaths (2019):** 18,300

| Notes: | a SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control. e. Age-standardized estimates are presented for all indicators except salt intake. |

---

**Prevalence of hypertension – global comparison (both sexes)**

Of the **341,000** adults aged 30–79 years with hypertension:

- **52%** of women diagnosed
- **44%** of men diagnosed
- **22%** of women treated
- **48%** of men treated
- **18%** of women controlled
- **25%** of men controlled

*In order to achieve a 50% control rate, 103,000 more people with hypertension would need to be effectively treated.*

---

**Trends in uncontrolled hypertension in adults aged 30–79 years**

If the progress scenario were achieved, 7000 deaths would be averted by 2040.

---

**Mortality**

- Probability of premature mortality from NCDs (%)
- Cardiovascular disease deaths
- Cardiovascular disease deaths attributable to high systolic blood pressure (%)

<table>
<thead>
<tr>
<th>Risk factors</th>
<th>both sexes</th>
<th>males</th>
<th>females</th>
<th>year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean population salt intake, adults aged 25+ years (g/day)</td>
<td>8</td>
<td>8</td>
<td>7</td>
<td>2019</td>
</tr>
<tr>
<td>Current tobacco use, adults aged 15+ years (%)</td>
<td>16</td>
<td>25</td>
<td>6</td>
<td>2019</td>
</tr>
<tr>
<td>Obesity, adults aged 18+ years (%)</td>
<td>17</td>
<td>8</td>
<td>25</td>
<td>2016</td>
</tr>
<tr>
<td>Total alcohol per capita consumption, adults aged 15+ years (litres)</td>
<td>6</td>
<td>10</td>
<td>2</td>
<td>2019</td>
</tr>
<tr>
<td>Physical inactivity, adults aged 18+ years (%)</td>
<td>33</td>
<td>29</td>
<td>37</td>
<td>2016</td>
</tr>
</tbody>
</table>

**National response**

| Targets | National target for blood pressure | ✔
| National target for salt consumption | ✔
| Surveillance | Conducted recent, national survey measuring raised blood pressure/hypertension | ✗
| Conducted recent, national survey on salt/sodium intake | ✗
| Functioning system for generating reliable cause-specific mortality data on a routine basis | ✗

---

Footnotes: a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control. e. Age-standardized estimates are presented for all indicators except salt intake.
**Nauru**

**Hypertension profile**

**Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)**

- Men: 42%
- Women: 44%
- Total: 40%

**Total population (2019):** 12,100
**Total deaths (2019):** no data

**Prevalence of hypertension – global comparison (both sexes)**

- Nauru
- Global

**Trends in uncontrolled hypertension in adults aged 30–79 years**

- Past trends
- Projected trends
- Global target

**Mortality**

- Probability of premature mortality from NCDs (%)
- Cardiovascular disease deaths
- Cardiovascular disease deaths attributable to high systolic blood pressure (%)

**Risk factors**

- Mean population salt intake, adults aged 25+ years (g/day)
- Current tobacco use, adults aged 15+ years (%)
- Obesity, adults aged 18+ years (%)
- Total alcohol per capita consumption, adults aged 15+ years (litres)
- Physical inactivity, adults aged 18+ years (%)

**National response**

**Targets**
- National target for blood pressure
- National target for salt consumption

**Surveillance**
- Conducted recent, national survey measuring raised blood pressure/hypertension
- Conducted recent, national survey on salt/sodium intake
- Functioning system for generating reliable cause-specific mortality data on a routine basis

**Footnotes:**
- a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.
- b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Age-standardized estimates are presented for all indicators except salt intake.
Nepal

Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)  

<table>
<thead>
<tr>
<th>Age-standardized prevalence (%)</th>
<th>Males</th>
<th>Females</th>
</tr>
</thead>
<tbody>
<tr>
<td>36% (2019)</td>
<td>40%</td>
<td>34%</td>
</tr>
</tbody>
</table>

Prevalence of hypertension – global comparison (both sexes)

Of the **3.9 million** adults aged 30–79 years with hypertension:

- **33%** diagnosed
- **19%** treated
- **7%** controlled

<table>
<thead>
<tr>
<th>% of population aged 30–79 years with hypertension</th>
</tr>
</thead>
<tbody>
<tr>
<td>□ 30% males</td>
</tr>
<tr>
<td>□ 36% females</td>
</tr>
<tr>
<td>□ 16% males</td>
</tr>
<tr>
<td>□ 9% females</td>
</tr>
</tbody>
</table>

Trends in uncontrolled hypertension in adults aged 30–79 years

Hypertension control rate scenarios

<table>
<thead>
<tr>
<th>% of population aged 30–79 years with hypertension</th>
</tr>
</thead>
<tbody>
<tr>
<td>□ 0%</td>
</tr>
<tr>
<td>□ 5%</td>
</tr>
<tr>
<td>□ 10%</td>
</tr>
<tr>
<td>□ 15%</td>
</tr>
<tr>
<td>□ 20%</td>
</tr>
<tr>
<td>□ 25%</td>
</tr>
<tr>
<td>□ 30%</td>
</tr>
<tr>
<td>□ 35%</td>
</tr>
<tr>
<td>□ 40%</td>
</tr>
<tr>
<td>□ 45%</td>
</tr>
<tr>
<td>□ 50%</td>
</tr>
<tr>
<td>□ 60%</td>
</tr>
<tr>
<td>□ 70%</td>
</tr>
<tr>
<td>□ 80%</td>
</tr>
<tr>
<td>□ 90%</td>
</tr>
<tr>
<td>□ 100%</td>
</tr>
</tbody>
</table>

Mortality

Probability of premature mortality from NCDs (%)

- **2019**
  - Cardiovascular disease deaths
  - Cardiovascular disease deaths attributable to high systolic blood pressure (%)

Risk factors

- Mean population salt intake, adults aged 25+ years (g/day)
- Current tobacco use, adults aged 15+ years (%)
- Obesity, adults aged 18+ years (%)
- Total alcohol per capita consumption, adults aged 15+ years (litres)
- Physical inactivity, adults aged 18+ years (%)

National response

<table>
<thead>
<tr>
<th>Targets</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>National target for blood pressure</td>
<td>✔</td>
</tr>
<tr>
<td>National target for salt consumption</td>
<td>✔</td>
</tr>
</tbody>
</table>

Surveillance

- Conducted recent, national survey measuring raised blood pressure/hypertension
- Conducted recent, national survey on salt/sodium intake
- Functioning system for generating reliable cause-specific mortality data on a routine basis

Footnotes:  
a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.  
b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg.  
c. SBP ≥140 mmHg or DBP ≥90 mmHg.  
d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.  
e. Age-standardized estimates are presented for all indicators except salt intake.
Netherlands (Kingdom of the)

Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)

- Men: 31%
- Women: 36%
- Global: 25%

Prevalence of hypertension – global comparison (both sexes)

Of the 4 million adults aged 30–79 years with hypertension:

- Diagnosed: 51%
- Treated: 42%
- Controlled: 23%

In order to achieve a 50% control rate, 1.1 million more people with hypertension would need to be effectively treated.

Trends in uncontrolled hypertension in adults aged 30–79 years

If the progress scenario were achieved, 56 000 deaths would be averted by 2040.

Mortality

- Probability of premature mortality from NCDs (%)
  - Year: 2019
  - Both sexes: 10
  - Males: 12
  - Females: 9

Cardiovascular disease deaths

- Year: 2019
  - Both sexes: 36 400
  - Males: 17 600
  - Females: 18 900

Cardiovascular disease deaths attributable to high systolic blood pressure (%)

- Year: 2019
  - Both sexes: 48
  - Males: 51
  - Females: 45

Risk factors

- Mean population salt intake, adults aged 25+ years (g/day)
  - Year: 2019
  - Both sexes: 8
  - Males: 9
  - Females: 7

- Current tobacco use, adults aged 15+ years (%)
  - Year: 2019
  - Both sexes: 23
  - Males: 25
  - Females: 20

- Obesity, adults aged 18+ years (%)
  - Year: 2019
  - Both sexes: 20
  - Males: 21
  - Females: 20

- Total alcohol per capita consumption, adults aged 15+ years (litres)
  - Year: 2019
  - Both sexes: 9
  - Males: 15
  - Females: 4

- Physical inactivity, adults aged 18+ years (%)
  - Year: 2019
  - Both sexes: 27
  - Males: 25
  - Females: 29

National response

- Targets
  - National target for blood pressure
  - National target for salt consumption

- Surveillance
  - Conducted recent, national survey measuring raised blood pressure/hypertension
  - Conducted recent, national survey on salt/sodium intake
  - Functioning system for generating reliable cause-specific mortality data on a routine basis

Footnotes:

a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.

b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.

e. Age-standardized estimates are presented for all indicators except salt intake. f. Data refer to tobacco smoking only, in the absence of sufficient data on all tobacco use.

Annex 2. Hypertension profiles and explanatory notes
New Zealand

Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)  

<table>
<thead>
<tr>
<th>Sex</th>
<th>% of population aged 30–79 years</th>
<th>% of population aged 30–79 years diagnosed</th>
<th>% of population aged 30–79 years treated</th>
<th>% of population aged 30–79 years controlled</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male</td>
<td>31%</td>
<td>63%</td>
<td>50%</td>
<td>27%</td>
</tr>
<tr>
<td>Female</td>
<td>34%</td>
<td>65%</td>
<td>52%</td>
<td>30%</td>
</tr>
</tbody>
</table>

Of the 968 000 adults aged 30–79 years with hypertension:

- In order to achieve a 50% control rate, 193 000 more people with hypertension would need to be effectively treated.

Prevalence of hypertension – global comparison (both sexes)  

- % of population aged 30–79 years with hypertension  
- Global New Zealand

Trends in uncontrolled hypertension in adults aged 30–79 years  

- Past trends - Projected trends - Global target

Hypertension control rate scenarios  

- If the progress scenario were achieved, 12 000 deaths would be averted by 2040.

Mortality

- Probability of premature mortality from NCDs (%)
  - Cardiovascular disease deaths
  - Cardiovascular disease deaths attributable to high systolic blood pressure (%)

Risk factors

- Mean population salt intake, adults aged 25+ years (g/day)
- Current tobacco use, adults aged 15+ years (%)
- Obesity, adults aged 18+ years (%)
- Total alcohol per capita consumption, adults aged 15+ years (litres)
- Physical inactivity, adults aged 18+ years (%)

National response

- Targets
  - National target for blood pressure
  - National target for salt consumption

- Surveillance
  - Conducted recent, national survey measuring raised blood pressure/hypertension
  - Conducted recent, national survey on salt/sodium intake
  - Functioning system for generating reliable cause-specific mortality data on a routine basis

Footnotes:

a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.  
b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg.  
c. SBP ≥140 mmHg or DBP ≥90 mmHg.  
d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.  
e. Age-standardized estimates are presented for all indicators except salt intake.  
f. Data refer to tobacco smoking only, in the absence of sufficient data on all tobacco use.
Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)a

Of the 904 000 adults aged 30–79 years with hypertension:

- 56% male diagnosed
- 50% male treated
- 26% male controlled
- 76% female diagnosed
- 69% female treated
- 42% female controlled

In order to achieve a 50% control rate, 144 000 more people with hypertension would need to be effectively treated.b

Projected hypertension control rates by scenario:d

- Business as usual
- Progress
- Aspirational

If the progress scenario were achieved, 10 000 deaths would be averted by 2040.

Mortality

- Probability of premature mortality from NCDs (%)
  - Both sexes: 15, 9800, 55
  - Males: 18, 4800, 56
  - Females: 13, 5000, 54
  - Year: 2019

Risk factors:

- Mean population salt intake, adults aged 25+ years (g/day)
  - Both sexes: 10, no data
  - Males: 11, no data
  - Females: 9, no data
  - Year: 2019

- Current tobacco use, adults aged 15+ years (%)
  - Both sexes: no data
  - Males: no data
  - Females: no data
  - Year: 2019

- Obesity, adults aged 18+ years (%)
  - Both sexes: 24, 4
  - Males: 18, 7
  - Females: 29, 2
  - Year: 2019

- Total alcohol per capita consumption, adults aged 15+ years (litres)
  - Both sexes: no data
  - Males: no data
  - Females: no data
  - Year: 2019

- Physical inactivity, adults aged 18+ years (%)
  - Both sexes: no data
  - Males: no data
  - Females: no data
  - Year: 2019

National response

- Targets
  - National target for blood pressure
  - National target for salt consumption

- Surveillance
  - Conducted recent, national survey measuring raised blood pressure/hypertension
  - Conducted recent, national survey on salt/sodium intake
  - Functioning system for generating reliable cause-specific mortality data on a routine basis

Footnotes: a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control. e. Age-standardized estimates are presented for all indicators except salt intake.
Niger

Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)$^a$ ♂ 42% ♂ 40% ♂ 43%

Total population (2019): 23 443 000
Total deaths (2019): 183 000

Prevalence of hypertension – global comparison (both sexes)$^a$

Of the 2.2 million adults aged 30–79 years with hypertension:

- 27% diagnosed
- 13% treated
- 6% controlled

- ♂ 19% diagnosed
- ♂ 12% treated
- ♂ 4% controlled
- ♂ 33% diagnosed
- ♂ 15% treated
- ♂ 8% controlled

In order to achieve a 50% control rate, 955 000 more people with hypertension would need to be effectively treated.$^b$

Trends in uncontrolled hypertension in adults aged 30–79 years$^c$

Hypertension control rate scenarios

If the progress scenario were achieved, 44 000 deaths would be averted by 2040.

Projected hypertension control rates by scenario$^d$

- Business as usual
- Progress
- Aspirational

Mortality

Probability of premature mortality from NCDs (%)
- Cardiovascular disease deaths
- Cardiovascular disease deaths attributable to high systolic blood pressure (%)

Risk factors$^e$

- Mean population salt intake, adults aged 25+ years (g/day)
- Current tobacco use, adults aged 15+ years (%)
- Obesity, adults aged 18+ years (%)
- Total alcohol per capita consumption, adults aged 15+ years (litres)
- Physical inactivity, adults aged 18+ years (%)

National response

Targets
- National target for blood pressure
- National target for salt consumption

Surveillance
- Conducted recent, national survey measuring raised blood pressure/hypertension
- Conducted recent, national survey on salt/sodium intake
- Functioning system for generating reliable cause-specific mortality data on a routine basis

Footnotes:
- a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.
- b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg.
- c. SBP ≥140 mmHg or DBP ≥90 mmHg.
- d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.
- e. Age-standardized estimates are presented for all indicators except salt intake.
**Nigeria**

**Hypertension profile**

**Total population (2019): 203 300 000**

**Total deaths (2019): 1 650 000**

**Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)**

- **36%**
- **33%**
- **39%**

---

**Prevalence of hypertension – global comparison (both sexes)**

- Nigeria
- Global

---

**Trends in uncontrolled hypertension in adults aged 30–79 years**

Past trends

- Projected trends

---

**Hypertension control rate scenarios**

- Projected hypertension control rates by scenario

---

**Mortality**

- Probability of premature mortality from NCDs (%)
- Cardiovascular disease deaths
- Cardiovascular disease deaths attributable to high systolic blood pressure (%)

---

**Risk factors**

- Mean population salt intake, adults aged 25+ years (g/day)
- Current tobacco use, adults aged 15+ years (%)
- Obesity, adults aged 18+ years (%)
- Total alcohol per capita consumption, adults aged 15+ years (litres)
- Physical inactivity, adults aged 18+ years (%)

---

**National response**

**Targets**

- National target for blood pressure
- National target for salt consumption

**Surveillance**

- Conducted recent, national survey measuring raised blood pressure/hypertension
- Conducted recent, national survey on salt/sodium intake
- Functioning system for generating reliable cause-specific mortality data on a routine basis

---

Footnotes:
- a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.
- b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg.
- c. SBP ≥140 mmHg or DBP ≥90 mmHg.
- d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.
- e. Age-standardized estimates are presented for all indicators except salt intake.
**Niue**

**Hypertension profile**

### Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)*

- **Total population (2019):** 1900
- **Total deaths (2019):** no data

#### Prevalence of hypertension – global comparison (both sexes)*

- Of the 340 adults aged 30–79 years with hypertension:
  - Diagnosed: 54% (♂ 50%, ♀ 58%)
  - Treated: 42% (♂ 38%, ♀ 46%)
  - Controlled: 19% (♂ 14%, ♀ 23%)

#### Trends in uncontrolled hypertension in adults aged 30–79 yearsc

- Past trends: past sex
- Projected trends: projected sex
- Global target: global target

#### Hypertension control rate scenarios

- Data not available

### Mortality

- Probability of premature mortality from NCDs (%)
  - Cardiovascular disease deaths: no data
  - Cardiovascular disease deaths attributable to high systolic blood pressure (%): 59 (♂ 59, ♀ 59)

### Risk factorsd

- Mean population salt intake, adults aged 25+ years (g/day): 8 (♂ 8, ♀ 9, both sexes 8)
- Current tobacco use, adults aged 15+ years (%): 50 (♂ 45, ♀ 16, both sexes 50)
- Obesity, adults aged 18+ years (%): 9 (♂ 8, ♀ 6, both sexes 9)
- Total alcohol per capita consumption, adults aged 15+ years (litres): no data
- Physical inactivity, adults aged 18+ years (%): 7 (♂ 8, ♀ 6, both sexes 7)

### National response

#### Targets
- National target for blood pressure
- National target for salt consumption

#### Surveillance
- Conducted recent, national survey measuring raised blood pressure/hypertension
- Conducted recent, national survey on salt/sodium intake
- Functioning system for generating reliable cause-specific mortality data on a routine basis

#### Treatment
- Guidelines for management of hypertension

---

Footnotes:  
a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.  
b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg.  
c. SBP ≥140 mmHg or DBP ≥90 mmHg.  
d. Age-standardized estimates are presented for all indicators except salt intake.
North Macedonia

Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)\(^a\)

- Functioning system for generating reliable cause-specific mortality data on a routine basis
- Conducted recent, national survey on salt/sodium intake
- Conducted recent, national survey measuring raised blood pressure/hypertension

Surveillance

- National target for blood pressure
- National target for salt consumption

Risk factors\(^e\)

- Mean population salt intake, adults aged 25+ years (g/day)
- Current tobacco use, adults aged 15+ years (%)
- Obesity, adults aged 18+ years (%)
- Total alcohol per capita consumption, adults aged 15+ years (litres)
- Physical inactivity, adults aged 18+ years (%)

Mortality

- Probability of premature mortality from NCDs (%)
- Cardiovascular disease deaths
- Cardiovascular disease deaths attributable to high systolic blood pressure (%)

National response

- Conducted recent, national survey measuring raised blood pressure/hypertension
- Conducted recent, national survey on salt/sodium intake
- Functioning system for generating reliable cause-specific mortality data on a routine basis

Footnotes:

- a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.
- b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg.
- d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.
- e. Age-standardized estimates are presented for all indicators except salt intake.
Norway

Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)\(^a\)

<table>
<thead>
<tr>
<th></th>
<th>Male</th>
<th>Female</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total population (2019):</td>
<td>5 348 000</td>
<td></td>
</tr>
<tr>
<td>Total deaths (2019):</td>
<td>40 900</td>
<td></td>
</tr>
</tbody>
</table>

Footnotes: a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.

e. Age-standardized estimates are presented for all indicators except salt intake. f. Data refer to tobacco smoking only, in the absence of sufficient data on all tobacco use.

Prevalence of hypertension – global comparison (both sexes)\(^a\)

Of the 1.2 million adults aged 30–79 years with hypertension:

<table>
<thead>
<tr>
<th></th>
<th>Male</th>
<th>Female</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diagnosed</td>
<td>64%</td>
<td>62%</td>
</tr>
<tr>
<td>Treated</td>
<td>47%</td>
<td>48%</td>
</tr>
<tr>
<td>Controlled</td>
<td>29%</td>
<td>29%</td>
</tr>
</tbody>
</table>

In order to achieve a 50% control rate, 236 000 more people with hypertension would need to be effectively treated.\(^b\)

Trends in uncontrolled hypertension in adults aged 30–79 years\(^c\)

Hypertension control rate scenarios

If the progress scenario were achieved, 13 000 deaths would be averted by 2040.

Mortality

<table>
<thead>
<tr>
<th>Probability of premature mortality from NCDs (%)</th>
<th>both sexes</th>
<th>males</th>
<th>females</th>
<th>year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiovascular disease deaths</td>
<td>9</td>
<td>10</td>
<td>7</td>
<td>2019</td>
</tr>
<tr>
<td>Cardiovascular disease deaths attributable to high systolic blood pressure (%)</td>
<td>10 300</td>
<td>4900</td>
<td>5400</td>
<td>2019</td>
</tr>
<tr>
<td>Mean population salt intake, adults aged 25+ years (g/day)</td>
<td>49</td>
<td>50</td>
<td>47</td>
<td>2019</td>
</tr>
<tr>
<td>Current tobacco use, adults aged 15+ years (%)</td>
<td>17</td>
<td>18</td>
<td>16</td>
<td>2019</td>
</tr>
<tr>
<td>Obesity, adults aged 18+ years (%)</td>
<td>23</td>
<td>24</td>
<td>23</td>
<td>2016</td>
</tr>
<tr>
<td>Total alcohol per capita consumption, adults aged 15+ years (litres)</td>
<td>7</td>
<td>10</td>
<td>3</td>
<td>2019</td>
</tr>
<tr>
<td>Physical inactivity, adults aged 18+ years (%)</td>
<td>32</td>
<td>30</td>
<td>34</td>
<td>2016</td>
</tr>
</tbody>
</table>

Risk factors\(^e\)

National response

<table>
<thead>
<tr>
<th>Targets</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>National target for blood pressure</td>
<td>✔</td>
</tr>
<tr>
<td>National target for salt consumption</td>
<td>✔</td>
</tr>
</tbody>
</table>

Surveillance

- Conducted recent, national survey measuring raised blood pressure/hypertension
- Conducted recent, national survey on salt/sodium intake
- Functioning system for generating reliable cause-specific mortality data on a routine basis

- Footnotes: a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.

- e. Age-standardized estimates are presented for all indicators except salt intake. f. Data refer to tobacco smoking only, in the absence of sufficient data on all tobacco use.
Oman

Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019) a

- Total population (2019): 4 603 000
- Total deaths (2019): 16 300

**Prevalence of hypertension – global comparison (both sexes)** a

![Prevalence graph]

**Trends in uncontrolled hypertension in adults aged 30–79 years** c

- Past trends
- Projected trends
- Global target

**Hypertension control rate scenarios**

- diagnosis
- treated
- controlled

**Mortality**

<table>
<thead>
<tr>
<th>Probability of premature mortality from NCDs (%)</th>
<th>both sexes</th>
<th>males</th>
<th>females</th>
<th>year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiovascular disease deaths</td>
<td>21</td>
<td>22</td>
<td>20</td>
<td>2019</td>
</tr>
<tr>
<td>Cardiovascular disease deaths attributable to high systolic blood pressure (%)</td>
<td>7800</td>
<td>4600</td>
<td>3300</td>
<td>2019</td>
</tr>
</tbody>
</table>
| Risk factors** e**

- Mean population salt intake, adults aged 25+ years (g/day)
- Current tobacco use, adults aged 15+ years (%)
- Obesity, adults aged 18+ years (%)
- Total alcohol per capita consumption, adults aged 15+ years (litres)
- Physical inactivity, adults aged 18+ years (%)

**National response**

<table>
<thead>
<tr>
<th>Targets</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>National target for blood pressure</td>
<td>✔ Guidelines for management of hypertension</td>
</tr>
<tr>
<td>National target for salt consumption</td>
<td>✔</td>
</tr>
</tbody>
</table>

**Surveillance**

- Conducted recent, national survey measuring raised blood pressure/hypertension
- Conducted recent, national survey on salt/sodium intake
- Functioning system for generating reliable cause-specific mortality data on a routine basis

Footnotes:

- a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.
- b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg.
- c. SBP ≥140 mmHg or DBP ≥90 mmHg.
- d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.
- e. Age-standardized estimates are presented for all indicators except salt intake.

Annex 2. Hypertension profiles and explanatory notes
Pakistan
Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)a

<table>
<thead>
<tr>
<th>Prevalence of hypertension – global comparison (both sexes)a</th>
</tr>
</thead>
<tbody>
<tr>
<td>% of population aged 30–79 years with hypertension</td>
</tr>
<tr>
<td>Pakistan</td>
</tr>
<tr>
<td>60%</td>
</tr>
<tr>
<td>Global</td>
</tr>
<tr>
<td>50%</td>
</tr>
</tbody>
</table>

Of the 32.2 million adults aged 30–79 years with hypertension:

- % diagnosed: males 34%, females 54%
- % treated: males 25%, females 44%
- % controlled: males 8%, females 14%

In order to achieve a 50% control rate, 12.5 million more people with hypertension would need to be effectively treated.b

Mortality

<table>
<thead>
<tr>
<th>Probability of premature mortality from NCDs (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiovascular disease deaths</td>
</tr>
<tr>
<td>Cardiovascular disease deaths attributable to high systolic blood pressure (%)</td>
</tr>
</tbody>
</table>

Risk factors*

<table>
<thead>
<tr>
<th>Mean population salt intake, adults aged 25+ years (g/day)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Current tobacco use, adults aged 15+ years (%)</td>
</tr>
<tr>
<td>Obesity, adults aged 18+ years (%)</td>
</tr>
<tr>
<td>Total alcohol per capita consumption, adults aged 15+ years (litres)</td>
</tr>
<tr>
<td>Physical inactivity, adults aged 18+ years (%)</td>
</tr>
</tbody>
</table>

National response

<table>
<thead>
<tr>
<th>Targets</th>
</tr>
</thead>
<tbody>
<tr>
<td>National target for blood pressure</td>
</tr>
<tr>
<td>National target for salt consumption</td>
</tr>
<tr>
<td>Surveillance</td>
</tr>
<tr>
<td>Conducted recent, national survey measuring raised blood pressure/hypertension</td>
</tr>
<tr>
<td>Conducted recent, national survey on salt/sodium intake</td>
</tr>
<tr>
<td>Functioning system for generating reliable cause-specific mortality data on a routine basis</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Guidelines for management of hypertension</td>
</tr>
</tbody>
</table>

Footnotes: a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control. e. Age-standardized estimates are presented for all indicators except salt intake.

Global report on hypertension: the race against a silent killer

206
Palau

Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)\textsuperscript{a}

![Graph showing prevalence of hypertension globally compared to Palau.]

Of the 4900 adults aged 30–79 years with hypertension:

- Diagnosed: 54% males, 61% females
- Treated: 36% males, 45% females
- Controlled: 14% males, 20% females

Probabilities of premature mortality from NCDs (%)

- Cardiovascular disease deaths
- Cardiovascular disease deaths attributable to high systolic blood pressure (%)

Risk factors\textsuperscript{d}

- Mean population salt intake, adults aged 25+ years (g/day)
- Current tobacco use, adults aged 15+ years (%)
- Obesity, adults aged 18+ years (%)
- Total alcohol per capita consumption, adults aged 15+ years (litres)
- Physical inactivity, adults aged 18+ years (%)

National response

- National target for blood pressure
- National target for salt consumption
- Surveillance
  - Conducted recent, national survey measuring raised blood pressure/hypertension
  - Conducted recent, national survey on salt/sodium intake
  - Functioning system for generating reliable cause-specific mortality data on a routine basis

Footnotes: a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Age-standardized estimates are presented for all indicators except salt intake. e. Data refer to tobacco smoking only, in the absence of sufficient data on all tobacco use.
Panama
Hypertension profile

Total population (2019): 4 233 000
Total deaths (2019): 20 200

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)\(^{a}\)

Of the 718 000 adults aged 30–79 years with hypertension:

- **Diagnosed**: 67% (59% males, 76% females)
- **Treated**: 55% (46% males, 64% females)
- **Controlled**: 29% (21% males, 36% females)

In order to achieve a 50% control rate, 154 000 more people with hypertension would need to be effectively treated.\(^{b}\)

Prevalence of hypertension – global comparison (both sexes)\(^{a}\)

- **Panama**: 36% (37% males, 35% females)
- **Global**: 32% (32% males, 35% females)

Trends in uncontrolled hypertension in adults aged 30–79 years\(^{c}\)

- **Past trends**: 50% (45% males, 55% females)
- **Projected trends**: 40% (39% males, 42% females)
- **Global target**: 25%

Hypertension control rate scenarios

- **Projected hypertension control rates by scenario**:
  - Business as usual: 20% (18% males, 21% females)
  - Progress: 50% (45% males, 55% females)
  - Aspirational: 60% (55% males, 65% females)

Mortality

- **Probability of premature mortality from NCDs (%)**
  - Cardiovascular disease deaths
  - Cardiovascular disease deaths attributable to high systolic blood pressure (%)

Risk factors\(^{e}\)

- **Mean population salt intake, adults aged 25+ years (g/day)**
- **Current tobacco use, adults aged 15+ years (%)**
- **Obesity, adults aged 18+ years (%)**
- **Total alcohol per capita consumption, adults aged 15+ years (litres)**
- **Physical inactivity, adults aged 18+ years (%)**

National response

- **Targets**
  - National target for blood pressure
  - National target for salt consumption
- **Surveillance**
  - Conducted recent, national survey measuring raised blood pressure/hypertension
  - Conducted recent, national survey on salt/sodium intake
  - Functioning system for generating reliable cause-specific mortality data on a routine basis

Footnotes: a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control. e. Age-standardized estimates are presented for all indicators except salt intake.
Papua New Guinea

Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)²

- Total population (2019): 9,542,000
- Total deaths (2019): 60,600

---

Prevalence of hypertension – global comparison (both sexes)²

<table>
<thead>
<tr>
<th>Year</th>
<th>Male</th>
<th>Female</th>
</tr>
</thead>
<tbody>
<tr>
<td>2000</td>
<td>15%</td>
<td>10%</td>
</tr>
<tr>
<td>2005</td>
<td>18%</td>
<td>13%</td>
</tr>
<tr>
<td>2010</td>
<td>20%</td>
<td>15%</td>
</tr>
<tr>
<td>2015</td>
<td>22%</td>
<td>16%</td>
</tr>
<tr>
<td>2020</td>
<td>24%</td>
<td>17%</td>
</tr>
<tr>
<td>2025</td>
<td>25%</td>
<td>17%</td>
</tr>
</tbody>
</table>

---

Trends in uncontrolled hypertension in adults aged 30–79 years³

- Past trends
- Projected trends
- Global target

---

Hypertension control rate scenarios

- Both sexes
- Males
- Females
- Year

<table>
<thead>
<tr>
<th>Both sexes</th>
<th>Males</th>
<th>Females</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>325,000</td>
<td>180,000</td>
<td>145,000</td>
<td>2019</td>
</tr>
<tr>
<td>290,000</td>
<td>156,000</td>
<td>134,000</td>
<td>2020</td>
</tr>
</tbody>
</table>

---

Risk factors³

- Mean population salt intake, adults aged 25+ years (g/day)
- Current tobacco use, adults aged 15+ years (%)
- Obesity, adults aged 18+ years (%)
- Total alcohol per capita consumption, adults aged 15+ years (litres)
- Physical inactivity, adults aged 18+ years (%)

---

National response

- Targets
  - National target for blood pressure
  - National target for salt consumption
- Surveillance
  - Conducted recent, national survey measuring raised blood pressure/hypertension
  - Conducted recent, national survey on salt/sodium intake
  - Functioning system for generating reliable cause-specific mortality data on a routine basis

---

Footnotes:

a. SBP ≥140 mmHg or DBP ≥90 mmHg. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.

Annex 2. Hypertension profiles and explanatory notes
Paraguay

Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)

Of the 1.6 million adults aged 30–79 years with hypertension:

- 55% of the population are diagnosed with hypertension.
- 38% of the population are being treated for hypertension.
- 13% of the population have their blood pressure controlled.

In order to achieve a 50% control rate, 600 000 more people with hypertension would need to be effectively treated.

---

Mortality

- Probability of premature mortality from NCDs (%)
  - Total population (2019): 6 530 000
  - Total deaths (2019): 34 400!

- Cardiovascular disease deaths
- Cardiovascular disease deaths attributable to high systolic blood pressure (%)

Risk factors

- Mean population salt intake, adults aged 25+ years (g/day)
- Current tobacco use, adults aged 15+ years (%)
- Obesity, adults aged 18+ years (%)
- Total alcohol per capita consumption, adults aged 15+ years (litres)
- Physical inactivity, adults aged 18+ years (%)

National response

- National target for blood pressure
- National target for salt consumption

Surveillance

- Conducted recent, national survey measuring raised blood pressure/hypertension
- Conducted recent, national survey on salt/sodium intake

Footnotes:

a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.

b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg.

c. SBP ≥140 mmHg or DBP ≥90 mmHg.

d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.

e. Age-standardized estimates are presented for all indicators except salt intake.

f. Data refer to tobacco smoking only, in the absence of sufficient data on all tobacco use.

Global report on hypertension: the race against a silent killer

210
Notes:
Conducted recent, national survey on salt/sodium intake
Conducted recent, national survey measuring raised blood pressure/hypertension
Surveillance
Targets
National target for blood pressure
National target for salt consumption
Surveillance
Conducted recent, national survey measuring raised blood pressure/hypertension
Conducted recent, national survey on salt/sodium intake
Functioning system for generating reliable cause-specific mortality data on a routine basis
Risk factors
Mean population salt intake, adults aged 25+ years (g/day)
Current tobacco use, adults aged 15+ years (%)
Obesity, adults aged 18+ years (%)
Total alcohol per capita consumption, adults aged 15+ years (litres)
Physical inactivity, adults aged 18+ years (%)
Mortality
Probability of premature mortality from NCDs (%)
Cardiovascular disease deaths
Cardiovascular disease deaths attributable to high systolic blood pressure (%)
National response

Footnotes: a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.
e. Age-standardized estimates are presented for all indicators except salt intake. f. Data refer to tobacco smoking only, in the absence of sufficient data on all tobacco use.
Philippines

Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019) φ 34% φ 35% φ 33%

Prevalence of hypertension – global comparison (both sexes)³

Trends in uncontrolled hypertension in adults aged 30–79 years³

Hypertension control rate scenarios

Mortality

Probability of premature mortality from NCDs (%)
Cardiovascular disease deaths
Cardiovascular disease deaths attributable to high systolic blood pressure (%)

Risk factors²

Mean population salt intake, adults aged 25+ years (g/day)
Current tobacco use, adults aged 15+ years (%)
Obesity, adults aged 18+ years (%)
Total alcohol per capita consumption, adults aged 15+ years (litres)
Physical inactivity, adults aged 18+ years (%)

National response

Targets
National target for blood pressure
National target for salt consumption

Surveillance
Conducted recent, national survey measuring raised blood pressure/hypertension
Conducted recent, national survey on salt/sodium intake
Functioning system for generating reliable cause-specific mortality data on a routine basis

Treatment
Guidelines for management of hypertension

Global report on hypertension: the race against a silent killer

Footnotes: a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.

In order to achieve a 50% control rate, 4.8 million more people with hypertension would need to be effectively treated.

If the progress scenario were achieved, 514 000 deaths would be averted by 2040.
Poland

Hypertension profile

Total population (2019): 38 494 000
Total deaths (2019): 401 000

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)
- Males: 49%
- Females: 56%
- Overall: 43%

Prevalence of hypertension – global comparison (both sexes)

Of the 13 million adults aged 30–79 years with hypertension:
- 69% diagnosed
- 61% treated
- 32% controlled

In order to achieve a 50% control rate, 2.1 million more people with hypertension would need to be effectively treated.

Trends in uncontrolled hypertension in adults aged 30–79 years

Projected hypertension control rates by scenario:
- Business as usual
- Progress
- Aspirational

If the progress scenario were achieved, 119 000 deaths would be averted by 2040.

Mortality

Probability of premature mortality from NCDs (%)
- Both sexes: 17
- Males: 23
- Females: 12
- Year: 2019
- Total: 173 000
- Males: 77 200
- Females: 95 600
- Year: 2019

Risk factors

Mean population salt intake, adults aged 25+ years (g/day)
- Both sexes: 11
- Males: 13
- Females: 9
- Year: 2019

Cardiovascular disease deaths attributable to high systolic blood pressure (%)
- Both sexes: 50
- Males: 52
- Females: 48
- Year: 2019

National response

Targets
- National target for blood pressure
- National target for salt consumption

Surveillance
- Conducted recent, national survey measuring raised blood pressure/hypertension
- Conducted recent, national survey on salt/sodium intake
- Functioning system for generating reliable cause-specific mortality data on a routine basis

Treatment
- Guidelines for management of hypertension

Footnotes: a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control. e. Age-standardized estimates are presented for all indicators except salt intake.
Portugal

Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)  

<table>
<thead>
<tr>
<th>Sex</th>
<th>Prevalence (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male</td>
<td>32%</td>
</tr>
<tr>
<td>Female</td>
<td>37%</td>
</tr>
<tr>
<td>Both sexes</td>
<td>28%</td>
</tr>
</tbody>
</table>

Of the 2.7 million adults aged 30–79 years with hypertension:

- **Diagnosed**: 69% (Male: 64%, Female: 75%)
- **Treated**: 63% (Male: 57%, Female: 71%)
- **Controlled**: 45% (Male: 38%, Female: 52%)

In order to achieve a 50% control rate, 69,000 more people with hypertension would need to be effectively treated.

**Notes:**
- SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.
- **Control rate**: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg.
- Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.

**Mortality**

- **Probability of premature mortality from NCDs (%)**
  - Cardiovascular disease deaths: 11
  - Cardiovascular disease deaths attributable to high systolic blood pressure: 32,600

**Risk factors**

- **Mean population salt intake, adults aged 25+ years (g/day)**: 9
- **Current tobacco use, adults aged 15+ years (%)**: 25
- **Obesity, adults aged 18+ years (%)**: 21
- **Total alcohol per capita consumption, adults aged 15+ years (litres)**: 10
- **Physical inactivity, adults aged 18+ years (%)**: 43

**National response**

- **Targets**
  - National target for blood pressure
  - National target for salt consumption
- **Surveillance**
  - Conducted recent, national survey measuring raised blood pressure/hypertension
  - Conducted recent, national survey on salt/sodium intake
  - Functioning system for generating reliable cause-specific mortality data on a routine basis
- **Treatment**
  - Guidelines for management of hypertension

**Footnotes:**
- a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.
- b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg.
- c. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.
- d. Age-standardized estimates are presented for all indicators except salt intake.
- e. Data refer to tobacco smoking only, in the absence of sufficient data on all tobacco use.
Prevalence of hypertension – global comparison (both sexes)\(^a\)

Of the 497 000 adults aged 30–79 years with hypertension:

- In order to achieve a 50% control rate, 155 000 more people with hypertension would need to be effectively treated.\(^b\)

### Mortality

<table>
<thead>
<tr>
<th>Probability of premature mortality from NCDs (%)</th>
<th>both sexes</th>
<th>males</th>
<th>females</th>
<th>year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiovascular disease deaths</td>
<td>11</td>
<td>10</td>
<td>13</td>
<td>2019</td>
</tr>
<tr>
<td>Cardiovascular disease deaths attributable to high systolic blood pressure (%)</td>
<td>1500</td>
<td>930</td>
<td>560</td>
<td>2019</td>
</tr>
<tr>
<td>Mean population salt intake, adults aged 25+ years (g/day)</td>
<td>57</td>
<td>59</td>
<td>53</td>
<td>2019</td>
</tr>
<tr>
<td>Current tobacco use, adults aged 15+ years (%)</td>
<td>7</td>
<td>8</td>
<td>5</td>
<td>2019</td>
</tr>
<tr>
<td>Obesity, adults aged 18+ years (%)</td>
<td>12</td>
<td>22</td>
<td>2</td>
<td>2019</td>
</tr>
<tr>
<td>Total alcohol per capita consumption, adults aged 15+ years (litres)</td>
<td>35</td>
<td>33</td>
<td>43</td>
<td>2016</td>
</tr>
<tr>
<td>Physical inactivity, adults aged 18+ years (%)</td>
<td>37</td>
<td>33</td>
<td>49</td>
<td>2016</td>
</tr>
</tbody>
</table>

### National response

#### Targets
- National target for blood pressure
- National target for salt consumption

#### Surveillance
- Conducted recent, national survey measuring raised blood pressure/hypertension
- Conducted recent, national survey on salt/sodium intake
- Functioning system for generating reliable cause-specific mortality data on a routine basis

#### Treatment
- Guidelines for management of hypertension

Footnotes: a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control. e. Age-standardized estimates are presented for all indicators except salt intake.
A 50% hypertension control rate has already been achieved.

If the aspirational scenario were achieved, 78 000 deaths would be averted by 2040.

Footnotes: a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.

e. Age-standardized estimates are presented for all indicators except salt intake. f. Data refer to tobacco smoking only, in the absence of sufficient data on all tobacco use.
Republic of Moldova

Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)  

Prevalence of hypertension – global comparison (both sexes)

Trends in uncontrolled hypertension in adults aged 30–79 years

Hypertension control rate scenarios

Mortality

Risk factors

National response

Footnotes: a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control. e. Age-standardized estimates are presented for all indicators except salt intake.
Romania

Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)ª

<table>
<thead>
<tr>
<th>Age-standardized prevalence (%)</th>
<th>Both sexes</th>
<th>Males</th>
<th>Females</th>
</tr>
</thead>
<tbody>
<tr>
<td>48%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>53%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>44%</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Prevalence of hypertension – global comparison (both sexes)ª

Of the 6.6 million adults aged 30–79 years with hypertension:

- **68%** diagnosed
- **59%** treated
- **30%** controlled

In order to achieve a 50% control rate, 1.4 million more people with hypertension would need to be effectively treated.ª

Trends in uncontrolled hypertension in adults aged 30–79 years©

- **62%** past trends
- **56%** global target
- **60%** project trends

Hypertension control rate scenarios

- **62%** control rate
- **75%** control rate
- **66%** control rate
- **37%** control rate

Mortality

<table>
<thead>
<tr>
<th>Probability of premature mortality from NCDs (%)</th>
<th>Both sexes</th>
<th>Males</th>
<th>Females</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>21</td>
<td>144 000</td>
<td>61</td>
<td>14 000</td>
<td>2019</td>
</tr>
<tr>
<td>29</td>
<td>66 900</td>
<td>61</td>
<td>77 500</td>
<td>2019</td>
</tr>
</tbody>
</table>

Risk factorsª

- **13** mean population salt intake, adults aged 25+ years (g/day)
- **28** current tobacco use, adults aged 15+ years (%)
- **23** obesity, adults aged 18+ years (%)
- **17** total alcohol per capita consumption, adults aged 15+ years (litres)
- **35** physical inactivity, adults aged 18+ years (%)

National response

<table>
<thead>
<tr>
<th>Targets</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>National target for blood pressure</td>
<td>✔</td>
</tr>
<tr>
<td>National target for salt consumption</td>
<td>✔</td>
</tr>
</tbody>
</table>

Survelliance

- Conducted recent, national survey measuring raised blood pressure/hypertension
- Conducted recent, national survey on salt/sodium intake
- Functioning system for generating reliable cause-specific mortality data on a routine basis

Footnotes: a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≤140 mmHg or DBP ≤90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.

e. Age-standardized estimates are presented for all indicators except salt intake.
**Prevalence of hypertension – global comparison (both sexes)**

**Trends in uncontrolled hypertension in adults aged 30–79 years**

**Hypertension control rate scenarios**

**Mortality**

<table>
<thead>
<tr>
<th>Probability of premature mortality from NCDs (%)</th>
<th>both sexes</th>
<th>males</th>
<th>females</th>
<th>year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiovascular disease deaths</td>
<td>24</td>
<td>35</td>
<td>15</td>
<td>2019</td>
</tr>
<tr>
<td>Cardiovascular disease deaths attributable to high systolic blood pressure (%)</td>
<td>1 004 000</td>
<td>436 000</td>
<td>568 000</td>
<td>2019</td>
</tr>
</tbody>
</table>

**Risk factors**

<table>
<thead>
<tr>
<th>Mean population salt intake, adults aged 25+ years (g/day)</th>
<th>both sexes</th>
<th>males</th>
<th>females</th>
<th>year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Current tobacco use, adults aged 15+ years (%)</td>
<td>10</td>
<td>11</td>
<td>8</td>
<td>2019</td>
</tr>
<tr>
<td>Obesity, adults aged 18+ years (%)</td>
<td>27</td>
<td>42</td>
<td>13</td>
<td>2019</td>
</tr>
<tr>
<td>Total alcohol per capita consumption, adults aged 15+ years (litres)</td>
<td>23</td>
<td>18</td>
<td>27</td>
<td>2016</td>
</tr>
<tr>
<td>Physical inactivity, adults aged 18+ years (%)</td>
<td>10</td>
<td>18</td>
<td>4</td>
<td>2019</td>
</tr>
<tr>
<td>Total physical inactivity, adults aged 18+ years (%)</td>
<td>17</td>
<td>17</td>
<td>18</td>
<td>2016</td>
</tr>
</tbody>
</table>

**National response**

**Targets**
- National target for blood pressure
- National target for salt consumption

**Surveillance**
- Conducted recent, national survey measuring raised blood pressure/hypertension
- Conducted recent, national survey on salt/sodium intake

**Footnotes:**
- a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.
- b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg.
- c. SBP ≥140 mmHg or DBP ≥90 mmHg.
- d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.
- e. Age-standardized estimates are presented for all indicators except salt intake.
Www.1.1 million adults aged 30–79 years with hypertension:

- **Diagnosed**
  - Males: 18%
  - Females: 29%
- **Treated**
  - Males: 10%
  - Females: 11%
- **Controlled**
  - Males: 6%
  - Females: 6%

In order to achieve a 50% control rate, 481,000 more people with hypertension would need to be effectively treated.

- Of the 1.1 million adults aged 30–79 years with hypertension:
  - Males: 24%
  - Females: 11%
  - Population: 6%

If the progress scenario were achieved, 23,000 deaths would be averted by 2040.

### Mortality

- **Probability of premature mortality from NCDs (%)**
  - Both sexes: 20%
  - Males: 22%
  - Females: 19%
  - Year: 2019
  - Both sexes: 11,200
  - Males: 5,400
  - Females: 5,900
  - Year: 2019
- **Cardiovascular disease deaths**
  - Both sexes: 55
  - Males: 51
  - Females: 58
  - Year: 2019

### Risk factors

- **Mean population salt intake, adults aged 25+ years (g/day)**
  - Both sexes: 7
  - Males: 6
  - Females: 8
  - Year: 2019
- **Current tobacco use, adults aged 15+ years (%)**
  - Both sexes: 14
  - Males: 21
  - Females: 7
  - Year: 2019
- **Obesity, adults aged 18+ years (%)**
  - Both sexes: 6
  - Males: 2
  - Females: 9
  - Year: 2016
- **Total alcohol per capita consumption, adults aged 15+ years (litres)**
  - Both sexes: 2
  - Males: 3
  - Females: 1
  - Year: 2019
- **Physical inactivity, adults aged 18+ years (%)**
  - Both sexes: 15
  - Males: 11
  - Females: 18
  - Year: 2016

### National response

**Targets**
- National target for blood pressure
- National target for salt consumption

**Surveillance**
- Conducted recent, national survey measuring raised blood pressure/hypertension
- Conducted recent, national survey on salt/sodium intake
- Functioning system for generating reliable cause-specific mortality data on a routine basis

**Footnotes:**
- a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.
- b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg.
- c. SBP ≥140 mmHg or DBP ≥90 mmHg.
- d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.
- e. Age-standardized estimates are presented for all indicators except salt intake.
**Saint Kitts and Nevis**

**Hypertension profile**

**Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)**

- Of the 1.1 million population aged 30–79 years, 481,000 more people would need to be effectively treated.

**Of the 13,000 adults aged 30–79 years with hypertension:**

- 50% diagnosed
- 38% treated
- 17% controlled

**Data not available**

**Mortality**

- Probability of premature mortality from NCDs (%): 45% for both sexes, 45% for males, 45% for females
- Cardiovascular disease deaths: no data for both sexes, no data for males, no data for females
- Cardiovascular disease deaths attributable to high systolic blood pressure (%): 55% for both sexes, 61% for males, 49% for females

**Risk factors**

- Mean population salt intake, adults aged 25+ years (g/day): 7 for both sexes, no data for males, 6 for females
- Current tobacco use, adults aged 15+ years (%): 7 for both sexes, no data for males, 6 for females
- Obesity, adults aged 18+ years (%): 23 for both sexes, 15 for males, 30 for females
- Total alcohol per capita consumption, adults aged 15+ years (litres): 6 for both sexes, 10 for males, 3 for females
- Physical inactivity, adults aged 18+ years (%): 32 for both sexes, 24 for males, 40 for females

**National response**

- Targets:
  - National target for blood pressure: ✗
  - National target for salt consumption: ✗
- Surveillance:
  - Conducted recent, national survey measuring raised blood pressure/hypertension: ✗
  - Conducted recent, national survey on salt/sodium intake: ✗
  - Functioning system for generating reliable cause-specific mortality data on a routine basis: ✔

**Footnotes:**

a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Age-standardized estimates are presented for all indicators except salt intake.
Saint Lucia

Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019) a

<table>
<thead>
<tr>
<th>Sex</th>
<th>Prevalence of Hypertension (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Males</td>
<td>40%</td>
</tr>
<tr>
<td>Females</td>
<td>39%</td>
</tr>
</tbody>
</table>

Of the 40,000 adults aged 30–79 years with hypertension:

- Diagnosed: 69% (Males 57%, Females 80%)
- Treated: 52% (Males 38%, Females 66%)
- Controlled: 22% (Males 12%, Females 31%)

In order to achieve a 50% control rate, 11,000 more people with hypertension would need to be effectively treated.

### Mortality

- Probability of premature mortality from NCDs (%)
  - Both sexes: 40% (Males 39%, Females 41%)

### Risk factors

- Mean population salt intake, adults aged 25+ years (g/day): 7 (no data)
- Current tobacco use, adults aged 15+ years (%): 8 (no data)
- Obesity, adults aged 18+ years (%): 20, 12, 20, 15, 40, 27
- Total alcohol per capita consumption, adults aged 15+ years (litres): no data
- Physical inactivity, adults aged 18+ years (%): no data

### National response

**Targets**
- National target for blood pressure
- National target for salt consumption

**Surveillance**
- Conducted recent, national survey measuring raised blood pressure/hypertension
- Conducted recent, national survey on salt/sodium intake
- Functioning system for generating reliable cause-specific mortality data on a routine basis

**Treatment**
- Guidelines for management of hypertension

---

Footnotes:
- a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.
- b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg.
- c. SBP ≥140 mmHg or DBP ≥90 mmHg.
- d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.
- e. Age-standardized estimates are presented for all indicators except salt intake.
Saint Vincent and the Grenadines

Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)\(^a\)

- Conducted recent, national survey on salt/sodium intake
- Conducted recent, national survey measuring raised blood pressure/hypertension

National target for blood pressure

<table>
<thead>
<tr>
<th>Risk factors(^e)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean population salt intake, adults aged 25+ years (g/day)</td>
</tr>
<tr>
<td>Current tobacco use, adults aged 15+ years (%)</td>
</tr>
<tr>
<td>Obesity, adults aged 18+ years (%)</td>
</tr>
<tr>
<td>Total alcohol per capita consumption, adults aged 15+ years (litres)</td>
</tr>
<tr>
<td>Physical inactivity, adults aged 18+ years (%)</td>
</tr>
</tbody>
</table>

National response

<table>
<thead>
<tr>
<th>Targets</th>
</tr>
</thead>
<tbody>
<tr>
<td>National target for blood pressure</td>
</tr>
<tr>
<td>National target for salt consumption</td>
</tr>
<tr>
<td>Surveillance</td>
</tr>
<tr>
<td>Conducted recent, national survey measuring raised blood pressure/hypertension</td>
</tr>
<tr>
<td>Conducted recent, national survey on salt/sodium intake</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Guidelines for management of hypertension</td>
</tr>
</tbody>
</table>

Mortality

| Probability of premature mortality from NCDs (%) |
| Cardiovascular disease deaths |
| Cardiovascular disease deaths attributable to high systolic blood pressure (%) |

Trends in uncontrolled hypertension in adults aged 30–79 years\(^c\)

Projected hypertension control rates by scenario\(^d\)

If the progress scenario were achieved, 600 deaths would be averted by 2040.

<table>
<thead>
<tr>
<th>Hypertension control rate scenarios</th>
</tr>
</thead>
<tbody>
<tr>
<td>Projected hypertension control rates by scenario(^d)</td>
</tr>
</tbody>
</table>

Footnotes: a. SBP \(\geq 140\) mmHg or DBP \(\geq 90\) mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP \(<140\) mmHg and DBP \(<90\) mmHg. c. SBP \(\geq 140\) mmHg or DBP \(\geq 90\) mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control. e. Age-standardized estimates are presented for all indicators except salt intake.
Samoa

Hypertension profile

Total population (2019): 212 000
Total deaths (2019): 1210

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)\(^a\)

- Samoa: 38%
- Global: 39%
- Global: 38%

Prevalence of hypertension – global comparison (both sexes)\(^a\)

Of the 27 000 adults aged 30–79 years with hypertension:

- 35% diagnosed
- 20% treated
- 10% controlled

If the progress scenario were achieved, 770 deaths would be averted by 2040.

Mortality

- Probability of premature mortality from NCDs (%)
  - Both sexes: 31
  - Males: 33
  - Females: 29
  - Year: 2019

- Cardiovascular disease deaths
  - Both sexes: 450
  - Males: 230
  - Females: 220
  - Year: 2019

- Cardiovascular disease deaths attributable to high systolic blood pressure (%)
  - Both sexes: 52
  - Males: 54
  - Females: 50
  - Year: 2019

Risk factors\(^b\)

- Mean population salt intake, adults aged 25+ years (g/day)
  - Both sexes: 5
  - Males: 5
  - Females: 5
  - Year: 2019

- Current tobacco use, adults aged 15+ years (%)
  - Both sexes: 26
  - Males: 37
  - Females: 15
  - Year: 2019

- Obesity, adults aged 18+ years (%)
  - Both sexes: 47
  - Males: 40
  - Females: 55
  - Year: 2016

- Total alcohol per capita consumption, adults aged 15+ years (litres)
  - Both sexes: 2
  - Males: 4
  - Females: 1
  - Year: 2019

- Physical inactivity, adults aged 18+ years (%)
  - Both sexes: 13
  - Males: 8
  - Females: 17
  - Year: 2016

National response

Targets

- National target for blood pressure
- National target for salt consumption

Surveillance

- Conducted recent, national survey measuring raised blood pressure/hypertension
- Conducted recent, national survey on salt/sodium intake
- Functioning system for generating reliable cause-specific mortality data on a routine basis

Treatment

- Guidelines for management of hypertension

Footnotes: a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control. e. Age-standardized estimates are presented for all indicators except salt intake.
### Samoa

#### Hypertension profile

**Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)**

- No data

### Trends in uncontrolled hypertension in adults aged 30–79 years

- No data

### Hypertension control rate scenarios

- No data

### Mortality

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Both sexes</th>
<th>Males</th>
<th>Females</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Probability of premature mortality from NCDs (%)</td>
<td>no data</td>
<td>no data</td>
<td>no data</td>
<td>2019</td>
</tr>
<tr>
<td>Cardiovascular disease deaths</td>
<td>no data</td>
<td>no data</td>
<td>no data</td>
<td>2019</td>
</tr>
<tr>
<td>Cardiovascular disease deaths attributable to high systolic blood pressure (%)</td>
<td>50</td>
<td>50</td>
<td>49</td>
<td>2019</td>
</tr>
</tbody>
</table>

### Risk factors

<table>
<thead>
<tr>
<th>Risk factor</th>
<th>Both sexes</th>
<th>Males</th>
<th>Females</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean population salt intake, adults aged 25+ years (g/day)</td>
<td>8</td>
<td>9</td>
<td>7</td>
<td>2019</td>
</tr>
<tr>
<td>Current tobacco use, adults aged 15+ years (%)</td>
<td>no data</td>
<td>no data</td>
<td>no data</td>
<td>2019</td>
</tr>
<tr>
<td>Obesity, adults aged 18+ years (%)</td>
<td>no data</td>
<td>no data</td>
<td>no data</td>
<td>2016</td>
</tr>
<tr>
<td>Total alcohol per capita consumption, adults aged 15+ years (litres)</td>
<td>no data</td>
<td>no data</td>
<td>no data</td>
<td>2019</td>
</tr>
<tr>
<td>Physical inactivity, adults aged 18+ years (%)</td>
<td>no data</td>
<td>no data</td>
<td>no data</td>
<td>2016</td>
</tr>
</tbody>
</table>

### National response

#### Targets
- National target for blood pressure
- National target for salt consumption

#### Surveillance
- Conducted recent, national survey measuring raised blood pressure/hypertension
- Conducted recent, national survey on salt/sodium intake

#### Treatment
- Guidelines for management of hypertension

---

Footnote: a. Age-standardized estimates are presented for all indicators except salt intake.
Sao Tome and Principe

Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)  
- Sao Tome and Principe: 45%
- Male: 42%
- Female: 48%

Prevalence of hypertension – global comparison (both sexes)

Of the 27,000 adults aged 30–79 years with hypertension:
- Diagnosed: 50%
- Treated: 29%
- Controlled: 9%

Mortality

Probability of premature mortality from NCDs (%)
- Both sexes: 21%
- Males: 22%
- Females: 20%

Cardiovascular disease deaths
- Both sexes: 240
- Males: 90
- Females: 150

Cardiovascular disease deaths attributable to high systolic blood pressure (%)
- Both sexes: 60
- Males: 60
- Females: 60

Risk factors

Mean population salt intake, adults aged 25+ years (g/day)
- Both sexes: 7
- Males: 7
- Females: 7

Current tobacco use, adults aged 15+ years (%)
- Both sexes: 6
- Males: 10
- Females: 1

Obesity, adults aged 18+ years (%)
- Both sexes: 12
- Males: 7
- Females: 17

Total alcohol per capita consumption, adults aged 15+ years (litres)
- Both sexes: 5
- Males: 8
- Females: 2

Physical inactivity, adults aged 18+ years (%)
- Both sexes: 15
- Males: 10
- Females: 21

National response

Targets
- National target for blood pressure
- National target for salt consumption

Surveillance
- Conducted recent, national survey measuring raised blood pressure/hypertension
- Conducted recent, national survey on salt/sodium intake
- Functioning system for generating reliable cause-specific mortality data on a routine basis

Footnotes:  
a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.  
b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg.  
c. SBP ≥140 mmHg or DBP ≥90 mmHg.  
d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.  
e. Age-standardized estimates are presented for all indicators except salt intake.
Sao Tome and Principe

Trends in uncontrolled hypertension in adults aged 30–79 years

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)

Conducted recent, national survey measuring raised blood pressure/hypertension

Surveillance

Functioning system for generating reliable cause-specific mortality data on a routine basis

Footnotes: a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.

e. Age-standardized estimates are presented for all indicators except salt intake.
Senegal

Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)  
- 41% males, 37% females, 43% overall

Prevalence of hypertension – global comparison (both sexes)

<table>
<thead>
<tr>
<th>% of population aged 30–79 years</th>
<th>Senegal</th>
<th>global</th>
</tr>
</thead>
<tbody>
<tr>
<td>40%</td>
<td>50%</td>
<td>60%</td>
</tr>
</tbody>
</table>

Trends in uncontrolled hypertension in adults aged 30–79 years

- Past trends: red line, projected trends: purple line, global target: yellow line

Hypertension control rate scenarios

- Projected hypertension control rates by scenario:
  - Business as usual: green line
  - Progress: blue line
  - Aspirational: red line

Mortality

- Probability of premature mortality from NCDs (%)
- Cardiovascular disease deaths
- Cardiovascular disease deaths attributable to high systolic blood pressure (%)

Risk factors

- Mean population salt intake, adults aged 25+ years (g/day)
- Current tobacco use, adults aged 15+ years (%)
- Obesity, adults aged 18+ years (%)
- Total alcohol per capita consumption, adults aged 15+ years (litres)
- Physical inactivity, adults aged 18+ years (%)

National response

- Targets
  - National target for blood pressure
  - National target for salt consumption
- Surveillance
  - Conducted recent, national survey measuring raised blood pressure/hypertension
  - Conducted recent, national survey on salt/sodium intake
  - Functioning system for generating reliable cause-specific mortality data on a routine basis

Treatment

- Guidelines for management of hypertension

Footnotes:
- a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.
- b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg.
- c. SBP ≥140 mmHg or DBP ≥90 mmHg.
- d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.
- e. Age-standardized estimates are presented for all indicators except salt intake.
Serbia

Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019) a

Functioning system for generating reliable cause-specific mortality data on a routine basis

Surveillance

National target for blood pressure

National target for salt consumption

Surveillance

Conducted recent, national survey measuring raised blood pressure/hypertension

Conducted recent, national survey on salt/sodium intake

Functioning system for generating reliable cause-specific mortality data on a routine basis

Footnotes: a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control. e. Age-standardized estimates are presented for all indicators except salt intake. f. Data refer to tobacco smoking only, in the absence of sufficient data on all tobacco use.
Seychelles
Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)\(^a\)

Total population (2019): 104,000
Total deaths (2019): 770

Of the 24,000 adults aged 30–79 years with hypertension:

- **Diagnosed**: 66% (59% males, 74% females)
- **Treated**: 55% (47% males, 65% females)
- **Controlled**: 27% (19% males, 36% females)

In order to achieve a 50% control rate, 5,500 more people with hypertension would need to be effectively treated.\(^b\)

### Mortality

<table>
<thead>
<tr>
<th>Probability of premature mortality from NCDs (%)</th>
<th>both sexes</th>
<th>males</th>
<th>females</th>
<th>year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiovascular disease deaths</td>
<td>21</td>
<td>27</td>
<td>15</td>
<td>2019</td>
</tr>
<tr>
<td>Cardiovascular disease deaths attributable to high systolic blood pressure (%)</td>
<td>230</td>
<td>120</td>
<td>110</td>
<td>2019</td>
</tr>
<tr>
<td>Obesity, adults aged 18+ years (%)</td>
<td>61</td>
<td>63</td>
<td>60</td>
<td>2019</td>
</tr>
</tbody>
</table>

### Risk factors\(^e\)

<table>
<thead>
<tr>
<th>Mean population salt intake, adults aged 25+ years (g/day)</th>
<th>both sexes</th>
<th>males</th>
<th>females</th>
<th>year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Current tobacco use, adults aged 15+ years (%)</td>
<td>7</td>
<td>7</td>
<td>7</td>
<td>2019</td>
</tr>
<tr>
<td>Obesity, adults aged 18+ years (%)</td>
<td>21</td>
<td>35</td>
<td>7</td>
<td>2019</td>
</tr>
<tr>
<td>Total alcohol per capita consumption, adults aged 15+ years (litres)</td>
<td>14</td>
<td>8</td>
<td>21</td>
<td>2016</td>
</tr>
<tr>
<td>Physical inactivity, adults aged 18+ years (%)</td>
<td>12</td>
<td>18</td>
<td>5</td>
<td>2019</td>
</tr>
<tr>
<td></td>
<td>19</td>
<td>18</td>
<td>20</td>
<td>2016</td>
</tr>
</tbody>
</table>

### National response

**Targets**
- National target for blood pressure □
- National target for salt consumption □

**Surveillance**
- Conducted recent, national survey measuring raised blood pressure/hypertension ▼
- Conducted recent, national survey on salt/sodium intake ▼

**Treatment**
- Guidelines for management of hypertension □

---

Footnotes: a. SBP \(\geq 140\) mmHg or DBP \(\geq 90\) mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP \(\geq 140\) mmHg or DBP \(\geq 90\) mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control. e. Age-standardized estimates are presented for all indicators except salt intake.
### Seychelles

Aged 30–79 years

- Functioning system for generating reliable cause-specific mortality data on a routine basis
- Conducted recent, national survey on salt/sodium intake

### National targets

- National target for salt consumption
- National target for blood pressure

### National response

- **Physical inactivity, adults aged 18+ years (%):**
- **Total alcohol per capita consumption, adults aged 15+ years (litres):**
- **Obesity, adults aged 18+ years (%):**
- **Current tobacco use, adults aged 15+ years (%):**
- **Mean population salt intake, adults aged 25+ years (g/day):**
- **Cardiovascular disease deaths attributable to high systolic blood pressure (%):**
- **Cardiovascular disease deaths:**
- **Probability of premature mortality from NCDs (%):**

### Footnotes

- a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.
- b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg.
- c. SBP ≥140 mmHg or DBP ≥90 mmHg.
- d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.
- e. Age-standardized estimates are presented for all indicators except salt intake.

---

### Sierra Leone

**Hypertension profile**

- **Total population (2019):** 8 047 000
- **Total deaths (2019):** 67 200

**Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)**

<table>
<thead>
<tr>
<th> </th>
<th>41%</th>
<th>38%</th>
<th>43%</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Prevalence of hypertension – global comparison (both sexes)</strong></td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr>
<td><strong>Trends in uncontrolled hypertension in adults aged 30–79 years</strong></td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr>
<td><strong>Hypertension control rate scenarios</strong></td>
<td> </td>
<td> </td>
<td> </td>
</tr>
</tbody>
</table>

**Mortality**

- **Probability of premature mortality from NCDs (%):**
- **Cardiovascular disease deaths:**
- **Cardiovascular disease deaths attributable to high systolic blood pressure (%):**

**Risk factors**

- **Mean population salt intake, adults aged 25+ years (g/day):**
- **Current tobacco use, adults aged 15+ years (%):**
- **Obesity, adults aged 18+ years (%):**
- **Total alcohol per capita consumption, adults aged 15+ years (litres):**
- **Physical inactivity, adults aged 18+ years (%):**

**National response**

- **Targets**
  - National target for blood pressure
  - National target for salt consumption
- **Surveillance**
  - Conducted recent, national survey measuring raised blood pressure/hypertension
  - Conducted recent, national survey on salt/sodium intake
  - Functioning system for generating reliable cause-specific mortality data on a routine basis

**Footnotes:**

- a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.
- b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg.
- c. SBP ≥140 mmHg or DBP ≥90 mmHg.
- d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.
- e. Age-standardized estimates are presented for all indicators except salt intake.
Singapore
Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019) a  
Total population (2019): 5,866,000  
Total deaths (2019): 26,800

Prevalence of hypertension – global comparison (both sexes) a

Of the 1.3 million adults aged 30–79 years with hypertension:

- 66% of the population aged 30–79 years with hypertension
- 61% of the population aged 30–79 years with hypertension
- 38% of the population aged 30–79 years with hypertension

In order to achieve a 50% control rate, 151,000 more people with hypertension would need to be effectively treated.b

Trends in uncontrolled hypertension in adults aged 30–79 years c

Hypertension control rate scenarios

Projected hypertension control rates by scenario d

Mortality

Probability of premature mortality from NCDs (%)

Cardiovascular disease deaths
Cardiovascular disease deaths attributable to high systolic blood pressure (%)

Risk factors e

Mean population salt intake, adults aged 25+ years (g/day)
Current tobacco use, adults aged 15+ years (%) f
Obesity, adults aged 18+ years (%)
Total alcohol per capita consumption, adults aged 15+ years (litres)
Physical inactivity, adults aged 18+ years (%)

National response

Targets
National target for blood pressure
National target for salt consumption
Surveillance
Conducted recent, national survey measuring raised blood pressure/hypertension
Conducted recent, national survey on salt/sodium intake
Functioning system for generating reliable cause-specific mortality data on a routine basis

Treatment
Guidelines for management of hypertension

Footnotes: a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control. e. Age-standardized estimates are presented for all indicators except salt intake. f. Data refer to tobacco smoking only, in the absence of sufficient data on all tobacco use.

232
Slovakia

Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)  

- Gender: Male 43%, Female 47%, Total 38%

Prevalence of hypertension – global comparison (both sexes)  

- Slovakia: 40%
- Global: 50%

Trends in uncontrolled hypertension in adults aged 30–79 years  

- Past trends: Male 68%, Female 78%
- Projected trends: Male 68%, Female 78%
- Global target: Male 68%, Female 78%

Mortality

- Probability of premature mortality from NCDs (%): Both sexes 15, Males 21, Females 10, Year 2019
- Cardiovascular disease deaths: Both sexes 16,800, Males 8,600, Females 8,200, Year 2019
- Cardiovascular disease deaths attributable to high systolic blood pressure (%): Both sexes 58, Males 59, Females 56, Year 2019

Risk factors

- Mean population salt intake, adults aged 25+ years (g/day): Both sexes 13, Males 15, Females 11, Year 2019
- Current tobacco use, adults aged 15+ years (%): Both sexes 32, Males 38, Females 25, Year 2019
- Obesity, adults aged 18+ years (%): Both sexes 21, Males 21, Females 20, Year 2016
- Total alcohol per capita consumption, adults aged 15+ years (litres): Both sexes 10, Males 17, Females 5, Year 2019
- Physical inactivity, adults aged 18+ years (%): Both sexes 35, Males 31, Females 38, Year 2016

National response

- Targets: National target for blood pressure, National target for salt consumption
- Surveillance: Conducted recent, national survey measuring raised blood pressure/hypertension, Conducted recent, national survey on salt/sodium intake, Functioning system for generating reliable cause-specific mortality data on a routine basis

Footnotes:  
a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.  
b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg.  
c. SBP ≥140 mmHg or DBP ≥90 mmHg.  
d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.  
e. Age-standardized estimates are presented for all indicators except salt intake.  
f. Data refer to tobacco smoking only, in the absence of sufficient data on all tobacco use.

Annex 2. Hypertension profiles and explanatory notes  

233
Slovenia

Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)\(^a\)

- Total population (2019): 2 113 000
- Total deaths (2019): 20 500

<table>
<thead>
<tr>
<th>Prevalence of hypertension – global comparison (both sexes)(^a)</th>
</tr>
</thead>
<tbody>
<tr>
<td>% of population aged 30–79 years with hypertension</td>
</tr>
<tr>
<td>Slovenia</td>
</tr>
<tr>
<td>63%</td>
</tr>
</tbody>
</table>

Of the 699 000 adults aged 30–79 years with hypertension:

- 63% diagnosed
- 52% treated
- 23% controlled

In order to achieve a 50% control rate, 182 000 more people with hypertension would need to be effectively treated.\(^b\)

Trends in uncontrolled hypertension in adults aged 30–79 years\(^c\)

Hypertension control rate scenarios

- Projected hypertension control rates by scenario\(^d\)
  - Business as usual
  - Progress
  - Aspirational

Mortality

- Probability of premature mortality from NCDs (%)
- Cardiovascular disease deaths
- Cardiovascular disease deaths attributable to high systolic blood pressure (%)

Risk factors\(^e\)

- Mean population salt intake, adults aged 25+ years (g/day)
- Current tobacco use, adults aged 15+ years (%)
- Obesity, adults aged 18+ years (%)
- Total alcohol per capita consumption, adults aged 15+ years (litres)
- Physical inactivity, adults aged 18+ years (%)

National response

- Targets
  - National target for blood pressure
  - National target for salt consumption
- Surveillance
  - Conducted recent, national survey measuring raised blood pressure/hypertension
  - Conducted recent, national survey on salt/sodium intake
  - Functioning system for generating reliable cause-specific mortality data on a routine basis

- Treatment
  - Guidelines for management of hypertension

Footnotes:

- a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.
- b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg.
- c. SBP ≥140 mmHg or DBP ≥90 mmHg.
- d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.
- e. Age-standardized estimates are presented for all indicators except salt intake.
- f. Data refer to tobacco smoking only, in the absence of sufficient data on all tobacco use.
Slovenia

Trends in uncontrolled hypertension in adults aged 30–79 years

Prevalence of hypertension – global comparison (both sexes)

Of the 58,000 adults aged 30–79 years with hypertension:

- In order to achieve a 50% control rate, 25,000 more people with hypertension would need to be effectively treated.

Mortality

- Probability of premature mortality from NCDs (%)
  - Both sexes: 39 in 2019, 44 in 2023
  - Males: 44 in 2019, 49 in 2023
  - Females: 34 in 2019, 38 in 2023

- Cardiovascular disease deaths attributable to high systolic blood pressure (%)
  - Both sexes: 1800 in 2019, 1100 in 2023
  - Males: 1100 in 2019, 750 in 2023
  - Females: 780 in 2019, 430 in 2023

Risk factors

- Mean population salt intake, adults aged 25+ years (g/day)
  - Both sexes: 7 g/day in 2019, 7 g/day in 2023
  - Males: 7 g/day in 2019, 7 g/day in 2023
  - Females: 7 g/day in 2019, 7 g/day in 2023

- Obesity, adults aged 18+ years (%)
  - Both sexes: 23% in 2019, 18% in 2023
  - Males: 18% in 2019, 13% in 2023
  - Females: 37% in 2019, 27% in 2023

- Total alcohol per capita consumption, adults aged 15+ years (litres)
  - Both sexes: 18 litres in 2019, 13 litres in 2023
  - Males: 18 litres in 2019, 13 litres in 2023
  - Females: 2 litres in 2019, 1 litre in 2023

- Physical inactivity, adults aged 18+ years (%)
  - Both sexes: 11% in 2019, 7% in 2023
  - Males: 17% in 2019, 11% in 2023
  - Females: 5% in 2019, 7% in 2023

National response

- National target for blood pressure
- National target for salt consumption
- Surveillance
  - Conducted recent, national survey measuring raised blood pressure/hypertension
  - Conducted recent, national survey on salt/sodium intake
  - Functioning system for generating reliable cause-specific mortality data on a routine basis

Footnotes:

a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.

b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.

e. Age-standardized estimates are presented for all indicators except salt intake.

f. Data refer to tobacco smoking only, in the absence of sufficient data on all tobacco use.

Annex 2. Hypertension profiles and explanatory notes
Somalia

Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)  

| Age-standardized prevalence of hypertension among adults aged 30–79 years (2019) | 36% | 33% | 39% |

Prevalence of hypertension – global comparison (both sexes)  

Trends in uncontrolled hypertension in adults aged 30–79 years  

Hypertension control rate scenarios  

Mortality  

Probability of premature mortality from NCDs (%)  
Cardiovascular disease deaths  
Cardiovascular disease deaths attributable to high systolic blood pressure (%)  

Risk factors  

Mean population salt intake, adults aged 25+ years (g/day)  
Current tobacco use, adults aged 15+ years (%)  
Obesity, adults aged 18+ years (%)  
Total alcohol per capita consumption, adults aged 15+ years (litres)  
Physical inactivity, adults aged 18+ years (%)  

National response  

Targets  
National target for blood pressure  
National target for salt consumption  
Surveillance  
Conducted recent, national survey measuring raised blood pressure/hypertension  
Conducted recent, national survey on salt/sodium intake  
Functioning system for generating reliable cause-specific mortality data on a routine basis  

Treatment  
Guidelines for management of hypertension  

Footnotes: a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control. e. Age-standardized estimates are presented for all indicators except salt intake.
**South Africa**

**Hypertension profile**

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)\(^a\)  

Of the 10.8 million adults aged 30–79 years with hypertension:

- **53%** were diagnosed
- **47%** were treated
- **24%** were controlled

In order to achieve a 50% control rate, 3 million more people with hypertension would need to be effectively treated.\(^b\)

**Mortality**

<table>
<thead>
<tr>
<th>Probability of premature mortality from NCDs (%)</th>
<th>both sexes</th>
<th>males</th>
<th>females</th>
<th>year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiovascular disease deaths</td>
<td>24</td>
<td>28</td>
<td>20</td>
<td>2019</td>
</tr>
<tr>
<td>Cardiovascular disease deaths attributable to high systolic blood pressure (%)</td>
<td>87 800</td>
<td>42 600</td>
<td>45 200</td>
<td>2019</td>
</tr>
<tr>
<td></td>
<td>64</td>
<td>63</td>
<td>65</td>
<td>2019</td>
</tr>
</tbody>
</table>

**Risk factors**\(^e\)

<table>
<thead>
<tr>
<th>Mean population salt intake, adults aged 25+ years (g/day)</th>
<th>both sexes</th>
<th>males</th>
<th>females</th>
<th>year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Current tobacco use, adults aged 15+ years (%)(^f)</td>
<td>6</td>
<td>7</td>
<td>6</td>
<td>2019</td>
</tr>
<tr>
<td>Obesity, adults aged 18+ years (%)</td>
<td>20</td>
<td>34</td>
<td>7</td>
<td>2019</td>
</tr>
<tr>
<td>Total alcohol per capita consumption, adults aged 15+ years (litres)</td>
<td>28</td>
<td>15</td>
<td>40</td>
<td>2016</td>
</tr>
<tr>
<td>Physical inactivity, adults aged 18+ years (%)</td>
<td>9</td>
<td>15</td>
<td>3</td>
<td>2019</td>
</tr>
<tr>
<td></td>
<td>38</td>
<td>28</td>
<td>47</td>
<td>2016</td>
</tr>
</tbody>
</table>

**National response**

**Targets**
- National target for blood pressure
- National target for salt consumption

**Surveillance**
- Conducted recent, national survey measuring raised blood pressure/hypertension
- Conducted recent, national survey on salt/sodium intake
- Functioning system for generating reliable cause-specific mortality data on a routine basis

**Treatment**
- Guidelines for management of hypertension

---

Footnotes: a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control. e. Age-standardized estimates are presented for all indicators except salt intake. f. Data refer to tobacco smoking only, in the absence of sufficient data on all tobacco use.
South Sudan

Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)\textsuperscript{a}

<table>
<thead>
<tr>
<th>% of population aged 30–79 years with hypertension</th>
<th>34%</th>
<th>32%</th>
<th>36%</th>
</tr>
</thead>
<tbody>
<tr>
<td>South Sudan</td>
<td>41%</td>
<td>25%</td>
<td>11%</td>
</tr>
</tbody>
</table>

In order to achieve a 50% control rate, 404 000 more people with hypertension would need to be effectively treated.\textsuperscript{a}

Prevalence of hypertension – global comparison (both sexes)\textsuperscript{a}

Of the 1 million adults aged 30–79 years with hypertension:

- 33% of males
- 47% of females

Data not available

Trends in uncontrolled hypertension in adults aged 30–79 years\textsuperscript{c}

<table>
<thead>
<tr>
<th>% of population aged 30–79 years</th>
<th>2000</th>
<th>2005</th>
<th>2010</th>
<th>2015</th>
<th>2020</th>
<th>2025</th>
</tr>
</thead>
<tbody>
<tr>
<td>South Sudan</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>global</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Mortality

<table>
<thead>
<tr>
<th>Probability of premature mortality from NCDs (%)</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiovascular disease deaths</td>
<td>17</td>
</tr>
<tr>
<td>Cardiovascular disease deaths attributable to high systolic blood pressure (%)</td>
<td>8400</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Risk factors\textsuperscript{d}</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean population salt intake, adults aged 25+ years (g/day)</td>
<td>59</td>
</tr>
<tr>
<td>Current tobacco use, adults aged 15+ years (%)</td>
<td>7</td>
</tr>
<tr>
<td>Obesity, adults aged 18+ years (%)</td>
<td>7</td>
</tr>
<tr>
<td>Total alcohol per capita consumption, adults aged 15+ years (litres)</td>
<td>58</td>
</tr>
<tr>
<td>Physical inactivity, adults aged 18+ years (%)</td>
<td>8</td>
</tr>
</tbody>
</table>

National response

<table>
<thead>
<tr>
<th>Targets</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>National target for blood pressure</td>
<td>✔</td>
</tr>
<tr>
<td>National target for salt consumption</td>
<td>❌</td>
</tr>
</tbody>
</table>

Surveillance

- Conducted recent, national survey measuring raised blood pressure/hypertension
- Conducted recent, national survey on salt/sodium intake
- Functioning system for generating reliable cause-specific mortality data on a routine basis

Footnotes: a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Age-standardized estimates are presented for all indicators except salt intake.
Spain

Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019) a

- **Total population (2019):** 47 131 000
- **Total deaths (2019):** 427 000

| Age-standardized prevalence of hypertension among adults aged 30–79 years (2019) a |
|---------------------------------|---|---|---|
| % of population aged 30–79 years | ♂ | ♀ |
| Spain                           | 65% | 54% | 31% |

- Of the **9.9 million** adults aged 30–79 years with hypertension:
  - diagnosed: ♂ 71% ♀ 62%
  - treated: ♂ 51% ♀ 48%
  - controlled: ♂ 30% ♀ 35%

In order to achieve a 50% control rate, 1.7 million more people with hypertension would need to be effectively treated. a

- **Prevalence of hypertension – global comparison (both sexes) a**

- **Trends in uncontrolled hypertension in adults aged 30–79 years c**

- **Hypertension control rate scenarios**

- **Projected hypertension control rates by scenario d**

### Mortality

- Probability of premature mortality from NCDs (%)
- Cardiovascular disease deaths
- Cardiovascular disease deaths attributable to high systolic blood pressure (%)

### Risk factors e

- Mean population salt intake, adults aged 25+ years (g/day)
- Current tobacco use, adults aged 15+ years (%)
- Obesity, adults aged 18+ years (%)
- Total alcohol per capita consumption, adults aged 15+ years (litres)
- Physical inactivity, adults aged 18+ years (%)

### National response

- **Targets**
  - National target for blood pressure
  - National target for salt consumption
- **Surveillance**
  - Conducted recent, national survey measuring blood pressure/hypertension
  - Conducted recent, national survey on salt/sodium intake
  - Functioning system for generating reliable cause-specific mortality data on a routine basis

### Footnotes:

- a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.
- b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.
- e. Age-standardized estimates are presented for all indicators except salt intake.
- f. Data refer to tobacco smoking only, in the absence of sufficient data on all tobacco use.
Sri Lanka

Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019) ≤ 36% ≤ 34% ≤ 37%

Prevalence of hypertension – global comparison (both sexes) a

Trends in uncontrolled hypertension in adults aged 30–79 years c

Hypertension control rate scenarios

Mortality

Probability of premature mortality from NCDs (%)
Cardiovascular disease deaths
Cardiovascular disease deaths attributable to high systolic blood pressure (%)

Risk factors e

Mean population salt intake, adults aged 25+ years (g/day)
Current tobacco use, adults aged 15+ years (%)
Obesity, adults aged 18+ years (%)
Total alcohol per capita consumption, adults aged 15+ years (litres)
Physical inactivity, adults aged 18+ years (%)

National response

Targets
National target for blood pressure
National target for salt consumption
Surveillance
Conducted recent, national survey measuring raised blood pressure/hypertension
Conducted recent, national survey on salt/sodium intake
Functioning system for generating reliable cause-specific mortality data on a routine basis

Treatment
Guidelines for management of hypertension

Footnotes:

a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.
b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg.
c. SBP ≥140 mmHg or DBP ≥90 mmHg.
d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.
e. Age-standardized estimates are presented for all indicators except salt intake.
Sudan

Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019) a

Prevalence of hypertension – global comparison (both sexes) a

Trends in uncontrolled hypertension in adults aged 30–79 years c

Hypertension control rate scenarios

Mortality

Probability of premature mortality from NCDs (%)
Cardiovascular disease deaths
Cardiovascular disease deaths attributable to high systolic blood pressure (%)

Risk factors e

Mean population salt intake, adults aged 25+ years (g/day)
Current tobacco use, adults aged 15+ years (%)
Obesity, adults aged 18+ years (%)
Total alcohol per capita consumption, adults aged 15+ years (litres)
Physical inactivity, adults aged 18+ years (%)

National response

Targets
National target for blood pressure
National target for salt consumption

Surveillance
Conducted recent, national survey measuring raised blood pressure/hypertension
Conducted recent, national survey on salt/sodium intake
Functioning system for generating reliable cause-specific mortality data on a routine basis

Footnotes: a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control. e. Age-standardized estimates are presented for all indicators except salt intake.
Suriname

Hypertension profile

**Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)**

<table>
<thead>
<tr>
<th>Country</th>
<th>% of population aged 30–79 years with hypertension</th>
</tr>
</thead>
<tbody>
<tr>
<td>Suriname</td>
<td>33%</td>
</tr>
</tbody>
</table>

**Of the 116 000 adults aged 30–79 years with hypertension:**

- **Diagnosed**: 64%
- **Treated**: 50%
- **Controlled**: 21%

**Mortality**

- **Probability of premature mortality from NCDs (%)**
  - Both sexes: 23%
  - Males: 1500
  - Females: 49
- **Cardiovascular disease deaths**
  - Both sexes: 18%
  - Males: 710
  - Females: 48
- **Cardiovascular disease deaths attributable to high systolic blood pressure (%)**
  - Both sexes: 28%
  - Males: 810
  - Females: 49

**Risk factors**

- **Mean population salt intake, adults aged 25+ years (g/day)**
  - Both sexes: 7
  - Males: no data
  - Females: no data
- **Current tobacco use, adults aged 15+ years (%)**
  - Both sexes: 26
  - Males: 19
  - Females: 7
- **Obesity, adults aged 18+ years (%)**
  - Both sexes: 26
  - Males: 11
  - Females: 3
- **Total alcohol per capita consumption, adults aged 15+ years (litres)**
  - Both sexes: 44
  - Males: 38
  - Females: no data
- **Physical inactivity, adults aged 18+ years (%)**
  - Both sexes: 23
  - Males: 28
  - Females: 18

**National response**

- **Targets**
  - National target for blood pressure
  - National target for salt consumption
- **Surveillance**
  - Conducted recent, national survey measuring raised blood pressure/hypertension
  - Conducted recent, national survey on salt/sodium intake
  - Functioning system for generating reliable cause-specific mortality data on a routine basis
- **Treatment**
  - Guidelines for management of hypertension

**Footnotes:**

- a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.
- b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg.
- c. SBP ≥140 mmHg or DBP ≥90 mmHg.
- d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.
- e. Age-standardized estimates are presented for all indicators except salt intake.
Sweden

Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)\(^a\)

<table>
<thead>
<tr>
<th>Sex</th>
<th>Prevalence of Hypertension (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Males</td>
<td>30%</td>
</tr>
<tr>
<td>Females</td>
<td>36%</td>
</tr>
<tr>
<td>Total</td>
<td>25%</td>
</tr>
</tbody>
</table>

Total population (2019): 10 268 000
Total deaths (2019): 92 200

Prevalence of hypertension – global comparison (both sexes)\(^a\)

Trends in uncontrolled hypertension in adults aged 30–79 years\(^c\)

Hypertension control rate scenarios

Mortality

Probability of premature mortality from NCDs (%)
- Cardiovascular disease deaths
- Cardiovascular disease deaths attributable to high systolic blood pressure (%)

Risk factors\(^e\)

Mean population salt intake, adults aged 25+ years (g/day)
Current tobacco use, adults aged 15+ years (%)
Obesity, adults aged 18+ years (%)
Total alcohol per capita consumption, adults aged 15+ years (litres)
Physical inactivity, adults aged 18+ years (%)

National response

Targets
- National target for blood pressure
- National target for salt consumption
- Surveillance
  - Conducted recent, national survey measuring raised blood pressure/hypertension
  - Conducted recent, national survey on salt/sodium intake
  - Functioning system for generating reliable cause-specific mortality data on a routine basis

Treatment
- Guidelines for management of hypertension

Footnotes:
- a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.
- b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg.
- c. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.
- d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.
- e. Age-standardized estimates are presented for all indicators except salt intake.
Switzerland

Hypertension profile

**Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)**

- Of the 1.5 million adults aged 30–79 years with hypertension:
  - 73% diagnosed
  - 56% treated
  - 37% controlled

**Trends in uncontrolled hypertension in adults aged 30–79 years**

- Projected control rates by scenario:
  - Business as usual
  - Progress
  - Aspirational

**Mortality**

- Probability of premature mortality from NCDs (%)
  - Cardiovascular disease deaths
  - Cardiovascular disease deaths attributable to high systolic blood pressure (%)

**Risk factors**

- Mean population salt intake, adults aged 25+ years (g/day)
- Current tobacco use, adults aged 15+ years (%)
- Obesity, adults aged 18+ years (%)
- Total alcohol per capita consumption, adults aged 15+ years (litres)
- Physical inactivity, adults aged 18+ years (%)

**National response**

- Targets
  - National target for blood pressure
  - National target for salt consumption

- Surveillance
  - Conducted recent, national survey measuring raised blood pressure/hypertension
  - Conducted recent, national survey on salt/sodium intake
  - Functioning system for generating reliable cause-specific mortality data on a routine basis

**Footnotes:**

- a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.
- b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg.
- c. SBP ≥140 mmHg or DBP ≥90 mmHg.
- d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.
- e. Age-standardized estimates are presented for all indicators except salt intake.
- f. Data refer to tobacco smoking only, in the absence of sufficient data on all tobacco use.

Global report on hypertension: the race against a silent killer
Syrian Arab Republic

Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)

- Total population (2019): 20,098,000
- Total deaths (2019): 89,300

![Prevalence of hypertension – global comparison (both sexes)](image)

<table>
<thead>
<tr>
<th>% of population aged 30–79 years with hypertension</th>
<th>2000</th>
<th>2005</th>
<th>2010</th>
<th>2015</th>
<th>2020</th>
<th>2025</th>
</tr>
</thead>
<tbody>
<tr>
<td>Both sexes</td>
<td>22%</td>
<td>26%</td>
<td>18%</td>
<td>19,200</td>
<td>19,800</td>
<td>2019</td>
</tr>
<tr>
<td>Males</td>
<td>26%</td>
<td>39,000</td>
<td>52%</td>
<td>52%</td>
<td>53%</td>
<td>2019</td>
</tr>
<tr>
<td>Females</td>
<td>18%</td>
<td>19,200</td>
<td>18%</td>
<td>18%</td>
<td>19%</td>
<td>2019</td>
</tr>
</tbody>
</table>

![Trends in uncontrolled hypertension in adults aged 30–79 years](image)

- Probability of premature mortality from NCDs (%)
- Cardiovascular disease deaths
- Cardiovascular disease deaths attributable to high systolic blood pressure (%)

<table>
<thead>
<tr>
<th>Risk factors</th>
<th>2019</th>
<th>2016</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Probability of premature mortality from NCDs (%)</td>
<td>6%</td>
<td>7%</td>
<td>5%</td>
</tr>
<tr>
<td>Cardiovascular disease deaths</td>
<td>28%</td>
<td>21%</td>
<td>35%</td>
</tr>
<tr>
<td>Cardiovascular disease deaths attributable to high systolic blood pressure (%)</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
</tr>
</tbody>
</table>

![Mortality](image)

- Mean population salt intake, adults aged 25+ years (g/day)
- Current tobacco use, adults aged 15+ years (%)
- Obesity, adults aged 18+ years (%)
- Total alcohol per capita consumption, adults aged 15+ years (litres)
- Physical inactivity, adults aged 18+ years (%)

<table>
<thead>
<tr>
<th>National response</th>
<th>2019</th>
<th>2016</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean population salt intake, adults aged 25+ years (g/day)</td>
<td>6.0</td>
<td>7.0</td>
<td>5.0</td>
</tr>
<tr>
<td>Current tobacco use, adults aged 15+ years (%)</td>
<td>28%</td>
<td>21%</td>
<td>35%</td>
</tr>
<tr>
<td>Obesity, adults aged 18+ years (%)</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
</tr>
<tr>
<td>Total alcohol per capita consumption, adults aged 15+ years (litres)</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
</tr>
<tr>
<td>Physical inactivity, adults aged 18+ years (%)</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
</tr>
</tbody>
</table>

Footnotes: a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control. e. Age-standardized estimates are presented for all indicators except salt intake.
**Tajikistan**

**Hypertension profile**

<table>
<thead>
<tr>
<th>Total population (2019): 9,337,000</th>
<th>Total deaths (2019): 50,000</th>
</tr>
</thead>
</table>

**Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)**

- **Tajikistan**: 47% males, 51% females
- **Global**: 43%

<table>
<thead>
<tr>
<th>% of population aged 30–79 years</th>
<th>0%</th>
<th>10%</th>
<th>20%</th>
<th>30%</th>
<th>40%</th>
<th>50%</th>
<th>60%</th>
<th>70%</th>
<th>80%</th>
<th>90%</th>
<th>100%</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Tajikistan</strong></td>
<td>40%</td>
<td>44%</td>
<td>48%</td>
<td>52%</td>
<td>56%</td>
<td>60%</td>
<td>64%</td>
<td>68%</td>
<td>72%</td>
<td>76%</td>
<td>80%</td>
</tr>
<tr>
<td><strong>Global</strong></td>
<td>40%</td>
<td>41%</td>
<td>42%</td>
<td>43%</td>
<td>44%</td>
<td>45%</td>
<td>46%</td>
<td>47%</td>
<td>48%</td>
<td>49%</td>
<td>50%</td>
</tr>
</tbody>
</table>

**Prevalence of hypertension – global comparison (both sexes)**

<table>
<thead>
<tr>
<th>% of population aged 30–79 years</th>
<th>0%</th>
<th>10%</th>
<th>20%</th>
<th>30%</th>
<th>40%</th>
<th>50%</th>
<th>60%</th>
<th>70%</th>
<th>80%</th>
<th>90%</th>
<th>100%</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Tajikistan</strong></td>
<td>55%</td>
<td>52%</td>
<td>49%</td>
<td>46%</td>
<td>43%</td>
<td>40%</td>
<td>37%</td>
<td>34%</td>
<td>31%</td>
<td>28%</td>
<td>25%</td>
</tr>
<tr>
<td><strong>Global</strong></td>
<td>55%</td>
<td>54%</td>
<td>53%</td>
<td>52%</td>
<td>51%</td>
<td>50%</td>
<td>49%</td>
<td>48%</td>
<td>47%</td>
<td>46%</td>
<td>45%</td>
</tr>
</tbody>
</table>

**Trends in uncontrolled hypertension in adults aged 30–79 years**

<table>
<thead>
<tr>
<th>% of population aged 30–79 years</th>
<th>2000</th>
<th>2005</th>
<th>2010</th>
<th>2015</th>
<th>2020</th>
<th>2025</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Tajikistan</strong></td>
<td>50%</td>
<td>45%</td>
<td>40%</td>
<td>35%</td>
<td>30%</td>
<td>25%</td>
</tr>
<tr>
<td><strong>Global</strong></td>
<td>50%</td>
<td>49%</td>
<td>48%</td>
<td>47%</td>
<td>46%</td>
<td>45%</td>
</tr>
</tbody>
</table>

**Mortality**

- Probability of premature mortality from NCDs (%)
  - Cardiovascular disease deaths: 28% males, 25% females
  - Cardiovascular disease deaths attributable to high systolic blood pressure (%)

**Risk factors**

- Mean population salt intake, adults aged 25+ years (g/day)
- Current tobacco use, adults aged 15+ years (%)
- Obesity, adults aged 18+ years (%)
- Total alcohol per capita consumption, adults aged 15+ years (litres)
- Physical inactivity, adults aged 18+ years (%)

**National response**

<table>
<thead>
<tr>
<th>Targets</th>
<th>National target for blood pressure</th>
<th>✔</th>
<th>National target for salt consumption</th>
<th>×</th>
</tr>
</thead>
<tbody>
<tr>
<td>Surveillance</td>
<td>Conducted recent, national survey measuring raised blood pressure/hypertension</td>
<td>✔</td>
<td>Conducted recent, national survey on salt/sodium intake</td>
<td>✔</td>
</tr>
<tr>
<td></td>
<td>Functioning system for generating reliable cause-specific mortality data on a routine basis</td>
<td>×</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Treatment**

- Guidelines for management of hypertension

Footnotes: a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control. e. Age-standardized estimates are presented for all indicators except salt intake.
Notes:

* 13.5 million adults aged 30–79 years with hypertension:

- Of the 13.5 million adults aged 30–79 years with hypertension:
  - In order to achieve a 50% control rate, 3.1 million more people with hypertension would need to be effectively treated.

** Hypertension profile

Thailand

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)

- Of the 13.5 million adults aged 30–79 years with hypertension:
  - Projected hypertension control rates by scenario:
    - Business as usual
    - Progress
    - Aspirational

Mortality

- Probability of premature mortality from NCDs (%)
- Cardiovascular disease deaths
- Cardiovascular disease deaths attributable to high systolic blood pressure (%)

Risk factors

- Mean population salt intake, adults aged 25+ years (g/day)
- Current tobacco use, adults aged 15+ years (%)
- Obesity, adults aged 18+ years (%)
- Total alcohol per capita consumption, adults aged 15+ years (litres)
- Physical inactivity, adults aged 18+ years (%)

National response

- National target for blood pressure
- National target for salt consumption
- Surveillance
  - Conducted recent, national survey measuring raised blood pressure/hypertension
  - Conducted recent, national survey on salt/sodium intake
  - Functioning system for generating reliable cause-specific mortality data on a routine basis

Footnotes:

a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.

b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg.

c. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.

d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.

e. Age-standardized estimates are presented for all indicators except salt intake.
Timor-Leste

Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019) a

<table>
<thead>
<tr>
<th>Country</th>
<th>both sexes</th>
<th>males</th>
<th>females</th>
<th>year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total population</td>
<td>35%</td>
<td>34%</td>
<td>37%</td>
<td></td>
</tr>
<tr>
<td>Total deaths</td>
<td>7550</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Prevalence of hypertension – global comparison (both sexes) a

Of the 141 000 adults aged 30–79 years with hypertension:

- 36% diagnosed
- 23% treated
- 12% controlled

Trends in uncontrolled hypertension in adults aged 30–79 years c

Hypertension control rate scenarios

- If the progress scenario were achieved, 4200 deaths would be averted by 2040.

Mortality

Probability of premature mortality from NCDs (%)

<table>
<thead>
<tr>
<th>Risk factor</th>
<th>both sexes</th>
<th>males</th>
<th>females</th>
<th>year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiovascular disease deaths</td>
<td>20</td>
<td>21</td>
<td>18</td>
<td>2019</td>
</tr>
<tr>
<td>Cardiovascular disease deaths attributable to high systolic blood pressure (%)</td>
<td>2000</td>
<td>970</td>
<td>1000</td>
<td>2019</td>
</tr>
<tr>
<td>Total population salt intake, adults aged 25+ years (g/day)</td>
<td>60</td>
<td>62</td>
<td>57</td>
<td>2019</td>
</tr>
</tbody>
</table>

Risk factors e

- Mean population salt intake, adults aged 25+ years (g/day)
- Current tobacco use, adults aged 15+ years (%)
- Obesity, adults aged 18+ years (%)
- Total alcohol per capita consumption, adults aged 15+ years (litres)
- Physical inactivity, adults aged 18+ years (%)

National response

<table>
<thead>
<tr>
<th>Targets</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>National target for blood pressure</td>
<td>✔</td>
</tr>
<tr>
<td>National target for salt consumption</td>
<td>✗</td>
</tr>
<tr>
<td>Surveillance</td>
<td>Treatment</td>
</tr>
<tr>
<td>Conducted recent, national survey measuring raised blood pressure/hypertension</td>
<td>✗</td>
</tr>
<tr>
<td>Conducted recent, national survey on salt/sodium intake</td>
<td>✗</td>
</tr>
<tr>
<td>Functioning system for generating reliable cause-specific mortality data on a routine basis</td>
<td>✗</td>
</tr>
</tbody>
</table>

Footnotes: a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control. e. Age-standardized estimates are presented for all indicators except salt intake.
Togo

Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019) a

Prevalence of hypertension – global comparison (both sexes) a

Trends in uncontrolled hypertension in adults aged 30–79 years c

Hypertension control rate scenarios

Mortality

Probability of premature mortality from NCDs (%)
Cardiovascular disease deaths
Cardiovascular disease deaths attributable to high systolic blood pressure (%)

Risk factors e

Mean population salt intake, adults aged 25+ years (g/day)
Current tobacco use, adults aged 15+ years (%)
Obesity, adults aged 18+ years (%)
Total alcohol per capita consumption, adults aged 15+ years (litres)
Physical inactivity, adults aged 18+ years (%)

National response

Targets
National target for blood pressure
National target for salt consumption

Surveillance
Conducted recent, national survey measuring raised blood pressure/hypertension
Conducted recent, national survey on salt/sodium intake
Functioning system for generating reliable cause-specific mortality data on a routine basis

Footnotes: a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control. e. Age-standardized estimates are presented for all indicators except salt intake.
**Tonga**

**Hypertension profile**

**Total population (2019):** 105 000  
**Total deaths (2019):** 620

**Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)**

- **43%** males
- **40%** females
- **47%** overall

---

**Prevalence of hypertension – global comparison (both sexes)**

- **Tonga**
- **Global**

**Trends in uncontrolled hypertension in adults aged 30–79 years**

- Past trends
- Projected trends
- Global target

**Hypertension control rate scenarios**

- If the progress scenario were achieved, 240 deaths would be averted by 2040.

**Mortality**

<table>
<thead>
<tr>
<th>Probability of premature mortality from NCDs (%)</th>
<th>both sexes</th>
<th>males</th>
<th>females</th>
<th>year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiovascular disease deaths</td>
<td>25</td>
<td>30</td>
<td>20</td>
<td>2019</td>
</tr>
<tr>
<td>Cardiovascular disease deaths attributable to high systolic blood pressure (%)</td>
<td>150</td>
<td>90</td>
<td>60</td>
<td>2019</td>
</tr>
<tr>
<td>54</td>
<td>55</td>
<td>52</td>
<td>2019</td>
<td></td>
</tr>
</tbody>
</table>

**Risk factors**

<table>
<thead>
<tr>
<th>Risk factors</th>
<th>both sexes</th>
<th>males</th>
<th>females</th>
<th>year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean population salt intake, adults aged 25+ years (g/day)</td>
<td>7</td>
<td>8</td>
<td>7</td>
<td>2019</td>
</tr>
<tr>
<td>Current tobacco use, adults aged 15+ years (%)</td>
<td>31</td>
<td>47</td>
<td>15</td>
<td>2019</td>
</tr>
<tr>
<td>Obesity, adults aged 18+ years (%)</td>
<td>48</td>
<td>41</td>
<td>55</td>
<td>2016</td>
</tr>
<tr>
<td>Total alcohol per capita consumption, adults aged 15+ years (litres)</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>2019</td>
</tr>
<tr>
<td>Physical inactivity, adults aged 18+ years (%)</td>
<td>17</td>
<td>8</td>
<td>26</td>
<td>2016</td>
</tr>
</tbody>
</table>

**National response**

<table>
<thead>
<tr>
<th>Targets</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>National target for blood pressure</td>
<td>Guidelines for management of hypertension</td>
</tr>
<tr>
<td>National target for salt consumption</td>
<td>✔</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Surveillance</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Conducted recent, national survey measuring raised blood pressure/hypertension</td>
<td>✔</td>
</tr>
<tr>
<td>Conducted recent, national survey on salt/sodium intake</td>
<td>✔</td>
</tr>
<tr>
<td>Functioning system for generating reliable cause-specific mortality data on a routine basis</td>
<td>×</td>
</tr>
</tbody>
</table>

---

**Footnotes:**  

a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.  

b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg.  
c. SBP ≥140 mmHg or DBP ≥90 mmHg.  
d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.  
e. Age-standardized estimates are presented for all indicators except salt intake.  
f. Data refer to tobacco smoking only, in the absence of sufficient data on all tobacco use.
Trinidad and Tobago

Hypertension profile

Total population (2019): 1,520,000
Total deaths (2019): 9,440

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)  

Of the 354,000 adults aged 30–79 years with hypertension:

- 52% diagnosed
- 40% treated
- 17% controlled

In order to achieve a 50% control rate, 101,000 more people with hypertension would need to be effectively treated.

Trends in uncontrolled hypertension in adults aged 30–79 years

Projected hypertension control rates by scenario:
- Business as usual
- Progress
- Aspirational

Mortality

Probability of premature mortality from NCDs (%)
Cardiovascular disease deaths
Cardiovascular disease deaths attributable to high systolic blood pressure (%)

Risk factors

Mean population salt intake, adults aged 25+ years (g/day)
Current tobacco use, adults aged 15+ years (%)
Obesity, adults aged 18+ years (%)
Total alcohol per capita consumption, adults aged 15+ years (litres)
Physical inactivity, adults aged 18+ years (%)

National response

Targets
- National target for blood pressure
- National target for salt consumption

Surveillance
- Conducted recent, national survey measuring raised blood pressure/hypertension
- Conducted recent, national survey on salt/sodium intake
- Functioning system for generating reliable cause-specific mortality data on a routine basis

Footnotes: a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control. e. Age-standardized estimates are presented for all indicators except salt intake.
### Tunisia

**Hypertension profile**

#### Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)

- **Of the 2.1 million** adults aged 30–79 years with hypertension:
  - **45%** diagnosed
  - **37%** treated
  - **15%** controlled

- **Further information:**
  - **Diagnosed:** 36% men, 54% women
  - **Treated:** 30% men, 43% women
  - **Controlled:** 10% men, 19% women

- **In order to achieve a 50% control rate, 752 000 more people with hypertension would need to be effectively treated.**

#### Trends in uncontrolled hypertension in adults aged 30–79 years

- **Past and projected trends:**
  - **2000:** 35% (men), 45% (women)
  - **2025:** 25% (men), 35% (women)

- **Global target:**
  - **2025:** 15% (men), 20% (women)

#### Hypertension control rate scenarios

- **Progress and aspirational scenarios:**
  - **2023:** 45% (men), 55% (women)
  - **2025:** 55% (men), 65% (women)
  - **2030:** 65% (men), 75% (women)
  - **2035:** 75% (men), 85% (women)
  - **2040:** 85% (men), 95% (women)

#### Mortality

- **Probability of premature mortality from NCDs (%):**
  - Both sexes: 16 (2019)
  - Males: 19 (2019)
  - Females: 12 (2019)

- **Cardiovascular disease deaths:**
  - Both sexes: 33 900 (2019)
  - Males: 17 300 (2019)
  - Females: 16 600 (2019)

- **Cardiovascular disease deaths attributable to high systolic blood pressure (%):**
  - Both sexes: 51 (2019)
  - Males: 50 (2019)
  - Females: 53 (2019)

#### Risk factors

- **Mean population salt intake, adults aged 25+ years (g/day):**
  - Both sexes: 6 (2019)
  - Males: 7 (2019)
  - Females: 5 (2019)

- **Obesity, adults aged 18+ years (%):**
  - Both sexes: 25 (2019)
  - Males: 48 (2019)
  - Females: 2 (2019)

- **Physical inactivity, adults aged 18+ years (%):**
  - Both sexes: 30 (2019)
  - Males: 26 (2019)
  - Females: 34 (2019)

#### National response

- **Targets**
  - National target for blood pressure ✔
  - National target for salt consumption ✔

- **Surveillance**
  - Conducted recent, national survey measuring raised blood pressure/hypertension ✔
  - Conducted recent, national survey on salt/sodium intake ✔

- **Functioning system for generating reliable cause-specific mortality data on a routine basis:**
  - ✔

#### Treatment

- Guidelines for management of hypertension ✔

---

**Footnotes:**
- a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.
- b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg.
- c. SBP ≥140 mmHg or DBP ≥90 mmHg.
- d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.
- e. Age-standardized estimates are presented for all indicators except salt intake.
Türkiye

Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)\(^a\)

<table>
<thead>
<tr>
<th>both sexes</th>
<th>males</th>
<th>females</th>
<th>year</th>
</tr>
</thead>
<tbody>
<tr>
<td>33%</td>
<td>31%</td>
<td>34%</td>
<td></td>
</tr>
</tbody>
</table>

Prevalence of hypertension – global comparison (both sexes)\(^a\)

<table>
<thead>
<tr>
<th>% of population aged 30–79 years</th>
<th>Türkiye</th>
</tr>
</thead>
<tbody>
<tr>
<td>53%</td>
<td></td>
</tr>
</tbody>
</table>

Trends in uncontrolled hypertension in adults aged 30–79 years\(^c\)

<table>
<thead>
<tr>
<th>% of population aged 30–79 years</th>
<th>past trends</th>
<th>projected trends</th>
<th>global target</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Mortality

Probability of premature mortality from NCDs (%)

Cardiovascular disease deaths

Cardiovascular disease deaths attributable to high systolic blood pressure (%)

Risk factors\(^e\)

Mean population salt intake, adults aged 25+ years (g/day)

Current tobacco use, adults aged 15+ years (%)

Obesity, adults aged 18+ years (%)

Total alcohol per capita consumption, adults aged 15+ years (litres)

Physical inactivity, adults aged 18+ years (%)

National response

Targets

National target for blood pressure
National target for salt consumption

Surveillance

Conducted recent, national survey measuring raised blood pressure/hypertension
Conducted recent, national survey on salt/sodium intake
Functioning system for generating reliable cause-specific mortality data on a routine basis

Footnotes: a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control. e. Age-standardized estimates are presented for all indicators except salt intake.

Annex 2. Hypertension profiles and explanatory notes
**Turkmenistan**

**Hypertension profile**

**Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)**

- Total population (2019): 6 158 000
- Total deaths (2019): 36 900
- Male: 39%
- Female: 38%
- Global: 40%

**Prevalence of hypertension – global comparison (both sexes)**

![Graph showing prevalence of hypertension](image)

- Turkmenistan
- Global

**Trends in uncontrolled hypertension in adults aged 30–79 years**

![Graph showing trends in uncontrolled hypertension](image)

**Hypertension control rate scenarios**

- If the progress scenario were achieved, 32 000 deaths would be averted by 2040.

**Mortality**

- Probability of premature mortality from NCDs (%)
- Cardiovascular disease deaths
- Cardiovascular disease deaths attributable to high systolic blood pressure (%)

**Risk factors**

- Mean population salt intake, adults aged 25+ years (g/day)
- Current tobacco use, adults aged 15+ years (%)
- Obesity, adults aged 18+ years (%)
- Total alcohol per capita consumption, adults aged 15+ years (litres)
- Physical inactivity, adults aged 18+ years (%)

**National response**

- National target for blood pressure
- National target for salt consumption
- Surveillance
  - Conducted recent, national survey measuring raised blood pressure/hypertension
  - Conducted recent, national survey on salt/sodium intake
  - Functioning system for generating reliable cause-specific mortality data on a routine basis

**Footnotes:**

- a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.
- b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg.
- c. SBP ≥140 mmHg or DBP ≥90 mmHg.
- d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.
- e. Age-standardized estimates are presented for all indicators except salt intake.

---

In order to achieve a 50% control rate, 357 000 more people with hypertension would need to be effectively treated.
**Tuvalu**

**Hypertension profile**

**Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)**

- **Total population (2019): 11,000**
- **Total deaths (2019): no data**

### Prevalence of hypertension – global comparison (both sexes)

- **Tuvalu:** 60%
- **Global:** 30%

### Trends in uncontrolled hypertension in adults aged 30–79 years

- **Past trends:**
  - Female: 50%
  - Male: 49%
  - Global: 51%
- **Projected trends:**
  - Female: 50%
  - Male: 49%
  - Global: 51%

### Hypertension control rate scenarios

- **Diagnosed:**
  - Female: 33%
  - Male: 20%
  - Global: 6%
- **Treated:**
  - Female: 36%
  - Male: 19%
  - Global: 6%
- **Controlled:**
  - Female: 36%
  - Male: 19%
  - Global: 6%

### Mortality

- **Probability of premature mortality from NCDs (%):**
  - Both sexes: 50%
  - Males: 49%
  - Females: 51%
- **Cardiovascular disease deaths:**
  - Both sexes: 52
  - Males: 53
  - Females: 52
- **Cardiovascular disease deaths attributable to high systolic blood pressure (%):**
  - Both sexes: 52
  - Males: 53
  - Females: 52

### Risk factors

- **Mean population salt intake, adults aged 25+ years (g/day):**
  - Both sexes: 7
  - Males: 8
  - Females: 7
- **Current tobacco use, adults aged 15+ years (%):**
  - Both sexes: 36
  - Males: 50
  - Females: 22
- **Obesity, adults aged 18+ years (%):**
  - Both sexes: 52
  - Males: 47
  - Females: 56
- **Total alcohol per capita consumption, adults aged 15+ years (litres):**
  - Both sexes: 1
  - Males: 2
  - Females: 0
- **Physical inactivity, adults aged 18+ years (%):**
  - Both sexes: 27
  - Males: 18
  - Females: 37

### National response

- **Targets**
  - National target for blood pressure
  - National target for salt consumption
- **Surveillance**
  - Conducted recent, national survey measuring raised blood pressure/hypertension
  - Conducted recent, national survey on salt/sodium intake
  - Functioning system for generating reliable cause-specific mortality data on a routine basis

### Footnotes:

- a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.
- b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg.
- c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Age-standardized estimates are presented for all indicators except salt intake.
- e. Data refer to tobacco smoking only, in the absence of sufficient data on all tobacco use.

---

**Annex 2. Hypertension profiles and explanatory notes**
**Uganda**

**Hypertension profile**

Total population (2019): 42,949,000  
Total deaths (2019): 228,000

### Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)*

<table>
<thead>
<tr>
<th>Sex</th>
<th>Prevalence (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>♂</td>
<td>33%</td>
</tr>
<tr>
<td>♀</td>
<td>31%</td>
</tr>
<tr>
<td>♂</td>
<td>34%</td>
</tr>
</tbody>
</table>

Of the **3.2 million** adults aged 30–79 years with hypertension:

- **25%** diagnosed
- **13%** treated
- **7%** controlled

### Trends in uncontrolled hypertension in adults aged 30–79 years

<table>
<thead>
<tr>
<th>Year</th>
<th>% of population aged 30–79 years with hypertension</th>
</tr>
</thead>
<tbody>
<tr>
<td>2000</td>
<td>34%</td>
</tr>
<tr>
<td>2005</td>
<td>25%</td>
</tr>
<tr>
<td>2010</td>
<td>18%</td>
</tr>
<tr>
<td>2015</td>
<td>8%</td>
</tr>
<tr>
<td>2020</td>
<td>0%</td>
</tr>
<tr>
<td>2025</td>
<td>0%</td>
</tr>
</tbody>
</table>

### Hypertension control rate scenarios

- **Past trends**
- **Projected trends**
- **Global target**
- **Business as usual**
- **Progress**
- **Aspirational**

### Mortality

- Probability of premature mortality from NCDs (%)
- Cardiovascular disease deaths
- Cardiovascular disease deaths attributable to high systolic blood pressure (%)

### Risk factors

<table>
<thead>
<tr>
<th>Factor</th>
<th>% of population</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean population salt intake, adults aged 25+ years (g/day)</td>
<td>7</td>
</tr>
<tr>
<td>Current tobacco use, adults aged 15+ years (%)</td>
<td>9</td>
</tr>
<tr>
<td>Obesity, adults aged 18+ years (%)</td>
<td>5</td>
</tr>
<tr>
<td>Total alcohol per capita consumption, adults aged 15+ years (litres)</td>
<td>12</td>
</tr>
<tr>
<td>Physical inactivity, adults aged 18+ years (%)</td>
<td>6</td>
</tr>
</tbody>
</table>

### National response

#### Targets

- National target for blood pressure
- National target for salt consumption

#### Surveillance

- Conducted recent, national survey measuring raised blood pressure/hypertension
- Conducted recent, national survey on salt/sodium intake
- Functioning system for generating reliable cause-specific mortality data on a routine basis

#### Treatment

- Guidelines for management of hypertension

Footnotes: a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control. e. Age-standardized estimates are presented for all indicators except salt intake.
Hypertension profile

Ukraine

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)

Total population (2019): 44 211 000
Total deaths (2019): 594 000

Prevalence of hypertension – global comparison (both sexes)

Of the 13.2 million adults aged 30–79 years with hypertension:

- Diagnosed: 65%
- Treated: 49%
- Controlled: 14%

In order to achieve a 50% control rate, 4.7 million more people with hypertension would need to be effectively treated.

Trends in uncontrolled hypertension in adults aged 30–79 years

Mortality

Probability of premature mortality from NCDs (%)

Cardiovascular disease deaths

Cardiovascular disease deaths attributable to high systolic blood pressure (%)

Risk factors

Mean population salt intake, adults aged 25+ years (g/day)

Current tobacco use, adults aged 15+ years (%)

Obesity, adults aged 18+ years (%)

Total alcohol per capita consumption, adults aged 15+ years (litres)

Physical inactivity, adults aged 18+ years (%)

National response

Targets

- National target for blood pressure
- National target for salt consumption

Surveillance

- Conducted recent, national survey measuring raised blood pressure/hypertension
- Conducted recent, national survey on salt/sodium intake
- Functioning system for generating reliable cause-specific mortality data on a routine basis

Notes:

- Hypertension profile
- Uganda
- Functioning system for generating reliable cause-specific mortality data on a routine basis
- Conducted recent, national survey measuring raised blood pressure/hypertension
- National target for salt consumption
- Physical inactivity, adults aged 18+ years (%)
- Obesity, adults aged 18+ years (%)
- Current tobacco use, adults aged 15+ years (%)
- Mean population salt intake, adults aged 25+ years (g/day)
- Probability of premature mortality from NCDs (%)
- Cardiovascular disease deaths
- Cardiovascular disease deaths attributable to high systolic blood pressure (%)
- Mean population salt intake, adults aged 25+ years (g/day)
- Current tobacco use, adults aged 15+ years (%)
- Obesity, adults aged 18+ years (%)
- Total alcohol per capita consumption, adults aged 15+ years (litres)
- Physical inactivity, adults aged 18+ years (%)

Footnotes: a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control. e. Age-standardized estimates are presented for all indicators except salt intake.

Annex 2. Hypertension profiles and explanatory notes
**United Arab Emirates**

**Hypertension profile**

---

**Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)**

- **Of the 1.8 million** adults aged 30–79 years with hypertension:
  - **43%** were diagnosed, **37%** were treated, and **20%** were controlled.

---

**Prevalence of hypertension – global comparison (both sexes)**

- **United Arab Emirates**

---

**Trends in uncontrolled hypertension in adults aged 30–79 years**

- Past trends: **United Arab Emirates** vs. **global**

---

**Hypertension control rate scenarios**

- Projected hypertension control rates by scenario:
  - Business as usual
  - Progress
  - Aspirational

---

**Mortality**

- Probability of premature mortality from NCDs (%)
  - Both sexes: **19** in 2019, **7600** in 2019, **61** in 2019
  - Males: **20** in 2019, **6100** in 2019, **61** in 2019
  - Females: **15** in 2019, **1500** in 2019, **59** in 2019

- Cardiovascular disease deaths: **61** in 2019

- Cardiovascular disease deaths attributable to high systolic blood pressure (%)
  - Both sexes: **32** in 2019, **28** in 2019, **no data** in 2019
  - Males: **3** in 2019, **28** in 2019, **no data** in 2019
  - Females: **no data** in 2019, **5** in 2019, **41** in 2019

---

**Risk factors**

- Mean population salt intake, adults aged 25+ years (g/day): **7** in 2016, **32** in 2019, **41** in 2019
- Current tobacco use, adults aged 15+ years (%): **no data** in 2019, **32** in 2019, **2** in 2019
- Obesity, adults aged 18+ years (%): **32** in 2019, **39** in 2019, **59** in 2019
- Total alcohol per capita consumption, adults aged 15+ years (litres): **no data** in 2019, **7** in 2019, **7** in 2019
- Physical inactivity, adults aged 18+ years (%): **no data** in 2019, **2** in 2019, **59** in 2019

---

**National response**

- **Targets**
  - National target for blood pressure
  - National target for salt consumption
- **Surveillance**
  - Conducted recent, national survey measuring raised blood pressure/hypertension
  - Conducted recent, national survey on salt/sodium intake
  - Functioning system for generating reliable cause-specific mortality data on a routine basis

---

**Footnotes:**

a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.

b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg.

c. SBP ≥140 mmHg or DBP ≥90 mmHg.

d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.

e. Age-standardized estimates are presented for all indicators except salt intake.
United Arab Emirates

Trends in uncontrolled hypertension in adults

Functioning system for generating reliable cause-specific mortality data on a routine basis

Surveillance

National target for blood pressure

National target for salt consumption

Surveillance

Conducted recent, national survey measuring raised blood pressure/hypertension

Conducted recent, national survey on salt/sodium intake

Functioning system for generating reliable cause-specific mortality data on a routine basis

Notes:

- Total population (2019): 66 779 000
- Total deaths (2019): 615 000

**United Kingdom of Great Britain and Northern Ireland**

**Hypertension profile**

**Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)**

<table>
<thead>
<tr>
<th>Indicator</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>SBP &lt;140 mmHg or DBP ≤90 mmHg</td>
<td>✔</td>
</tr>
<tr>
<td>15% of population aged 30–79 years</td>
<td>✔</td>
</tr>
<tr>
<td>20% of population aged 30–79 years</td>
<td>✔</td>
</tr>
<tr>
<td>25% of population aged 30–79 years</td>
<td>✔</td>
</tr>
<tr>
<td>30% of population aged 30–79 years</td>
<td>✔</td>
</tr>
<tr>
<td>40% of population aged 30–79 years</td>
<td>✔</td>
</tr>
<tr>
<td>45% of population aged 30–79 years</td>
<td>✔</td>
</tr>
<tr>
<td>50% of population aged 30–79 years</td>
<td>✔</td>
</tr>
<tr>
<td>60% of population aged 30–79 years</td>
<td>✔</td>
</tr>
<tr>
<td>70% of population aged 30–79 years</td>
<td>✔</td>
</tr>
<tr>
<td>80% of population aged 30–79 years</td>
<td>✔</td>
</tr>
<tr>
<td>90% of population aged 30–79 years</td>
<td>✔</td>
</tr>
<tr>
<td>100% of population aged 30–79 years</td>
<td>✔</td>
</tr>
</tbody>
</table>

**Prevalence of hypertension – global comparison (both sexes)**

- In order to achieve a 50% control rate, 2.2 million more people with hypertension would need to be effectively treated.

**Trends in uncontrolled hypertension in adults aged 30–79 years**

**Hypertension control rate scenarios**

- Projected hypertension control rates by scenario:
  - Business as usual
  - Progress
  - Aspirational

**Mortality**

<table>
<thead>
<tr>
<th>Indicator</th>
<th>2019</th>
<th>2023</th>
<th>2025</th>
<th>2030</th>
<th>2035</th>
<th>2040</th>
</tr>
</thead>
<tbody>
<tr>
<td>Probability of premature mortality from NCDs (%)</td>
<td>26%</td>
<td>30%</td>
<td>23%</td>
<td>26%</td>
<td>30%</td>
<td>23%</td>
</tr>
<tr>
<td>Cardiovascular disease deaths</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardiovascular disease deaths attributable to high systolic blood pressure (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Risk factors**

- Mean population salt intake, adults aged 25+ years (g/day)
- Current tobacco use, adults aged 15+ years (%)
- Obesity, adults aged 18+ years (%)
- Total alcohol per capita consumption, adults aged 15+ years (litres)
- Physical inactivity, adults aged 18+ years (%)

**National response**

- Treatment: Guidelines for management of hypertension

Footnotes:

- a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.
- b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP ≤140 mmHg and DBP ≤90 mmHg.
- c. SBP ≥140 mmHg or DBP ≥90 mmHg.
- d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.
- e. Age-standardized estimates are presented for all indicators except salt intake.
- f. Data refer to tobacco smoking only, in the absence of sufficient data on all tobacco use.

Annex 2. Hypertension profiles and explanatory notes

259
**United Republic of Tanzania**

**Hypertension profile**

<table>
<thead>
<tr>
<th>Total population (2019):</th>
<th>59 873 000</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total deaths (2019):</td>
<td>322 000</td>
</tr>
</tbody>
</table>

**Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)**

- Of the **4.9 million** adults aged 30–79 years with hypertension:
  - **34%** diagnosed
  - **15%** treated
  - **7%** controlled

In order to achieve a 50% control rate, **2.1 million more people with hypertension** would need to be effectively treated.

**Trends in uncontrolled hypertension in adults aged 30–79 years**

- Past trends: United Republic of Tanzania, global
- Projected trends: global target

**Mortality**

<table>
<thead>
<tr>
<th>Probability of premature mortality from NCDs (%)</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiovascular disease deaths</td>
<td>33%</td>
</tr>
<tr>
<td>Cardiovascular disease deaths attributable to high systolic blood pressure (%)</td>
<td></td>
</tr>
</tbody>
</table>

**Risk factors**

<table>
<thead>
<tr>
<th>Year</th>
<th>both sexes</th>
<th>males</th>
<th>females</th>
</tr>
</thead>
<tbody>
<tr>
<td>2019</td>
<td>17</td>
<td>18</td>
<td>17</td>
</tr>
<tr>
<td>2019</td>
<td>39 500</td>
<td>19 100</td>
<td>20 400</td>
</tr>
<tr>
<td>2019</td>
<td>65</td>
<td>71</td>
<td>58</td>
</tr>
</tbody>
</table>

**National response**

**Footnotes:**
- a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.
- b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg.
- c. SBP ≥140 mmHg or DBP ≥90 mmHg.
- d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.
- e. Age-standardized estimates are presented for all indicators except salt intake.
United States of America

Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>United States of America</td>
<td>32%</td>
<td>34%</td>
<td>29%</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Of the 69.3 million adults aged 30–79 years with hypertension:

- In order to achieve a 50% control rate, 693,000 more people with hypertension would need to be effectively treated.

Hypertension control rate scenarios

- If the aspirational scenario were achieved, 1.2 million deaths would be averted by 2040.

Mortality

- Probability of premature mortality from NCDs (%)
  - Cardiovascular disease deaths
  - Cardiovascular disease deaths attributable to high systolic blood pressure (%)

Risk factors

- Mean population salt intake, adults aged 25+ years (g/day)
- Current tobacco use, adults aged 15+ years (%)
- Obesity, adults aged 18+ years (%)
- Total alcohol per capita consumption, adults aged 15+ years (litres)
- Physical inactivity, adults aged 18+ years (%)

National response

- Targets
  - National target for blood pressure
  - National target for salt consumption
- Surveillance
  - Conducted recent, national survey measuring raised blood pressure/hypertension
  - Conducted recent, national survey on salt/sodium intake

Footnotes: a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.

1.2 million deaths would be averted by 2040.
Uruguay

Hypertension profile

Total population (2019): 3 428 000
Total deaths (2019): 34 800

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)

<table>
<thead>
<tr>
<th>Sex</th>
<th>Prevalence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Males</td>
<td>42%</td>
</tr>
<tr>
<td>Females</td>
<td>46%</td>
</tr>
<tr>
<td>Overall</td>
<td>39%</td>
</tr>
</tbody>
</table>

Prevalence of hypertension – global comparison (both sexes)

<table>
<thead>
<tr>
<th>Region</th>
<th>Prevalence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Uruguay</td>
<td>67%</td>
</tr>
<tr>
<td>Global</td>
<td>55%</td>
</tr>
<tr>
<td>Controlled</td>
<td>29%</td>
</tr>
</tbody>
</table>

Of the 857 000 adults aged 30–79 years with hypertension:

- 67% diagnosed
- 55% treated
- 29% controlled

In order to achieve a 50% control rate, 167 000 more people with hypertension would need to be effectively treated.

Trends in uncontrolled hypertension in adults aged 30–79 years

<table>
<thead>
<tr>
<th>Year</th>
<th>Past Trends</th>
<th>Projected Trends</th>
<th>Global Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>2000</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2005</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2010</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2015</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2020</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2025</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Hypertension control rate scenarios

- If the progress scenario were achieved, 11 000 deaths would be averted by 2040.

Mortality

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Probability of premature mortality from NCDs (%)</th>
<th>Cardiovascular disease deaths</th>
<th>Cardiovascular disease deaths attributable to high systolic blood pressure (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>61%</td>
<td>73%</td>
<td>63%</td>
</tr>
</tbody>
</table>

Risk factors

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean population salt intake, adults aged 25+ years (g/day)</td>
<td>2019</td>
</tr>
<tr>
<td>Current tobacco use, adults aged 15+ years (%)</td>
<td>2019</td>
</tr>
<tr>
<td>Obesity, adults aged 18+ years (%)</td>
<td>2019</td>
</tr>
<tr>
<td>Total alcohol per capita consumption, adults aged 15+ years (litres)</td>
<td>2019</td>
</tr>
<tr>
<td>Physical inactivity, adults aged 18+ years (%)</td>
<td>2016</td>
</tr>
</tbody>
</table>

National response

<table>
<thead>
<tr>
<th>Targets</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>National target for blood pressure</td>
<td>✔</td>
</tr>
<tr>
<td>National target for salt consumption</td>
<td>✔</td>
</tr>
<tr>
<td>Surveillance</td>
<td>Guidelines for management of hypertension</td>
</tr>
<tr>
<td>Conducted recent, national survey measuring raised blood pressure/hypertension</td>
<td>❌</td>
</tr>
<tr>
<td>Conducted recent, national survey on salt/sodium intake</td>
<td>❌</td>
</tr>
<tr>
<td>Functioning system for generating reliable cause-specific mortality data on a routine basis</td>
<td>✔</td>
</tr>
</tbody>
</table>

Footnotes: a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control. e. Age-standardized estimates are presented for all indicators except salt intake.

Global report on hypertension: the race against a silent killer
Uruguay

Conducted recent, national survey on salt/sodium intake

National target for salt consumption

Physical inactivity, adults aged 18+ years (%)

Total alcohol per capita consumption, adults aged 15+ years (litres)

Mean population salt intake, adults aged 25+ years (g/day)

Cardiovascular disease deaths attributable to high systolic blood pressure (%)

Hypertension profile

e. Age-standardized estimates are presented for all indicators except salt intake.
and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.

Project 157 000 deaths would be averted by 2040.

If the progress scenario were achieved,

Probability of premature mortality from NCDs (%)

Cardiovascular disease deaths

Cardiovascular disease deaths attributable to high systolic blood pressure (%)

Risk factors

Mean population salt intake, adults aged 25+ years (g/day)

Current tobacco use, adults aged 15+ years (%)

Obesity, adults aged 18+ years (%)

Total alcohol per capita consumption, adults aged 15+ years (litres)

Physical inactivity, adults aged 18+ years (%)

National response

Targets

National target for blood pressure

National target for salt consumption

Surveillance

Conducted recent, national survey measuring raised blood pressure/hypertension

Conducted recent, national survey on salt/sodium intake

Functioning system for generating reliable cause-specific mortality data on a routine basis

Footnotes: a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.

Annex 2. Hypertension profiles and explanatory notes
**Vanuatu**

**Hypertension profile**

**Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)**

<table>
<thead>
<tr>
<th>Sex</th>
<th>Prevalence (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Males</td>
<td>40%</td>
</tr>
<tr>
<td>Females</td>
<td>37%</td>
</tr>
<tr>
<td>All</td>
<td>42%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Total population (2019): 304 000</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total deaths (2019): 2130</td>
</tr>
</tbody>
</table>

**Prevalence of hypertension – global comparison (both sexes)**

- **Vanuatu**
- **Global**

**Trends in uncontrolled hypertension in adults aged 30–79 years**

- **Past trends**
- **Projected trends**
- **Global target**

**Hypertension control rate scenarios**

- **Diagnosed**: 24% (M), 14% (F), 5% (Global)
- **Treated**: 36% (M), 16% (F), 6% (Global)
- **Controlled**: 4% (M), 4% (F), 6% (Global)

**Mortality**

- Probability of premature mortality from NCDs (%)
  - Cardiovascular disease deaths
  - Cardiovascular disease deaths attributable to high systolic blood pressure (%)

**Risk factors**

- Mean population salt intake, adults aged 25+ years (g/day)
- Current tobacco use, adults aged 15+ years (%)
- Obesity, adults aged 18+ years (%)
- Total alcohol per capita consumption, adults aged 15+ years (litres)
- Physical inactivity, adults aged 18+ years (%)

**National response**

- **Targets**
  - National target for blood pressure
  - National target for salt consumption
- **Surveillance**
  - Conducted recent, national survey measuring raised blood pressure/hypertension
  - Conducted recent, national survey on salt/sodium intake
  - Functioning system for generating reliable cause-specific mortality data on a routine basis

**Footnotes:**

- a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.
- b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg.
- c. SBP ≥140 mmHg or DBP ≥90 mmHg.
- d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.
- e. Age-standardized estimates are presented for all indicators except salt intake.
- f. Data refer to tobacco smoking only, in the absence of sufficient data on all tobacco use.

**Global report on hypertension: the race against a silent killer**

264
Venezuela (Bolivarian Republic of)

Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)

Prevalence of hypertension – global comparison (both sexes)

![Graph showing prevalence of hypertension globally and for Venezuela, with notes on salt/sodium intake, surveillance, and targets.]

Of the 5.3 million adults aged 30–79 years with hypertension:

- 72% diagnosed
- 63% treated
- 33% controlled

In order to achieve a 50% control rate, 925 000 more people with hypertension would need to be effectively treated.

Mortality

- Probability of premature mortality from NCDs (%)
  - Cardiovascular disease deaths
  - Cardiovascular disease deaths attributable to high systolic blood pressure (%)

Risk factors

- Mean population salt intake, adults aged 25+ years (g/day)
- Current tobacco use, adults aged 15+ years (%)
- Obesity, adults aged 18+ years (%)
- Total alcohol per capita consumption, adults aged 15+ years (litres)
- Physical inactivity, adults aged 18+ years (%)

National response

- Targets
  - National target for blood pressure
  - National target for salt consumption
  - Surveillance
  - Conducted recent, national survey measuring raised blood pressure/hypertension
  - Conducted recent, national survey on salt/sodium intake
  - Functioning system for generating reliable cause-specific mortality data on a routine basis

- Treatment
  - Guidelines for management of hypertension

Footnotes: a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension. b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg. c. SBP ≥140 mmHg or DBP ≥90 mmHg. d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control. e. Age-standardized estimates are presented for all indicators except salt intake.
**Viet Nam**

**Hypertension profile**

**Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)**

- **Total population (2019):** 95,777,000
- **Total deaths (2019):** 728,000

<table>
<thead>
<tr>
<th>% of population aged 30–79 years with hypertension</th>
<th>both sexes</th>
<th>males</th>
<th>females</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vietnam</td>
<td>47%</td>
<td>42%</td>
<td>53%</td>
</tr>
<tr>
<td>Global</td>
<td>30%</td>
<td>26%</td>
<td>34%</td>
</tr>
<tr>
<td>World</td>
<td>13%</td>
<td>11%</td>
<td>15%</td>
</tr>
</tbody>
</table>

**Trends in uncontrolled hypertension in adults aged 30–79 years**

- Of the **14.3 million** adults aged 30–79 years with hypertension:
  - **47%** diagnosed
  - **30%** treated
  - **13%** controlled

**Surveillance**

- Conducted recent, national survey measuring raised blood pressure/hypertension
- Conducted recent, national survey on salt/sodium intake
- Functioning system for generating reliable cause-specific mortality data on a routine basis

**Risk factors**

- **Mean population salt intake, adults aged 25+ years (g/day)**
  - both sexes: 10
  - males: 11
  - females: 10

- **Current tobacco use, adults aged 15+ years (%)**
  - both sexes: 25
  - males: 48
  - females: 2

- **Obesity, adults aged 18+ years (%)**
  - both sexes: 2
  - males: 2
  - females: 3

- **Total alcohol per capita consumption, adults aged 15+ years (litres)**
  - both sexes: 9
  - males: 15
  - females: 4

- **Physical inactivity, adults aged 18+ years (%)**
  - both sexes: 25
  - males: 20
  - females: 31

**Targets**

- National target for blood pressure
- National target for salt consumption

**Footnotes:**

a. SBP ≥ 140 mmHg or DBP ≥ 90 mmHg or taking medication for hypertension.

b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP < 140 mmHg and DBP < 90 mmHg.

c. SBP ≥ 140 mmHg or DBP ≥ 90 mmHg.

d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.

e. Age-standardized estimates are presented for all indicators except salt intake.
Yemen

Hypertension profile

Total population (2019): 31 547 000
Total deaths (2019): 170 000

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)  

- Both sexes: 29%
- Males: 29%
- Females: 30%

Prevalence of hypertension – global comparison (both sexes)

Of the 2.2 million adults aged 30–79 years with hypertension:

- Diagnosed: 45% (41% males, 49% females)
- Treated: 37% (34% males, 39% females)
- Controlled: 17% (13% males, 20% females)

In order to achieve a 50% control rate, 751 000 more people with hypertension would need to be effectively treated.

Trends in uncontrolled hypertension in adults aged 30–79 years

- Past trends: 50% (45% males, 55% females)
- Projected trends: 30% (25% males, 35% females)
- Global target: 10% (10% males, 10% females)

Hypertension control rate scenarios

- If the progress scenario were achieved, 115 000 deaths would be averted by 2040.

Projected hypertension control rates by scenario:

- Business as usual
- Progress
- Aspirational

Mortality

- Probability of premature mortality from NCDs (%)
  - Both sexes: 28% (2019)
  - Males: 31% (2019)
  - Females: 25% (2019)
- Cardiovascular disease deaths
  - Both sexes: 52 600 (2019)
  - Males: 27 100 (2019)
  - Females: 25 600 (2019)
- Cardiovascular disease deaths attributable to high systolic blood pressure (%)
  - Both sexes: 52 (2019)
  - Males: 49 (2019)
  - Females: 56 (2019)

Risk factors

- Mean population salt intake, adults aged 25+ years (g/day)
  - Both sexes: 6 (2019)
  - Males: 7 (2019)
  - Females: 5 (2019)
- Current tobacco use, adults aged 15+ years (%)
  - Both sexes: 21 (2019)
  - Males: 33 (2019)
  - Females: 8 (2019)
- Obesity, adults aged 18+ years (%)
  - Both sexes: 17 (2016)
  - Males: 12 (2016)
  - Females: 22 (2016)
- Total alcohol per capita consumption, adults aged 15+ years (litres)
  - Both sexes: 0 (2019)
  - Males: 0 (2019)
  - Females: 0 (2019)
- Physical inactivity, adults aged 18+ years (%)
  - Both sexes: no data (2016)
  - Males: no data (2016)
  - Females: no data (2016)

National response

- Targets
  - National target for blood pressure
  - National target for salt consumption

- Surveillance
  - Conducted recent, national survey measuring raised blood pressure/hypertension
  - Conducted recent, national survey on salt/sodium intake
  - Functioning system for generating reliable cause-specific mortality data on a routine basis

- Treatment
  - Guidelines for management of hypertension

Footnotes:
- a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.
- b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg.
- c. SBP ≥140 mmHg or DBP ≥90 mmHg.
- d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.
- e. Age-standardized estimates are presented for all indicators except salt intake.

Annex 2. Hypertension profiles and explanatory notes
**Zambia**

**Hypertension profile**

**Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)**

<table>
<thead>
<tr>
<th>Sex</th>
<th>% of population aged 30–79 years</th>
<th>Male</th>
<th>Female</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>32%</td>
<td>30%</td>
</tr>
<tr>
<td><strong>Of the 1.3 million</strong> adults aged 30–79 years with hypertension:</td>
<td></td>
<td></td>
<td>34%</td>
</tr>
</tbody>
</table>

**In order to achieve a 50% control rate, 534 000 more people with hypertension would need to be effectively treated.**

**Notes:**
- SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.
- Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg.
- Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.
- Age-standardized estimates are presented for all indicators except salt intake.

**Mortality**

<table>
<thead>
<tr>
<th>Risk factor</th>
<th>Probability of premature mortality from NCDs (%)</th>
<th>Cardiovascular disease deaths</th>
<th>Cardiovascular disease deaths attributable to high systolic blood pressure (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Both sexes</td>
<td>25</td>
<td>16 700</td>
<td>52</td>
</tr>
<tr>
<td>Males</td>
<td>29</td>
<td>8800</td>
<td>52</td>
</tr>
<tr>
<td>Females</td>
<td>21</td>
<td>7900</td>
<td>52</td>
</tr>
<tr>
<td>Year</td>
<td>2019</td>
<td>2019</td>
<td>2019</td>
</tr>
</tbody>
</table>

**Risk factors**

<table>
<thead>
<tr>
<th>Risk factor</th>
<th>Mean population salt intake, adults aged 25+ years (g/day)</th>
<th>Current tobacco use, adults aged 15+ years (%)</th>
<th>Obesity, adults aged 18+ years (%)</th>
<th>Total alcohol per capita consumption, adults aged 15+ years (litres)</th>
<th>Physical inactivity, adults aged 18+ years (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Both sexes</td>
<td>7</td>
<td>15</td>
<td>8</td>
<td>4</td>
<td>22</td>
</tr>
<tr>
<td>Males</td>
<td>6</td>
<td>25</td>
<td>4</td>
<td>12</td>
<td>19</td>
</tr>
<tr>
<td>Females</td>
<td>8</td>
<td>4</td>
<td>12</td>
<td>1</td>
<td>25</td>
</tr>
</tbody>
</table>

**National response**

<table>
<thead>
<tr>
<th>National target for blood pressure</th>
<th>National target for salt consumption</th>
<th>Conducted recent, national survey measuring raised blood pressure/hypertension</th>
</tr>
</thead>
<tbody>
<tr>
<td>✗</td>
<td>✗</td>
<td>✗</td>
</tr>
</tbody>
</table>

**Treatment**

<table>
<thead>
<tr>
<th>Guidelines for management of hypertension</th>
</tr>
</thead>
<tbody>
<tr>
<td>✗</td>
</tr>
</tbody>
</table>

Footnotes:
- a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.
- b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg.
- c. SBP ≥140 mmHg or DBP ≥90 mmHg.
- d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.
- e. Age-standardized estimates are presented for all indicators except salt intake.
Zimbabwe
Hypertension profile

Age-standardized prevalence of hypertension among adults aged 30–79 years (2019)\(^a\)  
- Total population (2019): 15 355 000  
- Total deaths (2019): 118 000

Prevalence of hypertension – global comparison (both sexes)\(^a\)

Trends in uncontrolled hypertension in adults aged 30–79 years\(^c\)

Hypertension control rate scenarios

Mortality

Probability of premature mortality from NCDs (%)  
- Cardiovascular disease deaths
- Cardiovascular disease deaths attributable to high systolic blood pressure (%)

Risk factors\(^e\)

National response

Targets
- National target for blood pressure
- National target for salt consumption

Surveillance
- Conducted recent, national survey measuring raised blood pressure/hypertension
- Conducted recent, national survey on salt/sodium intake
- Functioning system for generating reliable cause-specific mortality data on a routine basis

Footnotes:  
- a. SBP ≥140 mmHg or DBP ≥90 mmHg or taking medication for hypertension.  
- b. Control rate: adults aged 30–79 years receiving treatment, with blood pressure SBP <140 mmHg and DBP <90 mmHg.  
- c. SBP ≥140 mmHg or DBP ≥90 mmHg.  
- d. Progress and aspirational scenarios reflect a theoretical scaling up of treatment and control.  
- e. Age-standardized estimates are presented for all indicators except salt intake.

Annex 2. Hypertension profiles and explanatory notes

269
Explanatory notes

Profile header

**Total population (2019):** The total population estimates for the year 2019 were taken from the most recent United Nations Population Division World Population Prospects (1). Data were rounded to two to four significant digits depending on the value.

**Total deaths (2019):** Mortality estimates for all deaths were taken from the WHO Global Health Estimates 2019 (2). Values were rounded to two to four significant digits depending on the value.

**Hypertension prevalence and related graphs and statements**

**Age-standardized prevalence of hypertension among adults aged 30–79 years (2019):** Prevalence of hypertension (defined as having systolic blood pressure (SBP) ≥140 mmHg, diastolic blood pressure (DBP) ≥90 mmHg, or taking medication for hypertension) among adults aged 30–79. A total of 1201 population-based studies that included measured blood pressure and data on blood pressure treatment in 104 million individuals aged 30–79 years were used to estimate trends in hypertension and hypertension diagnosis, treatment and control from 1990 to 2019. Full details of input and data methods are available in the related publication (3). Age-standardized estimates were produced by applying the age-specific estimates to the WHO Standard Population.

**Number of adults aged 30–79 years with hypertension (2019):** The number of adults aged 30–79 with hypertension was computed by multiplying the crude prevalence of hypertension by the number of adults aged 30–79 from the 2019 United Nations Population Division World Population Prospects (4).

**Coverage of previous diagnosis, treatment and control of hypertension among adults aged 30–79 years with hypertension (2019):** Coverage of previous diagnosis, treatment (taking medication) and control (or effective treatment, defined as taking medication for hypertension and having SBP <140mmHg and DBP <90mmHg) among adults aged 30–79 years with hypertension (as defined above). Full details of input and data methods are available in the related publication (3). Age-standardized estimates were computed by weighting age-specific coverage by the product of the WHO Standard Population weight and the prevalence of hypertension for the age group as defined above.
Additional people with hypertension needing treatment to achieve 50% control rate (2019): For countries who have not yet attained a 50% control rate, these figures were calculated by subtracting the crude estimates of the proportion of people aged 30–79 years with hypertension whose hypertension was controlled from 0.5. This difference was then multiplied by the number of people with hypertension in the country (calculated as described above) to arrive at the number of people who would need to be effectively treated (i.e. have their hypertension controlled) to attain a 50% control rate. Values were rounded to two to four significant digits depending on value.

Trends in uncontrolled hypertension in adults aged 30–79 years (2019): Uncontrolled hypertension, also referred to as raised blood pressure, is defined as having systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg, regardless of diagnosis or treatment status, among adults aged 30–79 years. It was computed by subtracting the prevalence of controlled hypertension (out of all adults aged 30–79) from the prevalence of hypertension. Full details of input and data methods used to estimate the prevalence of hypertension and proportion of hypertension that is controlled are available in the related publication (3). Age-standardized estimates were produced using the WHO Standard Population. Uncontrolled hypertension was projected to 2025 assuming that rates of change 2010-2019 continue to 2025, using methods described elsewhere (5). A 2025 global voluntary target on blood pressure, endorsed by the World Health Assembly in 2013, envisages a 25% reduction in uncontrolled hypertension by 2025 against a 2010 baseline (6). For each country, the global target is depicted as a 25% relative reduction from the country’s 2010 baseline prevalence.

Hypertension control rate scenarios (2023–2040): Three hypertension control scenarios from a related publication are shown (7). These were designed to reflect realistic scale-up patterns for hypertension care. The assumptions underlying the scenarios were informed by rates of change in blood pressure treatment and control observed in high-performing countries, as well as recent experiences implementing the HEARTS technical package in several countries. Specifically:

- Business as usual scenario: the proportion of adults with hypertension who were treated and whose hypertension was controlled continues to increase at the rate of change observed in the recent past;
- Progress scenario: increases in hypertension treatment and control accelerate to rates historically observed in high-performing countries, until around 50% effective coverage is reached;
- Aspirational scenario: hypertension treatment and control rates increase more rapidly than observed in best-performing countries, but similar to increases observed in specific settings and for other interventions, until around 75% effective coverage is reached.
For all scenarios, annual increases in hypertension coverage were modeled using a parabolic function, which implies that improvements in hypertension coverage occur faster at intermediate coverage levels as compared to low or high coverage levels. This approach is intended to represent the slowing of progress that countries inevitably experience as they expand health care to harder-to-reach populations.

Deaths averted if progress or aspirational scenario achieved by 2040: Holding all else equal, expected deaths from ischaemic heart disease (IHD), hypertensive heart disease (HHD), ischaemic, and haemorrhagic stroke in each year 2023–2040 under each of the three scenarios above were computed. Methods for computing expected deaths are described in Annex 1. Averted deaths are the expected deaths (summed over the years 2023–2040) under the business as usual scenario less the expected deaths under the progress/aspirational scenario (summed over the years 2023–2040).

Mortality

Probability of premature mortality from NCDs (2019): Percentage of 30-year-old-people who would die before their 70th birthday from any of cardiovascular diseases, cancer, diabetes or chronic respiratory diseases, assuming that s/he would experience current mortality rates at every age and s/he would not die from any other cause of death (e.g. injuries or HIV/AIDS). Probability of death between exact age 30 and exact age 70 was calculated using cause-specific mortality rates in each five-year age group and standard life table methods. The estimates were derived from the WHO Global Health Estimates 2019 (2).

Cardiovascular disease deaths (2019): Mortality estimates for cardiovascular diseases were taken from the WHO Global Health Estimates 2019 (2). Values were rounded to two to four significant digits depending on the value.

Cardiovascular disease deaths attributable to high systolic blood pressure (2019): Percentage of cardiovascular deaths that would have been averted in 2019 if all adults had theoretical minimum risk level of systolic blood pressure, estimated to be in the range 110–115 mmHg. Estimates are from the Global Burden of Disease 2019 study (8), and additional details on methods can be found in a related publication (9).

Risk factors

Mean population salt intake, adults aged 25+ years (g/day): Mean daily population salt intake, in grams/day, among adults aged 25+ years. Estimates for mean population sodium intake were calculated by the Institute for Health Metrics and Evaluation (IHME). More information is available on their website: https://www.healthdata.org/results/gbd_summaries/2019/diet-high-sodium-level-3-risk Estimates were converted to salt intake by multiplying by 2.5.
Current tobacco use, adults aged 15+ (2019): Age-standardized estimates for tobacco use prevalence for the population aged 15 years or older. Estimates were based on a modelling process published elsewhere (10). Estimates were produced only for countries who had at least two nationally representative population-based surveys with prevalence rates broken down by age and sex, completed from 1990–2020 (and if only two, they were at least two years apart), one of which was in the field since 2013. Twenty-nine countries did not meet these criteria and thus do not have any estimates. For 56 countries, the estimate only reflects tobacco smoking as there was insufficient survey data on all tobacco use. These are noted with a footnote on these countries’ profiles (11).

Obesity, adults aged 18+ years (2016): Age-standardized prevalence of obesity (defined as having a body mass index ≥30 kg/m²) among adults aged 18+ years. Based on measured height and weight. Input data and methods are described in the related publication (12). Age-standardized estimates were produced by applying the crude estimates to the WHO Standard Population.

Total alcohol per capita consumption, adults aged 15+ years (litres) (2019): Total alcohol per capita consumption (APC) is defined as the total (sum of three-year average recorded and three-year average unrecorded APC, adjusted for three-year average tourist consumption) amount of alcohol consumed per adult (15+ years) over a calendar year, in litres of pure alcohol. Recorded alcohol consumption refers to official statistics (production, import, export, and sales or taxation data), while the unrecorded alcohol consumption refers to alcohol which is not taxed and is outside the usual system of governmental control. Tourist consumption accounts for tourists visiting the country and inhabitants visiting other countries. Positive figures denote alcohol consumption of outbound tourists being greater than alcohol consumption by inbound tourists, negative numbers the opposite. Tourist consumption is based on UN tourist statistics. Recorded alcohol per capita (15+) consumption of pure alcohol is calculated as the sum of beverage-specific alcohol consumption of pure alcohol (beer, wine, spirits, other) from different sources: the first priority in the decision tree is given to government statistics; second are country-specific alcohol industry statistics in the public domain based on interviews or field work (GlobalData, formerly Canadean; IWSR-International Wine and Spirit Research; Wine Institute, historically World Drink Trends), or data from the International Organisation of Vine and Wine (OIV); third is the Food and Agriculture Organization of the United Nations’ statistical database (FAOSTAT); and fourth is data from alcohol industry statistics in the public domain based on desk review. For countries, where the data source is FAOSTAT the unrecorded consumption may be included in the recorded consumption. As from the introduction of the “Other” beverage-specific category, beer includes malt beers, wine includes wine made from grapes, spirits include all distilled beverages, and other includes one or several other alcoholic beverages, such as fermented beverages made from sorghum, maize, millet, rice, or cider, fruit wine, fortified wine.
Physical inactivity, adults aged 18+ (2016): Percentage of adults aged 18+ years attaining less than 150 minutes of moderate-intensity physical activity per week, or less than 75 minutes of vigorous-intensity physical activity per week, or equivalent. Full details of methods have been previously published (13). The estimates were based on self-reported physical activity captured using the GPAQ (Global Physical Activity Questionnaire), the IPAQ (International Physical Activity Questionnaire) or a similar questionnaire covering activity at work/in the household, for transport, and during leisure time. Where necessary, adjustments were made for the reported definition (in case it was different to the indicator definition), for known over-reporting of activity of the IPAQ, for survey coverage (in case a survey only covered urban areas), and for age coverage (in case the survey age range was narrower than 18+ years). No estimates were produced for countries with no data. Age-standardized estimates were produced by applying the crude estimates to the WHO Standard Population.

National response

National targets for salt, blood pressure (2021): Data were drawn from country responses to the WHO 2021 NCD country capacity survey (NCD CCS) (14). The NCD CCS is a web-based survey of NCD focal points or designated colleagues within the ministry of health or a national institute or agency in all WHO Member States. While all Member States responded to the 2021 NCD CCS, it is possible for countries to leave questions blank or respond “don’t know”, resulting in “no data” or “don’t know” values on the profiles. For the question on national targets, respondents were asked to provide documentation of national targets which are based on the WHO Global monitoring framework for NCDs (15). Countries reported as having national targets for either salt or blood pressure on their profiles have submitted evidence of these targets to WHO.

National guidelines on hypertension management (2021): Data were drawn from country responses to the WHO 2021 NCD country capacity survey (14). Respondents indicated whether evidence-based national guidelines/protocols/standards are available for the management (diagnosis and treatment) of cardiovascular diseases through a primary care approach recognized/approved by government or competent authorities and could submit multiple guidelines addressing cardiovascular diseases. Supporting documents submitted by countries for this question were reviewed for evidence of guidelines specifically addressing hypertension.

Conducted recent, national survey measuring raised blood pressure/hypertension, salt/sodium intake (2021): Data were drawn from country responses to the WHO 2021 NCD Country Capacity Survey (14). Countries with a positive value on their profile had to have indicated that they have conducted a recent (i.e. in the past five years since the 2021 NCD country capacity survey), national adult risk factor survey covering the risk factor and provided documentation of...
the survey. Data for those countries who have implemented an NCD risk factor survey covering blood pressure or salt under WHO’s technical guidance since 2021 have been updated accordingly.

**Functioning system for generating reliable cause-specific mortality data on a routine basis (2023):** Countries with a functioning system for generating reliable cause-specific mortality data on a routine basis ensure that the International Form of Medical Certificate of the Cause of Death is completed by certifiers, the International Classification of Diseases (ICD) is used to code the causes of death, and that data compiled are made available to policy-makers and researchers. The WHO collects mortality data, including cause of death, from civil registration systems in the WHO mortality database through a routine annual call for data. Data are considered to generate reliable cause-specific mortality data on a routine basis if: 1. Data from the five most recent reporting years are, on average, at least 70% usable (usability is calculated as: (Completeness (%)) × (1 - Proportion Garbage)), 2. At least five years of cause-of-death data have been reported to the WHO in the last 10 years, and 3. The most recent year of data reported to the WHO is no more than five years old.

**Annex 2 references**


